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Abstract 
 
 Previous research has shown the personality factors of impulsivity and 
conscientiousness are linked to engagement in health related risk-taking behaviours 
in the general population.  Study 1 aimed to investigate how useful the personality 
traits of rash-spontaneous impulsivity (as conceptualised by Dawe and Loxton’s 
(2004) two factor model of impulsivity) and conscientiousness were in 
differentiating between regular (at least monthly) ecstasy users (REU) who engaged 
in additional risk-taking behaviours (e.g., sexual risk-taking, drug driving) versus 
REU who did not, as well as their ability to predict REU’s engagement in additional 
risk-taking behaviours.  Rash-spontaneous impulsivity scores were significantly 
higher in REU deemed at risk for the categories of sexual, alcohol driving and binge 
risk.  Interestingly, rash-spontaneous impulsivity scores were significantly lower in 
REU who engaged in injecting risk-taking behaviours than REU who did not.  In a 
predictive fashion, rash-spontaneous impulsivity successfully predicted REU who 
drove under the influence of alcohol, cannabis and party drugs.  There were no 
differences in conscientiousness scores between REU who engaged in risk-taking 
behaviours versus REU who did not for any domain of risk-taking, and 
conscientiousness did not predict engagement in any risk-taking behaviour.  On a 
whole, findings from Study 1 contributed to the validity of models that implicate 
rash-spontaneous impulsivity in contributing to substance use and risk-taking 
behaviours, whilst providing contrary results to models that implicate 
conscientiousness’ role in protecting against risk-taking behaviours.  Whilst this 
study was exploratory in nature, these preliminary findings suggest that the rash-
spontaneous factor of impulsivity plays a role in risky behaviours over and beyond 
regular ecstasy use.   
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 Study 2 aimed to further investigate the extent to which both factors of Dawe 
and Loxton’s (2004) model of impulsivity, rash-spontaneous impulsivity and reward 
sensitivity, as well as conscientiousness were able to predict engagement in risk-
taking behaviours as well as harm reduction behaviours in a larger, online sample of 
REU.  Study 2 also measured and controlled for the role that attitudes towards sex 
and driving practices may play in predicting sexual and driving risk-taking 
behaviours.  Results indicated that riskier attitudes towards safer sex were predictive 
of a greater frequency of engagement in risky sexual behaviours.  Notably, driving 
attitudes were not successful predictors of drug driving behaviour.  In relation to 
personality, rash-spontaneous impulsivity was a significant predictor of injecting 
risk-taking behaviours, and it approached significance in relation to predicting binge 
and overdose risk-taking behaviours.  Additionally, rash-spontaneous impulsivity 
was a significant predictor of harm reduction behaviours in an inverse fashion.  
Reward sensitivity and conscientiousness were not significant predictor variables in 
relation to any domain of risk-taking or of engaging in harm reduction behaviour.  
On a whole, findings from Study 2 contributed to the validity of models that 
implicate rash-spontaneous impulsivity in substance use and risk-taking behaviours, 
whilst providing contrary results to the involvement of reward sensitivity and 
conscientiousness.  The clinical application and usefulness of these results regarding 
the development and implementation of harm reduction programs are discussed.   
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The Role of the Two-Factor Model of Impulsivity and Conscientiousness in Risk-
Taking and Harm Reduction Behaviours among Regular Ecstasy Users  
 
Thesis Rationale and Aims 
 
 Through two separate research studies, the current thesis seeks to examine 
the role Dawe and Loxton’s (2004) two-factor model of impulsivity and 
conscientiousness may play on predicting regular ecstasy users’ (REU) engagement 
in other health related risk-taking behaviours (e.g., sexual risk-taking and drug 
driving), over and beyond regular ecstasy use, as well as REU’s engagement in harm 
reduction behaviours.   
 
 Study 1 investigates the usefulness of rash-spontaneous impulsivity and 
conscientiousness in differentiating between REU who engaged in risk-taking 
behaviours versus REU who did not, as well as their ability to successfully predict 
REU’s engagement in risk-taking behaviours.  Study 2 investigates the usefulness of 
both factors of impulsivity, rash-spontaneous and reward sensitivity, as well as 
conscientiousness in predicting REU’s engagement in risk-taking behaviours.  
Additionally, Study 2 measures and controls for the sexual and driving attitudes of 
REU, and includes an attempt to predict engagement in harm reduction practices in 
addition to involvement in risk-taking behaviours.     
 
 The literature review and introduction to Study 1 contains chapters of 
background information and previous research regarding ecstasy and its known 
effects, relevant models of personality, the personality factor of rash-spontaneous 
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impulsivity and the personality factor of conscientiousness.  The introduction to 
Study 2 contains background information and previous research regarding the second 
proposed factor of impulsivity, reward sensitivity, the role of attitudes on behaviour 
and harm reduction practices employed by REU. 
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 Chapter 1: Ecstasy: An Introduction  
 
 The use of mind altering substances is a centuries old practice that has been 
part of virtually every culture and society throughout the world.  Recently, the 
Australian Institute of Health and Welfare (AIHW, 2008) surveyed nearly 25,000 
Australians in relation to their lifetime and recent use of licit and illicit drugs.  
Results revealed that 90% of Australians aged 14 and older had tried alcohol at some 
point in their lives, with 83% consuming alcohol in the 12 months prior to the 
survey.  With regards to illicit substances, almost 2 in every 5 Australians aged 14 
and older (38%) had used an illicit drug at some point in their life, with more than 1 
in 7 (13%) having used an illicit drug within the preceding 12 months.  The most 
commonly reported illicit drug used in the previous 12 months was cannabis (9%), 
followed by ecstasy (4%), the drug at the focus of this research (AIHW, 2008). 
 
 3,4-Methylenedioxymethamphetamine (MDMA) or ‘ecstasy’ was originally 
synthesised by a German scientist in 1912, becoming patented in 1913.  Despite a 
lack of any meaningful, controlled clinical trials, it is believed that human 
consumption began in the late 1960s, with many psychotherapists using it with their 
patients as a regular part of therapy to enhance communication and lower inhibitions.  
By 1984 ecstasy was still legal and its use was widespread among youth in North 
America.  Ecstasy is thought to have come to Australia in 1984-85, with its 
popularity taking off in 1989-90.  It is said that the widespread and unashamed use of 
ecstasy brought about its downfall, in addition to emerging research that the drug 
was indeed not harmless (ABC, 2001).  In 1985 the US Drug Enforcement Agency 
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made ecstasy a controlled substance, with Australia following suit in 1987 (ABC, 
2001; NIDA, 2001).   
 
 MDMA is a chemical belonging to the amphetamine family.  It has properties 
of both stimulant and hallucinogenic drugs, in that it increases the speed of activities 
in the nervous system, and users may also experience distorted perception (ADF, 
2006; NIDA, 2001).  The majority of users take ecstasy orally in a tablet or capsule 
form, but the drug may also be taken as a powder, smoked, injected or snorted.  A 
‘typical’ dose of ecstasy has been reported to contain between 60-120 milligrams of 
MDMA (NIDA, 2001), or 80-150 milligrams of MDMA (Oesterheld, Armstrong & 
Cozza, 2004).  However, in reality, the pharmacological content of drugs sold and 
consumed as ecstasy could contain any combination of a number of various 
substances that may or may not be related to MDMA.  For the purposes of this paper, 
the term ecstasy will be used to describe the drug that people consume intentionally 
as they believe to be MDMA, regardless of the actual drug content.   
 
 Pharmacologically, MDMA works in the brain by increasing the activity of 
particular neurotransmitters.  It is known that MDMA triggers a large increase in 
release of the neurotransmitter serotonin (5-hydroxytryptamine, or 5-HT), causing an 
atypical flood of serotonin into the synapse.  MDMA also prevents the re-uptake of 
serotonin, allowing it to remain in the synapse for a longer period of time.  In 
addition, MDMA stimulates the release of the neurotransmitter dopamine, although to 
a lesser extent than serotonin (NIDA, 2001).   
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 The impact of MDMA on dopaminergic neurons appears to be transient, 
whilst its impact on serotonergic neurons appears to be longer lasting (NIDA, 2001).  
Evidence from both animal and human studies suggests that one long-term 
consequence of MDMA use is a persistent, significant depletion of serotonin levels 
(see Figure 1) (NIDA, 2001; Evenden, 1999; Hatzidimitriou, McCann & Ricaurte, 
1999; Reneman, Endert, Bruin, Lavalaye, Feenstra, Wolff, & Booij, 2002; Saadat, 
Elliot, Green, & Morgan, 2006; Morgan, 1998).  Therefore, current evidence 
suggests that MDMA is neurotoxic in relation to serotonin neurons, causing 
irreparable damage to serotonin axons and serotonergic axon terminals, as well as 
reducing the number of serotonin transporters and causing the loss of serotonin 
uptake sites (Copeland, Dillon & Gascoigne, 2004; McCann, Szabo, Scheffel, 
Dannals & Ricaurte, 1998; NIDA, 2001).  As McCann and colleagues (1998) 
conclude, ‘people who use MDMA as a recreational drug are unwittingly putting 
themselves at risk of developing brain 5-HT neural injury.’  
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Figure 1  
Serotonin depletion in squirrel monkeys, persisting after seven years.  Dark-field 
photomicrograph of serotonin axons in the frontal cortex of a control squirrel 
monkey, two weeks post MDMA treatment and 7 years post MDMA treatment 
(Hatzidimitriou, McCann & Ricaurte, 1999). 
 
 
  
 
 The serotonin neurotransmitter system (Figure 2) is one of the most 
widespread in the central nervous system, extending from the brain stem and lower 
brain regions to virtually every region throughout the rest of the brain, with 
exception of the cerebellum. Brain serotonin neurons have been shown to be heavily 
involved in mood regulation, as well as playing a role in memory and cognition, 
impulse control, aggression, appetite / thirst control, sexual function, body 
temperature, sleep and hormonal control (NIDA, 2001).   
 
 Following consumption of MDMA, serotonin is released in large amounts, 
which results in temporary amplified feelings of elation, joy and an overall sense of 
well-being.  However, by releasing large amounts of serotonin, MDMA causes the 
brain to become significantly depleted of serotonin, contributing to unpleasant 
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‘comedown’ symptoms, which may include mood fluctuations, poor concentration, 
loss of energy, irritability, restlessness, nausea, chills, sweating, teeth clinching, 
muscle cramping and blurred vision (Curran & Travill, 1997; Degenhardt & Hall, 
2010; NIDA, 2008; NIDA, 2001).  These effects are typically transient with recovery 
usually occurring 1 – 3 days later (Curran & Travill, 1997; Degenhardt & Hall, 
2010).    
 
 MDMA also acutely affects the dopamine neurotransmitter system (Figure 
2).  Dopamine is a neurotransmitter present in regions of the brain that regulate 
movement, emotion, cognition, motivation and feelings of pleasure. The dopamine 
system rewards natural behaviours, such as eating and sex, by producing pleasant 
effects.  MDMA acutely increases synaptic dopamine levels; however, these 
increases are generally smaller than serotonin increases (Degenhardt & Hall, 2010; 
NIDA, 2008).      
 
 Dopamine is involved in various pathways throughout the brain, one of 
which is the mesolimbic pathway.  This pathway begins in the ventral tegmental area 
of the midbrain and connects to the limbic systems via the nucleus accumbens.  This 
pathway is known to be involved in modulating behavioural responses to stimuli that 
activate feelings of reward and reinforcement (Stahl, 2008).  Activation of the 
mesolimbic dopamine system has been argued to represent a neuronal substrate for 
the rewarding or reinforcing properties of drugs of abuse (Jentsch & Taylor, 1999).  
Initially, drug use produces a sensitization of the mesolimbic dopaminergic system 
that results in an increase over time in the incentive value of the drug itself, as well 
as drug-related conditioned stimuli. This involves an increase in ‘‘wanting’’ drugs 
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that occurs through a sensitizing or hyper-responsivity of motivational processes in 
response to drug cues.  It is this reinforcement value that is thought to contribute to 
drug dependence, cravings and relapse (Dawe, Gullo & Loxton, 2004).  The effects 
of drugs within these cortical regions is also believed to underlie some of the 
alterations in learning, memory, attention and cognition that are associated with 
long-term drug use (Jentsch & Taylor, 1999).   
 
Figure 2 
Serotonin and Dopamine Pathways in the Brain (Ensor, 2005) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 Despite its illegality and long-term adverse effects, the popularity of ecstasy 
has been increasing.  The AIHW (2008) national survey revealed that in Australia, 
the use of ecstasy has risen significantly over recent years, from 2.4% of the 
population having reported to have ever used ecstasy in 1995, to 8.9% reporting they 
had used the drug in 2007.  In terms of recent use of ecstasy (use in the 12 months 
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prior to survey), the prevalence of ecstasy use rose from 0.9% in 1995 to 3.5% in 
2007.  Of Australians aged 18-19 who had ever used illicit drugs, 9.1% of them had 
used ecstasy, second only to cannabis (19%).  Furthermore, in 2007, the group most 
likely to have ever used ecstasy were 20-29 year old males (25.7%), with 13.8% of 
this group reporting recent ecstasy use.  For males and females collectively, the 20-
29 year age group had the highest prevalence of recent ecstasy use (11.2%) than any 
other age group.   
 
Ecstasy: Two Distinct Groups of Users? 
 
Human beings are indeed complex, as are the influences that contribute to 
why people behave as they do.  Specifically, why some individuals partake in risk-
taking behaviours whilst others do not poses an interesting and important research 
question.  In the realm of alcohol and drug research, understanding the differences 
that distinguish between risk-takers and non risk-takers is of particular interest, as the 
implications of engaging in risk-taking behaviour whilst under the influence of 
substances may not only affect the individual, but society at large.   
 
Most people accept the idea that individuals who consume an illicit drug such 
as ecstasy are engaging in risk-taking behaviour, however calculated that risk may 
be.  Within this population of people who may collectively and loosely be described 
as risk-takers, it is interesting that research shows (e.g., Matthews & Bruno, 2006) 
that only some of these individuals engage in other risk-taking behaviours, such as 
unsafe sexual practices or driving under the influence of alcohol and / or other drugs.  
Therefore, within this collective group of risk-takers, there appears to be two distinct 
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sub-groups – those individuals who regularly consume ecstasy but do not partake in 
other risk-taking behaviours, and those individuals who regularly consume ecstasy as 
well as engaging in other risk-taking behaviours. 
 
There could be many influences as to why an individual who regularly takes 
ecstasy chooses to engage or not engage in other risk-taking behaviours.  Sex and 
age are probable influences.  Another such influence may be that the individual 
engages in risk-taking behaviours due to a side effect of the drug(s) itself; for 
example, experiencing disinhibition when under the influence of alcohol.  An 
individual’s attitudes towards the behaviour are also likely to be important.  
However, in addition to these influences, it also stands to reason that there is 
something intrinsic within the individual, something in their personality, which may 
either be a contributing or protective factor with regards to the extent to which the 
individual engages in other risk-taking behaviours.   
 
The current research focuses on this final influential factor, in that it aims to 
determine what characteristics of personality may distinguish between regular 
consumers of ecstasy who engage in other risk-taking behaviours versus those who 
do not.  Research of this type is important to determine if personality factors can 
differentiate and potentially predict membership of these two groups.  Results of this 
research may assist in the development of harm reduction programs, in that the 
results may provide guidance in choosing not only who to target, but how to target 
individuals who are deemed at risk based on these characteristics, thus providing 
valuable information to ensure intervention programs are successful.     
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Chapter 2: Models of Personality 
  
 This chapter aims to review key models of personality and how they 
potentially relate to explaining differences between REU who engage in risk-taking 
behaviours versus REU who do not.      
 
There are many diverse theories of personality that have been proposed by a 
range of philosophers and psychologists over the centuries.  Despite fundamental 
differences between theories, the goals of each personality theorist are the same – to 
postulate a theory of personality that depicts what human beings are like, and to 
explain why individuals are like the way they are.  With these common goals, all 
personality theories therefore attempt to explain both human nature and individual 
differences.  The differences between personality theories are largely due to theorists 
offering diverse descriptions, explanations and methodologies, with each theorist 
using their own language and terms in order to describe their unique personality 
theory.  However, despite the varied personality theories that abound, elements that 
are generally focused upon in most personality theories include the role of genetics, 
traits, culture / society, learning, personal choice, unconscious mechanisms and / or 
cognitive processes (Hergenhahn & Olson, 1999).   
 
There are several theories of personality that are particularly pertinent to the 
current discussion of risk-taking behaviours amongst individuals who regularly use 
ecstasy.  This paper will focus on theories postulated by Eysenck, Costa and 
McCrae, Gray and Cloninger, each described below.  Other health models, such as 
the Health Belief Model (Rosenstock, 1966) and the Theory of Planned Behaviour 
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(Ajzen & Fishbein, 1980) may well have explanatory power in relation to health 
risk-taking behaviour, and are discussed in detail in subsequent chapters relating to 
Study 2.      
 
Eysenck’s Three Factor Model of Personality 
 
Eysenck developed his initial theory of personality in the 1940s, making 
revisions throughout the 1970s.  He emphasised empirical determination and 
measurement of basic psychological qualities possessed by all people, as he was 
primarily concerned with explaining the personality of normal adults as opposed to 
psychopathology.  His measures include the Eysenck Personality Inventory (EPI), 
the Eysenck Personality Questionnaire (EPQ) and the Revised EPQ (EPQ-R) 
(Hergenhahn & Olson, 1999).   
 
Eysenck’s model of personality placed importance on the role that biological 
and genetic factors have on determining personality.  His theory is based primarily 
on two neurobiological systems: the ascending reticular activating system (ARAS) 
and the limbic system (of which Eysenck referred to as the visceral brain).  The 
ARAS is responsible for patterns of excitation and inhibition of the cerebral cortex, 
whilst the limbic system regulates emotional expression and controls autonomic 
responses such as heartbeat, blood pressure and sweating (Hergenhahn & Olson, 
1999).   
 
The focus of Eysenck’s theory is the concept of temperament, defined as the 
emotional, motivational and non-ability related cognitive aspects of behaviour.  With 
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this focus, Eysenck believed important traits are those that are relatively permanent, 
have clear biological origins and that influence secondary behavioural patterns 
acquired through learning.  In other words, he postulated that traits are biologically 
influenced by the ARAS and limbic system, rather than being learned (Hergenhahn 
& Olson, 1999).   
 
Eysenck based his personality theory on the statistical technique of factor 
analysis, and his model and associated measures are hierarchical in nature.  A 
hierarchical model is one in which items at the narrowest level are factor analysed to 
derive factors at the second level, these factors are again factor analysed to derive 
factors at the third level, and so forth.  At the bottom and narrowest level of 
Eysenck’s hierarchy are behaviours, such as talking with a friend on a single 
occasion.  At the second level are recurring behaviours, called habits, such as talking 
with friends on multiple occasions.  As people who engage in one type of behaviour 
tend to engage in other similar behaviours, at the third level are intercorrelated sets 
of habits, called traits, such as the construct of sociability. At the top of Eysenck’s 
hierarchy are intercorrelated sets of traits, called types or superfactors, such as 
extraversion.  In this statistical manner, Eysenck theorised there are three 
superfactors to describe human personality: extraversion, neuroticism and 
psychoticism.  Each of these dimensions of personality, described in more detail 
below, is orthogonal, meaning they are independent of one another (Acton, 2003; 
Hergenhahn & Olson, 1999).     
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Extraversion 
 
 
Eysenck’s first factor, extraversion (vs. introversion), is the degree to which a 
person is outgoing, talkative, has a high degree of positive affect, is interactive with 
other people and desires external stimulation (Acton, 2003).  Individuals with high 
scores on the extraversion dimension may be characterised as active, sociable, 
expressive, assertive, ambitious, enthusiastic, spirited, vivacious and zestful (Costa 
& McCrae, 1995).   
 
According to Eysenck’s arousal theory of extraversion, different degrees of 
extraversion may be attributed to different levels of arousal in the cerebral cortex.  
Arousal can be measured by skin conductance, brain waves or sweating.  There is 
some ‘optimal’ level of cortical arousal, and performance deteriorates as one 
becomes more or less aroused than this optimal level.  Thus, at very low and very 
high levels of arousal, performance is low, but at a more optimal midlevel of arousal, 
performance is maximised (Acton, 2003).  According to Eysenck’s theory, 
individuals with a high degree of extraversion are believed to have low levels of 
cortical arousal, while individuals with a high degree of introversion (i.e., low 
extraversion) are believed to have high levels of cortical arousal.  Due to this 
underlying difference in brain physiology, it is theorised that extraverts seek 
excitement and social activity in an effort to heighten their arousal level to an 
optimal level of performance, while introverts tend to avoid excitement and social 
activity and need peace and quiet in an effort to keep arousal at a minimum 
(Hergenhahn & Olson, 1999).   
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Neuroticism  
 
 
Eysenck’s second factor, neuroticism (vs. emotional stability), is the enduring 
tendency to experience negative emotional states such as depression and anxiety 
(Acton, 2003).  Individuals with high scores on the neuroticism dimension may be 
characterised as anxious, unhappy, dependent, hypo-chondriacal, guilty, obsessive, 
fearful, nervous and having inferior self-esteem (Costa & McCrae, 1995).   
 
Neuroticism, according to Eysenck’s theory, is based on activation thresholds 
in the sympathetic nervous system, the part of the brain that is responsible for the 
fight or flight response in the face of danger.  Activation of this system can be 
measured by heart rate, blood pressure, cold hands, sweating and muscular tension.  
Eysenck postulated that individuals with a high degree of neuroticism have low 
activation thresholds for the sympathetic nervous system, and therefore experience 
negative affect in the face of relatively minor stressors.  This theory postulates that 
individuals that are high on neuroticism are more sensitive to environmental 
stimulation and often do not perform well or experience negative affect under 
pressure.  On the contrary, those who are low on neuroticism have high sympathetic 
nervous system activation thresholds, and therefore experience negative affect only 
in the face of major stressors.  These people often react calmly and coolly when 
under pressure.  Neuroticism can be distinguished from negative affect itself, in that 
those disposed to experience negative affect (e.g., anxiety) may tend to avoid 
situations that cause it (Acton, 2003; Hergenhahn & Olson, 1999).   
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Psychoticism 
 
 
Individuals with high scores on Eysenck’s third factor, psychoticism (vs. 
impulse control), may be characterised as tough minded, nonconformists, 
uncooperative, hostile, risk-takers, manipulators, sensation seekers, being 
irresponsible and behaving in an impulsive manner.  Although Eysenck also 
maintained that this factor is also intended to assess a predisposition to psychotic 
disorders, Costa and McCrae (1995) suggest it measures something closer to a lack 
of conventional socialization, in that high scorers are guided neither by sympathy for 
others, nor by respect for rules.  The physiological basis suggested by Eysenck for 
psychoticism involves high levels of testosterone and low monoamine oxidase 
enzyme levels; however, these are not well established (Acton, 2003; Hergenhahn & 
Olson, 1999; Jang, 1998; Costa & McCrae, 1995).   
 
In summary, Eysenck’s model of personality, derived from factor analysis 
and grounded in neurobiology, maintains there are three crucial factors that describe 
human personality: extraversion, neuroticism and psychoticism.  In applying 
Eysenck’s theory, the development of personality is directed by genetically endowed 
traits but is tempered by environmental factors.  Eysenck maintained that person 
variables (genetics and biological dispositions) and situation variables always 
interact to cause behaviour.  Therefore, personality traits influence the kinds of 
situations individuals find aversive and avoid, as well as those that individuals enjoy 
and seek.  Because our personalities guide us toward some environments and turn us 
away from others, our personalities can influence the kinds of behaviours, 
experiences and learning that we encounter (Hergenhahn & Olson, 1999).   
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In relation to the current study, Eysenck’s theory of personality provides a 
reasonable explanation as to why some individuals may take ecstasy, as well as why 
some may take part in other risk-taking behaviours.  Based on Eysenck’s theory, the 
risk-taker as subject in this research may be particularly well explained by the 
extraversion and psychoticism factors, in that persons with low cortical arousal (i.e. 
extraverts) seek sensation and excitement, and persons high in psychoticism are 
characterised as sensation seekers and risk-takers.  Therefore, Eysenck’s theory 
would imply that regular consumers of ecstasy who partake in risk-taking behaviours 
are likely to score high on the extraversion and psychoticism factors..  For example, 
while this has not been examined directly in ecstasy consumers, in a study 
comparing never, current and ex- tobacco smokers on the EPQ-R, Arai, Hosokawa, 
Fukao, Izumi and Hisamichi (1997) found that current and ex-smokers scored higher 
on the extraversion and psychoticism scales than never smokers for both sexes.  
Heavy smokers and those who commenced smoking prior to the legally permitted 
age scored higher on the psychoticism scale than light smokers and those who started 
smoking after the legally permitted age.  Therefore, both the extraversion and 
psychoticism factor appeared to have played a part in this risk-taking behaviour.  
 
The Five Factor Model of Personality  
 
The Five Factor Model (FFM) of personality, developed by Costa and 
McCrae (1992), offers an alternative theory as it postulates there are five factors that 
are required to describe human personality, as opposed to Eysenck’s three.  The FFM 
traits are grounded in a comprehensive biosocial model that includes a genetic and 
environmental position on causation of behaviour.  The five factors are measured by 
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the Revised Neuroticism, Extraversion, Openness Personality Inventory (NEO-PI-R) 
(Costa & McCrae, 1992; Goldberg, 1993; Zuckerman, Kuhlman, Joireman, Teta & 
Kraft, 1993).    
 
The FFM, like Eysenck’s model, is based on the statistical method of factor 
analysis and is hierarchical in nature.  The FFM organises personality traits into five 
broad domains: extraversion, neuroticism, conscientiousness, openness to experience 
and agreeableness, each described below (Bogg & Roberts, 2004).   
 
Extraversion   
 
 
Extraversion in the FFM is essentially identical to Eysenck’s description.  To 
briefly summarise, extraversion is the degree to which a person is outgoing and 
interactive with other people, as well as indicating the individual’s proneness 
towards positive emotions and socialibility (Lynam, Leukefeld & Clayton, 2003).  
People with a high degree of extraversion are characterised by energy, positive 
emotions and the tendency to seek stimulation and the company of others.  In the 
FFM, extraversion has been associated with higher sensitivity in the mesolimbic 
dopamine system to potentially rewarding stimuli (Goldberg, 1993; Lynam, 
Leukefeld & Clayton, 2003), whereas in the Eysenck model different degrees of 
extraversion are attributed to the more global assessment of different levels of 
arousal in the cerebral cortex (Hergenhahn & Olson, 1999).   
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Neuroticism 
 
Neuroticism in the FFM is again essentially identical to the description in the 
Eysenck model.  To briefly summarise, neuroticism refers to the tendency to 
experience negative emotions.  Individuals with a high degree of neuroticism tend to 
experience a range of unpleasant emotions easily, are emotionally reactive and 
respond emotionally to events that would not affect people with a lower degree of 
neuroticism (Lynam, Leukefeld & Clayton, 2003; Goldberg, 1993). 
 
Conscientiousness 
 
The conscientiousness factor of the FFM is concerned with the way people 
control, regulate and direct impulses.  A high degree of conscientiousness is 
characterised by a tendency to show self-discipline, act dutifully and aim for 
achievement.  Highly conscientiousness people have a high ability to plan, organise 
and complete tasks and tend to mostly engage in planned rather than spontaneous 
behaviour.  High scorers on this factor may be characterised as organised, thorough 
and reliable, whereas low scorers on this factor may be characterised as careless, 
negligent and unreliable (Lynam, Leukefeld & Clayton, 2003; Goldberg, 1993).   
 
Openness to Experience 
 
The openness to experience factor describes the imaginative and creative 
aspects of personality.  Individuals who score high on this factor are characterised as 
open, imaginative, curious, interested in culture, have an appreciation for art, 
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emotion, adventure, and unusual ideas as well as enjoying a variety of experiences.  
Higher levels of openness to experience have been linked to activity in the ascending 
dopaminergic system and the functions of the dorsolateral prefrontal cortex (Lynam, 
Leukefeld & Clayton, 2003; Goldberg, 1993).  
 
Agreeableness 
 
Agreeableness describes the degree to which a person is concerned with 
cooperation and social harmony.  Individuals with a high degree of agreeableness 
have a tendency to be compassionate and cooperative, rather than being suspicious 
and antagonistic towards others.  Individuals who score high on the agreeableness 
factor value getting along with others, and are generally trusting, straightforward, 
empathic, considerate, generous, friendly, and have an optimistic view of human 
nature.  People who score low on the agreeableness factor tend to be characterised as 
arrogant, hostile, selfish, manipulative, and unconcerned about others (Lynam, 
Leukefeld & Clayton, 2003; Goldberg, 1993). 
 
When viewed hierarchically, the FFM does not intend to reduce the complex 
tapestry of personality to a mere five traits; rather, it seeks to provide a framework in 
which to organise the many individual differences that characterise humankind. As 
such, the five broad domains of the FFM incorporate hundreds, if not thousands, of 
traits (Goldberg, 1993).  Costa and McCrae (1995) proposed six facets within each 
domain on the basis of their research with the NEO-PI-R, described in Table 1 below 
(Lynam, Leukefeld & Clayton, 2003).  Facets of particular interest to the present 
research, such as excitement-seeking, deliberation and impulsiveness, are italicised.   
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Table 1 
Description of Facets within the Five Factor Domains (Lynam, Leukefeld & 
Clayton., 2003) 
Domain Descriptor  
Extraversion  
Warmth affectionate, attached vs. cold, aloof, reserved, 
indifferent 
Gregariousness sociable, outgoing vs. withdrawn, isolated 
Assertiveness enthusiastic, forceful vs. unassuming, quiet, resigned 
Activity active, energetic, vigorous vs. passive, lethargic 
Excitement-Seeking adventurous, rash vs. cautious, monotonous, dull 
Positive Emotions  high-spirited vs. placid, anhedonic 
Neuroticism   
Anxiousness fearful, apprehensive vs. relaxed, unconcerned, cool 
Angry Hostility  bitter, angry vs. even-tempered 
Trait Depression pessimistic, glum, despondent vs. optimistic 
Self-Consciousness timid, embarrassed vs. self-assured, glib, shameless 
Impulsiveness tempted, reckless vs. controlled, restrained 
Vulnerability  fragile, helpless vs. stalwart, brave, fearless 
Conscientiousness  
Competence efficient, perfectionistic vs. lax, negligent 
Order organised, methodical, ordered vs. haphazard, 
disorganized, sloppy 
Dutifulness dutiful, reliable, dependable, rigid vs. casual, 
undependable 
Achievement-Striving purposeful, ambitious, workaholic vs. aimless 
Self-Discipline  industrious, devoted, dogged vs. negligent, hedonistic 
Deliberation reflective, thorough, ruminative vs. careless, hasty 
Openness to Experience  
Fantasy imaginative, dreamer, unrealistic vs. practical, concrete 
Aesthetic  aesthetic vs. unaesthetic 
Feelings emotionally responsive, sensitive vs. unresponsive, 
constricted 
Actions novelty seeking, eccentric vs. routine, habitual stubborn 
Ideas curious, odd, peculiar, strange vs. pragmatic, rigid 
Values broad-minded, tolerant vs. traditional, dogmatic, biased
Agreeableness  
Trust trusting, gullible vs. sceptical, cynical, suspicious, 
paranoid 
Straightforwardness honest, confiding vs. cunning, manipulative, deceptive 
Altruism giving, sacrificial vs. selfish, stingy, greedy, 
exploitative 
Compliance cooperative, docile vs. oppositional, combative, 
aggressive 
Modesty self-effacing, meek vs. confident, boastful, arrogant 
Tender-Mindedness concerned, compassionate, empathic vs. callous, 
ruthless 
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In relation to the current discussion, the FFM also provides a reasonable 
explanation as to why some individuals may take ecstasy, as well as why some may 
take part in other risk-taking behaviours.  The FFM would likely describe the risk-
taker, as per the subject in this research, as high on the extraversion and openness to 
experience factors, whilst low on the neuroticism and conscientiousness factors.  A 
study by Schmitt (2004) examined how the FFM personality traits related to risky 
forms of sexual behaviour across the general population in 52 countries.  He found 
that impulsive sensation seeking (combined low scores on the agreeableness and 
conscientiousness factors), was the strongest personality correlate of risky sexual 
behaviour.  Results also indicated that low scores on either the agreeableness or 
conscientiousness factor were associated with higher levels of relationship infidelity, 
and that sexual promiscuity was significantly related to higher levels of extraversion.   
 
In addition, Flory, Lynam, Milich, Leukefeld and Clayton (2002) examined 
the relationship of the FFM to symptoms of alcohol and cannabis abuse, after 
controlling for symptoms of antisocial personality disorder and internalizing 
psychopathology.  Results indicated that symptoms of alcohol abuse / dependence 
could be described by a pattern of high extraversion and low conscientiousness, 
whereas symptoms of cannabis abuse / dependence were characterised by low 
extraversion and high openness to experience.  For both sets of symptoms, the 
personality variables accounted for more than 10% of the variance. 
 
In response to the FFM, Eysenck suggested that factors other than his three 
are either components of extraversion, neuroticism or psychoticism, or combinations 
of two of them.  For example, Eysenck regarded the conscientiousness and 
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agreeableness factors of the FFM to be components of psychoticism (Zuckerman et 
al., 1993).  In reply, Costa and McCrae (1995) stated the view that agreeableness and 
conscientiousness are facets of a broader domain of psychoticism suggests they 
should show similar patterns of correlates. The authors argue their data provides little 
support for this view, and that the data suggest that agreeableness and 
conscientiousness appear to have distinct correlates, thus constituting different 
dimensions of personality.  
 
In comparing the two, Jang (1998) argued that Eysenck’s model combines 
both descriptive and causal aspects of personality in one theory.  By doing so, 
Eysenck’s model is supported by more credible evidence than purely descriptive 
models, such as the FFM.  Secondly, Eysenck’s model is descriptively 
comprehensive by proposing a hierarchy of four levels and by making a clear 
distinction amongst those levels.  Despite the FFM also being hierarchical, Jang 
argued it seems to blend lower-level factors with higher-level superfactors; namely, 
the dimensions of agreeableness and conscientiousness are traits at the third level 
that combine as part of the superfactor of psychoticism at the top level of Eysenck’s 
model.  Furthermore, the FFM includes intellect, or openness, at the top level, 
whereas Eysenck draws a clear line between temperament and cognitive ability and 
treats intelligence differently.  Additionally, Eysenck’s model is compelling due to 
its experimental approach to the study of personality, which makes the model more 
testable.  Consequently, this model is likely to generate more specific predictions, as 
knowledge about the functioning of the specified physiological structures already 
exists (Jang, 1998).   
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Gray and the Two Dimensional Model of Personality  
 
Gray’s reinforcement sensitivity theory (Gray, 1970) and its later revised 
version (Gray & McNaughton, 2000) proposes there are individual differences in the 
sensitivity, or the reactivity, of basic brain behavioural systems that respond to 
reinforcing stimuli.  Based on this theory, Gray postulates there are two independent 
dimensions of personality and motivation, namely impulsivity and anxiety (or 
proneness to these), that represent individual differences in the sensitivity of two 
neurological systems when the individual is responding to environmental cues.  The 
trait of anxiety is based on an avoidance, “behavioural inhibition system” (BIS) and 
the trait of impulsivity is based on an appetitive, “behavioural approach system” 
(BAS).  As BIS and BAS are theorised to represent different structures in the 
nervous system, these sensitivities are presumed to be orthogonal; therefore, within a 
given population, there should be people with all combinations of high and low BIS 
and BAS sensitivity.  In Gray’s model, impulsivity is closely related to Eysenck and 
the FFM’s extraversion factor, whereas Gray’s anxiety is closely related to Eysenck 
and the FFM’s neuroticism factor (Carver & White, 1994; Acton, 2003).   
 
The BIS / BAS Scales (Carver & White, 1994) were developed as a self-
report questionnaire to measure Gray’s theory of personality traits.  The BIS / BAS 
Scales focus on items that tap emotional responses to appetitive and aversive stimuli.  
The scales provide a single score for BIS and three subscale scores for BAS: (1) 
BAS reward responsiveness, which includes items that measure anticipation and 
positive response towards reward (2) BAS drive, which includes items that tap 
persistence in obtaining desired goals and (3) BAS fun seeking, which includes 
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statements that are indicative of a willingness to seek out and spontaneously 
approach potentially rewarding experiences (Dawe & Loxton, 2004; Acton, 2003).   
  
Behavioural Inhibition System (BIS) 
 
The major brain structure theorised to underlie the BIS is the 
septohippocampal system, part of the limbic system, comprising the hippocampus 
proper, dentate gyrus, entorhinal cortex, subicular area (subiculum) and the posterior 
cingulate cortex, its monoaminergic afferents from the brainstem, and its neocortical 
projection in the frontal lobe (Dawe, Gullo & Loxton, 2004; Carver & White, 1994).   
 
Gray (1970; Gray & McNaughton, 2000) has argued that this physiological 
mechanism controls the experience of anxiety in response to anxiety-relevant cues.  
The BIS, according to Gray, is sensitive to signals of punishment, non-reward, and 
novelty, and inhibits behaviour that may lead to negative or painful outcomes. Thus, 
BIS activation causes inhibition of movement toward goals.  Gray also theorises that 
BIS functioning is responsible for the experience of negative feelings such as fear, 
anxiety, frustration and sadness in response to these cues.  In terms of individual 
differences in personality, a greater BIS sensitivity should be reflected in greater 
proneness to anxiety, provided the person is exposed to the proper situational cues.  
Additionally, individuals with a more reactive BIS are more likely to inhibit 
approach behaviour that is accompanied by subjective feelings of anxiety / 
frustration (Dawe, Gullo & Loxton, 2004; Carver & White, 1994).  Thus, it could be 
theorised that a high BIS sensitivity would be related to non-substance use and non 
risk-taking behaviour, as the outcome of substance use may be viewed as potentially 
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negative and such individuals would then avoid this behaviour.  However, previous 
research regarding the role of BIS sensitivity in substance use behaviour is unclear.  
Some studies report a significant negative correlation between substance use 
problems and BIS sensitivity (e.g., Franken & Muris, 2006; Genovese & Wallace, 
2007; Hundt et al., 2008; Kimbrel et al., 2007; Pardo et al., 2007; Simons et al., 
2008), some suggest substance use problems are associated with high BIS sensitivity 
(e.g., Kambouropoulos & Staiger, 2004; Taylor et al., 2006) and others failed to find 
a significant association (e.g., Jorm et al., 1999; Knyazev, 2004; Loxton & Dawe, 
2006, 2007; Loxton et al., 2008; O’Connor et al., 2009).  Clearly more research is 
needed to clarify this relationship, both in community samples and within drug using 
populations.   
 
Behavioral Activation System (BAS) 
 
The BAS is the physiological mechanism thought to control appetitive 
motivation.  The underlying neural substrate of BAS is proposed to involve 
dopaminergic systems, in particular the mesolimbic dopaminergic pathways.  As 
stated previously, this is one of the critical (although not only) pathways underlying 
the positively reinforcing effects of natural reinforcers such as food, sex and drugs of 
abuse.  Further, the dopamine circuits have been found to activate in response to 
conditioned cues of reward, prior to the consummation of reinforcing substances 
(Dawe & Loxton, 2004; Dawe, Gullo & Loxton, 2004).   
 
 The BAS is thought to be sensitive to signals of reward, non-punishment and 
escape from punishment.  Activity in this system causes the person to begin, or 
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increase, movement toward goals.  Gray (1970; Gray & McNaughton, 2000) also 
theorises the BAS is responsible for the experience of positive feelings such as hope, 
elation and happiness.  In terms of individual differences in personality, those with a 
higher BAS sensitivity are more prone to engage in goal-directed efforts and to 
experience positive affect in situations containing cues of impending reward (Dawe 
& Loxton, 2004; Carver & White, 1994).  Thus, it would be expected that high BAS 
sensitivity would likely be positively associated with substance use and other risk-
taking behaviours.  In line with this, previous research has shown that higher BAS 
sensitivity is associated with ecstasy use (Egan, Kambourpoulos & Staiger, 2010), 
and that individuals with problematic substance use such as drug addicted inpatients 
(Franken, Muris & Georgieva, 2006), alcohol misusing high school girls (Loxton & 
Dawe, 2001) and hazardous drinking men and women (Kambouropoulos & Staiger, 
2007) reported hjgher levels of BAS sensitivity when compared to controls (for a 
more comprehensive review see Bijttebier, Beck, Claes & Vandereycken, 2009). 
 
 In summary, Gray (1970; Gray & McNaughton, 2000) proposes there are two 
general motivational systems that underlie behaviour and affect: the behavioural 
inhibition system and the behavioural activation system.  In relation to the focus of 
the current study, Johnson, Turner and Iwata (2003) assessed how levels of 
behavioural inhibition and activation related to lifetime diagnoses of depression, 
anxiety, drug / alcohol abuse and dependence, attention deficit hyperactivity disorder 
and conduct disorder in a sample of 1,803 individuals between the ages of 19 and 21.  
Results implicated the role of BIS as a vulnerability factor for both depression and 
anxiety, and implicated the role of BAS (Fun Seeking) as a vulnerability factor for 
both drug abuse and non-comorbid alcohol diagnoses.   
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In conclusion, the BAS is of particular interest to the current research, given 
its known association with the dopaminergic systems and its well established 
reinforcing links with illicit drugs.  Gray’s (1970) theory could therefore be used to 
understand the motivational influences behind continued substance use, as well as 
other risk-taking behaviours.  To apply Gray’s theory, for example, an individual 
with a higher BAS and lower BIS sensitivity may be more likely to both use ecstasy 
and drive under the influence, whereas an individual with high BAS and BIS 
sensitivities may be more likely to use ecstasy, but may be less likely to drive under 
the influence.   
 
In comparing Gray’s model with Eysenck’s, Gray does not concur that 
extraversion and neuroticism are crucial factors of personality.  In Gray’s opinion, 
extraversion and neuroticism are secondary consequences of the interactions between 
the impulsivity and anxiety systems.  Gray’s impulsivity (BAS) factor would be 
consistent with individuals that are high on both neuroticism and extraversion, whilst 
Gray’s anxiety (BIS) factor is consistent with individuals that are high on 
neuroticism but low on extraversion.  In Gray’s view, a person whose BIS is more 
powerful than their BAS becomes introverted, whilst a person whose BAS is 
relatively more powerful than their BIS becomes extraverted.  Thus, from Gray's 
perspective, the superfactor of extraversion reflects the relative strength of both 
impulsivity and anxiety, whereas neuroticism reflects their joint strength, in which a 
rise in the sensitivity of either system provides an increase in the degree of 
neuroticism.  Gray's theory also envisages that extraverts exhibit superior 
conditioning with a rewarding unconditioned stimulus, as opposed to Eysenck's 
prediction that introverts exhibit superiority in conditioning (Jang, 1998).  In relation 
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to drug use, Gray’s theory could imply that extraverts would become dependent 
more quickly following substance use.   
 
Cloninger and the Tridimensional Model of Personality  
 
Cloninger’s biosocial tridimensional model of personality postulates there are 
three genetically independent, but functionally interactive, dimensions of 
personality: harm avoidance (HA), novelty seeking (NS) and reward dependence 
(RD).  Cloninger considered each of these factors to be moderately heritable, 
normally distributed, developmentally and situationally stable, and associated with 
specific neural systems that mediate various stimulus-response relationships.  
Cloninger proposed that individual differences in the expression of these three 
dimensions are a reflection of genetic sensitivity in neurological systems, as the three 
factors are postulated to be related to brain systems regulated principally by 
dopamine, serotonin and noradrenaline (Dawe & Loxton, 2004; Howard, Kivlahan & 
Walker, 1995).  Cloninger (1987) proposed that NS is related to activity in the 
dopaminergic system, HA is related to activity in the serotonergic system and RD is 
related to the influence of noradrenaline on the association of conditioned signals of 
reward or punishment.  The Tridimensional Personality Questionnaire (TPQ; 
Cloninger, Przybeck, & Svrakic, 1991) and the Temperament and Character 
Inventory (TCI; Cloninger, Svrakic, Przybeck & Wetzel, 1994) are assessments used 
to measure the three traits (Acton, 2003).  In recent revisions to the theory (e.g., 
Cloninger, Svrakic & Przybeck, 1993), Cloninger proposed a fourth basic dimension 
labelled persistence (PS; originally subsumed under RD), and added three "character 
traits" assumed to develop in adulthood (see Cloninger & Svrakic, 1997).   However, 
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this paper will focus on the 3 aforementioned factors of Cloninger’s tridimensional 
model.   
 
Unlike Eysenck and the FFM model, Cloninger’s model is not based on 
factor analysis; rather, his theory ties phenotypical variation in personality (i.e., the 
observable characteristics of personality) to neurobiological substrates, emphasising 
the importance of gene-environment interaction (Howard, Kivlahan & Walker, 
1995).  Conceptually, Cloninger’s theory of personality is most similar to Gray’s 
model.  Cloninger’s HA dimension is nearly equivalent to Gray’s BIS, and 
Cloninger’s NS and RD factors are conceptually equivalent to Gray’s BAS.  
Therefore in essence, Cloninger’s HA factor is similar to Eysenck and the FFM’s 
neuroticism factor, whilst NS and RD dimensions are similar to the aforementioned 
extraversion factor (Acton, 2003).   
Harm Avoidance (HA) 
 
The higher order trait of harm avoidance regards the “tendency to respond 
intensely to aversive stimuli and their conditioned signals, thereby facilitating 
learning to inhibit behaviour in order to avoid punishment, novelty and frustrative 
omission of expected rewards” (Howard, Kivlahan & Walker, 1995).  In other 
words, harm avoidance concerns sensitivity to, and avoidance of, punishing stimuli.  
Individual differences in harm avoidance are theorised to reflect variation in a 
behavioural inhibition brain system that regulates passive avoidance and extinction 
responses to conditioned signals of punishment, novelty and frustrative non-reward; 
conceptually, this is the same as Gray’s BIS.  The harm avoidance dimension is 
thought to be linked to the serotonergic system (Carver & White, 1994; Dawe & 
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Loxton, 2004).  Harm avoidance consists of four lower order traits: anticipatory 
worry and pessimism versus uninhibited optimism, fear of uncertainty, shyness with 
strangers and fatigability and asthenia versus vigour (Cloninger et al., 1994). 
 
Individuals with a high degree of harm avoidance may be described as 
cautious, careful, tense, apprehensive, nervous, timid, doubtful, discouraged, 
insecure, passive, fearful, pessimistic, inhibited, shy, easily fatigable and 
apprehensive worriers.  Such people tend to be inhibited and shy in most social 
situations, have low energy levels, require more reassurance and encouragement and 
are unusually sensitive to criticism and punishment.  In contrast, individuals with a 
low degree of harm avoidance may be described as bold, confident, daring, 
courageous, composed, relaxed, optimistic, carefree, uninhibited, outgoing and 
energetic.  Such people tend to be outgoing and confident in most social situations, 
have high energy levels and impress others as dynamic, lively and vigorous (Carver 
& White, 1994; Cloninger et al., 1994; Dawe & Loxton, 2004; Howard, Kivlahan & 
Walker, 1995).   
 
Novelty Seeking (NS)  
 
Cloninger’s novelty seeking dimension regards the tendency to engage in 
exploratory activity and to experience exhilaration / excitement in response to novel 
stimuli that may be cues of potential reward or relief of punishment.  This dimension 
is associated with the neural system mediating exploratory pursuit responses to novel 
stimuli, and appetitive approach responses to potential rewards or their conditioned 
signals (Carver & White, 1994; Dawe & Loxton, 2004; Howard, Kivlahan & 
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Walker, 1995).  Novelty seeking consists of four lower order traits: exploratory 
excitability versus stoic rigidity, impulsiveness versus reflection, extravagance 
versus reserve and disorderliness versus regimentation (Cloninger et al., 1994).   
 
Individuals with a high degree of novelty seeking may be described as 
impulsive, exploratory, curious, enthusiastic, exuberant, easily bored, fickle, 
excitable, quick-tempered, extravagant and disorderly.  Such people are enthusiastic 
and quick to engage with whatever is new and unfamiliar, leading to an exploration 
of potential rewards.  In contrast, individuals with a low degree of novelty seeking 
may be described as reflective, rigid, loyal, stoic, indifferent, uninquiring, 
unenthusiastic, frugal, reserved, tolerant of monotony, systematic, slow tempered, 
orderly and persistent (Carver & White, 1994; Cloninger et al., 1994; Dawe & 
Loxton, 2004; Howard, Kivlahan & Walker, 1995).  
 
Reward Dependence (RD) 
 
The dimension of reward dependence reflects differences in resistance to 
extinction of previously rewarded behaviour, and a tendency towards maintaining 
behaviour previously associated with reward.  Cloninger associated this dimension 
with the behavioural maintenance neural system that mediates resistance to 
extinction of conditioned signals of reward or relief of punishment.  This dimension 
is postulated as the basis for individual differences regarding the ability to delay 
gratification.  Although not in its entirety, some qualities of this dimension 
conceptually represent Gray’s BAS (Carver & White, 1994; Howard, Kivlahan & 
Walker, 1995).  Reward dependence consists of three lower order traits: 
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sentimentality versus tough mindedness, attachment versus detachment and 
dependence versus independence (Cloninger et al., 1994).    
 
Individuals who have a high degree of reward dependence may be described 
as tender-hearted, loving, warm, sensitive, dedicated, dependent, sociable, persistent, 
ambitious and sentimental.  Such people seek social contact and are open to 
communication with others, finding people they like everywhere they go.  They are 
sensitive to social cues, which facilitates warm social interactions and understanding 
other people’s feelings.  Individuals with a low degree of reward dependence may be 
described as practical, detached, tough-minded, cold, socially insensitive and 
irresolute.  Such people are content to be alone, prefer to keep their distance, rarely 
initiate communication with others and have difficulty finding something in common 
with other people.  Their views are often practical and objective (Carver & White, 
1994; Cloninger et al., 1994; Howard, Kivlahan & Walker, 1995).   
 
 In summary, Cloninger’s tridimensional model postulates there are three 
main factors of personality: harm avoidance, novelty seeking and reward dependence 
(Table 2).  Cloninger relates these factors to the dopaminergic and serotonergic 
neural pathways, which are both of interest to the current research given their well 
established links to natural reinforcers, such as illicit drugs.  In a meta-analysis of 
studies utilising the TPQ in a population of substance users, Howard, Kivlahan and 
Walker (1995) conclude that some studies indicate the three factors are 
independently associated with substance use.  In particular, individuals with a low 
degree of HA, a high degree of NS and a low degree of RD had the highest rates of 
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substance use.  However, evidence for the discriminant, convergent, concurrent and 
predictive validity of NS is much stronger than for HA and RD.   
 
Table 2  
Descriptors of High / Low Scorers on Cloninger’s Temperament Dimensions 
(Cloninger & Svrakic, 1997)  
 Descriptors of Extreme Variants 
Temperament Dimension High Low 
Harm Avoidance Pessimistic, fearful, shy, 
fatigable  
Optimistic, daring, 
outgoing, energetic 
Novelty Seeking Exploratory, impulsive, 
extravagant, irritable  
Reserved, rigid, frugal, 
stoical  
Reward Dependence Sentimental, open, warm, 
sympathetic  
Critical, aloof, detached, 
independent  
 
  
 Moreover, a large number of studies have concluded that high NS 
consistently predicts alcohol and other substance abuse and problems (see Sher, 
Bartholow & Wood, 2000).  These authors aimed to predict substance use disorders 
from the TPQ and EPQ.  Results indicted that within each personality system, traits 
that relate most clearly to disinhibition or behavioural undercontrol (i.e., TPQ-NS 
and EPQ-Psychoticism) were the most consistent predictors of substance use 
disorders, as individuals with higher baseline scores on these measures were more 
likely than their lower scoring peers to receive a substance use disorder diagnosis 
(Sher, Bartholow & Wood, 2000).   
 
 Furthermore, genetic analysis of data from 2,680 adult Australian twin pairs 
demonstrated significant genetic contributions to variation in scores on the HA, NS 
and RD scales of the TPQ, accounting for between 54% and 61% of the stable 
variation in these traits (Heath, Cloninger & Martin, 1994).   
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Personality Models: Relevance to REU and Risk-Taking 
 
 
 Four diverse theories of personality have been presented (see Table 3).  Each 
of these theories is particularly pertinent to the current discussion of risk-taking 
behaviours amongst individuals who regularly use ecstasy.  All of these theories, 
despite different theoretical foundations and language, have elements of similarity.  
In particular, two important aspects of personality are noted in each theory – which 
will be broadly referred to here as sensation seeking and conscientiousness.  The 
sensation seeking aspect relates to elements of personality that might describe a 
person as adventurous, carefree, reckless, excitement-seeking, extraverted, social, 
desiring external stimulation, risk-taking, impulsive, uninhibited, confident, novelty 
seeking, exploratory and enjoying a variety of experiences.  Of the personality 
theories presented, this overall aspect represents high scorers on Eysenck’s 
extraversion and psychoticism factors, Costa and McCrae’s extraversion and 
openness to experience factors, Gray’s BAS and Cloninger’s novelty seeking and 
reward dependence factors.     
 
 The second aspect, conscientiousness, relates to elements of personality that 
might describe a person as self-disciplined, dutiful, cautious, controlled, ruminative, 
inhibited, reflective and engaging in planned as opposed to spontaneous behaviour.  
Of the personality theories presented, this overall aspect represents high scorers on 
Eysenck and Costa and McCrae’s neuroticism factor, Costa and McCrae’s 
conscientiousness factor, Gray’s BIS and Cloninger’s harm avoidance factor.    
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 It is these two elements, sensation seeking and conscientiousness, that are of 
particular interest to the current research, due to their hypothesised implications in 
the realm of substance use and abuse, as well as engagement in additional risk-taking 
behaviours, such as driving under the influence of drugs, taking sexual risks, and the 
like.  Each of these aspects of personality and related research findings will be 
explored in the next section.    
 
Table 3 
Summary of Personality Traits Included in Eysenck, Costa and McCrae, Gray and 
Cloninger’s Models 
Trait    Description 
Eysenck     
  Extraversion  Sociable, lively, active, assertive, sensation seeking, carefree,  
   dominant, expressive, ambitious, enthusiastic, spirited 
  Neuroticism   Anxious, depressed, unhappy, guilty, tense, irrational, fearful,  
   shy, moody, emotional, inferior self-esteem    
  Psychoticism  Aggressive, egocentric, impersonal, impulsive, antisocial,  
   creative, tough-minded, nonconformists, uncooperative 
Costa & McCrae 
  Extraversion  Sociable, lively, active, assertive, sensation seeking, carefree,  
   dominant, expressive, ambitious, enthusiastic, spirited 
  Neuroticism   Anxious, depressed, unhappy, guilty, tense, irrational, fearful,  
   shy, moody, emotional, inferior self-esteem  
  Conscientiousness Organised, self-disciplined, thorough, engage in planned, non 
   spontaneous behaviour 
  Openness to  Open, imaginative, curious, enjoy a variety of experiences   
     Experience 
  Agreeableness Compassionate, cooperative, trusting, generous, friendly 
Gray 
  BIS   Anxious, sensitivity to signals of punishment / non- reward, 
   inhibiting behaviour that may lead to negative outcome 
  BAS   Hopeful, elated, happy, sensitivity to signals of reward,  
   movement towards goals, approaching rewarding experiences 
Cloninger 
  Harm Avoidance Cautious, apprehensive, fatigable, inhibited, sensitive to  
   punishment, tense, insecure, shy, pessimistic  
  Novelty Seeking Impulsive, excitable, exploratory, quick tempered, fickle,  
   extravagant, disinhibited, curious easily bored 
  Reward  Ambitious, sympathetic, warm, industrious, sentimental,        
   Dependence  persistent, dependent, dedicated, tender-hearted  
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Chapter 3: Sensation Seeking / Impulsivity 
  
 
 The concept of sensation seeking is based on the idea that different 
individuals have different optimal levels of stimulation or arousal.  Sensation seeking 
is that aspect of personality that describes a person as adventurous, risk-taking, 
impulsive, uninhibited and exploratory.  It is represented in research literature by 
many names, with each term having a slightly different focus.  For example, 
Zuckerman (1979, p.10) described sensation seeking as “the need for varied, novel, 
and complex sensations and experiences, and the willingness to take physical and 
social risks for the sake of such experiences.” Similarly, Arnett (1994, p. 290) 
considered sensation seeking as “a predisposition, a potential, which may be 
expressed in a variety of ways depending on other aspects of the individual’s 
personality and (especially) depending on how the socialization environment guides, 
shapes, or suppresses that predisposition.  Sensation seeking is not only a potential 
for taking risks, but is more generally a quality of seeking intensity and novelty in 
sensory experience, which may be expressed in multiple areas of a person’s life.” 
 
 The term impulsivity is often used interchangeably with sensation seeking.  
The definition of impulsivity, which Evenden (1999, p.348) aptly quotes as covering 
a wide range of “actions that are poorly conceived, prematurely expressed, unduly 
risky, or inappropriate to the situation and that often result in undesirable outcomes” 
is generally accepted.  However, research on this broad concept of impulsivity has 
illustrated that impulsivity is likely multi-factorial.  Monterosso and Ainslie (1999) 
concluded that the construct of impulsivity has been imprecise in the clinical 
literature, given the numerous scales, sub-scales and behavioural measures that have 
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been created to measure it.  They suggest that given the modest inter-correlations 
between many of the existing impulsivity measures, there are different underlying 
conceptions of the construct.  Similarly, Evenden (1999) believes impulsivity is the 
end result of several different, independent factors, which interact to change 
behaviour.  In what he terms “varieties of impulsivity,” Evenden (1999) postulates 
there are several related phenomena, each potentially influenced by different 
biological mechanisms, which lead to different forms of impulsive behaviour.  In a 
similar vein, Enticott and Ogloff (2006) separate impulsivity into three distinct 
levels: the individual level (i.e., who is impulsive), the expression level (i.e., the 
behavioural expression, observation, and quantification of impulsivity), and the 
causal level (i.e., the processes/ mechanisms causing the behavioural expression of 
impulsivity).   
 
In the present study, the sensation seeking / impulsivity construct will be 
regarded in accordance with Dawe and Loxton’s (2004) conceptualisation, in that 
impulsivity is viewed as a continuum of a personality trait, with two independent 
dimensions: reward sensitivity and rash-spontaneous impulsivity (Table 4).  Reward 
sensitivity refers to individual differences in attending to and approaching appetitive 
stimuli.  The underlying motivational system reflects Gray’s BAS dimension, 
theorised to be associated with activity in the mesolimbic dopamine system.  The 
reward sensitivity component is typically measured using self-report questionnaires, 
such as the BAS-Drive and BAS-Reward Responsiveness scales, and behavioural 
measures including the Card Arrangement Reward Responsiveness Objective Test 
(CARROT, Powell, Al-Adawi, Morgan & Greenwood, 1996).   
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The rash-spontaneous component of impulsivity is characterised by a 
generalised sensation seeking / impulsiveness temperament, and refers to the 
tendency to act spontaneously and with little regard for future consequences.  This 
factor is proposed to reflect individual differences in the functioning of the 
orbitofrontal cortex and the ventromedial prefrontal cortex, which are areas of the 
brain involved in impulse control and decision making (Dawe & Loxton, 2004).  
Rash-spontaneous impulsivity is typically measured by self-report questionnaires 
such as Eysenck and Eysenck’s Impulsivity Scale, Cloninger’s Novelty Seeking 
Scale, Zuckerman’s Sensation Seeking Scale and the Barrett Impulsiveness Scale.  
Behavioural measures of rash impulsivity involve tasks where participants show a 
tendency to make high risk choices that may result in a potential payoff despite 
potential losses, such as gambling tasks (Loxton, Wan, Ho, Cheung, Tam, Leung & 
Stadlin, 2008).   
 
Table 4  
Two Independent Factors of Impulsivity (Dawe & Loxton, 2004) 
Impulsivity 
Reward Sensitivity / Drive Rash-spontaneous  
A purposeful drive to obtain rewarding 
stimuli 
Measured by: 
Gray’s BAS-Drive and BAS-Reward 
Responsiveness scales 
Sensitivity to Reward (SPSRQ) 
The tendency to act rashly and without 
consideration of consequences  
Measured by: 
Eysenck Impulsiveness Scale 
Cloninger Novelty-Seeking Scale 
Zuckerman’s Sensation Seeking Scale 
Barrett Impulsiveness Scale 
Arnett Inventory of Sensation Seeking 
 
 
Dawe and Loxton’s (2004) two factor model of impulsivity has been 
confirmed by other research (e.g., Egan, 2010; Franken & Muris, 2006).  Most 
recently, Gullo, Ward, Dawe, Powell and Jackson (2011) employed structural 
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equation modelling to compare the fit of one- and two-factor models of impulsivity 
to alcohol and drug use data provided by British and Australian young adults.  
Results supported the two-factor model, with rash impulsiveness being the more 
robust predictor.   
 
Conceptualising the construct of impulsivity as having two independent 
dimensions proves powerful in the drug and alcohol field.  Historically, drug and 
alcohol research has focussed on definitions of impulsivity as behaving rash and 
spontaneously, without forethought of negative consequences.  Although true in part, 
it is also true that the acquisition and use of substances typically requires a 
significant amount of goal-directed planning.  This is evidenced in that regular 
ecstasy users anticipate the potential negative consequences arising from their use 
and take steps to eliminate these (Johnston, Barratt, Fry, Kinner, Stoové, Degenhardt, 
George, Jenkinson, Dunn & Bruno, 2005).  Therefore, a motivation to obtain and use 
rewarding substances, based in a heightened reward sensitivity drive (i.e. Gray’s 
BAS), together with rash-spontaneous impulsivity, enhance the understanding of 
substance use.  Although independent, these two factors may operate alongside one 
another, which would account for the inability to curb use (mediated by rash-
spontaneous impulsivity) once a reward-cued approach response (mediated by 
reward sensitivity) has been established (Dawe & Loxton, 2004).  Dawe and Loxton 
(2004) further hypothesise that reward sensitivity plays a role in cued-cravings and 
the motivation to use substances, but that rash-spontaneous impulsiveness influences 
actual drug-taking behaviour.   
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Furthermore, these two factors of impulsivity have paralleled developments 
in neuroscience research, where changes in the incentive value of rewarding 
substances has been linked to alterations in neural substrates involved in reward 
seeking, and with a diminished capacity to inhibit behaviour due to chronic drug 
exposure (Dawe, Gullo & Loxton, 2004).  These two components may reflect 
different underlying neural processes implicated in addictive behaviours, such that 
individuals prone to abuse drugs may have a more sensitive BAS. As a result, those 
individuals are more receptive to the reinforcing effects of drugs and other rewarding 
stimuli.  At the neurobiological level, this is reflected in the less efficient inhibitory 
dopaminergic synapses on striatal neurons believed to exist in persons with high 
BAS sensitivity (Dawe, Gullo & Loxton, 2004).  Rash-spontaneous impulsivity may 
also be a predictor of addiction proneness.  In an interesting study, Evans, Lawrence, 
Potts, Appel and Lees (2005) investigated risk factors for the development of 
dopamine dysregulation syndrome (DDS) in patients with Parkinson Disease.  
Parkinson Disease is a disorder of movement associated with the progressive 
degeneration of the dopaminergic nigrostriatal pathway.  During treatment, some 
patients’ motivation to take dopaminergic drugs becomes enhanced, and they 
subsequently develop a harmful pattern of compulsive dopaminergic drug use.  The 
sensitization of brain dopamine systems mediating reward by dopaminergic drugs is 
thought to underlie the development of DDS.  Results from this study indicated that 
novelty seeking personality traits (as measured by Cloninger’s TCI), greater past 
experimental drug use and greater alcohol intake were significant predictors of DDS.  
In their conclusions, the authors reported a clear relationship between rash-
spontaneous impulsivity and addiction proneness.  Similarly, Leyton, Boileau, 
Benkelfat, Diksic, Baker and Dagher (2002) concur in that subjects given a 
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moderately low oral dose of d-amphetamine (0.3 mg/kg) significantly increased the 
amount of extracellular dopamine in the human striatum.  This is not surprising 
given the pharmacology of this drug; however, importantly, a relatively high score 
on Novelty Seeking measures predicted greater amphetamine-induced dopamine 
release and amphetamine induced drug wanting, despite the dosage levels of these 
drugs being insufficient to directly affect mood.   
 
In conclusion, in the current thesis, the impulsivity construct will be viewed 
as having two independent factors: reward sensitivity and rash-spontaneous 
impulsivity.  In relation to the current research, Study 1 will focus only on the rash-
spontaneous factor of impulsivity and its links to risk-taking behaviours, whilst 
Study 2 focuses on both factors.   
 
Rash-Spontaneous Impulsivity and Risk-Taking 
 
 
 The rash-spontaneous factor of impulsivity has been implicated in various 
risk-taking behaviours such as alcohol and drug use, engaging in risky sex and 
driving behaviours as well as problem gambling (e.g., Bogg & Roberts, 2004; 
Loxton, Nguyen, Casey & Dawe, 2008).  In a meta-analysis of 194 studies, Bogg 
and Roberts (2004) analysed the influence of rash-spontaneous impulsivity on health 
behaviours in terms of the amount of variance explained (see Table 5).  Results 
indicated that rash-spontaneous impulsivity was a very important factor in relation to 
explaining a good portion of the variance for excessive alcohol use, drug use, risky 
driving and risky sexual practices.   
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Table 5  
Influence of rash-spontaneous impulsivity on health behaviours in terms of variance 
explained in a meta-analysis of 194 studies (Bogg & Roberts, 2004) 
 
Health 
  Behaviour 
Rash-Spontaneous 
Impulsivity 
r 
 
 
N 
Excessive alcohol use .29 32,137 
Drug use .24 36,573 
Risky driving .25 10,171 
Risky sex .15 12,410 
 
 Generally speaking, there are an abundance of research studies that indicates 
the higher a person scores on measures of rash-spontaneous impulsivity, the more 
likely they are to engage or have engaged in risk-taking behaviours.  Table 6 reviews 
the current literature and details the relationship of rash-spontaneous impulsivity 
with health-related behaviours, such as substance use and risky sex, as well as other 
risky behaviours, such as risky driving and partaking in crime, and some key studies 
are summarised in the following sections.  For ease of comparison between studies, 
Table 6 only includes studies whose statistical methods included correlation and 
related techniques.   
 
Rash-Spontaneous Impulsivity and Substance Use   
 
In general, research has shown a positive relationship between rash-
spontaneous impulsivity and substance use, in that substance users tend to score 
higher on measures of rash-spontaneous impulsivity than people who do not use 
illicit substances, and in some studies, high rash-spontaneous impulsivity scores are 
a predictor of substance use (see Table 6).  For example, Schwarz, Burkhart and 
Green (1978) found a strong, positive relationship between rash-spontaneous 
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impulsivity and alcohol use, in that alcohol consumption was strongly related to an 
individual’s stimulus-seeking needs.  In particular, the disinhibition subscale (of 
Zuckerman’s Sensation Seeking Scale; SSS) was the most powerful predictor of 
drinking behaviour.  In relation to illicit substances, Dughiero, Schifano and Forza 
(2001) compared ecstasy users to a control group made up of drug-naïve controls, 
cannabis users, and users of illicit drugs other than ecstasy on Cloninger’s TPQ.  
Results indicated that the group of ecstasy users scored significantly higher on the 
Novelty Seeking scale than the control group as a whole.  The authors concluded that 
high Novelty Seeking scores are characteristic of people who use ecstasy, and the 
propensity to look selectively for novelties could possibly act as a pre-disposing 
factor for ecstasy use itself. 
 
 In a similar study, Butler and Montgomery (2004) administered the 
Impulsiveness, Venturesomeness and Empathy Questionnaire (IVE; Eysenck, 
Pearson, Easting & Allsopp, 1985) and Cloninger’s TPQ to 254 undergraduate 
university students.  The students were grouped according to their past drug use: 
non-drug users, cannabis only users, polydrug users that had not used ecstasy, low 
polydrug ecstasy users (used ecstasy less than 20 times), and polydrug high ecstasy 
users (used ecstasy more than 20 times).  Results indicated that all 3 polydrug groups 
had higher impulsiveness, venturesomeness and novelty seeking scores than the non-
drug user group.  Furthermore, Satinder and Black (1984) investigated the 
relationship between cannabis use and rash-spontaneous impulsivity on Zuckerman’s 
SSS.  Results indicated that people who used cannabis 3 or more times per week 
scored higher on all four subscales of the SSS, with the disinhibition subscale the 
greatest differential factor between cannabis users and non-users.   
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 Recently, Loxton, Wan, Ho, Cheung, Tam, Leung and Stadlin (2008) 
investigated the relationship between personality, ecstasy and related drug use and 
high risk drug related behaviour in 360 club drug users and 303 non-drug users in 
Hong Kong.  Club drug users scored significantly higher on the Chinese version of 
Zuckerman’s SSS than non-drug users.  Rash-spontaneous impulsivity was also 
significantly associated with risky drug related behaviour, such as cross border drug 
use and polydrug use.   
 
Rash-Spontaneous Impulsivity and Sexual Risk Taking  
 
 Sexual risk-taking is influenced by multiple and complex interactions among 
various relationship, situational and dispositional factors, one of which is rash-
spontaneous impulsivity.  It is important to gain an understanding of the 
determinants of sexual risk behaviour, as these factors are essential to the effective 
implementation of HIV/AIDS prevention programs (Kalichman, Heckman & Kelly, 
1996).   
 
 In general, most research has shown a positive relationship between rash-
spontaneous impulsivity and sexual risk-taking, in that people who report sexual 
risk-taking behaviours tend to score higher on measures of rash-spontaneous 
impulsivity, and in some studies, high rash-spontaneous impulsivity scores are a 
predictor of sexual risk-taking behaviour (see Table 6).  For example, Bogaert and 
Fisher (1995) examined the role of rash-spontaneous impulsivity in predicting 215 
university men’s number of sexual partners.  Results indicated that rash-spontaneous 
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impulsivity was the greatest predictor of the number of sexual partners in lifetime, 
and the maximum number of sexual partners in one month.   
 
 Sexual risk-taking behaviours have also been investigated in drug using 
populations, who as stated previously, tend to score higher on measures of rash-
spontaneous impulsivity.  For example, McCoul and Haslam (2001) found that the 
frequency of drug use (other than alcohol) significantly correlated with the frequency 
of unprotected sex and the number of sexual partners.  Likewise, Schafer, Blanchard 
and Fals-Stewart (1994) investigated what characteristics might differentiate 
between respondents who reported using a condom in their most recent sexual 
episode with a new partner as opposed to those who did not.  Data indicated that 
individuals who used drugs (other than alcohol) and did not use condoms scored 
significantly higher on measures of rash-spontaneous impulsivity.   
 
 Results from the 2005 Party Drugs Initiative (PDI) in Tasmania (Matthews & 
Bruno, 2006) indicated that 32% of regular ecstasy users (REU) who reported having 
penetrative sex in the 6 months prior to the interview (97 out of 100 individuals 
surveyed) never used protection when having penetrative sex with a casual partner.  
Overall, 68% of the sample reported using protection during sex in general, while 
58% reported using protection while under the influence of ecstasy or related party 
drugs.   
 
 Similarly, research by Topp, Hando and Dillon (1999) on the sexual 
behaviour practices of REU in Sydney indicates about half of the sample engaged in 
penetrative sex while under the influence of ecstasy.  While intoxicated, REU tended 
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to use protective barriers less often with casual partners.  Furthermore, McElrath 
(2005) examined the relationship between taking ecstasy, sexual behaviour and 
sexual risk-taking.  Results indicated that REU who engaged in sexual behaviours 
while intoxicated tended to take greater sexual risks, such as having multiple partners 
or engaging in sex without protective barriers.   
 
 Furthermore, Breen, Degenhardt, Kenner, Bruno, Jenkinson, Matthews and 
Newman (2006) classified REU into groups according to their typical use of alcohol 
when using ecstasy (no use, consume 1 – 5 standard drinks and consume more than 5 
standard drinks, i.e., binge use).  Of the 65% of REU who reported drinking alcohol 
while taking ecstasy, 69% reported to drink more than 5 standard drinks.  These 
binge drinkers were more likely to report having had three or more sexual partners in 
the past 6 months, and were less likely to report engaging in safe sexual practices 
with casual partners while under the influence of drugs. 
 
 Comparable results have also been found in the homosexual / bisexual 
population.  Dolezal, Meyer-Bahlburg, Remien and Petkova (1997) examined rash-
spontaneous impulsivity and substance use during sex as predictors of unprotected 
insertive and receptive anal and oral sex in 117 gay men.  Results indicated that 
alcohol use, drug use and rash-spontaneous impulsivity were each significantly 
associated with all 4 sexual risk behaviour variables.  In a similar population, 
Kalichman, Heckman and Kelly (1996) found that drug use before sex, sexual 
sensation seeking and nonsexual experience seeking significantly correlated with the 
frequency of unprotected anal intercourse in homosexual and bisexual men.  The 
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direct effect of sexual sensation seeking accounted for 80% of its total association 
with unprotected anal intercourse. 
 
Rash-Spontaneous Impulsivity and Driving under the Influence  
 
 Driving whilst under the influence of alcohol and / or drugs is a complex 
area.  Undoubtedly, there are situational, dispositional and risk-perception factors 
that contribute to whether or not an individual drives under the influence.  With the 
exception of alcohol, it is important to note that there is a paucity of research with 
regards to how long one should wait after taking a substance before driving a motor 
vehicle, in terms of ensuring that driving ability is not impaired.  This, in itself, is a 
complex and grey area.  According to Akram and Forsyth (2000), the half life of a 
drug, its rate of distribution and excretion affect the concentration of the drug which 
appears in the urine or blood at any given time.  Therefore, a positive test does not 
necessarily mean that the drug is still pharmacologically active or exerting a mind-
altering affect; it only indicates that the drug (or its metabolites) are present.  
Consequently, positive detection of a drug cannot conclusively prove it is causing 
driving impairment.  However, in light of this, guidelines with regards to 
recommended waiting times before driving a motor vehicle after taking an illicit 
substance are not known to exist.   
 
     Despite the lack of a precise definition of what constitutes ‘driving under the 
influence’ in relation to illicit drugs (which, for the purposes of this thesis, consistent 
with legal definition, will be considered as driving while an illicit substance is 
present in a person’s bloodstream), research indicates that this behaviour does occur.  
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For example, results from the Australian Institute of Health and Welfare (AIHW, 
2008) household survey of 25,000 Australians aged 14 yrs and older indicated that 1 
in 8 people (12.1%) admitted to driving a motor vehicle while under the influence of 
alcohol, while 2.9% reportedly drove a motor vehicle while under the influence of 
illicit drugs.  In an internet survey of 6,801 Australian drivers by Mallick, Johnston, 
Goren and Kennedy (2007), 12.6% reported driving under the influence of alcohol, 
while 12.3% reportedly drove under the influence of cannabis and 5.8% drove under 
the influence of ecstasy in the last 12 months.  Of the drivers who drove under the 
influence of ecstasy, 37.5% drove within 3 hours of consummation.   
 
In general, most research has shown a positive relationship between rash-
spontaneous impulsivity and driving risk-taking behaviours, in that people who 
reportedly engage in driving risk-taking behaviours such as driving under the 
influence tend to score higher on measures of rash-spontaneous impulsivity, and in 
some studies, high rash-spontaneous impulsivity scores are a predictor of driving 
risk-taking behaviour, or predict a future driving under the influence conviction (see 
Table 6; Arnett, 1990; Jonah, 1997; Perez & Torrubia, 1985).  For example, Yu and 
Williford (1993) developed and administered the Risk Sensation Seeking Scale 
(RISK) to 878 people across alcoholism treatment centres, drink driver programs, 
county jails and those on probation.  Results indicated that people who scored highly 
on the RISK were more likely to have engaged in high-risk driving practices, such as 
not obeying traffic rules and driving under the influence of alcohol.   
 
 Driving risk-taking behaviours have also been investigated in drug using 
populations, who as stated previously, tend to score higher on measures of rash-
 65
spontaneous impulsivity.  Results from the Tasmanian 2005 PDI (Matthews & 
Bruno, 2006) indicated that among REU who had driven a car in the 6 months prior 
to interview (80 of the 100 interviewed), 58% reportedly drove under the influence 
of alcohol, and 55% reportedly drove within one hour of taking ecstasy or a related 
drug (predominantly ecstasy, 91%).  Of those that drove under the influence of 
ecstasy or a related drug, the average number of times in the preceding six months 
was 3.5  (range 1-24).  Additionally, in an Australian national sample of REU, 
Matthews, Bruno, Johnston, Black, Degenhardt and Dunn (2009) found that 53% of 
REU had driven under the influence of ecstasy in the preceding 6 months.   
 
 Similarly, other research on drug driving indicates a number of concerns.  A 
survey by Akram (1997) found that 62% of ecstasy and related drug users had driven 
a motor vehicle whilst under the influence of such drugs.  Furthermore, Degenhardt, 
Dillon, Duff and Ross (2004) found that 43% of a sample of nightclub attendees in 
Melbourne reported they drove under the influence of ecstasy at some time, whilst 
60% reported they had been a passenger in a car where the driver was under the 
influence of ecstasy.  In a sample of Tasmanian injecting drug users, Bruno (2006) 
found that 63% reported driving within one hour of taking non-prescribed drugs, 
predominately methamphetamine (74%) and cannabis (62%).  Additionally, Darke, 
Kelly and Ross (2004) found that 83% of a sample of injecting drug users in Sydney 
reported having driven shortly after consuming drugs, with the common drugs being 
alcohol, amphetamines, cannabis, heroin and cocaine.  Of these, 59% reported 
having been involved in a motor vehicle accident, with 32% of these accidents 
occurring while drug driving.  Among these, 15% of drivers reported they were 
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injured during their drug driving accident, while 8% reported they had injured 
someone else while drug driving.     
 
 Research evidence indicates that drugs are often detected in accident 
involved drivers (Darke, Kelly & Ross, 2004; Kelly, Darke & Ross, 2004).  
However, as stated previously, the detection of drugs does not provide conclusive 
evidence that drugs played a causal role in the accident.  However, there is 
overwhelming evidence that alcohol produces significant impairment in driving 
performance, and that the risk of having an accident increases as the driver’s BAC 
increases (see Kelly, Darke & Ross (2004) for a review).  In relation to illicit drugs, 
however, the evidence is not as clear.  For example, whilst evidence from laboratory 
studies clearly indicates that cannabis produces significant impairment in driving 
performance in a dose-related pattern, the same level of impairment is not replicated 
in cannabis driving simulator studies.  In relation to stimulants such as ecstasy and 
cocaine, research has found inconsistent results, with some studies finding evidence 
of decreased performance, some increased performance and some no effect (Headen, 
1994; Kelly, Darke & Ross, 2004).  In addition to driving under the influence of a 
single drug, significant impairment in driving performance has also been found in 
relation to polydrug use, particularly when alcohol is one of the drugs involved 
(Kelly, Darke & Ross, 2004).    
 
 Research also indicates there are other factors involved in drug driving, 
namely age and sex.  Studies have concluded that younger drivers (aged 35 and 
below) are at increased driving risk due to factors such as limited driving experience 
and a greater propensity to engage in risk-taking behaviours.  In relation to sex, the 
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majority of studies indicate that males are more likely to report drug driving, 
although some studies indicate that female drug driving is on the increase (Kelly, 
Darke & Ross, 2004).   
 
 In summary, driving under the influence of alcohol and illicit drugs 
represents a public health safety issue.  Whilst the detrimental effects of alcohol on 
driving performance is well documented, there has been inconclusive evidence 
regarding the effects of illicit substances on driving performance.  Therefore, further 
research on the effects illicit drugs have on driving performance is needed in order to 
facilitate recommended guidelines in an aim to educate illicit drug users, with a goal 
of ultimately minimising the risks to themselves and others whilst driving.   
 
 In relation to the current thesis, personality correlates of REU who drug drive 
is of interest for the many reasons outlined above.  Of particular interest is the 
relationship between rash-spontaneous impulsivity and the choice to drug drive; as 
persons who tend to act rashly without consideration of potential consequences may 
be more likely to engage in this risky behaviour.  
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Table 6  
  
Details of Impulsivity Related Studies by Health-Related Outcome  
 
Author(s) Year Subjects Impulsivity 
Measure 
Behavioural Domain  Analytical Method Result 
 
Substance Use 
 
Arnett 1994 177 adolescents and 
adults 
AISS Illicit Drug Use (other than cannabis) Correlation 0.23* 
Greene et al 2000 724 male and female 
11 – 25 year olds 
SSS: DIS Illicit drug use in past 90 days Correlation 0.49** 
Kohn & 
Coulas 
1985 78 university 
students 
SSS Total 
SSS DIS 
Use of cannabis Correlation 0.19* 
0.37** 
Ripa et al 2001 691 males / females SSS (Danish) Use cannabis 
Use other illicit drugs 
Correlation 0.32*** 
0.20*** 
Vanzile et al 2006 1014 women ZKPQ Illicit drug use Confirmatory factor 
analysis 
0.37 
 
Sexual Risk 
 
Arnett 1994 116 male and female 
adolescents 
AISS 
SSS 
AISS 
SSS 
Sex without contraception  
 
Sex with someone not known well 
Correlation 0.02 
- 0.11 
0.28* 
0.01 
Arnett 1994 177 male and female 
adolescents and 
adults 
AISS Sex without contraception 
Sex with someone not known well 
Correlation 0.14 
0.30** 
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Author(s) Year Subjects Impulsivity 
Measure 
Behavioural Domain  Analytical Method Result 
Cooper et al 2000 1,666 male and 
female young adults 
EIS Condom use 
Risky sex (e.g., one-night stands, 
prostitution) 
Path analysis  
(total effect) 
-0.105*  
0.003  
Greene et al 2000 724 male and female 
11 – 25 year olds 
SSS: DIS Risky sex (number of sexual partners 
and use of protective measures) 
Correlation 0.25** 
Justus et al 2000 410 young adults SSS: DIS & BS Risky sex (one night stands or sex 
with a stranger) 
SEM 0.50** 
Kalichman 
et al  
1996 99 homosexual and 
bisexually active 
men 
 
Drug use before 
sex 
Sexual SSS  
NESS 
Unprotected anal intercourse 
 
Correlation 
 
 
 
0.26** 
 
0.27**  
0.28** 
Kalichman 
& Rompa 
1995 296 homosexual 
men 
 
 
 
 
 
 
 
 
158 heterosexual 
men and women 
Sexual SSS 
 
 
 
NESS 
 
 
 
 
 
Sexual SSS 
NESS 
Insertive anal intercourse without 
condom 
Receptive anal intercourse without 
condom 
Insertive anal intercourse without 
condom 
Receptive anal intercourse without 
condom 
 
 
Vaginal intercourse without condom 
Vaginal intercourse without condom 
Correlation 0.25** 
 
0.25** 
 
0.21** 
 
0.22* 
 
 
 
0.38** 
0.29** 
McCoul & 
Haslam 
2001 112 heterosexual 
men 
EIS 
 
Sexual SSS 
Frequency of unprotected sex 
Number of partners 
Correlation 0.27** 
0.17 
0.21* 
0.45*** 
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Author(s) Year Subjects Impulsivity 
Measure 
Behavioural Domain  Analytical Method Result 
McCoul & 
Haslam 
2001 104 homosexual 
men 
EIS 
 
Sexual SSS 
Frequency of unprotected sex 
Number of partners 
Correlation -0.13 
0.12 
0.03 
0.03 
Ripa et al 2001 691 males and 
females 
SSS (Danish 
translation) 
Risky sexual behaviour 
Extramarital intercourse 
Sexually transmitted diseases 
Correlation 0.18*** 
0.30*** 
0.20*** 
Vanzile et al 2006 1014 women ZKPQ Risky sexual behaviour Confirmatory factor 
analysis 
0.22 
 
Driving Risk – Alcohol  
 
Arnett et al 1997 139 male and female 
adolescents 
AISS DUI alcohol  Correlation 0.23* 
Arnett 1994 116 male and female 
adolescents 
AISS 
SSS 
DUI alcohol  Correlation 0.39** 
0.24* 
Arnett 1994 177 male and female 
adolescents (139)  
and adults (38) 
AISS DUI alcohol  Correlation 0.24* 
Greene et al  2000 724 male and female 
11 – 25 year old 
SSS: DIS DUI alcohol in the past year, or rode 
in car with drunk driver in past year 
Correlation 0.48** 
Little & 
Robinson 
1989 115 convicted DWIs 
in prison 
10 item SSS DWI recidivism Correlation 0.15 
Ripa et al. 2001 691 males and 
females 
SSS (Danish 
translation) 
DUI alcohol Correlation 0.19*** 
Stacy et al. 1991 614 men and women SSS DUI alcohol  SEM 0.25*** 
(males only) 
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Author(s) Year Subjects Impulsivity 
Measure 
Behavioural Domain  Analytical Method Result 
 
Driving Risk – Drugs 
 
Ames et al 2002 166 drug offenders 
in drug diversion 
program 
SS and 
Impulsivity Scale 
of ZKPQ 
DUI cannabis SEM 0.31* 
 
Other Risk-Taking Behaviours 
 
Arnett 1994 116 male and female 
adolescents 
AISS 
 
 
SSS 
Vandalism 
Theft worth < $50 
Theft worth > $50 
Correlation 0.38** 
0.51** 
0.31** 
0.05 
0.09 
0.01 
Arnett 1994 177 male and female 
adolescents (139)  
and adults (38) 
AISS Vandalism 
Shoplifting 
Theft worth > $50 
Correlation 0.33** 
0.19 
0.05 
Horvath & 
Zuckerman 
1993 447 university 
students 
SSS Crime risk (arrest for selling / buying 
drugs, shoplifting, DUI alcohol, 
perjury, forging cheques, vandalism) 
Multiple regression 
SEM 
0.27 
 
0.53*** 
 
Note. AISS = Arnett Inventory of Sensation Seeking; DUI = Driving under the influence; DWI = Driving while intoxicated; EIS = Eysenck Impulsivity Scale; 
NESS = Nonsexual Experience Seeking Scale; SEM = Structural Equation Modelling; SSS = Sensation Seeking Scale, of which there are four subscales: Thrill and 
Adventure Seeking (TAS), Disinhibition (Dis), Experience Seeking (ES) and Boredom Susceptibility (BS); ZKPQ = Zuckerman – Kuhlman Personality 
Questionnaire 
* p < 0.05, ** p < 0.01, *** p < 0.001
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Chapter 4: Conscientiousness 
 
 The second factor of interest in the current research is the personality variable 
of conscientiousness.  Conscientiousness refers to individual differences in the 
tendency to follow socially prescribed norms for impulse control, to be task oriented, 
to be goal (achievement) directed, to be well planned, to delay gratification and to 
generally follow norms and rules (Bogg & Roberts, 2004).  Conscientiousness is one 
of the five domains in Costa and McCrae’s Five Factor Model, as discussed 
previously, and is represented in various factors of other previously presented 
personality models.   
 
 Factor analysis research has indicated the broad characteristic of 
conscientiousness may be broken down into the 6 lower order facets of 
industriousness, order, responsibility, self-control, traditionalism and virtue (see 
Table 7).  These lower order facets of conscientiousness are important, as they are 
believed to measure different aspects of conscientiousness, and therefore may 
provide better predictions of behavioural outcomes than the overall composite 
measure (Roberts, Bogg, Walton, Chernyshenko & Stark, 2004).  This model of 
conscientiousness has been confirmed by other research (e.g., Roberts, 
Chernyshenko, Stark & Goldberg, 2005; Costa & McCrae, 1998).   
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Table 7 
Facets of Conscientiousness (Bogg & Roberts, 2004) 
Conscientiousness Facet Description of High Scorers  
Industriousness High levels of achievement and persistence, hard 
working, ambitious, confident, resourceful 
Order Well organised, efficient, regimented, good ability to 
plan 
Responsibility Reliable, dependable, like to be of service to others, 
frequently contribute time and money to community 
projects, cooperative  
Self-control Tendency to inhibit impulsive thoughts, feelings and 
behaviours, cautious, level-headed, able to delay 
gratification 
Traditionalism  High levels of conventionality and norm adherence, 
dislike change, do not challenge authority  
Virtue Adherence to a strong moral grounding, act in 
accordance with accepted rules of good moral 
behaviour 
  
  
 Several assessments have been developed to measure the overall construct of 
conscientiousness.  However, as Roberts, Chernyshenko, Stark and Goldberg (2005) 
point out, no one personality measure actually measures all six lower order facets.  
Therefore, multiple scales must be employed if all six facets are to be measured.  
Table 8 below details the major personality measures in terms of the lower order 
facets they assess. 
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Table 8 
Major Personality Measures Coded for the Six Lower Order Conscientiousness 
Facets (Bogg & Roberts, 2004) 
Facet of Conscientiousness Assessed by: 
Industriousness  CPI: Achievement via Conformance 
MPQ: Achievement  
Order 16PF: Control, Self-Disciplined 
HPI: Prudence: Mastery 
NEO-FFI, NEO-PI, NEO-PI-R: Conscientiousness 
TPQ: Disorderly/regimented, order 
Responsibility CPI: Conformity, Responsibility, Socialization  
EPQ: Psychoticism  
HPI: Prudence 
JPI: Responsbility  
Self-Control BIS 
CPI: Impulsivity  
EIS 
HPI: Prudence 
SSS: Disinhibition  
TPQ: Novelty Seeking  
Traditionalism  16PF: Conforming  
JPI: Conformity  
MPQ: Traditionalism  
Virtue CPI: Self-control 
HPI: Prudence  
 
Note.  16PF = 16 Personality Factor Questionnaire; BIS = Barrett Impulsivity Scale; CPI = California 
Psychological Inventory; EIS = Eysenck Impulsiveness Scale; EPQ = Eysenck Personality 
Questionnaire; HPI = Hogan Personality Inventory; JPI: Jackson Personality Inventory; MPQ = 
Multidimensional Personality Questionnaire; NEO-FFI = NEO-Five-Factor Inventory; NEO-PI = 
NEO-Personality Inventory; NEO-PI-R = NEO-Personality Inventory-Revised; SSS = Sensation 
Seeking Scale; TPQ = Tridimensional Personality Questionnaire 
 
 
 According to a meta-analysis of 194 studies by Bogg and Roberts (2004), the 
responsibility facet appears to be most closely linked to risk-taking behaviours.  
Research on the responsibility facet of conscientiousness reveals that low levels of 
responsibility have been associated with relationship infidelity and sexual 
promiscuity (Schmitt, 2004), along with substance use / abuse and antisocial 
behaviour (Lynam, Leukefeld & Clayton, 2003).  In addition, the responsibility facet 
of conscientiousness has been shown to be a negative predictor of drug use and 
 75
traffic risk (Roberts et al., 2005).  In their meta-analysis, Bogg and Roberts (2004) 
examined the relationship between the responsibility facet of conscientiousness and 
health-related behaviours (Table 9).  Results indicated that responsibility played a 
large part in the variance of determining health-related behaviours; these behaviours 
are described in more detail in the following sections.   
 
Table 9 
Influence of conscientiousness on risky health behaviours  
 
Health 
Behaviour 
Conscientiousness 
(Responsibility) 
  r 
 
 
N 
Excessive alcohol use -.18 32,137 
Drug use -.32 36,573 
Risky driving -.16 10,171 
Risky sex -.12 12,410 
 
Conscientiousness and Substance Use 
 
In general, research has shown a negative relationship between 
conscientiousness and substance use, in that substance users tend to score lower on 
measures of conscientiousness than people who do not use illicit substances (see 
Table 10).  For example, research has indicated lower scores on conscientiousness 
measures is significantly associated with cannabis use, stimulant use and the use of 
hallucinogens and opiates (e.g., Block, Block & Keyes, 1988; Hindelang, 1972).  
Furthermore, results of some studies indicate that low scores on conscientiousness 
measures have predicted alcohol and substance use disorders, and have distinguished 
between groups of users and non-users (see Table 10; e.g., Flory, Lynam, Milich, 
Leukefeld & Clayton, 2002; McGue, Slutske & Iacono, 1999).    
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Conscientiousness and Sexual Risk-Taking 
 
 
 In general, research has shown a negative relationship between 
conscientiousness and sexual risk-taking, in that people who reportedly engage in 
sexual risk-taking behaviours tend to score lower on measures of conscientiousness 
than people who do not engage in risky sexual behaviours (see Table 10).  For 
example, research has indicated that conscientiousness is significantly negatively 
associated with engaging in promiscuous sexual activity, having sex with a stranger 
and having unprotected sex with a new sexual partner (e.g., Hindeland, 1972; 
Vollrath, Knoch & Cassano, 1999).   
 
Conscientiousness and Driving under the Influence  
 
 Generally speaking, research has shown a negative relationship between 
conscientiousness and driving under the influence of alcohol.  For example, research 
has shown that individuals who reportedly drink drive tend to score lower on 
measures of conscientiousness than people who do not drink drive (see Table 10; 
Hindelang, 1972; Vollrath, Knoch & Cassano, 1999).  No research was found in 
relation to the direct relationship between conscientiousness and driving under the 
influence of illicit drugs.  However, the Bogg and Roberts (2004) meta-analysis (see 
Table 9) revealed inverse relationships between conscientiousness, drug use, and 
risky driving; therefore, it could be inferred from this meta-analysis that 
conscientiousness is likely to also be related to driving under the influence of illicit 
drugs in a negative fashion.  
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Table 10  
 
Details of Conscientiousness Related Studies by Health-Related Outcome  
 
Author(s) Year Subjects Conscientiousness Measure Behavioural Domain  Analytical  
Method 
Result 
 
Alcohol and Substance Use 
 
Block et al 1988 54 adolescent 
girls 
CAQ: Is fastidious 
 
CAQ: Favours conservative values 
 
CAQ: Behaves sympathetic manner 
CAQ: Judges self and others in 
conventional terms 
CAQ: High aspiration level for self 
Cannabis Use 
Stimulant / Opiate Use 
Cannabis Use 
Stimulant / Opiate Use 
Stimulant / Opiate Use 
Cannabis Use 
Stimulant / Opiate Use 
Cannabis Use 
Stimulant / Opiate Use 
Correlation -0.44** 
-0.58*** 
-0.62*** 
-0.66*** 
-0.27* 
-0.30* 
-0.40** 
-0.31* 
-0.30* 
Block et al  1988 51 adolescent 
boys 
CAQ: Is dependable 
 
CAQ: Favours conservative values 
 
CAQ: Behaves sympathetic manner 
CAQ: Is moralistic 
 
CAQ: Judges self and others in 
conventional terms 
CAQ: High aspiration level for self 
Cannabis Use 
Stimulant / Opiate Use 
Cannabis Use 
Stimulant / Opiate Use 
Stimulant / Opiate Use 
Cannabis Use 
Stimulant / Opiate Use 
Cannabis Use 
Stimulant / Opiate Use 
Cannabis Use 
Stimulant / Opiate Use 
Correlation -0.25 
-0.42** 
-0.54*** 
-0.54*** 
-0.35* 
-0.46*** 
-0.41** 
0.20 
-0.31* 
-0.38** 
-0.39** 
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Author(s) Year Subjects Conscientiousness Measure Behavioural Domain  Analytical  
Method 
Result 
Cook et al 1998 891 men and 
women 
CPI: Responsibility 
CPI: Socialization  
CPI: Self-control 
Units of alcohol 
consumed 
Correlation 0.06 
-0.12** 
-0.11** 
Flory et al  2002 481 men and 
women 
NEO-PI-R: Conscientiousness DSM Diagnosis of 
alcohol dependence  
Cannabis abuse / 
dependence 
Alcohol dependence 
Cannabis dependence  
Correlation 
 
 
Hierarchical 
Regression 
Analysis  
-0.26** 
 
-0.23** 
 
-0.23** 
0.12* 
Hindelang 1972 337 adolescents CPI: Responsibility  Using cannabis  
Sniffing glue 
Using LSD, methedrine / 
mescaline  
Using heroin  
Correlation -0.36** 
-0.16** 
-0.23** 
 
-0.13* 
Pfefferbaum & 
Woods 
1994 296 university 
students 
CPI: Self-control 
CPI: Socialization  
Use of tobacco, alcohol, 
cannabis and/or harder 
drugs in the last 4 wks 
Correlation -0.32** 
-0.44** 
Roberts & Bogg 2004 99 women CPI Combined score on 
Responsibility, Self-control, 
Socialization, & Achievement via 
Conformance subscales at age 21 
and 43 
Prediction of alcohol use 
at age 43 
Prediction of cannabis 
use at age 43 
Path 
coefficient 
0.26* 
-0.28* 
Roberts et al 2005 197 men and 
women  
Combined responsibility measures Drug use Correlation  -.24* 
Shoal & 
Giancola 
2003 311 adolescent 
boys 
MPQ: Constraint Frequency of substance 
use 
Substance use problems 
Correlation -0.33** 
-0.23** 
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Author(s) Year Subjects Conscientiousness Measure Behavioural Domain  Analytical  
Method 
Result 
 
Sexual Risk 
 
Hindelang 1972 337 adolescents CPI: Responsibility Engaging in promiscuous 
sexual activity  
 
Correlation -0.14** 
Vollrath et al 1999 683 male and 
female 
university 
students 
NEO-FFI: Conscientiousness Risky sexual behaviour 
(having sex with person one 
just met for the first time; 
having unprotected sex with 
new sexual partner) 
Correlation -.12** 
 
Driving Risk – Alcohol & Drugs 
 
Hindelang 1972 337 adolescents CPI: Responsibility DUI alcohol or drugs 
 
Correlation -0.18** 
Vollrath et al 1999 683 male and 
female 
university 
students 
NEO-FFI: Conscientiousness Drunk Driving Correlation -.05  
 
Crime Risk 
 
Hindelang 1972 337 adolescents CPI: Responsibility  Theft greater than $10  
Property destruction causing 
more than $10 damage  
 
Correlation -0.27** 
-0.32** 
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Author(s) Year Subjects Conscientiousness Measure Behavioural Domain  Analytical  
Method 
Result 
Pfefferbaum & 
Woods 
1994 296 university 
students 
CPI: Self-control 
CPI: Socialization 
Theft, shoplifting, stealing car 
or something out of a car, 
vandalism, setting fire to 
property, damaging property 
Correlation -0.33*** 
-0.25** 
 
Note.  CAQ = California Q-set; CPI = California Psychological Inventory; MPQ = Multidimensional Personality Questionnaire; NEO-FFI = NEO-Five-Factor 
Inventory; NEO-PI-R = NEO-Personality Inventory – Revised 
* p < 0.05, ** p < 0.01, *** p < 0.001 
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Chapter 5: Rash-Spontaneous Impulsivity and Conscientiousness –  
One Trait or Two? 
 
 
  All personality traits may be viewed on a continuum, in that the behavioural, 
outward expression of particular traits may be classified as ‘high,’ ‘moderate’ or 
‘low.’ The personality traits at the focus of the current research, rash-spontaneous 
impulsivity and conscientiousness, could, and have been, viewed as opposite ends of 
the continuum of a single trait.  This is particularly evident in research involving 
conscientiousness, in that it is often measured by impulsivity related scales; for 
example, in Bogg and Robert’s (1994) meta-analysis, numerous studies 
conceptualised conscientiousness as negative scores on various sensation seeking 
and impulsivity scales.  Furthermore, self-control, or the lack thereof, which is a 
manifestation of impulsiveness, has been identified as a lower order facet of 
conscientiousness.   
 
 Therefore, it is evident that these two aspects of personality are certainly 
related, and by definition, people high in conscientiousness are likely to be low in 
rash-spontaneous impulsivity in any given particular area.  However, these may not 
be perfect reflections of each other, and as such, the current research chooses to view 
these two personality factors as constructs in separate domains, given that the 
construct of impulsivity appears to have strong brain and neurological links 
underpinning its outward expression.    
 
 82
Chapter 6: The Role of Demographic Factors on Risk-Taking Behaviours 
 
 
 In addition to personality factors and attitudes, there are other factors that are 
known to be related to risk-taking behaviour.  Research has shown that scores on 
measures of rash-spontaneous impulsivity decline steadily with age from 
approximately 16 onwards (Zuckerman, Eysenck & Eysenck, 1978), whilst scores on 
measures of conscientiousness related traits tend to increase with age (Bogg & 
Roberts, 2004).  Therefore, one would expect that adolescents and young adults 
would be more likely than older people to engage in risky behaviour.  Additionally, 
research has indicated that in general, males tend to engage in more risk-taking 
behaviours than their female counterparts (e.g., Arnett, 1990; Zuckerman, Eysenck & 
Eysenck, 1978).  Therefore, one would expect that more males than females will be 
represented in terms of engaging in high risk behaviours.  In general, there are have 
been numerous studies (e.g., Arnett, 1994; Kelly, Darke & Ross, 2004; Nordfjærn, 
Jørgensen & Rundmo, 2010) that have shown younger males tend to engage in risk-
taking behaviours more frequently.   
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Chapter 7: Study 1 Research Aims and Hypotheses 
 
 
 In summary, previous research on personality has shown that high levels of 
rash-spontaneous impulsivity is associated with engagement in various health-related 
risk-taking behaviours, whilst high levels of conscientiousness appears to be a 
protective factor in relation to engagement in health-related risky behaviours.   
  
 Study 1 was an initial exploratory study that aimed to investigate the extent 
to which the personality traits of rash-spontaneous impulsivity and conscientiousness 
(responsibility facet) contribute to risk-taking behaviours in a sample of regular 
ecstasy users.  This study followed on from a study conducted by Dr. Allison 
Matthews in her work with the Tasmanian Party Drugs Initiative (PDI) in 2005, and 
utilised data collected as part of the 2006 Hobart PDI (now known as the Ecstasy and 
Related Drugs Reporting System, EDRS).  This study further investigated key results 
from the 2005 PDI study, namely the prevalence of sexual risk-taking and drug 
driving, and its association with the personality factors of impulsivity and 
conscientiousness.  This research aimed to examine if one or both of these 
personality factors were able to differentiate and potentially predict between those 
REU who engaged in risk-taking behaviours versus those REU who did not, with a 
view to better targeting harm reduction information.   
 
 In light of past research, the rash-spontaneous factor of impulsivity was 
expected to positively correlate with risk-taking behaviours.  It was further expected 
that this factor would be predictive of REU who engaged in risk-taking behaviours in 
contrast to their non risk-taking REU counterparts in a positive fashion.  In relation 
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to conscientiousness, the responsibility facet was expected to negatively correlate 
with risk-taking behaviours.  It was further expected that this factor would be 
predictive of REU who engaged in risk-taking behaviours in contrast to their non 
risk-taking REU counterparts in a negative fashion.  It was also expected that more 
males than females would engage in risk-taking behaviours, and that younger REU 
would engage in more risk-taking behaviours than older REU.    
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Chapter 8: Study 1 Method 
 
Party Drugs Initiative (PDI) 
 
The PDI was a companion project to the Illicit Drug Reporting System 
(IDRS), which has been conducted annually in every state and territory of Australia 
since 1999.  The PDI aimed to study trends in the use, price, purity and availability 
of ecstasy (methylenedioxymethamphetamine or MDMA) and related drugs (ERD), 
including methamphetamine, cocaine, lysergic acid diethylamide (LSD), ketamine, 
methylelenedioxyamphetamine (MDA) and gamma hydroxybutyrate (GHB).  In 
addition, the PDI examined the nature and incidence of risk behaviours, health 
related harms associated with ecstasy and related drug (ERD) use and where possible 
identified issues relevant to the development of harm reduction strategies.  The PDI 
was funded nationally by the Australian Government Department of Health and 
Ageing (Matthews & Bruno, 2006). 
 
Participants 
 
Participants included 200 regular ecstasy users (REU) who participated in the 
2005 and 2006 PDI data collection in Hobart, Tasmania.  Inclusion criteria for the 
PDI study included at minimum monthly use of ecstasy in the preceding 6 months 
before interview, and having resided in the greater Hobart area for the preceding 12 
months before interview.  Demographic characteristics of the sample are reported in 
Table 11. 
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Table 11 
Demographic characteristics of participants  
N = 200 % 
Mean age 24.3 (SD = 4.99) 
Male 56.5 
Employed full time 37.0 
Full-time student 31.5 
Employed part-time / casual 20.0 
Unemployed 9.5 
Marital status: single 51.5 
Marital status: regular partner 38.5 
Marital status: married / de facto 9.5 
Live in rented house / flat  72.0 
Live with parents or in family home 23.0 
Completed Year 12 83.5 
Completed post Year 12 courses (trade/technical/university) 49.0 
Heterosexual 92.0 
Bi-sexual 5.5 
 
 
Ecstasy was the main drug of choice for 55.5% of the sample, followed by 
13.0% preferring alcohol, 10.0% preferring cannabis and 8.5% preferring cocaine.  
The majority of the sample had never injected any drug (81.5%).  Tables 12 and 13 
detail the sample’s ecstasy use history and patterns of other drug use, respectively.   
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Table 12 
Participants’ ecstasy use history 
Mean age of first use 19.8 (SD = 4.12) 
Mean number of ecstasy tablets usually taken 2.1 (SD = 1.04) 
Main route of administration:  
     Swallowing 
     Snorting 
     Injecting 
 
93.5% 
3.5% 
1.0% 
Mean number of days used ecstasy in the last 6 months 17.8 (SD = 12.71) 
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Table 13 
 
Participants’ patterns of lifetime and recent use of other drugs 
 
Drug % Ever 
Used 
% Used 
Last 6 
Months 
Mean No. Days Used 
Last 6 Months 
Methamphetamine powder 86.0 69.5 7.32 (SD = 11.74) 
Methamphetamine base 42.0 31.5 14.71 (SD = 29.60) 
Crystal methamphetamine 35.5 18.5 9.84 (SD = 13.19) 
Pharmaceutical stimulants 47.0 14.0 8.43 (SD = 14.06) 
Cocaine 49.0 26.5 2.32 (SD = 1.52) 
LSD (lysergic acid diethylamide) 53.0 30.0 3.68 (SD = 3.91) 
MDA (methylelenedioxyamphetamine) 11.0 3.0 1.33 (SD = 0.52) 
Ketamine 23.5 8.5 2.41 (SD = 1.37) 
GHB (gamma hydroxybutyrate) 8.0 2.5 4.20 (SD = 5.50) 
Amyl Nitrate 45.0 13.0 4.58 (SD = 4.37) 
Nitrous Oxide 69.0 40.0 6.91 (SD = 7.91) 
Cannabis 100.0 85.5 64.20 (SD = 70.94) 
Alcohol 100.0 96.5 66.03 (SD = 46.28) 
Heroin 9.0 1.0 6.50 (SD = 4.95) 
Methadone 7.0 3.0 67.83 (SD = 87.38) 
Buprenorphine 2.5 1.5 62.33 (SD = 101.93) 
Other Opiates 25.0 11.5 17.65 (SD = 29.78) 
Benzodiazepines 44.0 29.0 11.79 (SD = 26.67) 
Mushrooms 68.5 47.5 3.89 (SD = 3.28) 
Anti-depressants 20.5 10.5 93.24 (SD = 86.88) 
Tobacco  91.5 82.0 134.46 (SD = 67.31) 
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Procedure 
 
 
Participants were recruited through posters and flyers distributed in the 
greater Hobart area (cafes, bars, nightclubs, clothing and music stores, university, 
youth services and hairdressers), internet forums (www.pillreports.com, 
www.freshdisko.com, and www.digitalthugz.com) and snowballing (Matthews & 
Bruno, 2006).  Snowball sampling (Goodman, 1961) is a method that aims to recruit 
new respondents through introductions from initial contact persons.  Snowball 
sampling methods are especially useful when researching hidden populations in 
which there are no useable sampling frames, such as in drug using populations that 
remain outside of treatment systems (Eland-Goossensen, van de Goor, Vollemans, 
Hendriks & Garretsen, 1997).   
 
Interested participants contacted the researchers through voicemail, email or 
SMS to leave their contact details.  Participants were then contacted by one of the 
PDI interviewers and asked a series of questions to determine if the participant met 
eligibility criteria.  Eligible participants were then provided with verbal information 
about the study, the interview content and process and the confidentiality and 
anonymity of the information that they may provide.  Once the participant gave their 
informal consent to participate, arrangements were made to meet with the PDI 
interviewer at an agreed time and location.   
 
Prior to commencing the PDI interview, participants were given further 
detailed information about the PDI through a written information sheet.  Participants 
were informed that the information they gave was strictly confidential, that they 
could not be personally identified in any way and that they were free to fully 
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withdraw at any time or decline to answer any questions.  Participants then signed a 
consent form to indicate they had read and understood the information given to them, 
and that their questions had been answered to their satisfaction.  Interviews took 
approximately 45 to 60 minutes and participants were reimbursed $30 for their time 
and expenses (Matthews & Bruno, 2006).   
 
Interviewers for the PDI included the Author in addition to research staff 
within the School of Psychology at the University of Tasmania.  Each interviewer 
was trained in the administration of PDI interviews and followed a standardised 
manual for interviews, provided by the National Drug and Alcohol Research Centre.   
 
Materials 
 
PDI Questionnaire 
 
The PDI questionnaire was a structured interview that assessed demographic 
information, patterns of ERD use (including frequency, quantity, and routes of 
administration), the price, purity and availability of ERD, perceived benefits and 
risks associated with ERD use, symptoms of dependence, risk-taking behaviours 
(including injecting drug use, overdose, driving and safe sex), other problems 
associated with ERD use (e.g., work / study, financial, social and legal problems), 
self-reported criminal activity and general trends in party drug markets (Matthews & 
Bruno, 2006).  A copy of the PDI questionnaire is included in Appendix A.   
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Arnett Inventory of Sensation Seeking (AISS)  
 
The Arnett Inventory of Sensation Seeking (AISS) (Arnett, 1994) was 
included as part of the PDI questionnaire in 2005 and 2006, which participants were 
encouraged to self-complete.  The AISS is a self-report measure that emphasises 
novelty (the quest for new, different and spontaneous experiences) and intensity (the 
desire for intense sensory experiences) as the two main components of sensation 
seeking.  Novelty and intensity partially align with Dawe and Loxton’s (2004) 
conceptualisation of rash-spontaneous impulsivity; however, despite not being a 
perfect match, due to the similarity between definitions of sensation seeking and 
impulsivity, parallels may be drawn.   
 
The AISS consists of 20 statements, which participants rate as to how well 
the statement describes them on a scale ranging from ‘describes me very well’ to 
‘does not describe me at all.’ Statements on the AISS include ‘When taking a trip, I 
think it is best to make as few plans as possible and just take it as it comes; I would 
never like to gamble with money, even if I could afford it; and, ‘I like the feeling of 
standing next to the edge of a high place and looking down.’  Statements on the 
AISS purposefully do not include risky or illegal behaviours; rather, the statements 
depict a wide range of behaviours in which the participant’s desire for novelty and 
intensity of sensory experience may be expressed.    
 
 The AISS is scored on a 4-point scale, with some statements scored in 
reverse.  A total score, as well as an intensity and novelty subscale score, is obtained 
by appropriate summation of individual questions.  Higher AISS scores are 
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indicative of higher degrees of sensation seeking, on a continuum rather than 
categorical nature.   
 
The AISS has been validated in adolescent and adult populations.  The 
novelty and intensity scales correlate at 0.41, with an internal reliability (Cronbach 
alpha) of 0.70 for the entire scale.  Males have been found to consistently score 
higher on the AISS than females, and adolescents have been found to score 
consistently higher than adults (Arnett, 1994).     
 
International Personality Item Pool Responsibility Scale (IPIP: Re) 
 
The International Personality Item Pool (IPIP) (Goldberg, Johnson, Eber, 
Hogan, Ashton, Cloninger & Gough, 2006) is a web-based, scientific collaboratory 
that provides access to measures of personality and individual differences in the 
public domain.  The IPIP website and scales are developed conjointly amongst 
scientists worldwide.  Included in only one year of data collection, the PDI (2006), 
was the IPIP scale of responsibility, which is based on the responsibility subscale of 
the California Psychological Inventory (CPI) (Gough & Bradley, 1996).  The domain 
of responsibility, as discussed in previous sections, is a facet of the trait of 
conscientiousness.  Participants were again encouraged to self-complete this 
assessment.   
 
The CPI, on which the IPIP: Re scale is based, is a self-report inventory 
concerned with normal aspects of personality, in that it was designed to evaluate 
interpersonal behaviour and social interaction within normal individuals.  The IPIP: 
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Re scale consists of 10 statements that describe people’s behaviour, such as ‘I return 
extra change with a cashier makes a mistake; I like to be of service to others; and, I 
take others’ interests into account.’  Participants were asked to use a rating scale to 
indicate how accurately each statement described them, ranging from ‘very 
inaccurate’ to ‘very accurate.’ Each statement is scored on a 5-point scale, with nine 
statements scored positively and 1 statement reversed scored.  A total score is 
obtained by appropriate summation of individual statements.  Higher scores are 
indicative of higher levels of conscientiousness (responsibility facet) related 
behaviour, on a continuum rather than categorical basis.   
 
The reliability of the IPIP: Re scale is moderate (α = .66) (Goldberg et al., 
2006).  The CPI has been used and validated in community samples as well as in 
illicit drug user populations (e.g., Bogg & Roberts, 2004; Roberts, Chernyshenko, 
Stark & Goldberg, 2005).   
 
Alcohol Use Disorders Identification Test (AUDIT) 
 
The AUDIT (Babor, de la Fuente, Saunders & Grant, 2001) was developed 
by the World Health Organization as a simple self-report method to screen for 
hazardous and harmful patterns of alcohol consumption, as well as symptoms of 
alcohol dependence.  The AUDIT was developed and evaluated over two decades, 
and has been found to provide an accurate measure of alcohol-related risk across 
gender, age and cultures.   
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The AUDIT consists of 10 questions that may be administered orally or 
through written self-report.  The AUDIT assesses recent alcohol use, alcohol 
dependence symptoms and alcohol related problems.  The AUDIT includes questions 
such as: ‘How often do you have a drink containing alcohol?  How often do you have 
six or more drinks on one occasion?  How often during the last year have you failed 
to do what was normally expected from you because of drinking?  Have you or 
someone else been injured as a result of your drinking?  Has a relative or a friend or 
a doctor or a another health worker been concerned about your drinking or 
suggested you cut down?’ 
 
Each question is scored on a 5-point scale, with scores ranging from 0 to 4.  
The scores from each question are then summed appropriately to provide an overall 
score.  A cut-off point of 8 is recommended to indicate hazardous and harmful 
alcohol use.  Scores between 8 – 15 indicate a medium level of alcohol problems, a 
score of 16 and above represents a high level of alcohol problems, and scores of 20 
and above are recommended for further diagnostic evaluation for alcohol 
dependence.   
 
Many large studies have been conducted to evaluate the validity, reliability, 
sensitivity and specificity of the AUDIT in various clinical and community samples, 
including samples of illicit drug users, all of which have indicated the AUDIT as the 
best international screening test (e.g., Skipsey, Burelson & Kranzler, 1997).  Since 
the AUDIT was first published in 1989, its reliability and validity has been 
established in research conducted in a variety of settings in many different countries, 
and has been translated into many languages.   
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Severity of Dependence Scale (SDS) 
 
The SDS (Gossop, Darke, Griffiths, Hando, Powis, Hall & Strang, 1995) is a 
short and easily administered scale that takes less than 1 minute to complete.  The 
SDS contains 5 items which are used to measure the degree of dependence 
experienced by users of different types of illicit drugs.  Items are concerned with the 
individual’s feelings of impaired control over their drug taking, and with the 
individual’s preoccupation and anxieties about their drug taking.  Sample questions 
include: ‘During the past year…Did you think your use of (drug) was out of control?  
Did you worry about your use of (drug)?  How difficult would you find it to stop or 
go without (drug)?’   
 
Each SDS item is scored on 4-point scale, ranging from 0 to 3.  A total SDS 
score is obtained by appropriate summation of the individual items.  Higher SDS 
scores are indicative of higher levels of dependence on a continuum rather than 
categorical or diagnostic basis. 
 
Research in Australian and English samples of heroin, cocaine and 
amphetamine users indicates the SDS is suitable as a measure of dependence 
(Gossop et al., 1995).  All SDS items load significantly with one single dependence 
factor, and total SDS scores are extremely highly correlated with the single 
dependence factor score.  In addition, total SDS scores are related to behavioural 
patterns of drug taking, such as dose, frequency of use, duration of use, daily use and 
degree of contact with other drug users, which in themselves are indicators of 
dependence (Gossop et al., 1995).   
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Development of Risk Categories 
 
Raw data included a number of single variables that were indicative of 
specific risk behaviours.  To create an overall assessment of engagement in risk 
behaviour, single variables were combined to form definitive categories of risk 
engagement for the following domains: sexual risk, alcohol driving risk, cannabis 
driving risk, party drugs driving risk, crime risk, binge risk, overdose risk and 
injecting risk, each of which are defined below.  Table 14 details the percentage of 
participants deemed to be at risk in each risk category.   
 
Sexual Risk Category 
 
 Participants were defined to be at sexual risk if the participant reported they 
used barriers for sex with casual partners in the last 6 months less than 100% of the 
time, or if the participant reported they used barriers for sex with casual partners 
whilst using party drugs in the last 6 months less than 100% of the time.  
  
Alcohol Driving Risk Category 
 
Participants were defined to be at alcohol driving risk if they reported to have 
driven under the influence of alcohol (over 0.05 BAC) in the last 6 months.   
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Cannabis Driving Risk Category 
 
Participants were defined to be at cannabis driving risk if they reported to 
have driven after taking cannabis in the last 6 months.   
 
Party Drug Driving Risk Category 
 
Participants were asked to report if they had driven after taking ecstasy, 
methamphetamine powder, methamphetamine base, crystal methamphetamine, 
cocaine, LSD, MDA, ketamine, GHB and amyl nitrite in the last 6 months.  These 
single categories were then collapsed so that participants were given an overall rating 
of whether or not they had driven after taking any of the above types of party drugs 
in the last 6 months; and if so, they were defined to be at party drug driving risk.   
 
Crime Risk Category  
 
To define whether a participant engaged in crime, several single variables 
within the PDI (Matthews & Bruno, 2006) were considered.  Namely, (1) if the 
participant reported they had been arrested in the last 12 months for dealing / 
trafficking, property crime, fraud, violent crime, alcohol and driving, and/or other 
drugs and driving; or (2) if the participant reported their drug use caused legal / 
police problems; or (3) if the participant self-reported engaging in property crime, 
dealing for cash profit, fraud and/or violent crime in the last month, then they were 
defined to have engaged in crime risk behaviours.   
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Binge Risk Category  
 
To define whether a participant was at binge risk, several single variables 
within the PDI were combined.  If the participant self-reported to have gone 48 hours 
without sleep on either ecstasy, methamphetamine powder, methamphetamine base, 
crystal methamphetamine, pharmaceutical stimulants, cocaine, LSD, MDA, 
ketamine, GHB and/or amyl nitrite, then they were defined to have engaged in binge 
risk behaviours.   
 
Overdose Risk Category  
 
To define whether a participant is at risk of overdose, several single variables 
within the PDI were again considered.  If (1) the participant reported they drank 
more than 5 standard drinks of alcohol when using or coming down from ecstasy; or 
(2) if the participant self-reported overdosing on ecstasy and alcohol in the last 6 
months; or (3) if the participant reported they used any type of methamphetamine 
when using or coming down from ecstasy; or (4) if the participant self-reported 
overdosing on ecstasy and any type of methamphetamine in the last 6 months; or (5) 
if the participant reported to use on average 2 or more ecstasy tablets at one time, 
then the participant was considered to be at risk of overdose.   
 
Injecting Risk Category 
 
To define whether a participant was at injecting risk, two variables within the 
PDI were combined; namely, if the participant reported they injected any drug in the 
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last 6 months, or if the participant reported their main route of administering ecstasy 
in the last 6 months was injecting, then they were defined to have engaged in 
injecting risk behaviours.   
 
Table 14  
Percentage of participants considered to be at risk in each risk category  
Risk Category % of Participants Engaging in this Risk 
Sexual Risk 59.0 
Alcohol Driving Risk 53.0 
Cannabis Driving Risk 44.0 
Party Drug Driving Risk 70.0 
Crime Risk 26.0 
Binge Risk 42.0 
Overdose Risk 94.0 
Injecting Risk 9.0 
 
Statistical Analyses  
 
Comparisons between risky and non-risky groups in relation to demographic, 
personality variables and measures of risk-taking in the PDI were initially examined 
using ANOVA analyses.  Mann-Whitney U tests were used when parametric 
assumptions were violated.  Binary logistic regression analysis in a backward step-
wise fashion was then applied to determine whether personality variables usefully 
contributed to the prediction of group membership (i.e., REU who engaged in risks 
versus those REU who did not) in conjunction with other factors that might also be 
associated with risk taking behaviours (e.g., age and sex).  
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Chapter 9: Study 1 Results 
 
Exploratory Analyses 
 
Exploratory analyses were run to identify differences between REU 
categorised in risk and non-risk groups in terms of demographic and personality 
variables.  
 
Demographic Variables   
 
 As discussed in preceding sections, previous research has illustrated the 
relationship between variables such as sex and age with measures of personality and 
risk-taking behaviours.  For example, research has shown that conscientiousness 
related traits increase with age, while engagement in risky health behaviours 
decreases with age (Bogg & Roberts, 2004).  In addition, sensation seeking and 
impulsivity has been found to be higher in males and younger people (Arnett, 1994).  
Therefore, it was expected that both sex and age would be significantly associated 
with some variables of risk-taking measured in this study.   
 
Sex  
 
There were no significant sex differences in relation to either of the sexual 
risk-taking variables.  With regards to driving risk variables, those that had driven 
under the influence of alcohol and/or driven after taking cannabis in the last 6 
months were significantly more likely to be male (67.1% v. 46.1%, χ2 [1, N = 85] = 
7.2, p = 0.01 and 76.2% v. 43.8%, χ2 [1, N = 63] = 15.2, p < 0.001, respectively) 
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than those that had not.  There were no significant sex differences in relation to 
driving soon after taking party drugs in the last 6 months (Table 15).   
 
In relation to crime risk, those who had been arrested in the last 12 months, 
reported legal / police problems due to drug use, and/or dealt drugs for cash profit in 
the last month were significantly more likely to be male (88.2% v. 53.6%, χ2 [1, N = 
17] = 7.6, p = 0.01; 90.9% v. 54.5%, χ2 [1, N = 11] = 5.6, p = 0.03 and 79.3% v. 
52.7%, χ2 [1, N = 29] = 7.2, p = 0.01, respectively) than those that had not.  There 
were no significant sex differences in relation to engaging in property crime, fraud or 
violent crime in the last month (Table 15).   
 
 Regarding binge risk variables, those who used any type of 
methamphetamine for more than 48 hours without sleep were significantly more 
likely to be male (68.8% v. 50.0%, χ2 [1, N = 64] = 6.2, p = 0.02) than those that had 
not.  A trend was also apparent, whereby those who used any stimulant for more than 
48 hours without sleep were more likely to be male (64.3% v. 50.0%, χ2 [1, N = 84] 
= 4.0, p = 0.06) than those that had not.  There were no sex differences in relation to 
using ecstasy, pharmaceutical stimulants, cocaine, MDA, LSD, ketamine, GHB or 
amyl nitrate for more than 48 hours without sleep (Table 15).   
 
With regards to overdose risk, participants who used two or more ecstasy 
pills in one session were significantly more likely to be male (63.2% v. 43.9%, χ2 [1, 
N = 133] = 6.6, p = 0.02) than those who did not.  Sex was not found to be 
significantly related to any other overdose risk variable.  Furthermore, there were no 
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significant sex differences noted in relation to injecting risk-taking behaviours.  
(Table 15). 
   
Age  
 
There were no significant age differences in relation to either of the sexual 
risk-taking variables.  With regards to driving risk variables, participants who drove 
soon after taking party drugs in the last 6 months were significantly older (M = 25.0, 
SD = 5.0) than those participants who had not (M = 22.9, SD = 3.9: F [1, 159] = 8.1, 
p = 0.01, respectively).  A trend was apparent whereby participants who drove under 
the influence of alcohol in the last 6 months (M = 24.8, SD = 5.2) were slightly older 
than participants who did not (M = 23.5, SD = 4.0: F [1, 159] = 3.2, p = 0.08).  No 
significant age differences were noted in relation to driving after taking cannabis 
(Table 15).   
 
In relation to crime risk, participants who engaged in violent crime in the last 
month were significantly younger (M = 18.7, SD = 1.2) than participants who did not 
(M = 24.4, SD = 5.0: F [1, 195] = 3.9, p = 0.05).  No significant age differences were 
noted in relation to any other crime risk-taking variable.  Furthermore, no significant 
age differences were noted in relation to any of the binge risk-taking variables (Table 
15). 
 
No significant results were observed regarding age and overdose risk-taking 
variables.  However, a trend was apparent whereby those who used any type of 
methamphetamine to come down from ecstasy tended to be older (M = 27.4, SD = 
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6.0) than participants who did not (M = 24.2, SD = 4.9: F [1, 198] = 2.9, p = 0.09).  
Additionally, age was not significantly related to either injecting risk-taking variable 
(Table 15).   
 
Sensation Seeking 
 
AISS Intensity  
 
No significant AISS Intensity score differences were noted in relation to 
either of the sexual risk-taking variables.  With regards to driving risk variables, 
participants who reported they drove under the influence of alcohol in the last 6 
months had significantly higher AISS Intensity scores (M = 28.6, SD = 4.0) than 
those who had not engaged in these behaviours (M = 25.6, SD = 4.6: F [1, 159] = 
19.5, p < 0.001).  No significant AISS Intensity score differences were noted in 
relation to driving under the influence of cannabis or party drugs.  Additionally, no 
significant AISS Intensity score differences were noted in relation to any of the 
crime risk-taking variables (Table 15).   
 
 In relation to binge risk variables, those who reported use of stimulants, 
ecstasy, any type of methamphetamine, ketamine and/or GHB for more than 48 
hours without sleep had significantly higher AISS Intensity scores (M = 28.0, SD = 
4.1; M = 28.1, SD = 4.0; M = 28.2, SD = 4.0; M = 33.5, SD = 3.1 and M = 32.3, SD = 
1.5, respectively) than those who did not (M = 26.0, SD = 4.6: F [1, 195] = 9.4, p = 
0.003; M = 26.1, SD = 4.6: F [1, 195] = 9.9, p = 0.002; M = 26.2, SD = 4.6: F [1, 
195] = 8.6, p = 0.004; M = 26.7, SD = 4.4: F [1, 195] = 9.4, p  = 0.002 and M = 26.8, 
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SD = 4.4: F [1, 195] = 4.7, p = 0.03, respectively).  No significant AISS Intensity 
score differences were noted in relation to using pharmaceutical stimulants, cocaine, 
MDA, LSD or amyl nitrate for more than 48 hours without sleep (Table 15).   
 
 Regarding overdose risk-taking variables, participants who used two or more 
ecstasy tablets in one session had significantly higher AISS Intensity scores (M = 
27.6, SD = 4.4) than those who used less than two tablets per session (M = 25.7, SD 
= 4.1: F [1, 196] = 9.0, p = 0.003).  No significant AISS Intensity score differences 
were noted in relation to any other overdose risk-taking variable (Table 15).    
 
With regards to injecting risk behaviours, a trend was noted whereby 
participants who had injected any drug in the last 6 months had lower AISS Intensity 
scores (M = 24.8, SD = 3.3) than those who had not (M = 27.2, SD = 4.0: F [1, 35] = 
3.8, p = 0.06) (Table 15).     
 
AISS Novelty  
 
 With regards to sexual risk-taking behaviours, a trend was noted whereby 
participants who used barriers for sex with casual partners whilst using party drugs 
less than 100% of the time in the last 6 months had lower AISS Novelty scores (M = 
30.1, SD = 4.0) than those who used barriers 100% of the time (M = 31.7, SD = 3.6: 
F [1, 78] = 3.1, p = 0.08) (Table 15).   
 
 With regards to driving risk variables, a trend was noted whereby participants 
who drove under the influence of alcohol in the last 6 months had slightly higher 
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AISS Novelty scores (M = 30.6, SD = 3.6) than those who did not (M = 29.4, SD = 
3.7: F [1, 159] = 3.7, p = 0.06).  No significant AISS Novelty score differences were 
noted in relation to driving under the influence of cannabis or other party drugs 
(Table 15).   
 
In relation to crime risk variables, participants who committed an act of fraud 
in the last month had a significantly higher AISS Novelty score (M = 32.9, SD = 2.7) 
than those who did not (M = 30.0, SD = 3.7: F [1, 195] = 4.1, p = 0.04).  No 
significant AISS Novelty score differences were noted in relation to any other crime 
risk variable (Table 15).   
 
With regards to binge risk variables, participants who used ecstasy, any type 
of methamphetamine, LSD or GHB for more than 48 hours without sleep had 
significantly higher AISS Novelty scores (M = 30.8, SD = 3.6; M = 30.9, SD = 3.8; 
M = 32.3, SD = 3.9 and M = 35.0, SD = 1.0, respectively) than those who did not (M 
= 29.7, SD = 3.8: F [1, 195] = 3.9, p = 0.05; M = 29.8, SD = 3.7: F [1, 195] = 3.8, p = 
0.05; M = 29.9, SD = 3.7: F [1, 195] = 6.4, p = 0.01 and M = 30.0, SD = 3.7: F [1, 
195] = 5.3, p = 0.02, respectively).  No significant AISS Novelty score differences 
were noted in relation to using pharmaceutical stimulants, cocaine, MDA, ketamine 
or amyl nitrate for more than 48 hours without sleep (Table 15).   
 
AISS Novelty scores were not significantly related to any overdose risk-
taking variable.  With regards to injecting risk, a trend was noted whereby 
participants who had injected a drug in the last 6 months had lower AISS Novelty 
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scores (M = 28.8, SD = 4.2) versus those who had not (M = 31.4, SD = 2.9: Mann-
Whitney U [1, 35] = 116.5, p = 0.10) (Table 15).     
 
Conscientiousness 
 
 Analyses revealed that scores on the conscientiousness measure were not 
significantly associated with any variables of risk-taking in any domain (Table 15).  
 
Summary of Exploratory Analyses: At-Risk Group versus Non-Risk Group 
 
 Table 16 details the differences in demographic and personality variables for 
participants in the at-risk group versus the non-risk group for each overall risk 
category.  For the sexual risk category, only AISS Intensity scores differed between 
the groups, with REU in the at-risk group scoring significantly higher.  For the 
alcohol driving risk category, REU in the at-risk group scored significantly higher on 
both AISS Intensity and Novelty, and were significantly more likely to be male and 
older than REU in the non-risk group.  For the cannabis driving risk category and the 
crime risk category, REU in the at-risk group were significantly more likely to be 
male.  For the party drug driving risk category, REU in the at-risk group were 
significantly older.  For the binge risk category, REU in the at-risk group had 
significantly higher AISS Intensity scores than REU in the non-risk group.  For the 
injecting risk category, REU in the at-risk group had significantly lower AISS 
Intensity scores and were significantly older than REU in the non-risk group.  No 
significant differences between groups were found for the overdose risk category.   
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Table 15 
Differences in Predictor Variables for Behavioural Risk Domains: Participants at Risk versus Participants Not at Risk (N = 200) 
 AISS Intensity AISS Novelty IPIP Responsibility Sex Age 
 Ps at 
Risk 
Ps 
Not at 
Risk 
F Ps at 
Risk 
Ps 
Not at 
Risk 
F Ps at 
Risk 
Ps 
Not at 
Risk 
F Risk 
% 
Male 
Non- 
Risk 
% 
Male 
χ2 Ps at 
Risk 
Ps 
Not at 
Risk 
F 
 
Sexual Risk Variables 
               
How often used barrier for sex 
with casual partners last 6 
months  
[Nrisk = 61(24)] 
28.1 
(4.9) 
27.7 
(4.1) 
0.3 30.4 
(4.0) 
31.2 
(3.7) 
1.1 39.1 
(5.5) 
40.1 
(5.1) 
0.4 63.9 56.9 0.6 24.0 
(6.8) 
23.8 
(4.2) 
0.0 
How often used barriers for sex 
with casual partners whilst using 
party drugs last 6 months  
[Nrisk = 41(28)] 
28.4 
(5.0) 
28.0 
(4.1) 
0.2 30.1 
(4.0) 
31.7 
(3.6) 
3.1^ 37.8 
(5.1) 
38.9 
(5.8) 
0.3 64.6 59.4 0.2 24.0 
(5.3) 
23.8 
(4.1) 
0.0 
 
Alcohol Driving Risk Variables 
               
Driven under the influence of 
alcohol last 6 months  
[Nrisk = 85(39)] 
28.6 
(4.0) 
25.6 
(4.6) 
19.5*** 30.6 
(3.6) 
29.4 
(3.7) 
3.7^ 38.4 
(5.9) 
37.9 
(8.0) 
0.1 67.1 46.1 7.2** 24.8 
(5.2) 
23.5 
(4.0) 
3.2^ 
 
Cannabis Driving Risk Variables 
             
Driven after taken cannabis last 6 
months [Nrisk = 63(33)] 
28.7 
(3.8) 
26.2 
(4.8) 
487.5# 
 
30.2 
(3.5) 
29.7 
(4.0) 
0.7 
 
38.3 
(6.9) 
37.4 
(8.8) 
0.2 
 
76.2 43.8 15.2*** 24.1 
(3.7) 
24.7 
(5.7) 
0.7 
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AISS Intensity AISS Novelty IPIP Responsibility Sex Age 
 
Party Drug Driving Risk Variables  
             
Driven after taken party drugs 
(ecstasy, any methamphetamine, 
cocaine, LSD, MDA, ketamine, 
GHB and/or amyl nitrate) last 6 
months [(Nrisk = 100(59)] 
27.6 
(4.6) 
26.5 
(4.4) 
2.2 29.7 
(3.8) 
30.5 
(3.4) 
1.9 37.9 
(8.0) 
38.9 
(3.5) 
0.3 60.0 52.5 0.9 25.0 
(5.0) 
22.9 
(3.9) 
8.1** 
 
Crime Risk Variables 
               
Arrested in the last 12 months 
for dealing / trafficking, property 
crime, fraud, violent crime, 
and/or driving under the 
influence of alcohol or other 
drugs [(Nrisk = 17(7)] 
27.4 
(3.9) 
26.8 
(4.5) 
0.3 30.1 
(4.2) 
30.1 
(3.7) 
0.0 40.0 
(4.0) 
38.4 
(6.7) 
0.4 88.2 53.6 7.6** 24.6 
(3.7) 
24.3 
(5.1) 
0.0 
Reported legal / police problems 
due to drug use [(Nrisk = 11(5)] 
28.1 
(3.6) 
26.8 
(4.5) 
0.8 30.6 
(3.5) 
30.1 
(3.8) 
0.2 37.0 
(6.0) 
38.6 
(6.7) 
0.3 90.9 54.5 5.6* 25.1 
(5.3) 
24.3 
(5.0) 
0.3 
Engaged in dealing for cash 
profit in the last month  
[(Nrisk = 29(20)] 
28.1 
(4.0) 
26.7 
(4.5) 
2.4 
 
29.5 
(3.2) 
30.2 
(3.8) 
0.9 
 
37.2 
(6.4) 
38.8 
(6.6) 
0.1 
 
79.3 52.7 7.2** 23.8 
(4.3) 
24.4 
(5.1) 
0.5 
 
Binge Risk Variables 
               
Used any stimulant more than 48 
hrs w/out sleep [(Nrisk = 84(44)] 
28.0 
(4.1) 
26.0 
(4.6) 
9.4** 30.7 
(3.7) 
29.7 
(3.7) 
2.9^ 38.2 
(6.5) 
38.9 
(6.9) 
0.3 64.3 50.0 4.0^ 24.1 
(4.2) 
24.5 
(5.5) 
0.3 
Used ecstasy more than 48 hrs 
w/out sleep [(Nrisk = 79(41)] 
28.1 
(4.0) 
26.1 
(4.6) 
9.9** 30.8 
(3.6) 
29.7 
(3.8) 
3.9* 37.7 
(6.4) 
39.2 
(6.8) 
1.2 
 
63.3 51.3 2.8 23.9 
(4.1) 
24.6 
(5.5) 
0.9 
Used any methamphetamine  
more than 48 hrs w/out sleep 
[(Nrisk = 64(34)] 
 
28.2 
(4.0) 
26.2 
(4.6) 
8.6** 30.9 
(3.8) 
29.8 
(3.7) 
3.8* 38.4 
(6.7) 
38.6 
(6.7) 
0.0 
 
68.8 50.0 6.2* 24.6 
(4.3) 
24.1 
(5.3) 
0.4 
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 AISS Intensity AISS Novelty IPIP Responsibility Sex Age 
Used cocaine more than 48 hrs 
w/out sleep [(Nrisk = 17(12)] 
28.2 
(3.7) 
26.7 
(4.5) 
1.8 30.6 
(3.6) 
30.1 
(3.8) 
0.4 36.8 
(7.6) 
38.8 
(6.5) 
0.1 64.7 55.2 0.6 24.3 
(4.9) 
24.3 
(5.0) 
0.0 
Used LSD more than 48 hrs 
w/out sleep [(Nrisk = 17(7)]  
27.9 
(2.8) 
26.8 
(4.6) 
1.1 32.3 
(3.9) 
29.9 
(3.7) 
6.4** 40.0 
(2.9) 
38.4 
(6.9) 
0.4 64.7 55.2 0.6 23.8 
(4.8) 
24.4 
(5.0) 
0.2 
 
Overdose Risk Variables 
               
Drink 5 or more standard drinks 
of alcohol when using ecstasy 
[(Nrisk = 144(65)] 
27.3 
(4.6) 
26.0 
(3.8) 
1.6 
 
30.3 
(3.7) 
30.3 
(3.8) 
0.0 
 
38.0 
(6.6) 
39.3 
(6.3) 
0.4 
 
56.9 70.8 1.6 24.0 
(3.7) 
23.9 
(3.9) 
0.0 
Drink 5 or more standard drinks 
of alcohol when coming down 
from ecstasy [(Nrisk = 74(27)] 
28.3 
(4.1) 
26.8 
(4.0) 
2.4 
 
30.8 
(3.6) 
29.7 
(3.6) 
1.5 
 
38.2 
(6.1) 
38.2 
(6.0) 
0.0 
 
67.6 61.9 0.2 24.1 
(3.4) 
23.8 
(3.3) 
0.1 
Used any methamphetamine 
when using ecstasy  
[(Nrisk = 32(15)] 
26.3 
(4.1) 
27.0 
(4.5) 
0.7 
 
30.1 
(3.9) 
30.1 
(3.7) 
0.0 
 
38.1 
(8.8) 
38.6 
(6.2) 
0.1 
 
59.4 56.0 0.1 25.1 
(4.7) 
24.2 
(5.0) 
1.0 
On average used 2 or more 
ecstasy tablets in one session 
[(Nrisk = 133(70)] 
27.6 
(4.4) 
25.7 
(4.1) 
9.0** 30.3 
(3.7) 
29.9 
(3.9) 
0.5 37.9 
(6.8) 
40.1 
(6.0) 
2.2 
 
63.2 43.9 6.6* 24.7 
(5.3) 
23.5 
(4.4) 
2.5 
 
Injecting Risk Variables 
               
Injected any drug last 6 months 
[(Nrisk = 17(9)] 
24.8 
(3.3) 
27.2 
(4.0) 
3.8^ 28.8 
(4.2) 
31.4 
(2.9) 
116.5#^ 38.0 
(9.3) 
40.4 
(7.7) 
0.4 76.5 70.0 0.2 27.4 
(5.9) 
26.4 
(6.2) 
0.3 
 
Note. The number in italics for Nrisk represents the smaller sample size for the IPIP variable; # indicates use of Mann-Whitney; -- indicates no data available for computation.  
The following variables were excluded due to Nrisk < 10: engaging in property crime, fraud and violent crime in the past month; use of pharmaceutical stimulants, MDA, 
ketamine, GHB and amyl nitrate for more than 48 hours without sleep; overdosed on ecstasy and alcohol last 6 months; used any methamphetamine to come down from 
ecstasy; overdosed on ecstasy and any type methamphetamine last 6 months; injecting main route of ecstasy administration last 6 months.   
^p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001 
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Table 16 
Differences in Predictor Variables for Overall Risk Domains: Participants at Risk versus Participants Not at Risk (N = 200) 
 AISS Intensity AISS Novelty IPIP Responsibility Sex Age 
 Ps at 
Risk 
Ps 
Not at 
Risk 
F Ps at 
Risk 
Ps 
Not at 
Risk 
F Ps at 
Risk 
Ps 
Not at 
Risk 
F Risk 
% 
Male 
Non- 
Risk % 
Male 
χ2 Ps at 
Risk 
Ps 
Not at 
Risk 
F 
Sexual Risk Category 
[(Nrisk = 66(27)] 
28.0 
(4.8) 
26.5 
(4.1) 
5.2* 30.6 
(3.9) 
29.9 
(3.5) 
1.6 39.0 
(5.3) 
38.7 
(6.5) 
0.03 63.6 54.8 1.4 24.1 
(6.7) 
24.3 
(3.6) 
0.1 
Alcohol Driving Risk 
Category  
[(Nrisk = 85(39)] 
28.6 
(4.0) 
25.6 
(4.6) 
19.5*** 30.6 
(3.6) 
29.4 
(3.7) 
3.7^ 38.4 
(5.9) 
37.9 
(8.0) 
0.1 67.1 46.1 7.2** 24.8 
(5.2) 
23.5 
(4.0) 
3.2^ 
Cannabis Driving Risk 
Category  
[(Nrisk = 63(33)] 
28.7 
(3.8) 
26.2 
(4.8) 
487.5# 
 
30.2 
(3.5) 
29.7 
(4.0) 
0.7 
 
38.3 
(6.9) 
37.4 
(8.8) 
0.2 
 
76.2 43.8 15.2*** 24.1 
(3.7) 
24.7 
(5.7) 
0.7 
Party Drug Driving Risk 
Category  
[(Nrisk = 100(59)] 
27.6 
(4.6) 
26.5 
(4.4) 
2.2 29.7 
(3.8) 
30.5 
(3.4) 
1.9 37.9 
(8.0) 
38.9 
(3.5) 
0.3 60.0 52.5 0.9 25.0 
(5.0) 
22.9 
(3.9) 
8.1** 
Crime Risk Category 
[(Nrisk = 52(30)] 
27.8 
(3.8) 
26.6 
(4.6) 
2.6 30.2 
(3.6) 
30.1 
(3.8) 
0.0 37.7 
(5.9) 
38.9 
(6.9) 
0.7 78.8 48.6 14.3*** 24.3 
(4.7) 
24.3 
(5.1) 
0.0 
Binge Risk Category 
[(Nrisk = 83(44)] 
27.9 
(4.0) 
26.1 
(4.6) 
8.2** 30.6 
(3.7) 
29.8 
(3.8) 
2.3 38.2 
(6.5) 
38.9 
(6.9) 
0.3 63.9 50.4 3.5 24.1 
(4.2) 
24.4 
(5.5) 
0.2 
Overdose Risk Category 
[(Nrisk = 188(92)] 
27.0 
(4.5) 
25.6 
(3.7) 
1.1 30.2 
(3.7) 
28.4 
(3.5) 
2.6 38.2 
(6.7) 
42.2 
(3.7) 
2.5 58.0 33.3 2.8 24.4 
(5.1) 
22.9 
(3.6) 
1.0 
Injecting Risk Category 
[(Nrisk = 17(9)] 
24.8 
(3.3) 
27.1 
(4.5) 
4.0* 28.8 
(4.2) 
30.2
(3.7) 
2.3 38.0 
(9.3) 
38.6 
(6.4) 
0.1 76.5 54.4 3.1 27.4 
(5.9) 
24.0 
(4.8) 
7.3** 
 
Note. The number in italics for Nrisk represents the smaller sample size for the IPIP variable. 
# Mann-Whitney U Test 
^p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001 
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Binary Logistic Regression Findings 
 
Binary logistic regression analysis in a backward step-wise fashion was 
applied to determine whether personality variables (AISS Intensity, AISS Novelty 
and IPIP Responsibility) usefully contributed to the prediction of group membership 
(i.e., REU who engage in risk-taking behaviours versus REU who do not), in 
addition to other factors that might also be associated with risk-taking behaviours, 
such as age and sex.   
 
Calculations were initially run including all measures of personality; which, 
due to the IPIP Responsibility Scale only being administered to half of the total 
sample, limited the overall sample size to a maximum 100 for each risk category.  
Analyses of these initial regression models revealed that the personality variable of 
conscientiousness did not significantly predict any category of risk, except for the 
overdose risk category.  Therefore, for those categories where the IPIP 
Responsibility Scale was not a significant predictor, regression analyses were re-run 
without this variable, providing a maximum sample size of 200, and therefore greater 
statistical power.  Thus, in the analyses and tables to follow, the IPIP Responsibility 
Scale has not been included with exception of the overdose risk category.    
 
Prediction of Sexual Risk-Taking Behaviours 
 
 Table 17 shows the binary logistic regression analyses for sexual risk-taking.  
A test of the full model was not significant, χ2 (4, N = 45) = 5.62, p = 0.23.  The final 
model, following the stepwise removal of non-significant variables, consisted of the 
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AISS Intensity variable, which significantly predicted sexual risk-taking behaviour, 
χ2 (1, N = 45) = 5.20, p = 0.02.  The variance accounted for by the final model 
however was small, with the Cox and Snell R2 = 0.03 and the Nagelkerke R2 = 0.04.  
The final model correctly predicted 9.1% individuals at sexual risk and 97.6% of 
individuals not at sexual risk, with an overall prediction rate of 66.7%.   
 
These findings imply that REU who scored higher on AISS Intensity 
measures were more likely to have demonstrated behaviours that defined them to be 
at greater sexual risk.  However, the model was clearly not useful, given the small 
proportion of variance explained and the low percentage of individuals at risk that 
were correctly predicted.   
 
Table 17 
Summary of Logistic Regression Analyses of Variables Predicting Sexual Risk-
Taking Behaviour  
Full Model B (SE) Wald Odds Ratio 
95% Confidence 
Interval 
Lower Upper 
Sex - 0.10 (0.36) 0.08 0.91 0.45 1.82 
Age - 0.02 (0.04) 0.24 0.98 0.92 1.05 
AISS Novelty 0.02 (0.05) 0.14 1.02 0.93 1.12 
AISS Intensity 0.07 (0.04) 2.69^ 1.07 0.99 1.17 
Constant  - 2.61 (1.76) 2.20 0.07 - - 
Model Summary: Cox and Snell R2 = 0.03, Nagelkerke R2 = 0.04.  Model χ2 (4, N = 45) = 5.62, p = 
0.23. 7.6% correctly predicted (at risk); 98.4% correctly predicted (not at risk); 66.7% correctly 
predicted (overall) 
 
Final Stepwise Entry Model
     
AISS Intensity  0.08 (0.04) 4.99* 1.08 1.01 1.16 
Constant  - 2.82 (1.00) 7.90** 0.06 - - 
Model Summary: Cox and Snell R2 = 0.03, Nagelkerke R2 = 0.04.  Model χ2 (1, N = 45) = 5.20, p = 
0.02.  9.1% correctly predicted (at risk); 97.6% correctly predicted (not at risk); 66.7% correctly 
predicted (overall) 
Note. Dashes indicate coefficients that were not calculated by the analysis.  The IPIP Responsibility 
Scale was excluded as previous analyses indicated it was not a significant predictor variable.   
^p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001 
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Prediction of Driving Risk-Taking Behaviours 
 
Alcohol Driving Risk 
 
 Table 18 shows the binary logistic regression analyses for alcohol driving 
risk.  A test of the full model was significant, χ2 (4, N = 81) = 22.35, p < 0.001.  
Following stepwise removal of redundant predictors, the final model consisted of the 
AISS Intensity variable and age, which together significantly predicted alcohol 
driving risk-taking behaviour, χ2 (2, N = 81) = 22.02, p < 0.001.  The variance 
accounted for by the final model was large, with the Cox and Snell R2 = 0.13 and the 
Nagelkerke R2 = 0.17.  The final model correctly predicted 68.2% individuals at 
alcohol driving risk and 67.1% of individuals not at risk, with an overall prediction 
rate of 67.7%.  These findings suggest that REU who were older and REU who 
scored higher on the AISS Intensity measure were more likely to have driven under 
the influence of alcohol in the last 6 months.   
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Table 18 
Summary of Logistic Regression Analyses of Variables Predicting Alcohol Risk 
Behaviour 
Full Model B (SE) Wald Odds Ratio 
95% Confidence 
Interval 
Lower Upper 
Sex - 0.19 (0.38) 0.26 0.83 0.39 1.74 
Age 0.07 (0.04) 2.80^ 1.07 0.99 1.16 
AISS Novelty 0.01 (0.05) 0.08 1.01 0.92 1.12 
AISS Intensity 0.15 (0.05) 9.69** 1.16 1.06 1.28 
Constant  - 5.91 (2.04) 8.40** 0.00 - - 
Model Summary: Cox and Snell R2 = 0.13, Nagelkerke R2 = 0.17.  Model χ2 (4, N = 81) = 22.35, p < 
0.001.  70.6% correctly predicted (at risk); 67.1% correctly predicted (not at risk); 68.9% correctly 
predicted (overall) 
 
Final Stepwise Entry Model
     
Age 0.07 (0.04) 3.11^ 1.07 0.99 1.16 
AISS Intensity 0.16 (0.04) 15.98*** 1.18 1.09 1.28 
Constant  - 6.05 (1.52) 15.85*** 0.00 - - 
Model Summary: Cox and Snell R2 = 0.13, Nagelkerke R2 = 0.17.  Model χ2 (2, N = 81) = 22.02, p < 
0.001.  68.2% correctly predicted (at risk); 67.1% correctly predicted (not at risk); 67.7% correctly 
predicted (overall) 
Note. Dashes indicate coefficients that were not calculated by the analysis.  The IPIP Responsibility 
Scale was excluded as previous analyses indicated it was a non significant predictor variable.   
^p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001 
 
Cannabis Driving Risk 
 
Table 19 displays the binary logistic regression analyses for cannabis driving 
risk.  A test of the full model was significant, χ2 (4, N = 63) = 20.95, p < 0.001.  
Following stepwise removal of redundant predictors, the final model consisted of 
AISS Intensity and sex, which together significantly predicted cannabis driving risk-
taking behaviour, χ2 (2, N = 63) = 19.56, p < 0.001.  The variance accounted for by 
the final model was medium to large, with the Cox and Snell R2 = 0.11 and the 
Nagelkerke R2 = 0.16.  The final model correctly predicted 46.0% individuals at risk 
and 76.5% of individuals not at risk, with an overall prediction rate of 64.6%.  These 
findings suggest that REU who were male and REU scoring higher on the AISS 
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Intensity measure were more likely to have driven after taking cannabis in the last 6 
months.   
 
Table 19 
Summary of Logistic Regression Analyses of Variables Predicting Cannabis Driving 
Risk Behaviour 
Full Model B (SE) Wald Odds  Ratio 
95% Confidence 
Interval 
Lower Upper 
Sex - 1.08 (0.40) 7.18** 0.34 0.16 0.75 
Age - 0.03 (0.04) 0.45 0.97 0.90 1.05 
AISS Novelty - 0.05 (0.05) 0.85 0.95 0.86 1.06 
AISS Intensity 0.10 (0.05) 4.23* 1.10 1.01 1.21 
Constant  - 0.66 (1.92) 0.12 0.52 - - 
Model Summary: Cox and Snell R2 = 0.12, Nagelkerke R2 = 0.17.  Model χ2 (4, N = 63) = 20.95, p < 
0.001.  52.4% correctly predicted (at risk); 73.5% correctly predicted (not at risk); 65.2% correctly 
predicted (overall) 
 
Final Stepwise Entry Model
     
Sex - 1.03 (0.40) 6.78** 0.36 0.16 0.78 
AISS Intensity  0.08 (0.04) 3.55^ 1.09 1.00 1.18 
Constant  - 2.32 (1.29) 3.22^ 0.01 - - 
Model Summary: Cox and Snell R2 = 0.11, Nagelkerke R2 = 0.16.  Model χ2 (2, N = 63) = 19.56, p < 
0.001.  46.0% correctly predicted (at risk); 76.5% correctly predicted (not at risk); 64.6% correctly 
predicted (overall) 
Note. Dashes indicate coefficients that were not calculated by the analysis.  The IPIP Responsibility 
Scale was excluded as previous analyses indicated it was a non significant predictor variable.   
^p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001 
 
 
Party Drug Driving Risk 
 
Table 20 shows the binary logistic regression analyses for party drug driving 
risk, which included driving after taking ecstasy, any type of methamphetamine, 
cocaine, LSD, MDA, ketamine, GHB and amyl nitrate in the last 6 months.  A test of 
the full model was significant, χ2 (4, N = 63) = 17.12, p = 0.002.  Following stepwise 
removal of redundant predictors, the final model consisted of age and both AISS 
sensation seeking variables, which together significantly predicted party drug driving 
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risk-taking behaviour, χ2 (3, N = 63) = 17.12, p = 0.001.  The variance accounted for 
by the final model was medium, with the Cox and Snell R2 = 0.10 and the 
Nagelkerke R2 = 0.14.  The final model correctly predicted 86.0% individuals at 
party drug driving risk and 42.6% of individuals not at risk, with an overall 
prediction rate of 69.6%.  These findings suggest that REU who were older, REU 
who had higher levels of AISS Intensity and REU who had lower levels of AISS 
Novelty were predictive of REU who had driven under the influence of party drugs 
in the past 6 months.   
 
Table 20 
Summary of Logistic Regression Analyses of Variables Predicting Party Drug 
Driving Risk Behaviour 
Full Model B (SE) Wald Odds  Ratio 
95% Confidence 
Interval 
Lower Upper 
Sex - 0.01 (0.39) 0.00 0.99 0.46 2.14 
Age 0.15 (0.05) 7.93** 1.16 1.05 1.29 
AISS Novelty - 0.11 (0.05) 4.66* 0.90 0.81 0.99 
AISS Intensity  0.09 (0.05) 3.28^ 1.09 0.99 1.20 
Constant  - 2.09 (2.10) 0.99 0.12 - - 
Model Summary: Cox and Snell R2 = 0.10, Nagelkerke R2 = 0.14.  Model χ2 (4, N = 63) = 17.12, p = 
0.002.  86.0% correctly predicted (at risk); 42.6% correctly predicted (not at risk); 69.6% correctly 
predicted (overall) 
 
Final Stepwise Entry Model
     
Age 0.15 (0.05) 7.94** 1.16 1.05 1.29 
AISS Novelty - 0.11 (0.05) 4.66* 0.90 0.81 0.99 
AISS Intensity 0.09 (0.04) 4.18* 1.09 1.00 1.19 
Constant  - 2.11 (1.94) 1.19 0.12 - - 
Model Summary: Cox and Snell R2 = 0.10, Nagelkerke R2 = 0.14.  Model χ2 (3, N = 63) = 17.12, p = 
0.001.  86.0% correctly predicted (at risk); 42.6% correctly predicted (not at risk); 69.6% correctly 
predicted (overall) 
Note. Dashes indicate coefficients that were not calculated by the analysis.  The IPIP Responsibility 
Scale was excluded as previous analyses indicated it was a non significant predictor variable.   
^p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001 
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Prediction of Crime Risk-Taking Behaviours 
 
 
Binary logistic regression analyses for crime risk-taking behaviours indicates 
a test of the full model was significant, χ2 (4, N = 99) = 15.37, p = 0.004.  Following 
stepwise removal of redundant predictors, the final model consisted only of sex, 
which significantly predicted crime risk-taking behaviour, χ2 (1, N = 99) = 14.48, p < 
0.001.  The variance accounted for by the final model was medium, with the Cox and 
Snell R2 = 0.07 and the Nagelkerke R2 = 0.10.  The final model was not successful in 
predicting any individuals at risk and therefore the usefulness of this model is poor.   
 
 
Prediction of Binge Risk-Taking Behaviours 
 
 
Table 21 shows the binary logistic regression analyses for binge risk-taking 
behaviours.  A test of the full model was not significant, χ2 (4, N = 97) = 8.91, p = 
0.06.  Following stepwise removal of redundant predictors, the final model consisted 
of the AISS Intensity variable, which significantly predicted binge risk-taking 
behaviour, χ2 (1, N = 97) = 8.08, p = 0.004.  The variance accounted for by the final 
model was small, with the Cox and Snell R2 = 0.04 and the Nagelkerke R2 = 0.05.  
The final model correctly predicted 28.0% individuals at binge risk and 82.6% of 
individuals not at risk, with an overall prediction rate of 59.9%.   
 
 According to the Wald chi-square criterion, binge risk-taking behaviour was 
predicted by the personality variable of AISS Intensity, suggesting that REU with 
higher levels of AISS Intensity were more likely to have engaged in binging 
behaviours.  However, the model’s usefulness is questioned due to the poor variance 
it explains and the low percentage of at-risk individuals that are correctly predicted.   
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Table 21 
Summary of Logistic Regression Analyses of Variables Predicting Binge Risk-Taking 
Behaviour 
Full Model B (SE) Wald Odds  Ratio 
95% Confidence 
Interval 
Lower Upper 
Sex - 0.24 (0.33) 0.53 0.79 0.41 1.51 
Age - 0.02 (0.03) 0.27 0.98 0.92 1.05 
AISS Novelty 0.02 (0.04) 0.15 1.02 0.93 1.11 
AISS Intensity 0.08 (0.04) 3.65^ 1.08 1.00 1.17 
Constant  - 2.44 (1.64) 2.22 0.09 - - 
Model Summary: Cox and Snell R2 = 0.04, Nagelkerke R2 = 0.06.  Model χ2 (4, N = 97) = 8.91, p = 
0.06.  25.6% correctly predicted (at risk); 80.9% correctly predicted (not at risk); 57.9% correctly 
predicted (overall) 
 
Final Stepwise Entry Model
     
AISS Intensity 0.10 (0.03) 7.64** 1.10 1.03 1.18 
Constant  - 2.91 (0.95) 9.44** 0.06 - - 
Model Summary: Cox and Snell R2 = 0.04, Nagelkerke R2 = 0.05.  Model χ2 (1, N = 97) = 8.08, p = 
0.004.  28.0% correctly predicted (at risk); 82.6% correctly predicted (not at risk); 59.9% correctly 
predicted (overall) 
Note. Dashes indicate coefficients that were not calculated by the analysis.  The IPIP Responsibility 
Scale was excluded as previous analyses indicated it was a non significant predictor variable.   
^p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001 
 
 
Prediction of Overdose Risk Taking Behaviours 
 
 
 Table 22 shows the binary logistic regression analyses for overdose risk-
taking behaviours.  It is important to note here that only 6% of the entire sample was 
defined to not be at risk of overdose.  This potentially could be due to the broad 
definition of what constituted ‘overdose risk.’ Therefore, the prediction of overdose 
risk-taking behaviours was more difficult, as it was unlikely that predictor variables 
would distinguish the small percentage of REU that were not overdose risks from the 
majority who were.   
 
When performing these analyses, the full model was non-significant; 
however, when the IPIP Responsibility scale was included, the model was able to 
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provide a statistically significant differentiation between risk groups.  In addition, 
there was an increased percentage of variance accounted for; however, the sample 
size in these calculations was limited to 99 due to the limited number of participants 
reporting on the conscientiousness measure.   
 
A test of the full model was not significant, χ2 (5, N = 99) = 9.09, p = 0.11.  
Following stepwise removal of redundant predictors, the final model consisted of age 
and conscientiousness, which significantly predicted overdose risk-taking behaviour, 
χ2 (2, N = 99) = 7.69, p = 0.02.  The variance accounted for by the final model was 
medium to large, with the Cox and Snell R2 = 0.08 and the Nagelkerke R2 = 0.19.  
The final model correctly predicted 100.0% individuals at overdose risk and 0.0% of 
individuals not at risk, with an overall prediction rate of 92.9%.  However, this 
model was not useful as it predicted everyone to be at risk and therefore did not 
discriminate between risk and non-risk taking groups.   
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Table 22 
Summary of Logistic Regression Analyses of Variables Predicting Overdose Risk-
Taking Behaviour 
Full Model B (SE) Wald Odds  Ratio 
95% Confidence 
Interval 
Lower Upper 
Sex - 0.60 (0.93) 0.42 0.55 0.09 3.41 
Age 0.21 (0.16) 1.76 1.23 0.91 1.68 
AISS Novelty 0.11 (0.13) 0.76 1.12 0.87 1.44 
AISS Intensity - 0.09 (0.12) 0.53 0.91 0.72 1.16 
IPIP Responsibility - 0.16 (0.10) 2.66^ 0.85 0.70  1.03 
Constant  3.82 (6.83) 0.31 45.46 - - 
Model Summary: Cox and Snell R2 = 0.09, Nagelkerke R2 = 0.22.  Model χ2 (5, N = 99) = 9.09, p = 
0.11.  100.0% correctly predicted (at risk); 14.3% correctly predicted (not at risk); 93.9% correctly 
predicted (overall) 
 
Final Stepwise Entry Model
     
Age 0.26 (0.15) 2.77^ 1.29 0.96 1.75 
IPIP Responsibility - 0.18 (0.11) 2.92^ 0.84 0.68 1.03 
Constant  3.92 (5.30) 0.55 50.38 - - 
Model Summary: Cox and Snell R2 = 0.08, Nagelkerke R2 = 0.19.  Model χ2 (2, N = 99) = 7.69, p = 
0.02.  100.0% correctly predicted (at risk); 0.0% correctly predicted (not at risk); 92.9% correctly 
predicted (overall) 
Note. Dashes indicate coefficients that were not calculated by the analysis. 
^p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001 
 
 
Prediction of Injecting Risk-Taking Behaviours 
 
 
Binary logistic regression analyses for injecting risk-taking behaviours 
indicates a test of the full model was significant, χ2 (4, N = 98) = 15.89, p = 0.003.  
Following stepwise removal of redundant predictors, the final model consisted of sex 
and the AISS Intensity variable, which significantly predicted injecting risk-taking 
behaviour, χ2 (2, N = 98) = 12.87, p = 0.002.  The variance accounted for by the final 
model was medium, with the Cox and Snell R2 = 0.06 and the Nagelkerke R2 = 0.14.  
The final model was not successful in predicting any individuals at risk.    
 
 According to the Wald chi-square criterion, injecting risk-taking behaviour 
was predicted by sex and AISS Intensity, suggesting that REU who were male that 
 121
REU who scored lower on AISS Intensity were more likely to have engaged in 
injecting risk-taking behaviours.  However, this model was not useful, as it was 
unable to correctly predict any individuals at risk. 
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Chapter 10: Study 1 Discussion 
 
 This study aimed to investigate the usefulness of personality traits, i.e., rash-
spontaneous impulsivity and conscientiousness (responsibility facet), in 
differentiating between REU who engage in risk-taking behaviours versus REU who 
do not, and their power to predict REU’s engagement in risk-taking behaviour.   
 
Drug Use Patterns 
 
 The most commonly used drugs in the current sample were ecstasy, alcohol, 
cannabis and methamphetamine powder.  This is consistent with findings from the 
AIHW (2008) survey regarding types of illicit drugs recently consumed in a larger, 
national sample.  In the current sample, generally speaking, REU were young adults 
(mean age 24.3) who lived in rental accommodation (72%), were employed and / or 
studying (89%) and had achieved Year 12 qualifications or beyond (83%).  
Approximately half of the sample was single.  This profile is similar to other groups 
of REU studied within Australia (e.g., Allott & Redman, 2006; Breen, Degenhardt, 
Kinner, Bruno, Jenkinson, Matthews & Newman, 2006; Degenhardt, Dillon, Duff & 
Ross, 2004; Matthews, Bruno, Johnson, Black, Degenhardt & Dunn, 2009).      
 
Demographic Variable Differences between REU at Risk and REU Not at Risk, and 
their Ability to Predict Engagement in Risk-Taking Behaviour   
 
 In relation to sex, it was expected that more males than females REU would 
engage in risk-taking behaviours.  This hypothesis was supported in that more males 
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than females were represented in the risky group for every risk-taking domain, 
significantly so for the domains of crime risk, alcohol driving risk and cannabis 
driving risk.  These findings support previous research that concluded more males 
tend to engage in risk-taking behaviours than females (e.g., Arnett, 1990; 
Zuckerman, Eysenck & Eysenck, 1978), and demonstrates this finding remains true 
in a sample of REU, which as a group may be defined as more risk-taking than the 
general population.   
 
In relation to the ability of sex to predict REU’s engagement in risk-taking 
behaviour, sex proved non-significant in relation to the domains of sexual and binge 
risk-taking.  Whilst sex was a significant predictor variable for the domains of crime 
and injecting risk, the final models generated for these risk categories were not 
useful, given they were unable to successfully predict any REU at risk.  However, 
sex was a significant predictor of REU who had driven under the influence of 
cannabis.  Together with rash-spontaneous impulsivity (intensity), these variables 
explained a moderate amount of the variance, with the final model correctly 
predicting 46% of REU at risk.  In relation to sex, REU who were male were more 
likely to have driven after taking cannabis.    
 
 Regarding age, younger REU were expected to engage in more risk-taking 
behaviours than older REU.  Results indicated there were no significant differences 
between groups for any of the risk-taking domains, with the exception of party drug 
driving risk and injecting risk, where REU in the at-risk group were older than REU 
in the non risk group.    
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Age was not a significant predictor variable with regards to predicting REU 
at risk for the domains of sexual and binge risk-taking.  Whilst age, together with 
conscientiousness, were significant predictor variables for the overdose risk domain, 
the final model generated was not useful as it was unable to successfully predict any 
REU at risk.  However, coupled with rash-spontaneous impulsivity (intensity), age 
was a significant predictor of REU who had driven under the influence of alcohol 
and party drugs.  For both of these categories, age and rash-spontaneous impulsivity 
explained a moderate amount of the variance and successfully predicted most 
participants at risk (68 – 86%).  In relation to age, these findings suggest that REU 
who drove under the influence tended to be older.   
 
 First and foremost, it should be noted that on a whole, the sample of REU 
were relatively young, with a mean age of 24 years.  However, there may be other 
possible reasons behind the age related findings.  In relation to driving risk, this may 
be explained in terms of access, in that older REU may be more likely to hold an 
unrestricted drivers licence and possess their own personal vehicle in comparison to 
younger REU.  It is also possible that younger REU may be on learner or provisional 
licence types, which restrict them to a zero-level blood alcohol content (BAC) when 
driving (as compared to the 0.05 BAC for unrestricted licences); therefore, younger 
REU on such licence types may be more inclined to organise alternative transport 
when partying due to the zero tolerance.  However, it should be noted that some 
research regarding driving risk (e.g., Kelly, Darke & Ross, 2004) has defined age 35 
and below as young.  Therefore, in comparison with other driving risk research, at 
risk, older REU in the current study would actually be considered young, which may 
also explain these disparate findings.   
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 With regards to the injecting risk finding, it could be that older REU have had 
more years of illicit drug experimentation and use, and it is possible that older REU 
have used a larger variety of illicit drugs and may have more entrenched drug habits, 
such as injecting.  However, only a very small percentage (9%) of the sample had 
actually injected a drug in the last 6 months, so this finding may also be influenced 
by a small sample size.  In relation to the crime risk-taking domain, the result that 
REU in both the risk and non risk groups were equal in age could be a reflection of 
the fact that the overall sample was relatively young, and the proportion of the 
sample defined to be at crime risk was relatively low (26%).     
 
Rash-Spontaneous Impulsivity: Differences between REU at Risk and REU Not at 
Risk, and its Ability to Predict Engagement in Risk-Taking Behaviour  
  
 Scores on rash-spontaneous impulsivity (intensity) were significantly higher 
for REU in the at risk group for the domains of sexual risk, alcohol driving risk and 
binge risk, suggesting that REU who engaged in these risk-taking behaviours had 
higher scores on the Intensity subscale of the AISS than REU in the non risk group, 
which may describe them as more rash-impulsive than their non risk counterparts.  
REU in the at risk group had higher rash-spontaneous impulsivity (intensity) scores, 
although not significantly greater than REU in the non risk group, for the domains of 
cannabis and party drug driving risk, crime risk and overdose risk.  These findings 
are congruent with other research (e.g., Arnett, 1990; Arnett, 1994; Arnett, 1997; 
Greene, Krcmar, Walters, Rubin & Hale, 2000; Horvath & Zuckerman, 1993) that 
have indicated a positive relationship between rash-spontaneous impulsivity and 
risk-taking behaviours such as these.  However, the present findings add to previous 
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research findings in that these relationships have now been established in a ‘risky’ 
cohort of regular ecstasy consumers.      
 
 Interestingly, rash-spontaneous impulsivity (intensity) scores were 
significantly lower for REU in the injecting risk category compared to REU in the 
non risk injecting group, suggesting that REU who injected a drug in the last 6 
months were less rash impulsive than REU who did not inject a drug in the last 6 
months.  This is contrary to other research findings (e.g., Checkley, Thompson, 
Crofts & Mijch, 1996; Lapworth, Dawe, Davis, Kavanagh, Young & Saunders, 
2009), which suggests that heightened impulsivity is associated with injecting drug 
use.  Although unlikely, this finding could be related to the different impulsivity 
measures used in each of these studies.  However, this result is most likely due to an 
aberration of the participants interviewed; or, related to the very small proportion of 
REU whose behaviours classified them in the injecting risk category (9%).  
However, further research is needed to clarify this result.    
 
 Scores on the Novelty subscale of the rash-spontaneous measure did not 
differ significantly between groups for any of the risk-taking domains.  This finding 
suggests that the individual differences in the propensity to seek out intense stimuli 
as opposed to novel stimuli may be more important in terms of risk-taking 
behaviour.  Additionally, this may also suggest that intensity related factors of 
environmental situations may be more influential than the novel factors of that same 
environment in terms of influencing risk-taking behaviour.  Therefore, it is possible 
that the Intensity subscale of the AISS is a better match conceptually to Dawe and 
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Loxton’s (2004) definition of rash-spontaneous impulsivity than the Novelty 
subscale.    
 
 In terms of predictive utility, rash-spontaneous impulsivity (intensity) was a 
significant predictor variable with regards to predicting REU whose behaviours 
categorised them in the at risk group for the sexual risk, alcohol driving risk, 
cannabis driving risk, party drug driving risk, binge risk and injecting risk domains.  
However, impulsivity (intensity) was not a useful predictor variable for the sexual 
risk, binge risk and injecting risk domains, due to the poor amount of variance 
explained and the low percentage of individuals successfully predicted to be at risk.     
 
 It is interesting that rash-spontaneous impulsivity was not a useful predictor 
in relation to sexual risk-taking, given that previous research has shown elevated 
impulsivity as predictive of sexual risk-taking behaviours (e.g., Cooper, Agocha & 
Sheldon 2000; Dolezal, Meyer-Bahlburg, Remien & Petkova, 1997; Justus, Finn & 
Steinmetz, 2000; Schafer, Blanchard & Fals-Stewart, 1994).  One explanation for 
this finding may be that the REU sampled were well educated, with 83% having 
obtained Year 12 qualifications or beyond.  Therefore, it could be inferred that the 
sample was well informed regarding safe sexual practices.  However, over half the 
sample (59%) demonstrated behaviours that defined them to be at sexual risk.  
Additionally, the effects of binge alcohol use on sexual risk-taking has been 
documented, in that REU who binge drink whilst also taking ecstasy tend to take 
greater sexual risks (e.g., Breen et al., 2006).  In the current sample, it is unknown if 
the REU defined to be at sexual risk had only used ecstasy, or if they had also been 
intoxicated by alcohol at the time of sexual risk-taking.  This could be an important 
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factor, given the different effects of ecstasy versus alcohol, in that a person only 
under the influence of ecstasy may retain more of their mental facilities than a person 
under the combined effect of ecstasy and alcohol, which may in turn affect the 
decision-making process with regards to using protective measures when having sex 
with a casual partner.   
 
 Rash-spontaneous impulsivity was more useful as a predictor variable within 
the driving domains.  With regards to predicting alcohol driving risk, rash-
spontaneous impulsivity (intensity) was a significant predictor of REU who had 
driven under the influence and proved to be a useful model explaining a moderate 
amount of variance, and correctly predicting most participants at risk (68%).  Rash-
spontaneous impulsivity (intensity) approached significance as a predictor variable 
for REU who had driven under the influence of cannabis.  Interestingly, rash-
spontaneous impulsivity also significantly predicted REU who had driven under the 
influence of party drugs.  In the final model, Intensity and Novelty acted inversely; 
with the final model suggesting that REU who had higher levels of Intensity and 
REU who had lower levels of Novelty were both predictive of driving under the 
influence of party drugs.  This final model proved useful, correctly predicting 86% of 
REU at risk.  This finding makes evident that the Intensity and Novelty subscales of 
the AISS conceptually differ and measure alternative aspects of the broader sensation 
seeking / impulsivity construct.  Generally, taking into account all of Study 1 
findings, it appears that the Novelty subscale of the AISS does not conceptually 
measure rash-spontaneous impulsivity as defined by Dawe and Loxton’s (2004) 
model; the Intensity subscale appears to be a better conceptual match to this 
construct.   
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 These findings add to previous research that has shown higher levels of rash-
spontaneous impulsivity are associated with driving under the influence of alcohol 
and cannabis (see Table 6 for review).  Results from the present research further 
implicate the importance of rash-spontaneous impulsivity as a predictive factor in 
alcohol and drug driving behaviour a sample of REU, who may collectively be 
deemed a ‘risky’ cohort.     
  
Conscientiousness: Differences between REU at Risk and REU Not at Risk, and its 
Ability to Predict Engagement in Risk-Taking Behaviour  
 
 The responsibility facet of conscientiousness was expected to differentiate 
between REU at risk and REU not at risk for all risk-taking categories, in that REU 
at risk were expected to have significantly lower levels of conscientiousness than 
REU not at risk.  This hypothesis was not supported, as analyses revealed no 
significant differences in conscientiousness scores between REU who engaged in 
risk-taking behaviours versus those who did not.  Furthermore, conscientiousness 
was not a significant predictor variable with regards to predicting which REU were 
at risk in any risk-taking domain, with the exception of the overdose category.  
Despite its significance in predicting REU at risk of overdose, the final model 
generated was clearly not useful, given it was unable to successfully predict REU at 
risk.     
 
 These findings were very surprising given that previous research (e.g., Bogg 
& Roberts, 2004) has shown significant negative relationships between 
conscientiousness and various health related risk-taking behaviours.  The failure to 
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replicate such findings may be due to the relatively small sample size that completed 
the conscientiousness measure in relation to the entire sample size.  A lack of 
significant association may also be due to the multi-faceted nature of the 
conscientiousness construct, in that it is possible the IPIP:Re assessment measure did 
not tap into the conscientiousness construct the way in which intended; however, 
there is no evidence this is the case.  Additionally, given the socially desirable nature 
of some questions on the assessment (e.g., ‘I return extra change when a cashier 
makes a mistake; I like to be of service to others; and I take others’ interests into 
account’), it is possible that some participants may have answered in a socially 
desirable, biased manner, which may have artificially inflated their conscientiousness 
score.  It is also possible that the sample group as a whole scored poorly (or highly) 
on the conscientiousness measure.  Norms are not available for the IPIP:Re measure; 
however, the highest score achievable on the IPIP:Re, 50, indicates an individual is 
highly conscientious.  The current sample appeared to report moderate to high levels 
of conscientiousness (M = 38.51, SD = 6.56, 1st quartile = 36, 3rd quartile = 43).  
Therefore, it is possible there was too little variation in conscientiousness scores to 
have a meaningful impact on risk-taking behaviour.   
   
Limitations  
 
 One limitation of the current study was its cross-sectional design; however, 
this type of design is often employed in alcohol and drug research, and therefore the 
results of this study are comparable with other similar research studies.  A further 
limitation is the study’s reasonably small sample size of 200 subjects.  However, the 
characteristics of the sample were similar to other groups of REU studied across 
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Australia (e.g., Breen et al., 2006; Degenhardt et al., 2004; Matthews & Bruno, 
2006), and therefore are deemed to be a representative sample of frequent ecstasy 
users.  This study also gathered data through face to face interviews; therefore, there 
is the potential for under-reporting, or reporting in a socially biased manner due to 
interviewer presence.   
 
 Additionally, due to the cross-sectional design, the data collected with 
regards to rash-spontaneous impulsivity cannot determine the direction of the 
impulsivity – risk-taking relationship.  In other words, the data collected is not 
conclusive as to whether high levels of rash-spontaneous impulsivity is a 
predisposing factor, or a consequence of drug use, given that prolonged drug use is 
thought to alter regions of the brain involved in rash-spontaneous impulsivity 
(Loxton et al., 2008; Jentsch & Taylor, 1999).  However, prospective studies have 
found that impulsivity measures in childhood and adolescence is predictive of later 
drug use (e.g., Brook, Whiteman, Gordon & Cohen, 1986; Brook, Morojele, Pahl & 
Brook, 2006; Caspi, Begg, Dickson, Harrington, Langley, Moffitt & Silva, 1997).  
Therefore, it is likely that an impulsive temperament predisposes individuals to drug 
experimentation and use, and that subsequent impairment of self-regulatory controls 
due to neural adaptation, may both escalate drug use and risky drug-related 
behaviour (Loxton et al., 2008; Dawe, Gullo & Loxton, 2004).    
 
 Lastly, the participants in this study collectively can be considered “risk-
takers” by virtue of their regular illicit drug use.  Therefore, this study provided an 
overall sample of risk-takers.  This is potentially a limitation with regards to 
confidently being able to generalise the findings to other populations.     
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Conclusions and Future Research    
 
 On a whole, findings of the current study contribute to the validity of models 
that implicate rash-spontaneous impulsivity in substance use and risk-taking 
behaviours (e.g., Dawe & Loxton, 2004), whilst providing contrary results to models 
that implicate conscientiousness’ role in risk-taking behaviours (e.g., Bogg & 
Roberts, 2004).  Whilst this study was exploratory in nature, these preliminary 
findings suggest that the rash-spontaneous factor of impulsivity plays a role in risky 
behaviours over and beyond just ecstasy use.  The role of conscientiousness is 
unclear.   
 
 As stated previously, the participants in this study collectively are considered 
“risk-takers” by virtue of their regular illicit drug use.  In order to better understand 
the influence of rash-spontaneous impulsivity and conscientiousness in general risk-
taking behaviour such as unsafe sex and drug driving, future research could compare 
the differences between these personality factors in groups of risk-takers (i.e., REU) 
versus groups of non-risk takers, such as a comparison group of drug naïve persons 
or a community based sample.  
 
 Future research measuring both factors of Dawe and Loxton’s (2004) two 
factor model of impulsivity would be useful to gain a better understanding of the two 
proposed facets of impulsivity, and how both of these relate to risk-taking behaviours 
in a sample of REU, who collectively as a group may already be considered ‘risky.’ 
Given that current findings found Intensity on a whole to be a more significant factor 
than Novelty, and considering the inverse relationship between Intensity and Novelty 
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for the party drug driving risk category, future research needs to carefully consider 
how rash-spontaneous impulsivity is measured based on theoretical underpinnings, 
as results appear to support there are many facets of the sensation seeking / 
impulsivity construct.  Additionally, given the paucity of existing literature, more 
research regarding the influence of conscientiousness on risk-taking behaviours in 
drug using populations is required in order to better understand these relationships.    
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Chapter 11: Study 2 Research Aims and Rationale 
 
 The second part of this thesis, Study 2, followed on from the results obtained 
in Study 1 in an effort to further investigate the ability of rash-spontaneous 
impulsivity and conscientiousness to predict engagement in risk-taking behaviours in 
a larger, online sample of REU.  Given the sensitive nature of the questions included 
in the survey, and the potential for participants to answer in a socially desirable 
manner, a web-based design was employed to ensure all participants complete 
anonymity.   
   
 In order to fully test Dawe and Loxton’s (2004) two-factor conceptualisation 
of impulsivity, Study 2 measured and explored the predictive utility of the second 
proposed factor of impulsivity, reward sensitivity, in addition to rash-spontaneous 
impulsivity.  In an effort to obtain a better conceptual match of Dawe and Loxton’s 
(2004) rash-spontaneous construct, Study 2 used a different measure of rash-
spontaneous impulsivity that provided a better fit conceptually. In an effort to clarify 
the relationship of conscientiousness on risk-taking behaviour in REU, Study 2 
retained the existing conscientiousness measure from Study 1.   
 
 Additionally, Study 2 measured and controlled for the sexual and driving 
attitudes of REU.  The reasons for this were twofold; first, to add to existing 
knowledge regarding the role of attitudes in predicting engagement in risk-taking 
behaviour in a sample of REU, and secondly, to control for their effects.  It is known 
that attitudes typically influence behaviour; therefore, in order to examine how well 
personality factors perform as predictor variables for risk-taking behaviours in REU, 
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Study 2 controlled for attitudinal variables.  Research regarding the role of attitudes 
is described in detail in the following section.   
 
 Furthermore, in relation to risk-taking behaviours, Study 2 narrowed its 
approach slightly from Study 1, and only included measures of sexual, drug driving, 
binge, overdose and injecting risk-taking behaviours.  These variables were viewed 
on a continuum basis (i.e., frequency of involvement in risk-taking behaviour), rather 
than the categorical basis used in Study 1, with the exception of injecting risk, which 
was viewed categorically due to the low rate of engagement in such behaviour 
among ecstasy users (Dunn, Day, Bruno, Degenhardt & Campbell, 2010).   
 
 Additionally, whereas Study 1 focused solely on risk-taking behaviours 
evident in REU, Study 2 also measured harm reduction practices employed by REU.  
REU’s engagement in harm reduction strategies was measured to add to the current 
small body of research knowledge in this area, and in an exploratory effort to 
examine relations between personality factors and engagement in harm reduction 
practices in a sample of REU.  Previous research regarding harm reduction practices 
utilised by REU is described in the following section.    
 
Reward Sensitivity, Substance Use and Risk-Taking 
  
 As stated in the literature review, the proposed second trait of impulsivity, 
reward sensitivity, refers to individual differences in attending to and approaching 
appetitive stimuli; i.e., having a purposeful drive to obtain rewarding stimuli.  The 
underlying motivational system reflects Gray’s BAS dimension, in particular BAS-
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Drive and BAS-Reward Responsiveness.  On a neurophysiological level, individual 
differences in reward sensitivity are related to the functioning of the mesolimbic 
dopamine system.  As stated previously, the mesolimbic dopamine pathway is 
critical in that it underlies the positively reinforcing effects of natural reinforcers 
such as food and sex, as well as drugs of abuse.  Essentially, individuals with a high 
BAS sensitivity are more prone to engage in approach behaviour and experience 
positive affect in situations with cues for reward (Dawe & Loxton, 2004).   
 
 There is a lack of research regarding the direct role of reward sensitivity in 
substance use and risk-taking behaviours, as the majority of studies on illicit drug 
use have focused on measures of rash-spontaneous impulsivity (Loxton, Nguyen, 
Casey & Dawe, 2008).  However, in the few studies that have measured reward 
sensitivity, preliminary results indicate that individuals high in reward sensitivity are 
at higher risk of substance abuse (Genovese & Wallace, 2007; Johnson, Turner & 
Iwata, 2003; Knyazev, Slobodskaya, Kharchenko & Wilson, 2004) and alcohol 
abuse diagnoses / alcohol misuse (Johnson, Turner & Iwata, 2003; Loxton & Dawe, 
2001).  Reward sensitivity has been shown to be directly associated with 
dysfunctional eating and drinking (Loxton & Dawe, 2006 & 2001) as well as 
problem gambling (O’Connor, Stewart & Watt, 2009; Loxton, Nguyen, Casey & 
Dawe, 2008).  However, contrary to expectations and other research findings, Voigt, 
Dillard, Braddock, Anderson, Sopory and Stephenson (2009) found that reward 
sensitivity served as a protective force against engagement in risky health behaviours 
such as sexual practices, alcohol consumption, drug and tobacco use, car safety, 
inactivity and poor diet.   
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 It is also thought that reward sensitivity may play a role in cued-cravings and 
motivation to use drugs (Dawe & Loxton, 2004).  Franken (2002) compared results 
on the BIS / BAS scales with cue elicited alcohol cravings in a sample of men and 
women from an inpatient alcoholism treatment program as well as the general 
population.  Results indicated that people with high BAS-Drive scores (i.e., high 
levels of reward sensitivity) experienced significantly more strong desires, intentions 
to drink alcohol and negative reinforcement craving during exposure to alcohol 
related cues than did people with low BAS-Drive scores.  Franken concluded his 
findings supported Gray’s personality theory (Gray, 1970; Gray & McNaughton, 
2000) that high BAS activity is positively correlated with increased desire for 
drinking alcohol.    
 
 In summary, there is a lack of research regarding the direct role of reward 
sensitivity in substance use and risk-taking behaviours; however, research to date has 
indicated a direct relationship between reward sensitivity and substance and alcohol 
use / misuse, problem gambling and dysfunctional eating.  Further research is needed 
in this area to expand on these preliminary findings.   
 
The Role of Attitudes in Risk-Taking Behaviour  
 
 Attitudes are “tendencies to evaluate an entity with some degree of favour or 
disfavour, ordinarily expressed in cognitive, affective and behavioural responses” 
(Eagly & Chaiken, 1993).   The utility of the attitude concept derives partly from its 
assumed ability to guide, influence, direct, shape and predict actual behaviour (Eagly 
& Chaiken, 1993).  In general, previous research has shown that attitudes 
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significantly and substantially predict future behaviour in the general population 
(e.g., Kraus, 1995; Howarth, 1988).  Therefore, in relation to the current research, in 
an attempt to understand why some REU engage in risky behaviours and others do 
not, in addition to personality, it is important to consider the influence of attitudes; 
particularly as previous research has shown attitudes often account for a large 
amount of the variance in predicting behaviour.    
 
Health Psychology Models of Risk-Taking Behaviour  
 
 As stated previously, health models have explanatory power in relation to 
explaining health risk-taking behaviour, but they are not the models of focus and 
therefore are beyond the scope of this review.  However, in an effort to promote 
understanding of reasons underlying the inclusion of attitudinal measures, two of 
these models will be explained briefly.   
 
 The theory of reasoned action (Ajzen & Fishbein, 1980; Fishbein, 1980 & 
1982) proposed there are two attitudes that combine to produce what is known as an 
intention, and this intention then leads to the performance or nonperformance of the 
behaviour in question.  First, an individual’s attitude regarding the behaviour reflects 
their judgement of whether or not the behaviour is a good thing to do.  This 
judgement is often based on the individual’s beliefs about the likely outcome of the 
behaviour, and whether the outcome would be rewarding.  Secondly, an individual’s 
attitude about a subjective norm reflects the impact of social pressure or influence 
regarding the behaviour’s acceptability or appropriateness.  This judgement is based 
on the individual’s beliefs regarding others’ opinions about the behaviour, and their 
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motivation to comply with those opinions.  Thus, attitudes regarding a behaviour 
impacts upon our intentions, which then either leads to engagement or non-
engagement in the behaviour (Caltabiano, Sarafino, Byrne & Martin, 2002).   
 
  The theory of reasoned action was revised to include the notion of perceived 
behavioural control, thus resulting in the theory of planned behaviour (Ajzen, 1991).  
The concept of behavioural control (similar to perceived self-efficacy) was 
introduced to account for behavioural intentions not always predicting actual 
behaviour, e.g., when the behaviour is not directly in control of the person, or the 
person perceives no control regarding the behaviour (i.e., lack of self-efficacy) 
(Caltabiano, Sarafino, Byrne & Martin, 2002).  For example, the theory of planned 
behaviour would propose that people will intend to use condoms if they evaluate 
condom use positively, if they believe significant others think they should use 
condoms, and if they feel confident in their ability to use condoms (Heeren, 
Jemmott, Mandeya & Tyler, 2007).   
 
The Influence of Sexual Attitudes on Sexual Risk-Taking Behaviours 
 
 Previous research has indicated that sexual attitudes, as well as other factors, 
are significant predictors of sexual risk-taking behaviour in general population 
samples.  For example, Heeren, Jemmott, Mandeya and Tyler (2007) found that 
condom use was significantly predicted by positive condom attitudes, whereby 
university students who reported a more favourable attitude towards using condoms, 
more normative support for condom use and greater self-efficacy to use condoms 
reported using condoms more frequently when they had sexual intercourse.  
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Similarly, Khumsaen and Gary (2009) found that positive attitudes towards condom 
use and a higher condom use self-efficacy were significantly related to increased use 
of condoms in a sample of Thai adolescents.  In this study, age and sex were not 
significant predictors of condom use behaviour.  On the contrary, Lou and Chen 
(2009) found that Taiwanese adolescents’ sexual attitudes had no direct effect on the 
practice of safer sexual behaviour.   
 
 In a sample of females aged 18 – 21, Morrison-Beedy, Carey, Feng and Tu 
(2008) found the frequency of condom protected vaginal sex was predicted by 
information (better HIV knowledge), motivation (stronger intentions to practice safer 
sex and more positive attitudes towards condoms), skills (lower perceived difficulty 
for condom use and for negotiation with a partner), mental health (lower 
psychological distress), alcohol (no binge drinking, more drinking days) and other 
drug use (non-use of ecstasy).  The frequency of unprotected vaginal sex was 
predicted by alcohol (fewer drinking days, fewer average number of drinks per 
drinking day, more binge drinking), other drug use (opiate and ecstasy use) and 
lower frequency of protected vaginal sex at baseline.   
 
 Results from research conducted with high-risk groups have also revealed 
that sexual attitudes, amongst other factors, are significant predictors of sexual risk-
taking behaviour.  For example, Robertson and Levin (1999) found that positive 
attitudes towards condoms and reported use of a condom at first sexual intercourse 
experience were significant predictors of subsequent condom use in a population of 
substance abusing juvenile offenders on probation or parole, with females having a 
more positive attitude about condoms than males.  In a population of opiate / cocaine 
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using adults, Rosengard, Anderson and Stein (2006) found that positive attitudes 
regarding condoms’ effects on pleasure and not feeling embarrassed about 
negotiating condom use with a partner were associated with greater likelihood of 
condom use.  In a population of injecting drug users, Bogart, Kral, Scott, Anderson, 
Flynn, Gilbert and Bluthenthal (2005) found that positive attitudes towards condoms 
were significantly associated with and predicted consistent condom use for vaginal, 
anal and oral sex in the previous 6 months.   
 
 Therefore, previous research conducted in various sample populations 
demonstrates the predictive relationship between an individual’s attitudes towards 
factors associated with condom use and safer sex, and their engagement in safer sex 
or risky sexual practices.  These studies indicate that although there are other factors 
implicated in the practice of safer sex or engagement in risky sexual behaviours (e.g., 
alcohol / drug use, self-efficacy, mental health), attitudes certainly play an important 
role which should be considered when measuring involvement in sexual risk-taking 
behaviour.   
 
The Influence of Driving Attitudes on Risky Driving Behaviours  
 
 Previous research has shown that driver attitudes, amongst other factors, are 
associated with and are significant predictors of risky driving behaviour.  For 
example, Whissell and Bigelow (2003) found a significant correlation between 
speeding attitudes (more permissive) and the number of speeding tickets.  In a 
sample of Norwegian drivers, Iversen and Rundmo (2004) found that attitudes 
towards traffic safety issues influenced the person’s involvement in traffic risk 
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behaviour, with attitudes regarding rule violations and speeding of particular 
importance.  They also found that variations in attitudes were related to age and sex 
(younger males held more negative attitudes).  Similarly, in a sample of Turkish 
drivers, Yilmaz and Çelĭk (2004) found that risky driver attitudes, less obedience to 
speed rules, risk-taking tendency in traffic and caring (less) about traffic accidents 
explained 71% of the variance in risky driver behaviour.  Specifically, people whose 
attitudes reflected a greater obedience to speed rules were less likely to engage in 
risky driver behaviour.   
 
  In a recent study, Nordfjærn, Jørgensen and Rundmo (2010) investigated the 
relationship between demographic characteristics (age, sex, education), personality 
factors (impulsivity, anxiety, normlessness [the belief that social deviance may serve 
as a utility to obtain goals]), driver attitudes (rule violations and speeding, careless 
driving of others, drinking and driving) and driver behaviour (rule violation / 
speeding, reckless / fun riding, not using seat belts, cautious / watchful driving, 
drinking and driving, attentiveness to children in traffic, obeying speed limits).  In a 
predictive model, a considerable amount of the variance in driver attitudes (56%), 
and a moderate amount of the variance in driver behaviour (30%) were explained by 
personality factors.  There was a strong positive relationship (β = 0.75) between 
driver attitudes and driver behaviour.  Of the demographic variables, sex had the 
strongest direct effect on driver attitudes, in that males had less ideal driver attitudes 
than females.  Increased age was a predictor of more ideal attitudes to driving and 
cautious behaviour in traffic.  With regard to personality factors, normlessness had 
the strongest relationship with driver attitudes, indicating that lower levels of this 
trait predicted more favourable attitudes towards traffic safety.  Normlessness also 
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predicted less ideal (i.e., riskier) driver behaviour.  Anxiety and sensation seeking 
showed only weak relations to driver attitudes and behaviour.    
 
 Therefore, previous research has demonstrated that driving attitudes are 
important predictors of driver risk behaviour, with attitudes towards rule violations 
and speeding of particular importance.  These studies also demonstrate that in 
general, younger males have less ideal attitudes and may be more involved in risky 
driving behaviour.  However, these studies have been conducted in the general 
population as opposed to substance using populations, and no studies measuring drug 
driving were found.  Therefore, in relation to the present research, previous findings 
will attempt to be extended to a population of REU and behaviourally, drug driving.  
In an attempt to understand the role personality factors have on drug driving 
behaviours in REU, it is important to also consider driver attitudes, as they 
potentially may contribute to drug driving behaviour.   
 
Harm Reduction Practices in Ecstasy Users  
 
 As stated previously, the prevalence of people using ecstasy in Australia is 
rising (AIHW, 2008), and the adverse effect of MDMA on various brain systems, 
particularly the serotonergic system, have been noted.  There is also concern in that 
ecstasy users are typically polydrug users (Akram & Galt, 1999; Allott & Redman, 
2006; Boys, Lenton & Norcross, 1997; Topp, Hando & Dillon, 1999; Winstock, 
Griffiths & Stewart, 2001), and due to little research in this area, the possible effects 
of drug interactions in combination with ecstasy have not been determined (Allott & 
Redman, 2006).   
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 It is known that MDMA use can bring about a range of negative physical 
side-effects, both whilst under the influence of the drug and during the ‘comedown’ 
period, such as weight loss, sweating, dry mouth, insomnia, headaches, nausea, 
fatigue, difficulty concentrating, loss of appetite, feelings of dissociation, 
tachycardia, tremors and jaw-clenching.  In the days following ecstasy use, users are 
likely to have lowered levels of serotonin, which is associated with a variety of 
problems such as depression, anxiety and sleeping difficulties.  Other subacute 
symptoms include agitation, decreased alertness, fatigue, decreased appetite, muscle 
aches and tight jaw (Baggott, 2002; Copeland, Dillon & Gascoigne, 2004).   
 
 Previous research is mixed in that some studies have concluded that ecstasy 
users are unaware of the risks associated with using MDMA, or that they perceive 
ecstasy is a relatively safe drug, whilst other studies have indicated that ecstasy users 
are aware of the risks associated with MDMA use, and want more information about 
the risks of using and how they can minimise such effects (e.g., Akram & Galt, 1999; 
Topp, Hando & Dillon, 1999).     
 
 Harm reduction is defined as the “use of strategies to prevent or reduce 
harmful consequences associated with illicit drug use” (Allott & Redman, 2006).  
Harm can include a range of physical, psychosocial and / or financial problems 
associated with drug use.  Therefore, the goal of harm reduction is to reduce or 
minimise any harm that may occur as a consequence of drug use.  Drug users who 
are provided with accurate information are then enabled to make a responsible, 
informed decision whereby they can reduce the risks associated with their drug use 
(Cohen, 1994).   
 145
 Previous research has shown that ecstasy users employ varied strategies in an 
effort to minimise related problems due to ecstasy use, such as reducing the amount 
of ecstasy used (Baggott, 2002; Hansen, Maycock & Lower, 2001; Topp, Hando & 
Dillon, 1999), testing ecstasy pills prior to consumption (de Wijngaart, Braam, de 
Bruin, Fris, Maalsté & Verbraeck,1999; Winstock, Wolff & Ramsey, 2001), 
managing ‘comedown’ symptoms by taking other illicit or prescription drugs (Boys, 
Lenton & Norcross, 1997; Hansen, Maycock & Lower, 2001), and attempting to 
avoid serotonergic neurotoxicity by taking antioxidants and / or antidepressants 
(Baggott, 2002; Copeland, Dillon & Gascoigne, 2004).   
 
 Akram and Galt (1999) conducted a survey among ecstasy and related drug 
users in the UK in an attempt to ascertain the prevalence and types of harm reduction 
strategies employed, if any.  Of the 125 users sampled, 82% reported employing one 
or more harm reduction strategy.  Drinking water to avoid heat stroke was the most 
commonly used strategy (90%), followed by chilling out (i.e., taking a break from 
dancing and not allowing the body to become overheated or exhausted) (82%).  The 
authors found that females were significantly more likely than males to take harm 
reducing steps.    
 
Allott and Redman (2006) administered an anonymous questionnaire to 116 
Australian ecstasy users in an exploratory effort to describe the prevalence and 
nature of harm reduction practices employed.  Results indicated that just over half 
the sample had altered their use of ecstasy in response to a dislike of using, most 
commonly being to decrease the frequency with which they used ecstasy, followed 
by decreasing the amount of ecstasy used per occasion, ceasing use and obtaining 
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ecstasy pills from a reliable source.  Results also indicated that every ecstasy user 
surveyed employed at least one strategy to avoid negative ecstasy side effects, most 
commonly drinking water, followed by limiting ecstasy use, chilling out, 
maintaining a healthy lifestyle and taking vitamins or other natural products.  Users 
reported drinking water, limiting ecstasy use, taking vitamins or natural products and 
maintaining a healthy lifestyle as strategies to avoid the ecstasy ‘comedown.’ With 
regards to strategies employed with the aim of reducing brain damage or 
neurotoxicity, most commonly used was limiting ecstasy use, drinking water, taking 
vitamins or natural products and maintaining a healthy lifestyle.  Interestingly, 
approximately one third of the sample reported using other illicit substances to avoid 
ecstasy’s negative side effects and the ‘comedown’ associated with use.   
 
Using a pill testing kit is another strategy employed by some REU in an 
effort to reduce harm.  As stated previously, tablets sold as ecstasy may or may not 
contain MDMA, and they may well contain a variety of other substances.  As 
Baggott (2002) states, “quality control of ecstasy has become an important issue to 
ecstasy users.”  In Allott and Redman’s (2006) study, 40% of the sample reported 
having tested ecstasy pills for the presence of MDMA.  The aim of pill testing is to 
provide users with information regarding the composition of purported MDMA 
tablets, as well as to bring ecstasy users into contact with public health organisations 
that offer testing, in an effort to facilitate information exchange between users and 
monitoring authorities (Baggott, 2002; Winstock, Wolff & Ramsey, 2001).    
 
However, the validity and reliability of pill testing methods has been 
questioned (e.g., Winstock, Wolff & Ramsey, 2001), due to varying levels of test 
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sophistication.  Winstock, Wolff and Ramsey (2001) argue against the usefulness of 
pill testing.  They argue that some pill testing methods give no indication of some 
harmful substances that may be present, that pill testing cannot confirm what the true 
psychoactive effect of the tablet may be and that pill testing gives no information 
regarding the strength of the tablet.  Additionally, they argue that users may be given 
false reassurance if pill testing identifies MDMA, which users may then falsely 
misinterpret to mean the tablet is safe to take.   
 
Another type of harm reduction method is known as pre-loading and post-
loading, defined as the use of pharmaceuticals and / or natural products prior and 
subsequent to ecstasy use to reduce any acute and / or longer-term adverse effects 
associated with use (Allott & Redman, 2006).  Studies have indicated the use of 
selective serotonin reuptake inhibitors (SSRIs), the serotonin precursor 5-hydroxy 
tryptophan (5-HTP) and the antioxidant Vitamin C are often used in an effort to 
reduce ecstasy-related neurotoxicity (McCann & Ricaurte, 1993; Oesterheld, 
Armstrong & Cozza., 2004; Tong & Boyer, 2002; Weir, 2000).   
 
 Allott and Redman (2006) also measured the prevalence and nature of pre- 
and post-loading practices in their sample of ecstasy users.  Of the 66% of ecstasy 
users that had heard of the practice, 41% engaged in pre-loading and 47% in post-
loading.  Users reported using multivitamins, 5-HTP, magnesium and fruit / fruit 
juice most commonly to pre-load, whilst using 5-HTP, multivitamins and fruit / fruit 
juice most commonly to post-load.  The most common reasons users gave for pre- 
and post-loading was to decrease the ‘comedown,’ followed by attempting to reduce 
brain damage or neurotoxicity.  One-third of pre-loaders did so every time they used 
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ecstasy, while nearly half of post-loaders did so every time they used ecstasy.  The 
authors also explored factors that differentiated between ecstasy users who pre- and / 
or post-loaded from those who did not.  Analyses revealed that being younger and 
having used ecstasy more than 50 times was significantly associated with pre-
loading, whilst using ecstasy more than 50 times and using ecstasy on a monthly or 
more often basis was significantly associated with post-loading.  Unlike Akram and 
Galt (1999), Allott and Redman (2006) did not find any sex differences in the overall 
use of harm reduction strategies.   
 
 It is unknown if pre- and post-loading practices are actually effective in 
reducing the short and / or long-term adverse effects or neurotoxicity associated with 
ecstasy use (Oesterheld, Armstrong & Cozza, 2004; Allott & Redman, 2006).  
However, regardless of their effectiveness, most substances used for pre- and post-
loading (e.g., vitamins, minerals, fruit, fruit juice, milk and turkey) are unlikely to 
cause harm.  Nonetheless, there is concern that REU engage in such practices due to 
the belief that they are protecting themselves, and as a result, maintain or increase 
their current level of ecstasy use, when in fact, there is a paucity of human research 
regarding the efficacy of such practices (Allot & Redman, 2006).   
 
 There is also cause for concern that some REU use ecstasy and other 
serotonin-enhancing substances, such as 5-HTP, selective serotonin reuptake 
inhibitors (SSRIs) or monoamine oxidase inhibitors (MAOIs) anti-depressant 
medication, lysergic acid diethylamide (LSD) and products with pseudoephedrine, 
concomitantly.  For example, REU have reported using anti-depressant medications 
in an attempt to counteract any potential damage that may result from depleted 
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serotonin levels due to ecstasy use.  Using ecstasy and other serotonin-enhancing 
substances in tandem could potentially result in dangerously high levels of serotonin, 
and bring about the potentially fatal condition known as ‘serotonin syndrome’ 
(Sternbach, 1991).  This syndrome can occur after ingestion of two or more 
serotonin-enhancing substances, and causes symptoms such as euphoria, drowsiness, 
sustained rapid eye movement, overreaction of the reflexes, rapid muscle contraction 
and relaxation in the ankle causing abnormal movements of the foot, clumsiness, 
restlessness, feeling drunk and dizzy, muscle contraction and relaxation in the jaw, 
sweating, intoxication, muscle twitching, rigidity, high body temperature, frequent 
mental status changes, shivering, diarrhoea, loss of consciousness and death 
(Copeland, Dillon & Gascoigne, 2004; Sternbach, 1991).  Although the prevalence 
of serotonin syndrome is thought to be low, it is still a risk and it is important that 
ecstasy users who use other serotonin-enhancing substances are well informed of the 
risks involved. 
 
 In summary, many REU appear to practice a wide range of harm reduction 
practices, despite their effectiveness being clinically undetermined.  However, there 
is a paucity of research in this area, and further information regarding the types of 
practices being employed by ecstasy users and the reasons behind this is imperative.  
Further research regarding drug interactions is also warranted, as is research 
regarding the clinical effectiveness of such harm reduction practices.  It would be 
ideal to provide REU with research-validated information regarding the efficacy of 
harm reduction practices, so that REU could then make educated decisions regarding 
their ecstasy use and the use of harm reduction strategies to minimise risk. 
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 In relation to Study 2, harm reduction practices employed by REU were 
explored in order to add to the existing small body of research knowledge.  
Additionally, relationships between personality factors and harm reduction strategies 
were examined to determine if rash-spontaneous impulsivity, reward sensitivity and / 
or conscientiousness are able to successfully predict REU who engage in harm 
reduction behaviour versus those who do not.  Identification of the differentiating 
factors between REU who engage in harm reduction behaviour versus those who do 
not could prove particularly important in the development of appropriate health 
intervention and treatment programs.  For example, if research establishes that low 
rash-spontaneous impulsivity or high conscientiousness significantly predicts 
engagement in harm reduction practices, successful programs may focus on helping 
such REU plan their ecstasy use, encourage the use of home pill testing kits and / or 
provide pamphlet or web-based information, etc.  If the same were true, on the 
contrary, targeting REU who are non harm reductionists (i.e., those higher in rash-
spontaneous impulsivity or lower in conscientiousness) also becomes a priority for 
intervention programs, so as to encourage as many REU as possible to engage in 
some type of harm reduction behaviour.  Such harm reduction programs targeting 
this sub-population may tend to focus on reaching users and providing information at 
clubs / dance sites, such as encouraging the consumption of fewer ecstasy tablets, 
encouraging non-mixing of ecstasy with other drugs, offering free bottles of water 
and / or free onsite pill testing.    
 
 151
Chapter 12: Study 2 Hypotheses 
 
 In light of previous research and findings from Study 1, the demographic 
factors of sex and age (i.e. being male and younger) were expected to predict 
engagement in risk-taking behaviours.  Given that previous research findings 
regarding the relationship between age, sex and engagement in harm reduction 
behaviour is mixed, these relationships were conducted in an exploratory manner 
with no conclusive expectations held.   
 
 With regard to attitudes, it was expected that less positive attitudes regarding 
safer sexual practices and driving would be predictive of REU who engaged in 
sexual risk behaviour and drug driving, or that more positive attitudes towards these 
behaviours would result in less risk-taking behaviour.  For example, individuals 
whose attitudes towards the practice of safer sex were considered risky or less safe 
may engage in sexual risk-taking behaviour more often than an individual who 
highly endorsed safe, non-risky attitudes towards the practice of safer sex.  Or, 
individuals who endorsed rules-based, safe, non-risky driving attitudes may engage 
in risky driving behaviours less often than those whose attitudes towards driving 
were considered risky or less safe.   
 
 In relation to personality factors, it was expected that the rash-spontaneous 
factor of impulsivity would be predictive of REU who engage in all domains of risk-
taking behaviours.  Although entirely exploratory, rash-spontaneous impulsivity was 
expected to either play a negative role with regard to predicting the use of harm 
reduction strategies, or be unrelated.  Despite the lack of significant relations in 
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Study 1, based on the large body of previous research findings, the personality factor 
of conscientiousness was expected to be predictive of REU who engage in risk-
taking behaviours in a negative fashion, and predictive of REU who engage in harm 
reduction behaviours in a positive fashion.  Given the paucity of available research 
regarding the role of reward sensitivity, exploration of this second factor of 
impulsivity was purely exploratory; therefore, no conclusive expectations were held 
regarding its predictive abilities.   
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Chapter 13: Study 2 Method 
 
Participants 
 
 Participants were 445 self-identified frequent ecstasy users who participated 
in the online survey or pencil / paper survey between May and November 2009 
(99.8% participated online).  Participation was open to anyone who self-identified 
using ecstasy in the preceding 6 months.   
 
 All surveys were systematically checked for validity in relation to stringent 
exclusion criteria.  Firstly, the surveys of participants who reported they had never 
used ecstasy or had not used ecstasy in the last 6 months were discarded.  This 
criterion was of priority as the study aimed to target people who self-reported regular 
ecstasy use in the preceding 6 months.  Secondly, the surveys of participants who 
chose not to complete all of the personality measures were eliminated.  Given the 
rationale and aims of this study, completion of all personality measures was a core 
component of data analyses and the potential clinical application of the results.  
Therefore, participants with missing personality data were removed so that all 
analyses reported in Study 2 related to the same, consistent group of REU.  Lastly, 
the remaining surveys were checked in relation to suspect bogus / exaggerated 
reporting.  Given the survey was hosted online, there was a risk that some 
participants may have given false or exaggerated responses.  Suspected cases were 
removed from the data set for validity reasons.  Following this process, a total of 196 
surveys were removed from the data set, resulting in a total of 249 participants 
(Figure 3).      
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Figure 3 
Participant flow diagram of exclusion criteria 
 
 
 
 
As the survey was hosted online, participants resided throughout the world.  
The majority of respondents lived in the United States of America (38.2%), followed 
by Australia (27.3%), New Zealand (8.8%), the United Kingdom (8.0%) and Canada 
(6.4%).  Participants from Sweden, Spain, Denmark, Ireland, France, Norway, 
Belgium, Germany and the Netherlands collectively accounted for 3.6% of the 
sample.  Other demographic characteristics of the sample are presented in Table 23.  
Compared to the Study 1 sample, participants in this online sample were younger 
(22.9 versus 24.3 years of age) and had a higher proportion of male respondents 
(62.7% versus 56.5%).   
 
 
 
 
 
 
Excluded (N = 196) 
 Never used ecstasy (N = 64) 
 Did not use ecstasy in the last 6 months (N = 15) 
 Did not complete all personality measures (N = 114) 
 Provided exaggerated or suspect bogus responses (N = 3) 
Final sample (N = 249) 
Completed online survey (N = 445) 
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Table 23  
Demographic characteristics of participants  
N = 249 % 
Mean age 22.9 (SD = 6.62) 
Male 62.7 
Employed full time 27.3 
Full-time student 20.9 
Employed part-time / casual 9.6 
Unemployed 7.2 
Heterosexual 82.7 
Gay male 2.4 
Lesbian 2.0 
Bi-sexual 12.0 
 
 
Ecstasy was the main drug of choice for 39.8% of the sample, followed by 
18.5% preferring cannabis, 12.4% preferring LSD and 8.8% preferring alcohol.  The 
majority of the sample had never injected any drug (82.7%).  The mean age of first 
ecstasy use was 19.3 years (SD = 4.60), with the mean number of ecstasy tablets 
usually taken per session was 2.7 (SD = 1.83).  The overwhelming majority of the 
sample ingested ecstasy orally (92.4%), whilst 6.8% reported their main route of 
ecstasy administration was snorting.   
 
Table 24 details the sample’s patterns of lifetime and recent use of ecstasy 
and other drugs.  The patterns of use of this online sample were comparable to the 
Study 1 sample for LSD, cannabis, alcohol and mushrooms.  However, participants 
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in the current sample reported higher lifetime and recent use of cocaine, ketamine 
and GHB, whilst reporting less overall and recent use of methamphetamine.     
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Table 24 
Participant’s patterns of lifetime and recent use of ecstasy and other drugs  
   Frequency of use in the last 6 months (among those using the drug in this period) 
 
Drug Ever used (%) Used last 6 
months (%) 
Less than 
monthly (%) 
Monthly (%) Fortnightly (%) Weekly (%) More than once 
a week (%) 
 
Ecstasy 
 
100.0 100.0 47.0 30.5 10.4 7.6 2.8 
Alcohol 
 
97.6 92.4 10.2 11.6 15.1 34.2 28.9 
Cannabis 
 
95.6 83.5 24.3 13.9 8.4 17.3 36.1 
Cocaine 
 
62.7 41.4 73.0 11.0 8.0 6.0 2.0 
Mushrooms 
 
60.2 30.9 76.3 10.5 11.8 1.3 0.0 
LSD  
 
57.0 31.7 62.3 23.4 10.4 3.9 0.0 
Ketamine 
 
47.8 23.3 76.8 8.9 3.6 3.6 7.1 
Methamphetamine 
(powder, base, 
crystal) 
 
47.4 28.9 69.4 13.9 5.6 2.8 8.3 
GHB 
 
20.1 8.4 57.1 9.5 9.5 14.3 9.5 
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Procedure 
 
 
 Participants were recruited through posters distributed in the greater Hobart 
area (cafes, university and vocational education providers).  Posters were also mailed 
to all Australian university psychology departments as well as approximately 70 
Technical and Further Education (TAFE) providers across Australia.  Internet forums 
such as www.bluelight.ru, www.freshdisko.com, www.tripme.co.nz, www.drugs-
forum.com, www.drugsandbooze.com, and www.legalhighsforum.com were also 
used for recruitment purposes.   
 
 Interested participants navigated to the online survey webpage and completed 
the study at a time convenient to themselves.  Prior to commencing the online 
survey, participants were presented with an information sheet, to which they had to 
give consent in order for the online survey to proceed.  It was estimated that 
participation would take most participants approximately 30 minutes, and 
participants were advised that all questions were optional.  At the end of the survey, 
participants were given the opportunity to enter a prize draw to win one of three 
$100 www.amazon.com gift vouchers to thank them for their participation.      
 
Materials 
 
 
Online Questionnaire  
 
 
The online questionnaire was a self-report survey that assessed several key 
areas: demographic information, patterns of ecstasy and related drug (ERD) use, 
health and harm reduction behaviours, driving practices, sexual experiences and 
personality.  For consistency purposes, items used in the online questionnaire were 
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based on items from the PDI questionnaire used in Study 1 (Matthews & Bruno, 
2006).  A copy of the online questionnaire may be found in Appendix B.   
 
Demographic Information and Patterns of ERD Use 
 
 As in Study 1 and consistent with the PDI questionnaire (Matthews & Bruno, 
2006), participants were asked to indicate their sex, age, country of residence, 
employment status and sexual identity.  Participants were also asked to indicate the 
age at which they first tried ecstasy, their usual route of ecstasy administration, their 
main drug of choice (i.e., favourite or preferred drug) and the nature / frequency of 
their ERD use in the past 6 months.   
 
Health and Harm Reduction Behaviours 
 
 Participants were asked to give information regarding overdose and binge use 
(defined as use for more than 48 hours without sleep) of stimulant drugs, as well as 
their use of ecstasy combined with alcohol and / or methamphetamine.  These items 
were consistent with items from the PDI questionnaire used in Study 1 (Matthews & 
Bruno, 2006).  Participants were also asked about a variety of harm reduction 
behaviours, such as finding out the content / purity of drugs before taking them, 
using pill testing kits, the practice of preloading and postloading, as well as other 
strategies used to minimise the comedown of ecstasy, and / or strategies used to 
reduce the longer-term negative side effects of using ecstasy.  Harm reduction items 
were again based on selected items from the PDI Questionnaire (Matthews & Bruno, 
 160
2006), as well as questions used in Allott and Redman’s (2006) study regarding harm 
reduction practices employed by a sample of Australian ecstasy users.   
 
Driving Practices 
 
 Participants that indicated they had driven a car in the previous 6 months 
were asked about driving under the influence of alcohol and illicit drugs, and the 
impact they felt this had on their driving ability.  These items were consistent with 
items from the PDI Questionnaire (Matthews & Bruno, 2006) used in Study 1.   
 
 Participants were also asked to answer questions regarding their attitudes 
towards risk-taking whilst driving.  Ulleberg and Rundmo (2002) derived a 60-item 
(unnamed) multidimensional scale by a series of factor analyses, combining items 
from the Young Driver Attitude Scale (YDAS; Malfetti, Rose, DeKorp & Basch, 
1989), driving attitude items based on studies by Rundmo (1998, 1996 & 1992) and 
self-reported acts of risk-taking whilst driving (Rundmo, 1996; Rundmo & Ulleberg, 
2000).  The final 60-item scale consisted of 11 attitude subscales: riding with an 
unsafe driver, speeding, concern about hurting others, drinking and driving, showing 
off skills to others, traffic flow versus rule obedience, joyriding, dare to speak up to 
an unsafe driver, risk for accidents, fatalism and violation of traffic rules, as well as a 
behavioural items scale.  Example items include, ‘It is better to drive smoothly than 
to always follow the traffic rules’, and ‘I think it’s okay to speed if traffic conditions 
allow you to do so.’ Ulleberg and Rundmo (2002) report the scalability, homogeneity 
of subscale items, and discriminant and content validity of the final scale were all 
satisfactory.   
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 In Ulleberg and Rundmo’s (2002) study, all 11 attitude subscales 
significantly correlated with self-reported driving risk-taking behaviour and accident 
frequency.  In relation to driving risk-taking behaviour, the strongest correlated 
subscales were speeding, traffic flow versus rule obedience and joyriding.  
Furthermore, Ulleberg and Rundmo’s (2002) multiple regression analyses revealed 
that 10 of the 11 attitude subscales were significant predictors of self-reported 
driving risk-taking behaviours, with the speeding subscale the best predictor.   
 
 In the current study, participants were asked to answer a total of 45 questions 
representing 9 of the 11 attitude subscales as well as the behavioural items scale.  
The attitude subscales riding with an unsafe driver and fatalism were not included 
due to the nature / wording of these questions, and because both subscales were 
amongst the weakest predictors of driving risk-taking behaviour.  For each attitude 
subscale question, participants were asked to rate their opinion about each statement 
on a 5-point Likert scale, ranging from ‘strongly agree’ to ‘strongly disagree’.  For 
the behavioural scale, participants were asked to indicate how often they engaged in 
various driving risk-taking behaviours on a 5-point Likert scale ranging from ‘never’ 
to ‘very often’.  Scores were appropriately summed so that the higher the score, the 
more the participant endorsed driving risk-taking attitudes and / or behaviours.  
 
Sexual Experiences 
 
 Participants were asked about their participation in sexual health check-ups 
and if they had ever been diagnosed with a sexually transmitted infection.  
Participants were also asked to indicate how many sexual partners they had in the 
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past 6 months, if they had sex with a casual partner in the previous 6 months, if they 
had sex whilst using ERD, and their frequency of protection use (e.g., condoms).  
These questions were consistent with questions from the PDI Questionnaire 
(Matthews & Bruno, 2006) used in Study 1.   
 
 Participants were also asked to answer questions regarding their sexual 
attitudes.  DeHart and Birkimer (1997) derived a 38-item Sexual Risks Scale, which 
is comprised of subscales measuring attitudes about safer sex, normative beliefs, 
intention to practice safer sex, expectations about the feasibility of safer sexual 
activity, perceived susceptibility to HIV/AIDS and substance use.  DeHart and 
Birkimer (1997) report the overall scale and individual subscales are all characterised 
by internal reliability and both construct and predictive validity, and that subscales 
are concise and reliable enough to use independently or in conjunction with one 
another.  Additionally, the wording used in this scale is reported to be broadly 
applicable with regards to gender, sexual orientation and sexual experience (DeHart 
& Birkimer, 1997).   
 
 In the current study, participants were asked to answer 26 questions 
representing 4 of the 6 subscales from the Sexual Risks Scale.  The intention to try to 
practice safer sex and the expectations about the feasibility of safer sexual activity 
subscales were not included, as the inclusion of these 2 subscales in the overall scale 
was exploratory, and the addition of these 2 subscales did not add accuracy to actual 
sexual risk prediction (DeHart & Birkimer, 1997).  Participants were asked to rate 
their opinion about each statement on a 5-point Likert scale, ranging from ‘almost 
never’ to ‘almost always’.  Example items include ‘Condoms ruin the natural sex 
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act’, and ‘The proper use of a condom could enhance sexual pleasure.’ Scores were 
appropriately summed so that the higher the score, the more the participant endorsed 
sexual risk-taking attitudes.   
 
Personality 
 
 The online survey concluded with 3 measures of personality, as well as a lie 
scale intended for validity purposes (each described below).   
 
International Personality Item Pool Responsibility Scale (IPIP: Re) 
 
As stated previously, the International Personality Item Pool (IPIP) is a web-
based, scientific collaboratory that provides access to measures of personality and 
individual differences in the public domain.  Consistent with Study 1, the online 
survey included the IPIP scale of responsibility (Goldberg et al., 2006), which is 
based on the responsibility subscale of the California Psychological Inventory (CPI) 
(Gough & Bradley, 1996).  The domain of responsibility, as discussed previously, is 
a facet of the trait conscientiousness.  In brief, the IPIP: Re scale consists of 10 
statements that describe people’s behaviour.  Example items included ‘I return extra 
change with a cashier makes a mistake’ and ‘I like to be of service to others.’  
Participants were asked to use a 5-point rating scale to indicate how accurately each 
statement described them.  Higher scores are indicative of higher levels of 
conscientiousness related behaviour, on a continuum rather than categorical basis.  
The reliability of the IPIP: Re scale is moderate (α = .66) (Goldberg et al., 2006).   
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BIS / BAS Scales 
  
 
 The BIS / BAS scales (Carver & White, 1994) were constructed to assess 
dispositional behavioural inhibition (BIS) and behavioural approach (BAS) 
sensitivities, based on Gray’s (1981, 1982) previously discussed theory that these 
two general motivational systems underlie human behaviour and affect.  The BIS / 
BAS scales are a self-report instrument including a total of 24 items.  Four of these 
items were “fillers” and were not included in the online survey as they did not 
contribute to the participant’s score.  For each of the 20 statements, participants were 
asked to indicate the degree to which they agreed or disagreed using a four-point 
Likert scale ranging from ‘very true for me’ to ‘very false for me.’ Example items 
included ‘I go out of my way to get things I want,’ ’I often act on the spur of the 
moment,’ and ‘I worry about making mistakes.’  
 
 The scales provided a single score for BIS and three subscale scores for BAS: 
(1) BAS reward responsiveness, which includes items that measure anticipation and 
positive response towards reward, (2) BAS drive, which includes items that tap 
persistence in obtaining desired goals, and (3) BAS fun seeking, which includes 
statements that are indicative of a willingness to seek out and spontaneously 
approach potentially rewarding experiences (Carver & White, 1994).  The BAS drive 
subscale was of particular interest to the current study as it provided the best 
conceptual measure of reward sensitivity.   
 
 Carver and White (1994) indicate the internal reliability of each scale as 
moderate / good (BAS drive α = .76).  Data regarding convergent and discriminant 
validity indicate that the BIS and BAS scales are related to, but also distinguishable 
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from alternative measures of similar constructs and measures of important alternative 
constructs (Carver & White, 1994).  Carver and White (1994) conclude that 
collectively their studies provide support for the idea that the BIS / BAS scales 
validly reflect individual differences in the sensitivity of the presumed underlying 
neurophysiological regulatory systems.   
 
Barratt Impulsiveness Scale (BIS-11) 
 
 The Barratt Impulsiveness Scale, Version 11 (BIS-11; Patton, Stanford & 
Barratt, 1995) is a 30-item self-report questionnaire designed to assess general 
impulsiveness, taking into account the multi-factorial nature of the construct.  The 
structure of the BIS-11 allows for the assessment of six first-order factors of 
impulsiveness (attention, motor, self-control, cognitive complexity, perseverance, 
cognitive instability) and three second-order factors of impulsiveness (attentional 
impulsiveness [attention and cognitive instability], motor impulsiveness [motor and 
perseverance] and nonplanning impulsiveness [self-control and cognitive 
complexity]).  Patton and colleagues (1995) report internal consistency coefficients 
ranging from 0.79 to 0.83 for various populations, including undergraduates, 
substance abuse patients, general psychiatric patients and prison inmates.   
 
 In the online survey, participants were asked to read each statement and 
indicate on a 4-point Likert scale how well the statement described them, ranging 
from ‘rarely / never’ to ‘almost always / always’.  Example items included ‘I do 
things without thinking,’ ‘I buy things on impulse,’ and ‘I am future oriented.’ A 
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total score was obtained by appropriate summation, with a higher score indicative of 
a higher level of impulsiveness, on a continuum rather than categorical basis.   
 
EPQ-R Short Scale Lie Scale 
 
 The Short Lie Scale from the Eysenck Personality Questionnaire Revised 
(Eysenck & Eysenck, 1991) was also included in the personality section of the online 
survey.  This scale was included with an intention to use this instrument to provide a 
measure of validity and socially desirable reporting from participants.  The Short Lie 
Scale consisted of 12 questions, which participants were asked to read and to 
indicate ‘yes’ or ‘no’ in response to each.  Items included questions such as ‘Have 
you ever blamed someone for doing something you really knew was your fault?’ and 
‘Have you ever said anything bad or nasty about someone?’   
 
 Participants were scored 1 point for each of the questions they answered in a 
socially biased way.  Therefore, a total score of 12 points was possible, with higher 
scores indicating the participant’s tendency to ‘fake good’ and answer in a socially 
desirable manner.  The Eysenck Personality Scales Manual (Eysenck & Eysenck, 
1991) states there is no definitive cut-off score beyond which participants should be 
eliminated; however, the authors recommend evaluating data given by the top 
scoring 5%.    In the current sample, the top scoring 5% recorded scores of 8 (n = 5), 
9 (n = 7) and 10 (n = 1).  The survey responses of these participants were evaluated 
and found to appear reliable and valid; therefore, none of these participants were 
eliminated from the sample.    
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Data Analysis: Dependent Variables of Risk-Taking and Harm Reduction  
 
 
 Five domains of risk-taking behaviour (sexual, drug driving, binge, overdose 
and injecting), as well as a harm reduction domain, were created based on variables 
within the online questionnaire (each described below).  Table 25 details the 
distributional properties of each dependent variable.   
 
Sexual Risk Category 
 
 Participants who indicated they had sex with a casual partner in the previous 
6 months (38.2% of the overall sample) were asked to indicate the frequency of 
which they used protection (e.g., condoms) during those encounters, either while or 
whilst not using party drugs.  Participants chose from 5 responses: ‘never’, ‘rarely’, 
‘sometimes’, ‘often’ or ‘every time.’  Responses were scored so that participants who 
reported to never use protection with casual partners were given a score of 4, 
whereas participants reporting to use protection ‘every time’ were scored 0.  
Therefore, the higher the score, the greater the sexual risk.    
 
Drug Driving Risk Category 
 
 Participants who indicated they had driven a car in the previous 6 months 
were asked if they had driven soon after taking illicit drugs in the previous 6 months.  
Those participants who indicated they had drug driven were asked to indicate the 
number of times they had drug driven in the previous 6 months.  Therefore, a 
participant’s score was indicative of the number of times they drug drove, with 
higher scores indicating more frequent engagement in drug driving behaviour.     
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Binge Risk Category 
 
Participants were asked if they used stimulants or related drugs (e.g., ecstasy, 
amphetamines, cocaine) for more than 48 hours continuously without sleep in the 
previous 6 months.  Participants who indicated yes were then asked to indicate the 
number of times they had engaged in this behaviour in the previous 6 months.  
Therefore, a participant’s score was indicative of the number of times they used 
stimulants or related drugs for more than 48 hours without sleep, with higher scores 
indicating of more frequent engagement in binge risk behaviour.   
 
Overdose Risk Category 
 
As consistent with Study 1, several single variables were considered with 
regards to determining if the participant was at risk of overdose.  Namely, those 
participants who indicated they had ever accidently overdosed on a stimulant drug, 
reported to usually (50% or more of the time) drink more than 5 standard drinks of 
alcohol when using ecstasy, and / or reported to usually (50% or more of the time) 
use any type of methamphetamine when using ecstasy were considered at risk of 
overdose.  Also, the number of ecstasy tablets the participant reported to usually 
consume in a typical session was also used as an indicator variable of overdose risk, 
in that risk of overdose increased with a higher number of tablets typically taken.  
These variables were combined into a latent measure of overdose risk, the process of 
which is detailed in the next section.   
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Injecting Risk Category  
 
Those participants who indicated they had ever injected any drug were 
deemed to be at injecting risk.   
 
Harm Reduction Category 
 
 
 As previously discussed, there is little research regarding harm reduction 
practices employed by ecstasy users.  Therefore, there is no widely accepted 
definition or set of criteria that differentiates between ecstasy users who are harm 
reducing and those who are not.  Therefore, this attempt to form an overall harm 
reduction variable was completely exploratory in nature.   
 
 In the current study, the harm reduction variable was viewed on a continuum 
rather than categorical basis.  To describe the extent to which participants were harm 
reducing, 6 single variables were considered.  A sum of the number of potentially 
‘harm reducing’ behaviours that participants endorsed was created from the 
following: finding out the content and purity of ecstasy tablets before taking them 
more than 50% of the time, ever pre-load before using ecstasy, ever post-load after 
using ecstasy, reduce how often they used ecstasy, decrease the amount of ecstasy 
taken on each occasion, and taking breaks or ‘chilling out’ when using ecstasy (with 
an aim to prevent overheating).  This yielded a graded ‘harm reduction’ score 
ranging from 0 (no strategies employed; not at all harm reducing) to 6 (all strategies 
employed; very harm reducing).   
 
 
 
 170
Table 25 
 
Distributional properties of dependent variables 
 
Dependent 
Variable 
Definition  Possible 
Range  
Observed 
Range  
Mean (SD) 
Sexual Risk Frequency of protection use 
with casual partners in last 6 
months (of those who had sex 
with a casual partner) 
0 – 4  
 
0 – 4  1.75 (1.66) 
Drug Driving 
Risk 
Number of times drug driven 
in previous 6 months 
0 – 193 0 – 182  6.17 (21.41) 
Binge Risk Number of times used 
stimulants for more than 48 
hours continuously without 
sleep in last 6 months 
0 – 193 0 – 30 1.36 (3.83) 
Overdose Risk Ever overdosed on a 
stimulant drug, use ecstasy 
with 5+ standard drinks or 
methamphetamine, how 
many tablets taken in a 
typical session 
-- -- -- 
Injecting Risk Ever injected any drug 0 – 1 0 – 1  0.16 (0.36) 
Harm 
Reduction 
Find out content / purity of 
ecstasy before taking, ever 
pre or post load, reduce 
frequency of ecstasy use, 
decrease amount of ecstasy 
taken per session, taking 
breaks when using ecstasy 
0 – 6  0 – 6 3.78 (1.49) 
Note.  Sexual Risk 0 = used protection ‘every time’, 4 = used protection ‘never’; Injecting Risk 0 = 
no, 1 = yes; Harm Reduction 0 = no strategies employed, 6 = all strategies employed.  -- Rather than 
observed variables, the latent variable is used for the Overdose Risk category.  
 
 
Statistical Analyses  
 
 
 Items comprising each domain of interest were initially assessed using 
Muthén and Muthén’s (2009) MPlus statistical modeling program (Version 5.21), 
with an intention to construct structural equation models using latent variables to 
hypothesise causal relationships among variables.  Hierarchical regression analyses 
was employed (using IBM SPSS Statistics) to assess the ability of personality 
measures (rash-spontaneous impulsivity, reward sensitivity and conscientiousness) to 
predict risk-taking and harm reduction behaviour.   
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Chapter 14: Study 2 Results 
 
Measurement Models 
 
 Items comprising each domain of interest were initially assessed using MPlus 
(Version 5.21: Muthén & Muthén, 2009) with an intention to conduct structural 
equation modelling using latent variables.  However, initial modelling using MPlus 
revealed poor measurement models (the fit of the individual items to the latent 
construct).  For example, when using MPlus to test how well individual items on the 
Barrett Impulsivity Scale (or its subscales) fit together to form an overall construct, 
analysis revealed poor model fit.  These could typically be improved to meet 
requirements for acceptable model fit by removing multiple items from the scales.  
Similar results were found in relation to the sexual and driving risk-taking variables, 
the sexual attitude, reward sensitivity and conscientiousness measures, and the harm 
reduction construct.  However, in relation to the overdose risk-taking construct, 
MPlus data analysis revealed quite a good model fit.   
 
 Despite MPlus analyses indicating that individual items comprising the latent 
personality constructs failed to meet standards for acceptable fit, this is not an 
uncommon experience when examining latent structures of scales, and these scales 
have been used in copious other research paradigms, as detailed in previous sections.  
Therefore, with a goal of contributing to research knowledge in this area, personality 
scales and the items comprising them were not altered in an effort to meet criteria for 
acceptable model fit.  Rather, and more consistent with the limited sample size, the 
modelling approach was changed from structural modelling using latent variables to 
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hierarchical regression modelling, retaining all personality scales (i.e., IPIP: Re, BIS 
/ BAS, BIS-11) as they were published, for consistency with the existing literature in 
this area.   
 
Multiple Regression Assumption Testing 
 
 
 Given that multiple regression makes a number of assumptions about the 
data, assumption testing was conducted prior to running multiple regression 
analyses.  In accordance with Pallant (2009) and Field’s (2005) recommendations, 
tests for the assumptions of sample size, multicollinearity, outliers, normality, 
linerarity, homoscedasticity and independence of residuals were conducted for each 
hierarchical multiple regression analysis. 
 
 An adequate sample size is important in social science research so that results 
obtained are able to be generalised (i.e., repeated) with other samples.  Stevens 
(1996; cited in Pallant, 2009) indicated that approximately 15 participants per 
predictor variable are needed to satisfy an appropriate sample size.  Tabachnick and 
Fidell (2007; cited in Pallant, 2009) recommend using the following formula for 
calculating sample size requirements: N > 50 + 8m (where m = number of 
independent variables).  Using these as a guide, all multiple regression analyses met 
the assumption of sample size, with the exception of sexual risk (actual n = 74, 
recommended n > 90), which was slightly below that recommended.   
 
 Multicollinearity exists when independent variables used in regression 
analyses are highly correlated (r = 0.90 and above) (Pallant, 2009).  To check this 
assumption, Pearson’s correlations between each of the independent variables were 
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assessed (Table 26).  Results indicated all independent variables were satisfactorily 
distinct from one another, hence meeting the assumption of multicollinearity.   
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Table 26 
 
Pearson’s correlation matrix for Study 2 variables  
 
 Sex Age IPIP:Re BasD BIS-11 SexAt DSS DSTF DSB SR DDR BR IR HR 
Sex  -0.04 -0.08 -0.02 0.01 -0.09 0.23*** 0.13^ 0.11 -0.00 0.01 0.05 0.07 0.05 
N  248 248 243 230 196 232 213 209 94 248 248 243 248 
Age   0.14* -0.08 -0.09 -0.05 -0.08 -0.08 -0.11 0.05 -0.11^ -0.09 0.05 0.06 
N   249 244 231 197 233 214 210 95 249 249 244 249 
IPIP:Re    -0.02 -0.12^ -0.06 -0.19** -0.14* -0.23** -0.12 0.00 0.02 -0.07 0.11^ 
N    244 231 197 233 214 210 95 249 249 244 249 
BasD     0.23** -0.07 0.13* 0.16* 0.19** 0.00 0.07 0.11^ 0.08 -0.09 
N     230 195 230 210 208 94 244 244 239 244 
BIS-11      -0.06 0.22** 0.29*** 0.36*** -0.17 0.12^ 0.15* 0.21** -0.19** 
N      186 218 201 197 91 231 231 227 231 
SexAt       -0.03 0.04 0.32*** -0.12 -0.01 -0.03 -0.03 0.11 
N       190 174 176 81 197 197 192 197 
DSS        0.74*** 0.69*** 0.14 0.20** 0.17* -0.01 -0.19** 
N        208 202 90 233 233 233 233 
DSTF         0.71*** 0.20^ 0.21** 0.20** 0.05 -0.16* 
N         186 83 214 214 209 214 
DSB          -0.08 0.25*** 0.15* 0.06 -0.28*** 
N          80 210 210 205 210 
SR           -0.12 0.11 0.03 -0.13 
N           95 95 94 95 
DDR            0.11^ 0.02 -0.11^ 
N            249 244 249 
BR             0.10 -0.08 
N             244 249 
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IR              0.02 
N              244 
HR               
N               
Note. Missing cases pairwise.  Overdose Risk Variable is not included as this was a latent variable.  IPIP:Re = International Personality Item Pool Responsibility Scale; BasD 
= Drive subscale of BIS / BAS scales; BIS-11 = Barrett Impulsivity Scale; SexAt = Attitudes to Safer Sex subscale of the Sexual Risks Scale; DSS = Speeding subscale of 
the driving scale; DSTF = Traffic flow versus rule obedience subscale of the driving scale; DSB = Behavioural subscale of the driving scale; SR = Sexual Risk Variable; 
DDR = Drug Driving Risk Variable; BR = Binge Risk Variable; IR = Injecting Risk Variable; HR = Harm Reduction Variable.  ^p < 0.10, *p < 0.05, **p < 0.01, ***p < 
0.001. 
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 All other results of assumption testing indicated that each dependent variable 
of interest met the remaining assumptions with one exception.  Each dependent 
variable initially produced Mahalanobis values larger than the recommended critical 
values, suggesting the presence of outliers.  Outliers are defined as cases that have a 
standardised residual of > 3.3 or < -3.3 (Pallant, 2009).  For each dependent variable, 
the presence and potential influence of outliers was checked by inspecting the 
Mahalanobis and Cook’s distances.  Critical values from Tabachnick and Fidell’s 
(2007) statistical text were used as cut-off criteria to deem if the Mahalanobis and 
Cook’s distances were acceptable.  For each variable, the offending case(s) were 
removed from the data set to ensure no violation of this assumption, and therefore 
ensuring these unusual cases did not impact on the regression analyses.  Details of 
removed cases are presented below in each relevant section.   
 
Prediction of Sexual Risk-Taking Behaviour 
  
 Preliminary assumption testing revealed the presence of 2 outliers, which 
were removed from the data set to ensure appropriate Mahalanobis and Cook’s 
distances values.  All other assumptions were met with the exception of sample size, 
as discussed above.  Hierarchical multiple regression was then used to assess the 
ability of sexual attitudes (as measured by the ‘Attitudes towards safer sex’ subscale 
of the Sexual Risks Scale) and personality measures (conscientiousness (IPIP:Re), 
reward sensitivity (BAS Drive) and rash spontaneous impulsivity (BIS-11)) to 
predict sexual risk-taking behaviour, after controlling for the influence of sex and 
age (Table 27).   
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 Sex and age were entered at Step 1, explaining 3.1% of the variance in sexual 
risk-taking behaviour.  This model was non-significant in predicting sexual risk-
taking behaviour, F(2, 71) = 1.13, p = 0.331.  After entry of attitudes towards safer 
sex at Step 2, the total variance explained by the model as a whole increased to 
11.2%, with sexual attitudes explaining an additional 8.2% of the variance in sexual 
risk-taking behaviour, after controlling for sex and age, ΔR² = .08, ΔF(1, 70) = 6.44, 
p = 0.013.  This model was significant in predicting sexual risk-taking behaviour, 
F(3, 70) = 2.95, p = 0.038.  After entry of the personality variables at Step 3, the total 
variance explained by the model as a whole increased to 24.4%, and was a 
significant predictor of sexual risk-taking behaviour, F(6, 67) = 3.61, p = 0.004, with 
the personality measures explaining an additional 13.2% of the variance in sexual 
risk-taking behaviour, after controlling for sex, age and attitudes towards safer sex, 
ΔR² = .13, ΔF(3, 67) = 3.90, p = 0.013.  In the final model, attitudes towards safer 
sex, t(67) = 2.24, p = 0.029 and rash-spontaneous impulsivity, t(67) = -2.72, p = 
0.008 were statistically significant predictors of sexual risk-taking behaviour, whilst 
conscientiousness approached significance, t(67) = -1.86, p = 0.068.   
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Table 27 
 
Summary of Hierarchical Regression Analyses of Variables Predicting Sexual Risk- 
 
Taking Behaviour, N = 74 
 
 b SE b β p 
Step 1 
   Constant 
   Sex 
   Age 
 
0.69 
-0.19 
0.06 
 
0.89 
0.41 
0.04 
 
 
-0.05 
0.17 
 
 
0.648 
0.144 
Step 2 
   Constant 
   Sex 
   Age 
   Attitudes to Safer Sex 
 
-0.66 
-0.32 
0.06 
0.04 
 
1.01 
0.40 
0.04 
0.02 
 
 
-0.09 
0.16 
0.29 
 
 
0.428 
0.164 
0.013* 
Step 3 
   Constant 
   Sex 
   Age 
   Attitudes to Safer Sex 
   Conscientiousness (IPIP: Re) 
   Reward Sensitivity (BAS Drive) 
   Rash Spontaneous (BIS-11) 
 
5.26 
-0.47 
0.05 
0.04 
-0.07 
0.02 
-0.04 
 
2.26 
0.38 
0.04 
0.02 
0.04 
0.09 
0.01 
 
 
-0.14 
0.15 
0.26 
-0.21 
0.02 
-0.32 
 
 
0.217 
0.185 
0.029* 
0.068^ 
0.860 
0.008** 
Note.  R² = 0.03 for Step 1, 0.11 for Step 2 and 0.24 for Step 3: ΔR² = 0.08 for Step 2 (p = .013), ΔR² 
= 0.13 for Step 3 (p = 0.013).  ^p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 
Prediction of Drug Driving Behaviour 
  
 
 Preliminary assumption testing revealed the presence of 2 outliers, which 
were removed from the data set to ensure appropriate Mahalanobis and Cook’s 
distances values.  All other assumptions were met.  Hierarchical multiple regression 
was used to assess the ability of driving attitudes (measured by the ‘speeding’ and 
‘traffic flow versus rule obedience’ subscales of Ulleberg and Rundmo’s (2002) 
driving scale), self-reported driving behaviours (measured by the ‘driving behaviour’ 
subscale of Ulleberg and Rundmo’s (2002) driving scale) and personality measures 
(conscientiousness (IPIP:Re), reward sensitivity (BAS Drive) and rash spontaneous 
impulsivity (BIS-11)) to predict drug driving behaviour, after controlling for the 
influence of sex and age (Table 28).  As stated previously, the ‘speeding’ and ‘traffic 
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flow versus rule obedience’ subscales were selected due to their strong correlations 
and predictive power with regard to self-reported driving risk-taking behaviour 
(Ulleberg & Rundmo, 2002).   
 
 Sex and age were entered in Step 1, explaining 1.6% of the variance in drug 
driving behaviour.  This model was not significant in predicting drug driving, F(2, 
165) = 1.38, p = 0.255.  After entry of driving attitudes and behaviours at Step 2, the 
total variance explained by the model as a whole increased to 8.3%, with driving 
attitudes and behaviours explaining an additional 6.7% of the variance in drug 
driving behaviour after controlling for sex and age, ΔR² = 0.07, ΔF(3, 162) = 3.93, p 
= 0.010.  This model was significant in predicting drug driving behaviour, F(5, 162) 
= 2.94, p = 0.014.  After entry of personality variables at Step 3, the total variance 
explained by the model as a whole was 9.1%, F(8, 159) = 1.98, p = 0.052, with the 
personality measures explaining an additional 0.8% of the variance in drug driving 
behaviour, after controlling for sex, age, driving attitudes and behaviours, ΔR² = 
0.01, ΔF(3, 159) = 0.44, p = 0.725.  No individual measures were found to be 
independent significant predictors of drug driving behaviour in any of the models.   
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Table 28 
 
Summary of Hierarchical Regression Analyses of Variables Predicting Drug Driving  
 
Behaviour, N = 168 
 
 b SE b β p 
Step 1 
   Constant 
   Sex 
   Age 
 
20.69 
-1.08 
-0.53 
 
8.19 
4.06 
0.32 
 
 
-0.02 
-0.13 
 
 
0.790 
0.100^ 
Step 2 
   Constant 
   Sex 
   Age 
   Attitudes: Speeding 
   Attitudes: Traffic Flow versus  
      Rule Obedience 
   Driving Behaviour   
 
-2.30 
-2.34 
-0.43 
0.20 
0.29 
 
0.57 
 
10.42 
4.07 
0.32 
0.67 
0.41 
 
0.43 
 
 
-0.05 
-0.10 
0.04 
0.09 
 
0.16 
 
 
0.566 
0.180 
0.762 
0.475 
 
0.189 
Step 3 
   Constant 
   Sex 
   Age 
   Attitudes: Speeding 
   Attitudes: Traffic Flow versus  
      Rule Obedience 
   Driving Behaviour  
   Conscientiousness (IPIP: Re) 
   Reward Sensitivity (BAS Drive) 
   Rash Spontaneous (BIS-11) 
 
-26.40 
-1.98 
-0.44 
0.25 
0.26 
 
0.57 
0.42 
0.09 
0.09 
 
23.74 
4.11 
0.32 
0.68 
0.41 
 
0.46 
0.44 
0.83 
0.16 
 
 
-0.04 
-0.11 
0.05 
0.08 
 
0.16 
0.08 
0.01 
0.05 
 
 
0.631 
0.173 
0.710 
0.529 
 
0.211 
0.339 
0.917 
0.558 
Note.  R² = 0.02 for Step 1, 0.08 for Step 2 and 0.09 for Step 3: ΔR² = 0.07 for Step 2 (p = .010), ΔR² 
= 0.01 for Step 3 (p = 0.725).  ^p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Prediction of Binge Risk-Taking Behaviour 
 
 Preliminary assumption testing revealed the presence of 3 outliers, which 
were removed from the data set to ensure appropriate Mahalanobis and Cook’s 
distances values.  All other assumptions were met.  Hierarchical multiple regression 
was used to assess the ability of personality measures (conscientiousness (IPIP:Re), 
reward sensitivity (BAS Drive) and rash spontaneous impulsivity (BIS-11)) to 
predict binge risk-taking behaviour, after controlling for the influence of sex and age 
 181
(Table 29).  Sex and age were entered in Step 1, explaining 1.1% of the variance in 
binge risk-taking behaviour.  This model was not significant in predicting binge risk-
taking behaviour, F(2, 223) = 1.28, p = 0.281.  After entry of personality variables at 
Step 2, the total variance explained by the model as a whole was 3.9%, F(5, 220) = 
1.79, p = 0.115, with personality measures explaining an additional 2.8% of the 
variance in binge risk-taking behaviour, after controlling for sex and age, ΔR² = .03, 
ΔF(3, 220) = 2.12, p = 0.098.  In the final model, no measures were found to be 
independent statistically significant predictors of binge risk-taking behaviour, 
although rash spontaneous impulsivity, t(220) = 1.79, p = 0.074 approached 
significance.   
 
Table 29 
 
Summary of Hierarchical Regression Analyses of Variables Predicting Binge Risk- 
 
Taking Behaviour, N = 226 
 
 b SE b β p 
Step 1 
   Constant 
   Sex 
   Age 
 
2.26 
0.52 
-0.05 
 
1.10 
0.55 
0.04 
 
 
0.06 
-0.08 
 
 
0.343 
0.228 
Step 2 
   Constant 
   Sex 
   Age 
   Conscientiousness (IPIP: Re) 
   Reward Sensitivity (BAS Drive) 
   Rash Spontaneous (BIS-11) 
 
-2.79 
0.55 
-0.05 
0.02 
0.14 
0.04 
 
3.05 
0.55 
0.04 
0.06 
0.11 
0.02 
 
 
0.07 
-0.07 
0.03 
0.09 
0.12 
 
 
0.310 
0.278 
0.707 
0.191 
0.074^ 
Note.  R² = 0.01 for Step 1 and 0.04 for Step 2: ΔR² = 0.03 for Step 2 (p = 0.098).  ^p < 0.10, *p < 
0.05, **p < 0.01, ***p < 0.001. 
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Prediction of Overdose Risk-Taking Behaviour 
 
 
 
 As stated previously, initial analyses involved using MPlus (Version 5.21: 
Muthèn & Muthèn, 2009) with an intention to conduct structural equation modelling 
using latent variables.  For the domain of overdose risk-taking behaviours, modelling 
using MPlus revealed a good measurement model (i.e., the fit of the individual items 
comprising the overdose risk-taking domain to a single, homogenous latent 
construct).  MPlus was used to assess the ability of personality measures 
(conscientiousness (IPIP:Re), reward sensitivity (BAS Drive) and rash spontaneous 
impulsivity (BIS-11)) to predict the latent construct of overdose risk-taking 
behaviour, after controlling for the influence of sex and age (Table 30).  Sex and age 
were entered in Step 1, explaining 10.1% of the variance in overdose risk-taking 
behaviour.  After entry of personality variables at Step 2, the total variance explained 
by the model as a whole was 22.6%.  In the final model, both sex and age were 
statistically significant predictors of overdose risk-taking behaviour, whilst reward 
sensitivity and rash spontaneous impulsivity approached significance.     
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Table 30 
Summary of MPlus Analyses of Variables Predicting Overdose Risk-Taking 
Behaviour, N = 229 
 b SE b β p 
Step 1      
   Constant 1.07 0.47   
   Sex 0.17 0.10 0.25 0.080^ 
   Age 0.01 0.01 0.21 0.092^ 
Step 2     
   Constant -2.29 1.39   
   Sex 0.21 0.11 0.27 0.049* 
   Age 0.01 0.01 0.23 0.048* 
   Conscientiousness (IPIP:Re) -0.002 0.01 -0.02 0.853 
   Reward Sensitivity (BAS Drive) 0.03 0.02 0.20 0.078^ 
   Rash Spontaneous (BIS-11) 0.01 0.004 0.25 0.056^ 
Note.  R² = 0.10 for Step 1 and 0.23 for Step 2.  ^p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 
Prediction of Injecting Risk-Taking Behaviour 
 
 
 
 Preliminary assumption testing revealed the presence of 3 outliers, which 
were removed from the data set to ensure appropriate Mahalanobis and Cook’s 
distances values.  All other assumptions were met.  Hierarchical multiple regression 
was used to assess the ability of personality measures (conscientiousness (IPIP:Re), 
reward sensitivity (BAS Drive) and rash spontaneous impulsivity (BIS-11)) to 
predict injecting risk-taking behaviour, after controlling for the influence of sex and 
age (Table 31).  Sex and age were entered in Step 1, explaining 1.1% of the variance 
in injecting risk-taking behaviour.  This model was not significant in predicting 
injecting risk-taking behaviour, F(2, 219) = 1.18, p = 0.311.  After entry of the 
personality variables at Step 2, the total variance explained by the model as a whole 
increased to 6.2%, F(5, 216) = 2.84, p = .016, with personality measures explaining 
an additional 5.1% of the variance in injecting risk-taking behaviour, after 
controlling for sex and age, ΔR²  = .05, ΔF(3, 216) = 3.93, p = .009.  In the final 
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model, rash spontaneous impulsivity, t(216) = 2.89, p = 0.004 was a statistically 
significant predictor of injecting risk-taking behaviour.   
 
 
Table 31 
 
Summary of Hierarchical Regression Analyses of Variables Predicting Injecting  
 
Risk-Taking Behaviour, N = 222 
 
 b SE b β p 
Step 1 
   Constant 
   Sex 
   Age 
 
0.03 
0.07 
0.00 
 
0.10 
0.05 
0.00 
 
 
  0.09 
0.07 
 
 
0.210 
0.331 
Step 2 
   Constant 
   Sex 
   Age 
   Conscientiousness (IPIP: Re) 
   Reward Sensitivity (BAS Drive) 
   Rash Spontaneous (BIS-11) 
 
-0.18 
0.06 
0.01 
-0.01 
0.00 
0.01 
 
0.29 
0.05 
0.00 
0.01 
0.01 
0.00 
 
 
0.08 
0.09 
-0.07 
0.02 
0.20 
 
 
0.226 
0.173 
0.273 
0.763 
0.004** 
Note.  R² = 0.01 for Step 1 and 0.06 for Step 2: ΔR² = 0.05 for Step 2 (p = 0.009).  ^p < 0.10, *p < 
0.05, **p < 0.01, ***p < 0.001. 
 
 
 
Prediction of Harm Reduction Behaviour 
 
 
 
 Preliminary assumption testing revealed the presence of 3 outliers, which 
were removed from the data set to ensure appropriate Mahalanobis and Cook’s 
distances values.  All other assumptions were met.  Hierarchical multiple regression 
was used to assess the ability of personality measures (conscientiousness (IPIP:Re), 
reward sensitivity (BAS Drive) and rash spontaneous impulsivity (BIS-11)) to 
predict harm reduction behaviours, after controlling for the influence of sex and age 
(Table 32).  Sex and age were entered in Step 1, explaining 0.7% of the variance in 
harm reduction behaviours.  This model was not significant in predicting harm 
reduction behaviours, F(2, 223) = 0.78, p = 0.462.  After entry of personality 
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variables at Step 2, the total variance explained by the model as a whole was 5.0%, 
F(5, 220) = 2.31, p = 0.045, with personality measures explaining an additional 4.3% 
of the variance in harm reduction behaviours, after controlling for sex and age, ΔR² = 
.04, ΔF(3, 220) = 3.32, p = .021.  In the final model, rash spontaneous impulsivity, 
t(220) = -2.35, p = 0.020 was a statistically significant predictor of engagement in 
harm reduction behaviour, with greater levels of rash-spontaneous impulsivity 
suggestive of lower levels of harm reduction behaviour.   
 
 
Table 32 
 
Summary of Hierarchical Regression Analyses of Variables Predicting Harm  
 
Reduction Behaviour, N = 226 
 
 b SE b β p 
Step 1 
   Constant 
   Sex 
   Age 
 
3.29 
0.19 
0.02 
 
0.42 
0.21 
0.02 
 
 
 0.06 
0.06 
 
 
0.379 
0.346 
Step 2 
   Constant 
   Sex 
   Age 
   Conscientiousness (IPIP: Re) 
   Reward Sensitivity (BAS Drive) 
   Rash Spontaneous (BIS-11) 
 
3.98 
0.20 
0.01 
0.03 
-0.03 
-0.02 
 
1.16 
0.21 
0.02 
0.02 
0.04 
0.01 
 
 
0.07 
0.04 
0.08 
-0.06 
-0.16 
 
 
0.324 
0.557 
0.216 
0.409 
0.020* 
Note.  R² = 0.01 for Step 1 and 0.05 for Step 2: ΔR² = 0.04 for Step 2 (p = .021).  ^p < 0.10, *p < 0.05, 
**p < 0.01, ***p < 0.001.   
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Chapter 15: Study 2 Discussion 
 
 
 Study 2 aimed to investigate the extent to which the personality traits of rash-
spontaneous impulsivity, reward sensitivity and conscientiousness were able to 
successfully predict REU who engage in risk-taking and / or harm reduction 
behaviours associated with their ecstasy use, over and beyond what demographic 
(i.e., sex and age) factors may predict.  This study also examined the role that 
attitudes towards sex and driving practices may play in predicting sexual and driving 
risk-taking behaviours, and how well personality variables perform as predictor 
variables in these risk-taking domains when attitudinal variables are controlled for.   
 
Demographic Variables as Predictors of Risk-Taking and Harm Reduction 
 
 It was hypothesised that sex and age (i.e., being male and being younger) 
would be successful predictors of engagement in risk-taking behaviour, whilst no 
expectations were held regarding the relationship between sex, age and the harm 
reduction variable.  Results of analyses indicated that sex and age were not 
significant predictor variables in relation to any domains of risk-taking or the harm 
reduction variable, with the exception of successfully predicting overdose risk-taking 
behaviour.  With regard to the overdose risk-taking domain, results indicated that 
older males were significantly more likely to engage in behaviours indicative of 
overdose risk.  Together, age and sex explained a moderate amount (10.1%) of the 
variance in overdose risk-taking behaviour.   
 
 The finding that demographic variables were not successful predictors of 
REU’s engagement in risk-taking behaviours is not altogether surprising, as despite a 
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consensus in the general population that younger males are more frequently involved 
in risk-taking behaviour, previous research has shown mixed results in this regard.  
Findings from Study 1 implicated sex as a successful significant predictor variable 
only for the domain of driving under the influence of cannabis, where males were 
more likely to engage in this behaviour.  In relation to age, results from Study 1 
showed that age only successfully predicted REU who drove under the influence of 
alcohol and party drugs, in that older REU were more likely to engage in these risk-
taking behaviours.  Sex and age did not successfully predict any of the other domains 
of risk-taking measured.  In a sample of REU, Topp, Hando and Dillon (1999) found 
no age or sex differences between those who had engaged in risky casual sex in the 
preceding month versus those who did not.  However, Greene et al.’s (2000) results 
revealed significant sex and age differences in every domain of risk-taking 
behaviour, in that older males were significantly more likely to engage in risky sex, 
risky driving and drink driving behaviours.  However, it should be noted that Greene 
et al.’s (2000) sample included adolescents and university students from the general 
population, which is a different sample to that of the current research.  It should also 
be noted that all participants in the current study are ‘risky’ to a degree because they 
all use illicit substances.  It is also important to keep in mind that the current sample 
on a whole was quite young, with a mean age of 22.9 years (1st quartile = 19 years, 
3rd quartile = 24 years).  Therefore, as most of the sample’s age fell within a very 
small age band, it is possible there was too little age variation to yield any significant 
findings.   
 
 With regards to the harm reduction variable, this study revealed age and sex 
were not significant predictor variables.  This finding is consistent with Allott and 
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Redman (2006), who found no sex differences in the overall use of harm reduction 
strategies in their sample of REU, but is in opposition to Akram and Galt (1999), 
who found that females were significantly more likely than males to take harm 
reducing steps in relation to their ecstasy use.  However, it is unknown if Akram and 
Galt’s (1999) finding was simply a difference between the sexes in behaviours, or if 
females were more prone to experience harm from MDMA.  This distinction is 
important to clarify in future research.  The finding that age was not a significant 
predictor variable was consistent with Akram and Galt’s (1999) results that no 
significant relationship existed between age and harm reduction, but is in 
contradiction to Allott and Redman’s (2006) results that being younger was 
significantly associated with pre-loading.  It should be noted that Allott and 
Redman’s (2006) sample were older than the current sample, with a mean age of 
26.5 years versus 22.9 years.  There have been few other studies regarding harm 
reduction strategies employed by REU; therefore, more research is clearly needed to 
clarify the relationship between demographic variables and harm reduction practices.   
 
 It may be concluded from Study 2 that age and sex are not predictor variables 
of importance with regards to successfully predicting REU’s engagement in health 
related risk-taking behaviours, or engagement in harm reduction behaviour.  These 
findings may be indicative of the nature of the sample group itself, given that both 
male and female REUs as a cohort are deemed ‘risky’, and due to the sample’s age 
falling within a very small age window.   
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Attitude Variables as Predictors of Risk-Taking  
 
 Previous research has shown that attitudes play an important role in 
predicting engagement in risk-taking behaviour.  It was expected that less positive 
attitudes regarding safer sexual practices and driving would be predictive of REU 
who engaged in sexual risk behaviour and drug driving, or that more positive 
attitudes towards these behaviours would result in less risk-taking behaviour.   
 
Sexual Attitudes as Predictors of Risky Sexual Behaviour  
 
 Results indicated that the role of an individual’s attitudes towards safer sex 
was an important variable in the outcome of how often the individual engaged in 
risky sexual behaviour.  Over and beyond demographic variables, attitudes towards 
safer sex were a significant predictor variable in a positive fashion, explaining an 
additional small amount (8.2%) of the variance in sexual risk-taking behaviour.  This 
finding implied that as a participant’s attitude score increased (i.e., attitudes endorsed 
became riskier), the more often they engaged in behaviours indicative of sexual risk-
taking.   
 
 Therefore, in the current study a significant relationship existed between less 
ideal attitudes towards condom use and safer sexual practices, in that negative 
attitudes predicted more frequent involvement in sexual risk-taking behaviour (i.e., 
unprotected sex with casual partners).  This finding is consistent with other research 
(e.g., Sterk, Klein & Elifson, 2004) that demonstrated negative attitudes towards 
condoms and safer sex practices were predictive of engagement in riskier sexual 
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behaviours, or that more positive condom attitudes predict greater adherence to safe 
sexual behaviour (Bogart et al., 2005; Heeren, Jemmott, Mandeya & Tyler, 2007; 
Khumsaen & Gary, 2009; Morrison-Beedy, Carey, Feng & Tu, 2008; Rosengard, 
Anderson & Stein, 2006).   
 
 As these results indicated that sexual attitudes only explained a small amount 
of the variance (8.2%) in sexual risk-taking behaviour, it is clear that attitudes 
provide only a piece of the puzzle in relation to understanding why REU engage in 
risk-taking behaviour.  Therefore, other contextual, situational and personal variables 
are clearly important in establishing the bigger picture.   
 
Driving Attitudes as Predictors of Drug Driving  
 
 As stated previously, two driving attitude scales (towards speeding and traffic 
flow versus rule obedience), and a driving behaviour scale were used to predict 
engagement in drug driving.  Contrary to expectations, none of these scales were 
significant predictors of drug driving.  However, these scales explained an additional 
6.7% of the variance beyond demographic factors, and coupled with age and sex, 
produced a significant model in predicting drug driving behaviour.  In this model, 
REU who were younger females and REU with riskier driving attitudes predicted 
drug driving behaviour.   
 
 The finding that driver attitudes were not independent predictors of driver 
behaviour is contrary to previous research findings (e.g., Nordfjærn, Jørgensen & 
Rundmo, 2010; Yilmaz & Çelĭk, 2004), which have clearly shown that driver 
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attitudes predicted driver behaviour, including driving under the influence of alcohol.  
However, the behaviour at focus for Study 2, drug driving behaviour, was not 
measured in these studies.     
 
 As discussed in previous sections, the driving subscales were selected due to 
their reported predictive power in risky driving practices (see Ulleberg & Rundmo, 
2002).  It is possible, although previous research suggests is unlikely, that REU’s 
attitudes towards speeding and traffic flow versus rule obedience may have little to 
do with whether or not they drug drive.  Additionally, it should also be noted that 
previous research regarding the predictive power of driving attitudes on driving 
behaviour, whilst including drink driving behaviour, have not included measures of 
drug driving.  There is the possibility that the prediction of drug driving behaviour 
differs substantially from the prediction of other risky driving behaviour, such as 
speeding and taking risks in traffic, which is what has been measured in other 
studies.  Clearly more research is needed on the possible myriad of factors not 
measured here (e.g., impaired cognitive capacity due to the effect of the drug(s), 
perceived impairment, another aspect of personality, peer pressure, lack of public 
transport, distance needed to travel, etc.) that may contribute to drug driving 
behaviour in a sample of REU.    
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Personality Variables as Predictors of Risk-Taking and Harm Reduction  
 
Rash-spontaneous Impulsivity  
 
 Results regarding the utility of rash-spontaneous impulsivity as a predictor 
variable were mixed.  As hypothesised, rash-spontaneous impulsivity was a 
significant predictor of injecting risk-taking behaviours in a positive fashion, and it 
approached significance in relation to predicting binge and overdose risk-taking 
behaviours.  Therefore, with respect to these risk-taking domains, it can be 
concluded that as REU’s scores on rash-spontaneous impulsivity measures increased 
(i.e., became more rash impulsive), they more likely they were to have engaged in 
injecting, binge and / or overdose risk-taking behaviours.  In relation to injecting, 
this finding is contrary to the finding in Study 1 that injecting risk-taking behaviour 
was predicted by rash-spontaneous impulsivity in a negative fashion, but aligns with 
previous research that suggests heightened impulsivity is associated with injecting 
drug use (e.g., Checkley, Thompson, Crofts & Mijch, 1996; Lapworth, Dawe, Davis, 
Kavanagh, Young & Saunders, 2009).   The alternate directions of rash-spontaneous 
impulsivity in Studies 1 and 2 is likely due to the very small number of injectors in 
each study, whereby the models generated have fit to the individual quirks of that 
particular small group rather than producing a generalisble model.     
 
Contrary to predicted, rash-spontaneous impulsivity was a significant 
predictor of sexual risk-taking behaviour in a negative fashion, in that a lower score 
on the rash-spontaneous measure (i.e., a tendency to be less rash-impulsive) 
predicted engagement in risky sexual behaviour.  In the model, addition of all three 
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personality measures explained an additional moderate amount (13.2%) of the 
variance in sexual risk-taking behaviour, after controlling for sex, age and attitudes 
towards safer sex.  This finding was very surprising given that previous research 
(e.g., Arnett, 1994; Cooper et al., 2000; Greene et al., 2000) has shown the tendency 
to make rash, impulsive decisions is related to engagement in sexual risk-taking.  
Additionally, rash-spontaneous impulsivity (intensity) was predictive of REU’s 
engagement in sexual risk-taking behaviours in Study 1, despite the final model 
proving non-useful given the small proportion of variance explained and the low 
percentage of individuals at risk that were correctly predicted.  It also makes sense 
that persons high in rash-spontaneous impulsivity, in the intensity of a sexual 
moment, may be more likely to forego using sexual protection with casual partners 
than someone who is less impulsive.  One potential explanation is that the sample as 
a whole was rather impulsive, and hence predictions made in general population 
samples do not hold true in a collectively impulsive sample.  On the rash-
spontaneous impulsivity measure, the highest possible score, 130, was descriptive of 
a very highly rash-spontaneous impulsive individual.  The average rash-spontaneous 
impulsivity score in the current sample was 68.68 (SD = 13.48; 1st quartile = 58, 3rd 
quartile = 78), which appears to be reflective of moderate to high rash-spontaneous 
impulsivity.  Average scores from the general population on this rash-spontaneous 
measure are unknown.    
 
 As predicted, rash-spontaneous impulsivity was a significant predictor of 
harm reduction behaviours, in that REU who scored lower on the rash-spontaneous 
measure (i.e., were less rash-impulsive) engaged in a greater number of harm 
reduction strategies.  Addition of all three personality factors explained a small 
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amount (4.3%) of the variance in harm reduction behaviour.  No previous research 
regarding rash-spontaneous impulsivity and REU’s level of engagement in harm 
reducing behaviours has been found; however, it stands to reason that persons who 
tend to act in a rash, spontaneous manner would be less likely to engage in harm 
reducing strategies in a planful way.  Thus, this finding forms the beginning of 
research knowledge into personality attributes of REU, specifically rash-spontaneous 
impulsivity, and its successful role in predicting those REU who engage in proactive 
harm reduction strategies.  This finding is important as it implicates the role rash-
spontaneous impulsivity plays in the engagement / non-engagement of harm 
reduction behaviour in a sample of REU.  This finding is also of particular 
importance for the development and refinement of appropriate harm reduction 
programs for REU.   
   
Reward Sensitivity 
 
 A small number of previous studies have indicated a direct relationship 
between reward sensitivity and substance and alcohol use / misuse.  However, there 
are no previous studies regarding the role of reward sensitivity as predicting health 
related risk-taking behaviours.  Due to the paucity of research regarding the role 
reward sensitivity may potentially play in relation to predicting REU’s engagement 
in risk-taking or harm reduction behaviours, no expectations were held with regards 
to its potential predictive power.   
 
 Overall, results from this study demonstrated that reward sensitivity was not 
statistically successful in predicting REU who engaged in any domain of risk-taking 
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behaviour or the harm reduction variable.  However, reward sensitivity did approach 
significance in relation to predicting overdose risk-taking behaviour in a positive 
fashion.  Despite not reaching levels of significance, results indicate that reward 
sensitivity was positively associated with all domains of risk-taking, in that a higher 
level of reward sensitivity was associated with more frequent engagement in all 
domains of risk-taking behaviour.  Although not significant, reward sensitivity was 
negatively associated with the harm reduction variable, in that a lower level of 
reward sensitivity was associated with more frequent involvement in harm reduction 
behaviour.  Despite these non-significant results, the relationship between reward 
sensitivity, risk-taking behaviours and harm reduction behaviour are pointing in the 
direction that is consistent with previous research (e.g., Loxton et al., 2008), albeit 
clearly contributing an extremely small proportion of the variance in these 
behaviours, if at all.  However, it is clear that further research regarding reward 
sensitivity is required to add to this research finding, specifically in a population of 
REU.   
 
Evaluation of the Two Factor Model of Impulsivity  
 
 Dawe and Loxton’s (2004) two factor model of impulsivity conceptualises 
there are two distinct factors of impulsivity, reward sensitivity and rash-spontaneous 
impulsivity, that play a role in the development of hazardous substance use.  
Generally speaking, there is a robust amount of research regarding the rash-
spontaneous factor, whilst research regarding reward sensitivity is less well 
developed.   
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 Results from Study 2 appear to confirm the validity of the two factor model 
of impulsivity, as reward sensitivity and rash-spontaneous impulsivity appear to be 
distinct factors in relation to the different roles they play in the prediction of risk-
taking and harm reduction behaviours evidenced in a sample of REU.  Specifically, 
results from this research provide more support for the role of rash-spontaneous 
impulsivity as a successful predictor variable than reward sensitivity.  This could be 
due to the fact that rash-spontaneous impulsivity, on a neurophysiological level, is 
proposed to be related to functioning in serotonin levels, whilst reward sensitivity is 
proposed to be related to the functioning of the mesolimbic dopamine system (Gullo 
& Dawe, 2008).  Given MDMA’s known primary effects on the serotonin system, it 
could be that specifically for a sample group of REU, the rash-spontaneous factor of 
impulsivity plays a more important role than reward sensitivity.   
 
 Additionally, differences in reward sensitivity reflect individual differences 
in an individual’s purposeful drive to obtain rewarding stimuli.  Gullo and Dawe 
(2008) liken an individual with heightened reward sensitivity as “a speeding motorist 
who travels toward their desired destination (i.e., a goal or reward) with great haste.” 
On a behavioural level, reward sensitivity has been related to reward conditioning, 
attention to reward cues and craving (Gullo & Dawe, 2008).  Therefore, as the 
current study behaviourally measured engagement in risk-taking behaviour and harm 
reduction behaviour, it may be that reward sensitivity is not as relevant or influential 
as rash-spontaneous impulsivity, when the goal is to differentiate between REU who 
engage in additional risk-taking behaviours versus those who do not.  Moreover, 
given that reward sensitivity plays a role in cued-cravings and motivation to use 
drugs (Dawe & Loxton, 2004), it could be hypothesised that reward sensitivity is 
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more relevant for drugs known to cause dependence, such as alcohol or opioids.  
Whether or not there is evidence for MDMA dependence is debated (see Degenhardt, 
Bruno & Topp (2010) for a review).  
 
Conscientiousness 
 
 Despite findings from Study 1, based on previous research (e.g., Bogg & 
Roberts, 2004; Caspi et al., 1995) conscientiousness was expected to play a 
significant role in predicting involvement in risk-taking behaviours in a negative 
fashion, and involvement in harm reduction behaviours in a positive fashion.  
However, results from Study 2 indicated this was not the case – conscientiousness 
was not a statistically significant predictor in relation to any domain of risk-taking or 
the harm reduction variable, although it did approach significance in relation to 
predicting sexual risk-taking in a negative fashion, in that individuals who scored 
lower on the conscientious measure (i.e., were less conscientious) were more likely 
to engage in sexual risky behaviours.    
 
 Again, it was surprising that conscientiousness was not a successful predictor 
variable of REU’s engagement in risk-taking behaviour, given that previous research 
(e.g, Bogg & Roberts, 2004; Flory et al., 2002; Roberts & Bogg, 2004) has 
implicated low levels of conscientiousness as predictive of various health-related 
risk-taking behaviours.  As stated previously, the failure to replicate such findings 
may be due to the multi-faceted nature of the conscientiousness construct, in that it is 
possible the IPIP:Re assessment measure did not tap into the conscientiousness 
construct the way in which intended; however, there is no evidence this is the case.  
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Additionally, given the socially desirable nature of some questions on the assessment 
(e.g., ‘I return extra change when a cashier makes a mistake; I like to be of service 
to others; and I take others’ interests into account’), it is possible that some 
participants may have answered in a socially desirable, biased manner, which may 
have artificially inflated their conscientiousness score.  It is also possible that the 
sample group as a whole scored poorly (or highly) on the conscientiousness measure.  
As stated previously, norms are not available for the IPIP:Re measure; however, the 
highest score achievable, 50, indicates an individual is highly conscientious.  As 
consistent with the sample in Study 1, the current sample appeared to report 
moderate to high levels of conscientiousness (M = 40.28, SD = 5.31, 1st quartile = 37, 
3rd quartile = 44).  Therefore, it is possible there was too little variation in 
conscientiousness scores to have a meaningful impact on risk-taking behaviour.   
 
  Thus, it may be concluded from Study 2 that conscientiousness is not a 
successful predictor variable with regards to predicting REU’s engagement in health 
related risk-taking behaviours, or engagement in harm reduction behaviour.  Despite 
significant, albeit small, findings between conscientiousness and health related risk-
taking behaviours in the general population, the current finding, which is consistent 
with results from Study 1, indicates that conscientiousness may not be a personality 
factor of importance in a sample of REU.   
 
Limitations  
 
 As the current study was hosted online, it is possible that the sample, 
although comparable to other studies involving REU, may have differed in 
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comparison to samples obtained in the more traditional face-to-face or pencil / paper 
methods of data collection.  Previous research has indicated (e.g., Johnston, Laslett, 
Miller, Jenkinson, Fry & Dietze, 2004) that web-based samples may access a 
different subpopulation than face to face and telephone interviews for 
psychostimulant users.  For example, in their research as part of the Victorian 
psychostimulant monitoring program, Johnston et al. (2004) found their web-based 
sample were younger, more likely to be students or employed, less likely to be in 
drug and alcohol treatment and less likely to have ever injected any drug than their 
face to face or telephone participants.  The samples also differed in that the web-
based sample accessed more cocaine users, which were not represented in the face to 
face interviews.  Similarly, Wang, Lee, Lew-Ting, Hsiao, Chen and Chen (2005) 
compared an internet versus pencil-paper administered drug use questionnaire.  
Results indicated that the internet group was a more diverse, representative sample, 
reported higher lifetime prevalence of drug use, and the response rate was higher 
than the pencil-paper group.  The authors concluded that internet based research may 
reach a larger, more diverse sample of drug users, and provides anonymity so that 
users feel more comfortable reporting sensitive information.  However, contextually, 
this may be country and culture dependent.   
 
 Further, online research may potentially impose a “technological divide” that 
may act as a barrier, particularly to lower income individuals that may not have 
internet access (Miller, Strang & Miller, 2010). As the current research was 
conducted online, only REU with internet access were able to complete the survey.  
However, there is no evidence to suggest there would be marked differences between 
REU who access the internet and those who do not.  It could be assumed from the 
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overall demographic characteristics of REU as a group that they are likely to access 
the internet, given they are young and have completed educational studies and / or 
are employed.   
 
 It should be noted that the sample obtained in Study 2 was international, 
representing a total of 14 countries, whereas the Study 1 sample were strictly 
accessed from Australia.  Despite this, the samples from each study were very 
comparable, with few if any differences noted.  Therefore, it can be concluded that 
REU as a collective group appear to have similar profiles across contextual and 
cultural settings, potentially allowing for the generalisability of findings across 
countries for other groups of REU.   
 
 Another limitation with regard to conducting this study online is the 
psychometric properties of internet administered tests.  Buchanan, Ali, Heffernan, 
Ling, Parrott, Rodgers and Scholey (2005) stated the equivalence between internet 
and pencil - paper tests cannot be taken for granted, and that online tests should be 
validated for the construct they intend to measure, as the characteristics of the testing 
medium may impact on the psychometric properties of a test and its power to 
reliably and validly measure the construct of interest.  However, the authors 
concluded that the differences between online and pencil - paper versions are usually 
minor.  Additionally, there is no evidence to suggest that psychometrics of the online 
assessments were altered.         
 
 As stated in relation to Study 1, another limitation of the current study was its 
cross-sectional design.  However, this type of design is often employed in alcohol 
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and drug research, and therefore the results of this study are believed to be 
comparable with other similar research studies.  A further limitation is the study’s 
reasonably small sample size of 249 subjects.  However, the characteristics of the 
sample were highly similar to other groups of REU studied across Australia, and 
therefore deemed likely to be a representative sample of REU.   
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Chapter 16: Overall Discussion 
 
 Studies 1 and 2 attempted to explore and clarify the role that personality 
factors (rash-spontaneous impulsivity, reward sensitivity and conscientiousness) play 
in relation to predicting engagement in health related risk-taking and harm reduction 
behaviours in a sample of REU.   
 
 Results from the two studies indicate that rash-spontaneous impulsivity, of 
the three personality factors measured, was the most successful and consistent 
predictor variable.  In Study 1, rash-spontaneous impulsivity scores were 
significantly higher in REU deemed at risk for the categories of sexual, alcohol 
driving and binge risk.  In a predictive fashion, rash-spontaneous impulsivity was 
able to successfully predict REU who drove under the influence of alcohol, cannabis 
and party drugs.  In Study 2, rash-spontaneous impulsivity was a significant 
predictor of injecting risk-taking behaviours, and it approached significance in 
relation to predicting binge and overdose risk-taking behaviours.  Additionally, rash-
spontaneous impulsivity was a significant predictor of harm reduction behaviours, in 
that REU who scored lower on the rash-spontaneous measure (i.e., were less rash-
impulsive) engaged in a greater number of harm reduction strategies.   
 
 Results from the two studies indicated that the other two personality variables 
of interest, reward sensitivity and conscientiousness, were not successful predictors 
of REU’s engagement in risk-taking or harm reduction behaviours.  Therefore, these 
two aspects of personality appear to be unimportant in relation to predicting whether 
a REU engages in additional health related risk-taking behaviours, over and beyond 
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their ecstasy use, particularly in the context of consideration of rash-spontaneous 
impulsivity.   
 
Clinical Application and Usefulness of Results  
 
 The results of this research add to the existing body of knowledge regarding 
the nature and prevalence of engagement in health related risk-taking behaviours and 
harm reduction strategies evidenced in two samples of REU.  This research has 
established previously unmeasured relationships regarding the ability of personality 
variables (rash-spontaneous impulsivity, reward sensitivity and conscientiousness) to 
predict risk-taking and harm reduction behaviour in a large sample of REU.   
 
 Specifically, the findings regarding rash-spontaneous impulsivity as a 
successful predictor variable of risk-taking and harm reduction behaviour, and the 
lack of predictive ability of the reward sensitivity and conscientiousness personality 
variables, were completely novel.  This research is also important in that it has begun 
to address the neglected area of harm reduction practices employed by REU.  It is 
hoped that research such as this will launch further interest and research into this 
understudied, yet very important, area.      
 
  This research is also important in that it establishes that among a group of 
REU who collectively may be defined as ‘risky,’ that there appears to be distinct 
sub-groups of REU who also engage in additional health related risk-taking 
behaviours, such as having unprotected sex with casual partners and driving under 
the influence of drugs.  Thus, it would appear that some REU are indeed more ‘risky’ 
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than others.  On the same token, there appears to be a distinct sub-group of REU who 
engage in harm reduction behaviours, thus lending support that some REU attempt to 
minimise harms associated with their ecstasy use, whilst other REU do not.  The 
personality factor of rash-spontaneous impulsivity appears to be the most reliable 
and successful attribute that distinguishes these ‘more risky’ REU from their ‘less 
risky’ REU counterparts, whilst personality attributes surrounding reward sensitivity 
and conscientiousness appear to be unrelated to engagement / non-engagement in 
these behaviours.  .   
 
 These results are potentially clinically significant in that they could alter the 
development of successful educational and harm reduction programs for REU.  In 
relation to addressing risk-taking behaviours, such as encouraging safer sexual 
practices and non drug driving, the nature of educational and harm reduction 
messages need to be tailored to the sub-group considered at risk.  Results of this 
study indicate that REU high in rash-spontaneous impulsivity are most at-risk for 
engaging in risk-taking behaviour.  Therefore, for example, if the goal was to 
promote condom use among REU, the harm reduction message may be most 
effective if condom use and safer sexual behaviours are associated with concepts 
such as sexual variety, new experiences, and sensual experimentation, etc., in that 
messages portraying safer sex as exciting, novel, and erotic may be more likely to 
appeal to persons high in rash-spontaneous impulsivity (Dolezal, Meyer-Bahlburg, 
Remien & Petkova, 1997).  Additionally, as findings from this study indicated that 
negative attitudes towards condoms and safer sex predicted more frequent 
involvement in sexual risk-taking behaviour (i.e., unprotected sex with casual 
partners), successful harm reduction programs also need to address such negative 
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attitudes towards using condoms (Sterk et al., 2004).  Therefore, a tailored, 
multifaceted campaign of this nature would be more effective than a campaign that 
aimed to provoke anxiety and / or fear about contracting HIV, for instance. 
 
 Results of this research also indicate that many REU reported to engage in 
some type of harm reduction behaviour to minimise the perceived ecstasy related 
harms associated with their regular ecstasy use.  This finding in itself is clinically 
important, as it indicates that many REU are seeking information and utilising 
various harm reduction strategies (albeit their clinical effectiveness is unknown) to 
minimise ecstasy related harm.  Therefore, this finding reveals there is currently a 
wonderful opportunity to educate and to provide reliable information to REU 
regarding effective harm reduction strategies.  It is encouraging that results of this 
study indicate that many REU are indeed open and receptive to such information.   
 
 Taken together, findings from this research implicate that successful 
education and harm reduction programs need to incorporate a component on 
encouraging proactive approaches to minimising ecstasy related harm, in addition to 
components that focus on addressing associated risk-taking behaviour.  Such a 
holistic approach that focuses on both reducing risk-taking behaviour (e.g., 
promoting safer sex, promoting public transport use instead of drug driving, etc.), 
together with promoting active engagement in harm reduction strategies (e.g., 
decreasing the amount of ecstasy taken, the use of pill testing kits, etc.) may be the 
most effective campaign to reduce overall harm.   
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Future Research 
 
 In general there is a paucity of research regarding the usefulness of 
personality factors in predicting REU’s engagement in health related risk-taking 
behaviours, over and beyond their regular ecstasy use.  The current studies lend 
support for the role of rash-spontaneous impulsivity, whilst concluding that reward 
sensitivity and conscientiousness were seemingly unimportant predictor variables.  
More research is needed in samples of REU regarding these three personality factors 
in order to add to the results obtained, and to support or refute the conclusions made 
from these two studies.   
  
 Lastly, research regarding the actual clinical effectiveness of harm reduction 
strategies currently being employed by REU is imperative.  Such research is needed 
in order to provide REU with research-validated information regarding the efficacy 
of harm reduction practices, so that REU are then able to make educated decisions 
regarding their ecstasy use and the use of harm reduction strategies.    
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SECTION A: 
Demographics 
1. Sex 
 
 Male .................................... 1 
 Female ................................ 0 
2. Age _________ years 
 
3. Postcode_______ 
 
3a. (If in NSW) Area where you live: 
 
 No fixed address .................. 0 
 Inner city .............................. 1 
 East ...................................... 2 
 Inner west ............................ 3 
 South west ........................... 4 
 West ..................................... 5 
 South ................................... 6 
 North .................................... 7 
 North west .......................... 7a 
 Non-metropolitan ................. 8 
 
Or (In other jurisdictions) Suburb you live in: 
 ______________________________ 
 
3b. What type of accommodation do you 
currently live in? 
 
Own house/flat ...................... 1 
Rented house/flat .................. 2 
Parents’/family house ............ 3 
Boarding house/hostel .......... 4 
Shelter/refuge ....................... 5 
Drug treatment residence ..... 6 
No fixed address/homeless .. .7 
Other accommodation ........... 8 
 (Specify_________________) 
 
4. What is the main language you speak 
at home? 
 
 English ................................ 1 
 Other ................................... 2 
 (Specify_________________) 
 
 
 
 
  
Party 
Drugs 
Initiative 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
National Drug and Alcohol 
Research Centre 
 
University of New South Wales 
 
©NDARC 2006 
Date____/____/06 
 
 
Interviewer ____________ 
 
State ______________ 
 
 2 
5. Are you of Aboriginal or Torres 
Strait Islander origin?  
(Mark one response only)  
No...........................................      0 
Yes, Aboriginal.....................        1 
Yes, Torres Strait Islander...         2 
Yes, both Aboriginal and  
Torres Strait Islander          3 
 
 
 
6. What grade of school did you 
complete? 
 
 Year__________ 
 
 
7. Have you completed any course 
after school? 
 
No ....................................... 0 
Yes, trade/technical ............ 1 
Yes, university/college ........ 2 
Specify qualification 
___________________________ 
 
 
8. How are you employed at the 
moment? (mark only one) 
 
Not employed ...................... 1 
Full time .............................. 2 
Part time/casual .................. 3 
Full time student ................. 5 
Home duties ........................ 6 
Other  .................................. 7 
 (Specify_________________) 
 
 
9. Are you currently in any form of 
drug treatment? 
 
 
 No ....................................... 0 
 Yes ..................................... 1 
 (Specify _______________) 
10. Have you ever been in prison? 
(i.e. convicted of an offence) 
 
Yes .................................. 1 
No .................................... 0 
 
 
11.  Which of the following best 
describes your sexual identity? 
(read out all responses) 
 
Heterosexual ............................... 1 
Gay male .................................... 2 
Lesbian ....................................... 3 
Bisexual ...................................... 4 
Other ........................................... 5 
 (Specify________________) 
 
 
12. What is your current 
relationship status? (read out all 
responses) 
 
 
Married/Defacto ........................ 1 
Regular partner ......................... 2 
Single ........................................ 3 
Separated ................................. 4 
Divorced ................................... 5 
Widow ....................................... 6 
Other ......................................... 7 
 (Specify___________________) 
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SECTION B: Drug use 
 
This section is about your use of 
ecstasy and other drugs. Some of the 
questions ask for a lot of detail that 
you might not remember; please 
estimate if you're not sure. And please 
remember again, everything you say is 
completely confidential. 
 
 
1. How old were you when you first 
tried ecstasy? 
 
________years 
 
 
2. How old were you when you first 
started to use ecstasy regularly?  
(at least once a month) 
 
________years 
 
3. Have you ever injected any drug? 
 
 No ....................................... 0  
 Yes ..................................... 1 
 
 If No Go to Q5 
 
 
3a. How old were you when you first 
injected any drug? 
 
________Years 
 
 
4. What drug did you first inject? 
(one response only) 
 
Ecstasy .............................................. 1 
Methamphetamine powder (speed/goey/whiz) ...... 2 
Methamphetamine base (paste/pure) ......... 3 
Crystal methamphetamine (ice/shabu) ........ 4 
Pharmaceutical stimulants .............. 4a 
Cocaine ............................................. 5 
Hallucinogens (LSD) ......................... 6 
MDA .................................................. 7 
Ketamine ........................................... 8 
GHB (GBH/liquid e/fantasy) .............. 9 
Heroin  ............................................. 10 
Methadone  ...................................... 11 
Other opiates ................................... 12 
Benzodiazepines ............................. 13 
Steroids ........................................... 14 
Other ................................................ 15 
 (Specify                                   ) 
 
 
5. What is your main drug of choice?   
i.e. favourite or preferred drug (one 
response only) 
 
Ecstasy  ................................................... 1 
Methamphetamine powder (speed/goey/whiz) ...... 2 
Methamphetamine base (paste/pure) ................ 3 
Crystal methamphetamine (ice/shabu) .............. 4 
Pharmaceutical stimulants ..................... 4a 
Cocaine ................................................... 5 
LSD .......................................................... 6 
Mushrooms ............................................ 6a 
MDA ......................................................... 7 
Ketamine ................................................. 8 
GHB (GBH/liquid e/fantasy) ..................... 9 
1,4B ....................................................... 9a 
GBL ....................................................... 9b 
Amyl nitrite ............................................. 10 
Nitrous oxide .......................................... 11 
Cannabis ............................................... 12 
Alcohol ................................................... 13 
Heroin .................................................... 14 
Methadone ............................................. 15 
Other opiates ......................................... 16 
Tobacco ................................................. 17 
Benzodiazepines ................................... 18 
Steroids ................................................. 19 
Can’t specify .......................................... 20 
Other ...................................................... 21 
 (Specify                                   ) 
 
 
6. How have you mainly used ecstasy 
in the last 6 months? (i.e. more than half 
the time) (one response only) 
 
Injected  ........................................... 1 
Snorted  ........................................... 2 
Swallowed ....................................... 3 
Shelved/shafted ............................... 4 
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7. Have you used the following drugs?  ......                 
*Interviewer note: Shelving/shafting refers to vaginal/anal administration 
**Interviewer note: After obtaining no. days used speed/base/crystal, ask TOTAL days used any meth 
*** Interviewer note: After obtaining no.days used ecstasy pills/powder; ask TOTAL days used any ecstasy 
# Read: Now looking at amounts used in a session (ie period of continuous use without sleep) 
What is the average amount you have used in a session in the last six months? 
What is the most amount of you have used in a session in the last six months? 
## Interviewer note: Only code ‘other amount’ when measure specified by participant is something other than that listed in previous column 
Drug Class 
Yes = 1, No = 0 
Ever 
used 
Age 
1st 
used 
Ever 
inject 
Injected 
last 6 
mths 
No 
days 
inject 
last 6 
Ever 
Smoke 
Smoke 
6 mths 
Ever 
snort 
Snort 
6 
mths 
Ever 
Swallow 
Swall 
6 
mths 
*Ever 
shelve/ 
shaft 
*Shelve/ 
shaft 6 
mths 
No 
days 
used 
last 
6 
***Days 
used 
any 
ecstasy 
**Days 
used 
any 
meth 
#Average 
amount 
used last 
6 mths 
## 
Average 
(specify 
other 
measure) 
Most 
used 
last 6 
mths 
## Most 
amount 
(specify 
other 
measure) 
1a. Ecstasy pills 
                
 
tabs  
 
 
tabs 
 
1b. Ecstasy powder 
               
grams  
 
grams 
 
2. Meth powder 
(speed/goey/whiz) 
                
 
grams  
 
 
grams 
 
3. Meth base 
(paste/pure) 
              
 
points  
 
 
points 
 
4. Crystal Meth 
(ice/shabu)  
              
 
points  
 
 
points 
 
4a. Pharmaceutical 
stimulants(Ritalin/dex) 
               
 
tabs  
 
 
tabs 
 
 
5. Cocaine  
               
 
grams  
 
grams 
 
 
6. LSD 
               
 
tabs  
 
tabs 
 
 
7. MDA 
               
 
caps  
 
caps 
 
 
8. Ketamine 
                
bumps  
 
bumps 
 
 
9. GHB  
(9GBH/liquid e/ 
fantasy 
            
 
 
mls  mls 
 
 
9a. 1,4b  
(B, BD, BDO) 
           
 
 
mls  mls 
 
9b. GBL 
            
mls  mls 
 
 
10. Amyl nitrate 
(rush) 
     
 
snorts  
 
snorts 
 
 
11. Nitrous oxide  
(bulbs) 
     
bulbs 
   
bulbs 
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7. Have you used the following drugs? (cont)        *Interviewer note: Shelving/shafting refers to vaginal/anal administration 
 
 
Drug Class 
Yes = 1, No = 0 
Ever used Age 1st used Ever inject Injected 
last 6 mths 
No days 
inject 
last 6 
Ever 
Smoke 
Smoke 6 
mths 
Ever 
snort 
Snort 6 
mths 
Ever 
Swall 
Swall 
6 mths 
*Ever 
shelve/ 
shaft 
*Shelve/ 
shaft 6 
mths 
No. days used 
6 mths 
 
 
12. Cannabis 
 
              
 
 
13. Alcohol  
              
 
 
14. Heroin 
              
 
 
15. Methadone 
              
 
 
15a. Buprenorphine 
              
 
 
16. Other opiates 
(morphine/codeine) 
              
 
 
17 Tobacco 
              
 
 
18. Anti-depressants 
              
 
 
19. Benzodiazepines 
(eg.serepax/valium) 
              
 
 
20a. Mushrooms 
              
 
 
20. Other (specify) 
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7a. What forms of ecstasy have you used in the last six months? 
(NOTE: *For Used: multiple responses allowed & For Form most used: mark one response only) 
            Yes = 1     No = 0 
 *Used **Form 
most 
used 
1a. Ecstasy pills (tablets)   
1b. Ecstasy powder  (includes MDMA powder)   
 
 
8. (a) In the last six months, have you used any stimulants or party drugs for more 
than 48 hours continuously without sleep? 
 
No  ...................................... 0 (Go to Q9) 
Yes ..................................... 1 
 
(aa) If yes, how many times have you done this in the past 6 months? 
 
______ times 
 
8. (b) Which drugs have you done this on in the last six months? (multiple 
responses allowed) 
 
Ecstasy .......................................................................... 1 
Meth powder (speed/goey/whiz) .................................... 2 
Meth base (paste/pure) .................................................. 3 
Crystal meth (ice or shabu) ............................................ 4 
Pharmaceutical stimulants ........................................... 4a 
Cocaine ......................................................................... 5 
LSD ................................................................................ 6 
Mushrooms .................................................................. 6a 
MDA ............................................................................... 7 
Ketamine ....................................................................... 8 
GHB (GBH/liquid e/fantasy/1,4B/GBL) .......................... 9 
Amyl nitrite ................................................................... 10 
Nitrous oxide ................................................................ 11 
Cannabis ..................................................................... 12 
Alcohol ......................................................................... 13 
Other ............................................................................ 14 
 (Specify                                                                           ) 
 
 
 
8. (c) What was the longest period you’ve done this for in the last six months?  
 
 
 
_________________________Hours 
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9.  When using ecstasy, what combinations of other drugs have you typically used in the last six months? 
(Interviewer note: refer back to last column in drug use table 7, p4 for drugs used last 6 mths) 
Yes = 1 No = 0 9a. Have you usually used other drugs 
with ecstasy in the last six months?  
 
 
Y/N (circle) 
 
If yes, ask about each drug  
If no, skip to 11b 
9b. Have you usually used other 
drugs while coming down from 
ecstasy?  
 
Y/N (circle) 
 
If yes, ask about each drug 
If no, skip to Section C 
Meth powder (speed)   
Meth base (paste/pure)   
Crystal meth (ice/shabu)   
Any meth*   
Pharm. Stimulant   
Cocaine   
LSD   
Mushrooms   
MDA   
Ketamine   
GHB (GBH/liquid e/fantasy,)   
Amyl nitrate (rush)   
Nitrous oxide (bulbs)   
Cannabis   
Alcohol** Usually drink?            Y/N 
More than 5 standard drinks per 
session?     Y/N 
Usually drink?          Y/N 
More than 5 standard drinks per 
session?   Y/N 
Heroin   
Methadone   
Buprenorphine   
Other opiates   
Tobacco**   
Anti depressants   
Benzodiazepines   
Other 
(specify________) 
  
*Interviewer note: Code any meth if participant does not use any specific from of meth ‘usually’ but uses at least one form more 
than two thirds of the time. If this option is coded, no other forms of meth should be coded 
**Prompt for alcohol use and tobacco if participant is a smoker.
 
 8
SECTION C: PRICE, PURITY and AVAILABILITY of PARTY DRUGS 
These questions are about the price, purity and availability of ecstasy and other party 
drugs. Please only answer them if you feel confident of your knowledge in this area. 
 
Ecstasy 
 
1. How much does ecstasy cost at the 
moment? 
 
$______tab 
$______powder 
 
or 
$______other measure (specify_________) 
 
1a. How much did ecstasy cost the last 
time you purchased it? 
 
$______tab 
$______powder 
 
or 
$______other measure (specify_________) 
 
2. Has the price of ecstasy changed in the 
last six months? 
 
Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuating .............................. 4 
 
3a. How strong would you say the ecstasy 
is at the moment? 
 
Don’t know ............................. 0 
Low ......................................... 1 
Medium ................................... 2 
High ........................................ 3 
Fluctuates ............................... 4 
 
4. Has the strength of ecstasy changed in 
the last six months? 
 
 Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing ...........  .................. 3 
Fluctuating .............................. 4 
5. How easy is it to get ecstasy at the 
moment? 
 
Don’t know .............................. 0 
Very easy ................................ 1 
Easy ........................................ 2 
Difficult .................................... 3 
Very difficult ............................. 4 
 
6. Has this changed in the last six 
months? 
 
Don’t know .............................. 0 
More difficult ............................ 1 
Stable ...................................... 2 
Easier ...................................... 3 
Fluctuates ................................ 4 
 
7. Who have you bought ecstasy from in 
the last six months? (multiple responses 
allowed) 
 
Used not scored ...................... 7 
Friends .................................... 1 
Known dealers ........................ 2 
Workmates .............................. 3 
Acquaintances ......................... 4 
Unknown dealers .................... 5 
Other ....................................... 6 
 (Specify                                   ) 
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8. What venues (locations) do you 
normally score (buy) ecstasy at? (multiple 
responses allowed) 
 
Used not scored ....................... 11 
Home ......................................... 1 
Dealer's home ............................ 2 
Friend's home ............................ 3 
Raves/doofs/dance parties ...... 12 
Nightclubs .................................. 6 
Pubs/Bars .................................. 7 
Private parties ............................ 8 
Day Clubs ................................ 8a 
Street ......................................... 9 
Agreed public location* ............ 13 
Work ........................................ 14 
Educational institute ................. 15 
Acquaintances house .............. 16 
Other ........................................ 10 
 (Specify                                   ) 
 
*eg. car, car park, train station, park 
  
 
8a. In the last six months where have you 
usually used ecstasy (ie where have you 
spent time while under the influence)? 
(read out all locations; record all that 
apply)  
 
Home ......................................... 1 
Dealer's home ............................ 2 
Friend's home ............................ 3 
Raves/doofs/dance parties ...... 13 
Nightclubs .................................. 6 
Pubs ........................................... 7 
Private party ............................... 8 
Day Club .................................. 8a 
Restaurant/ café ........................ 9 
Public place (street/park) ......... 10 
Car/other vehicle (passenger) . 14 
Car /other vehicle (driver) ........ 15 
Outdoors*  ................................ 16 
Live music event** ................... 17 
Work ........................................ 18 
Educational institute ................. 19 
Acquaintances house .............. 20 
Other ........................................ 12  
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals etc 
8b. Where were you the last time you 
used ecstasy? (one response only) 
 
Home ............................................ 1 
Dealer's home .............................. 2 
Friend's home ............................... 3 
Raves/doofs/dance parties ......... 13 
Nightclubs .................................... 6 
Pubs ............................................. 7 
Private party ................................. 8 
Day Clubs ................................... 8a 
Restaurant/ café ........................... 9 
Public place (street/park) ........... 10 
Car/other vehicle (passenger) .... 14 
Car /other vehicle (driver) ........... 15 
Outdoors*  .................................. 16 
Live music event** ...................... 17 
Work ........................................... 18 
Educational institute ................... 19 
Acquaintances house ................. 20 
Other .......................................... 12 
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals etc 
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Please remind participants that they do not have to answer any questions that 
they are uncomfortable answering. 
 
10.  How many different people have you purchased ecstasy from in the last 6 
months?  
 
 ______________ people 
 
 
10a.    In the last six months who did you usually purchase ecstasy for? 
(one response only) 
 
 Didn’t buy/get ecstasy in the last six months ................... 0 
 Yourself ...........................................................................  1 
 Yourself and others .......................................................... 2 
 Other only ........................................................................  3 
 
 
10b. In the last six months, how often did you purchase ecstasy? 
(one response only) 
 
 Did not purchase ecstasy in the last six months .............. 0 
 Monthly or less (1-6 times) ....  .......................................... 1 
 Fortnightly or less (7-12 times) ........................................ 2 
 Weekly or less (13-24 times) ........................................... 3 
 Three times a week or less (25-181+) ............................. 4 
 
 
10c. When you purchase ecstasy how many tabs (pills) do you usually obtain?  
 
 _____________amount (tabs/pills) 
 
 
11. Could you get other drugs from your main dealer in the last six months?  
‘Main dealer’ refers to the person you have most often purchased  
ecstasy from in the last six months (Interviewer note: If they have more than one 
‘main dealer’, ask them to refer to the person they have purchased the largest 
amount of from.) 
 
No  ...................................... 0 Go to Q12 
Yes ..................................... 1 Go to Q11a 
No main source ................... 2 Go to Q12 
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11a. Specify other drugs sold by your main ecstasy dealer (multiple responses allowed)  
We are only interested in what was available to you at time of purchase, NOT what the 
dealer said they could get for you if they tried. 
 
 1= Yes  0=No  
Meth powder  
Meth base  
Crystal meth  
Pharmaceutical stimulants  
Cocaine  
LSD  
Mushrooms  
MDA  
Ketamine  
GHB   
Cannabis  
Heroin  
Other (Specify____________)  
 
12. Do you know how much ecstasy you need to be in possession of to be charged with 
supply if you were caught by the police? 
 
No  0 (Go to question Q13) 
Yes   1 
 
12a. How much ecstasy (tablets or grams) would you need to be in possession of to be 
charged with supply if you were caught by the police?  
 
Amount _________ tabs/grams 
 
12b. Is this amount for (mark only one)? 
 
Don't know      0 
Pure MDMA       1 
Tablets sold as ecstasy regardless of MDMA purity  2 
 
13.  Do you know what the consequences are for being convicted with supplying ecstasy? 
 
Yes  0 
No  1(Go to Q`14) 
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13a. If yes, what are they? (mark all that apply) 
Fine  0 
Caution 1 
Prison Sentence 2 
Community Service 3 
Other____________ 4 
 
14. Do you think there is a difference between getting tablets for personal use or for your 
friends in the eyes of the police? 
 
Yes  0 
No  1(Go to next section) 
 
14a. If yes, what is the difference? 
 
Don’t know  0 
Heavier penalty  1 
Less of a penalty  2 
Same ...........................  ................ 3 
Other ____________ ..  ................ 4 
 
 13
 
Methamphetamine powder 
(speed/goey/whiz)  
Again, please only answer if you feel 
confident of your knowledge in this area. 
 
Note to interviewer: 
Participant able to answer?  Y/N (circle) 
If yes, ensure all questions coded 
 
1. How much does speed cost at the 
moment? 
 
$_______/gram 
or 
$______other measure (specify_________) 
 
1a.  How much did speed cost the last 
time you purchased it?  
 
$______/gram 
or 
$______other measure (specify_________) 
 
2. Has the price of speed changed in the 
last six months? 
 
Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
3. How strong would you say speed is at 
the moment? 
 
 Don’t know .............................. 0 
Low ......................................... 1 
Medium ................................... 2 
High ........................................ 3 
Fluctuates ............................... 4 
 
4. Has the strength of speed changed in 
the last six months? 
 
 Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
5. How easy is it to get speed at the 
moment? 
 
Don’t know .............................. 0 
Very easy ................................ 1 
Easy ........................................ 2 
Difficult .................................... 3 
Very difficult ............................. 4 
 
6. Has this changed in the last six 
months? 
 
 Don’t know .............................. 0 
More difficult ............................ 1 
Stable ...................................... 2 
Easier ...................................... 3 
 Fluctuates ................................ 4 
 
7. Who have you bought speed from in the 
last six months? (multiple responses 
allowed) 
 
Haven’t used speed ................ 0 
Used not scored ...................... 7 
Friends .................................... 1 
Known dealers ........................ 2 
Workmates .............................. 3 
Acquaintances ......................... 4 
Unknown dealers .................... 5 
Other ....................................... 6 
(Specify                                   ) 
 
8. What venues do you normally score 
speed at? (multiple responses allowed) 
 
Haven’t used speed ................ 0 
Used not scored ...................... 11 
Home ....................................... 1 
Dealer's home ......................... 2 
Friend's home .......................... 3 
Raves/doofs/dance parties ...... 12 
Nightclubs ............................... 6 
Pubs/Bars ................................ 7 
Private parties ......................... 8 
Day Clubs ............ ................... 8a 
Street ................... ................... 9 
Agreed public location* ........... 13 
Work .................... ................... 14 
Educational institute ................ 15 
Acquaintances house .............. 16 
Other ....................................... 10 
(Specify                                   ) 
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*eg. car, car park, train station, park 
8a. In the last six months where have you 
usually used speed (ie where have you 
spent time while under the influence)? 
(read out all locations; record all that 
apply) 
 
Haven’t used speed ................. 0 
Home ....................................... 1 
Dealer's home .......................... 2 
Friend's home .......................... 3 
Raves/doofs/dance parties ...... 13 
Nightclubs ................................ 6 
Pubs ......................................... 7 
Private party ............................. 8 
Day Clubs ................................ 8a 
Restaurant/ café ...................... 9 
Public place (street/park) ......... 10 
Car/other vehicle (passenger) . 14 
Car /other vehicle (driver) ........ 15 
Outdoors*  ................................ 16 
Live music event** ................... 17 
Work ........................................ 18 
Educational institute ................. 19 
Acquaintances house .............. 20 
Other ........................................ 12  
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals etc 
 
8b. Where were you the last time you 
used speed? (one response only) 
 
Haven’t used speed ................ 0 
Home ....................................... 1 
Dealer's home ......................... 2 
Friend's home .......................... 3 
Raves/doofs/dance parties ...... 13 
Nightclubs ............................... 6 
Pubs ........................................ 7 
Private party ............................ 8 
Day Clubs ................................ 8a 
Restaurant/ café ...................... 9 
Public place (street/park) ........ 10 
Car/other vehicle (passenger) . 14 
Car /other vehicle (driver) ........ 15 
Outdoors*  ............................... 16 
Live music event** ................... 17 
Work ........................................ 18 
Educational institute ................ 19 
Acquaintances house .............. 20 
Other ....................................... 12 
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals etc 
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Methamphetamine base (paste/pure) 
Again, please only answer if you feel  
confident of your knowledge in this area. 
 
Note to interviewer: 
Participant able to answer?  Y/N (circle) 
If yes, ensure all questions coded 
 
1. How much does base cost at the 
moment? 
$_______/point 
or 
$______other measure (specify_________) 
 
 
1a. How much did base cost the last time 
you purchased it? $______/point 
or 
$______other measure (specify 
_________) 
 
2. Has the price of base changed in the 
last six months? 
 
Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
 
3. How strong would you say base is at 
the moment? 
 
 Don’t know .............................. 0 
Low ......................................... 1 
Medium ................................... 2 
High ........................................ 3 
Fluctuates ............................... 4 
 
 
4  Has the strength of base changed in the 
last six months? 
 
 Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
 
5. How easy is it to get base at the 
moment? 
 
Don’t know ............................ 0 
Very easy .............................. 1 
Easy ...................................... 2 
Difficult .................................. 3 
Very difficult ........................... 4 
 
6. Has this changed in the last six 
months? 
 
 Don’t know ............................. 0 
More difficult ........................... 1 
Stable ..................................... 2 
Easier ..................................... 3 
 Fluctuates ............................... 4 
 
7. Who have you bought base from in the 
last six months? (multiple responses 
allowed) 
 
Haven’t used base .................. 0 
Used not scored ...................... 7 
Friends .................................... 1 
Known dealers ........................ 2 
Workmates .............................. 3 
Acquaintances ......................... 4 
Unknown dealers .................... 5 
Other ....................................... 6 
(Specify                                   ) 
 
8. What venues do you normally score 
base at? (multiple responses allowed) 
 
Haven’t used base .................. 0 
Used not scored .. ................... 11 
Home ................... ................... 1 
Dealer's home ..... ................... 2 
Friend's home ...... ................... 3 
Raves/doofs/dance parties ...... 12 
Nightclubs ............................... 6 
Pubs/Bars ................................ 7 
Private parties ......................... 8 
Day Club ................................. 8a 
Street ....................................... 9 
Agreed public location* ........... 13  
Work ........................................ 14 
Educational institute ................ 15 
Acquaintances house .............. 16 
Other ....................................... 10 
(Specify                                   ) 
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*eg. car, car park, train station, park 
8a. In the last six months where have you 
usually used base (ie where have you 
spent time while under the influence)? 
(read out all locations; record all that 
apply) 
 
Haven’t used base ........................ 0 
Home ............................................ 1 
Dealer's home ............................... 2 
Friend's home ............................... 3 
Raves/doofs/dance parties ......... 13 
Nightclubs ..................................... 6 
Pubs .............................................. 7 
Private party .................................. 8 
Day Club ..................................... 8a 
Restaurant/ café ........................... 9 
Public place (street/park) ............ 10 
Car/other vehicle (passenger) .... 14 
Car /other vehicle (driver) ........... 15 
Outdoors*  ................................... 16 
Live music event** ...................... 17 
Work ........................................... 18 
Educational institute .................... 19 
Acquaintances house ................. 20 
Other ........................................... 12  
(Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals etc 
 
8b. Where were you the last time you 
used base? (one response only) 
 
Haven’t used base ....................... 0 
Home ............................................ 1 
Dealer's home .............................. 2 
Friend's home ............................... 3 
Raves/doofs/dance parties ......... 13 
Nightclubs .................................... 6 
Pubs ............................................. 7 
Private party ................................. 8 
Day Club .................................... 8a 
Restaurant/ café ........................... 9 
Public place (street/park) ........... 10 
Car/other vehicle (passenger) .... 14 
Car /other vehicle (driver) ........... 15 
Outdoors*  .................................. 16 
Live music event** ...................... 17 
Work ........................................... 18 
Educational institute ................... 19 
Acquaintances house ................. 20 
Other .......................................... 12  
(Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals etc 
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Crystal Methamphetamine 
(crystal/ice/shabu) 
Again, please only answer if you feel  
confident of your knowledge in this area. 
 
Note to interviewer: 
Participant able to answer?  Y/N (circle) 
If yes, ensure all questions coded 
 
1. How much does crystal meth cost at the 
moment?  
$_______/point 
or 
$______other measure (specify_________) 
 
1a. How much did crystal meth cost the 
last time you purchased it? 
$______/point 
or 
$______other measure (specify_________) 
 
 
2. Has the price of crystal meth changed 
in the last six months? 
 
Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
3. How strong would you say crystal meth 
is at the moment? 
 
 Don’t know .............................. 0 
Low ......................................... 1 
Medium ................................... 2 
High ........................................ 3 
Fluctuates ............................... 4 
 
4. Has the strength of crystal meth 
changed in the last six months? 
 
 Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
5. How easy is it to get crystal meth at the 
moment? 
Don’t know .............................. 0 
Very easy ................................ 1 
Easy ........................................ 2 
Difficult .................................... 3 
Very difficult ............................. 4 
 
6. Has this changed in the last six 
months? 
 
 Don’t know .............................. 0 
More difficult ............................ 1 
Stable ...................................... 2 
Easier ...................................... 3 
 Fluctuates ................................ 4 
 
7. Who have you bought crystal meth from 
in the last six months? (multiple responses 
allowed) 
 
Haven’t used crystal ................ 0 
Used not scored ...................... 7 
Friends .................................... 1 
Known dealers ........................ 2 
Workmates .............................. 3 
Acquaintances ......................... 4 
Unknown dealers .................... 5 
Other ....................................... 6 
(Specify                                   ) 
 
8. What venues do you normally score 
crystal meth at? (multiple responses 
allowed) 
Haven’t used crystal ................ 0 
Used not scored .................... 11 
Home ....................................... 1 
Dealer's home ......................... 2 
Friend's home .......................... 3 
Raves/doofs/dance parties .... 12 
Nightclubs ............................... 6 
Pubs/Bars ................................ 7 
Private parties ......................... 8 
Day Clubs .............................. 8a 
Street ....................................... 9 
Agreed public location* ......... 13 
Work ...................................... 14 
Educational institute .............. 15 
Acquaintances house ............ 16 
Other ..................................... 10 
(Specify                                   ) 
 
 18
*eg. car, car park, train station, park 
8a. In the last six months where have you 
usually used crystal meth (ie where have 
you spent time while under the influence) 
? (read out all locations; record all that 
apply) 
 
Haven’t used crystal .................. 0 
Home ......................................... 1 
Dealer's home ............................ 2 
Friend's home ............................ 3 
Raves/doofs/dance parties ........ 13 
Nightclubs .................................. 6 
Pubs ........................................... 7 
Private party ............................... 8 
Day Clubs .................................. 8a 
Restaurant/ café ........................ 9 
Public place (street/park) ........... 10 
Car/other vehicle (passenger) ... 14 
Car /other vehicle (driver) .......... 15 
Outdoors*  .................................. 16 
Live music event** ..................... 17 
Work .......................................... 18 
Educational institute ................... 19 
Acquaintances house ................ 20 
Other .......................................... 12  
(Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals 
 
8b. Where were you the last time you 
used crystal? (one response only) 
 
Haven’t used crystal ................... 0 
Home .......................................... 1 
Dealer's home ............................ 2 
Friend's home ............................. 3 
Raves/doofs/dance parties ......... 13 
Nightclubs .................................. 6 
Pubs ........................................... 7 
Private party ............................... 8 
Day Clubs ................................... 8a 
Restaurant/ café ......................... 9 
Public place (street/park) ........... 10 
Car/other vehicle (passenger) .... 14 
Car /other vehicle (driver) ........... 15 
Outdoors*  .................................. 16 
Live music event** ...................... 17 
Work ........................................... 18 
Educational institute ................... 19 
Acquaintances house ................. 20 
Other .......................................... 12 
(Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals etc 
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Cocaine 
Again, please only answer if you feel  
confident of your knowledge in this area. 
 
Note to interviewer: 
Participant able to answer?  Y/N  (circle) 
If yes, ensure all questions coded 
 
1. How much does cocaine cost at the 
moment? 
$_______/gram 
or 
$______other measure (specify_________) 
 
 
1a. How much did cocaine cost the last 
time you purchased it? $______/gram 
or 
$______other measure (specify_________) 
 
 
 
2. Has the price of cocaine changed in the 
last six months? 
 
Don’t know ........................... 0 
Increasing ............................ 1 
Stable ................................... 2 
Decreasing ........................... 3 
Fluctuates ............................ 4 
 
 
3. How strong would you say cocaine is at 
the moment? 
 
 Don’t know ........................... 0 
Low ...................................... 1 
Medium ................................ 2 
High ..................................... 3 
Fluctuates ............................ 4 
 
 
4. Has the strength of cocaine changed in 
the last six months? 
 
 Don’t know ........................... 0 
Increasing ............................ 1 
Stable ................................... 2 
Decreasing ........................... 3 
Fluctuates ............................ 4 
5. How easy is it to get cocaine at the 
moment? 
 
Don’t know ........................... 0 
Very easy ............................. 1 
Easy ..................................... 2 
Difficult ................................. 3 
Very difficult .......................... 4 
 
6. Has this changed in the last 6 months? 
 
 Don’t know ........................... 0 
More difficult ......................... 1 
Stable ................................... 2 
Easier ................................... 3 
 Fluctuates ............................. 4 
 
7. Who have you bought cocaine from in 
the last six months? (multiple responses 
allowed) 
 
Haven’t used cocaine ........... 0 
Used not scored ................... 7 
Friends ................................. 1 
Known dealers ..................... 2 
Workmates ........................... 3 
Acquaintances ...................... 4 
Unknown dealers ................. 5 
Other .................................... 6 
(Specify                                   ) 
 
8. What venues do you normally score 
cocaine at? (multiple responses allowed) 
 
Haven’t used cocaine .............. 0 
Used not scored ...................... 11 
Home ....................................... 1 
Dealer's home ......................... 2 
Friend's home .......................... 3 
Raves/doofs/dance parties ...... 12 
Nightclubs ............................... 6 
Pubs/Bars ................................ 7 
Private parties ......................... 8 
Day Clubs ................................ 8a 
Street ....................................... 9 
Agreed public location* ........... 13 
Work ........................................ 14 
Educational institute ................ 15 
Acquaintances house .............. 16 
Other ....................................... 10 
(Specify                                   ) 
*eg. car, car park, train station, park 
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8a. In the last six months where have you 
usually used cocaine (ie where have you 
spent time while under the influence)? 
(read out all locations; record all that 
apply) 
 
Haven’t used cocaine ................ 0 
Home ......................................... 1 
Dealer's home ............................ 2 
Friend's home ............................ 3 
Raves/doofs/dance parties ........ 13 
Nightclubs .................................. 6 
Pubs ........................................... 7 
Private party ............................... 8 
Day Clubs .................................. 8a 
Restaurant/ café ........................ 9 
Public place (street/park) ........... 10 
Car/other vehicle (passenger) ... 14 
Car /other vehicle (driver) .......... 15 
Outdoors*  .................................. 16 
Live music event** ..................... 17 
Work .......................................... 18 
Educational institute ................... 19 
Acquaintances house ................ 20 
Other .......................................... 12  
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals 
 
8b. Where were you the last time you 
used cocaine? (one response only) 
 
Haven’t used cocaine ................... 0 
Home .......................................... 1 
Dealer's home ............................ 2 
Friend's home ............................. 3 
Raves/doofs/dance parties ......... 13 
Nightclubs .................................. 6 
Pubs ........................................... 7 
Private party ............................... 8 
Day Clubs ................................... 8a 
Restaurant/ café ......................... 9 
Public place (street/park) ........... 10 
Car/other vehicle (passenger) .... 14 
Car /other vehicle (driver) ........... 15 
Outdoors*  .................................. 16 
Live music event** ...................... 17 
Work ........................................... 18 
Educational institute ................... 19 
Acquaintances house ................. 20 
Other .......................................... 12  
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals 
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LSD/Trips 
Again, please only answer if you feel  
confident of your knowledge in this area. 
 
Note to interviewer: 
Participant able to answer?  Y/N  (circle) 
If yes, ensure all questions coded 
 
 
1. How much does LSD (trips) cost at the 
moment?  $_______/tab 
or 
$______other measure (specify_________) 
 
 
1a. How much did LSD cost the last time 
you purchased it? $______/tab 
or 
$______other measure (specify_________) 
 
 
2. Has the price of trips changed in the 
last six months? 
 
 Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
 
3. How strong would you say trips are at 
the moment? 
 
 Don’t know .............................. 0 
Low ......................................... 1 
Medium ................................... 2 
High ........................................ 3 
Fluctuates ............................... 4 
 
 
4. Has the strength of trips changed in the 
last six months? 
 
 Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
 
5. How easy is it to get trips at the 
moment? 
 
Don’t know .............................. 0 
Very easy ................................ 1 
Easy ........................................ 2 
Difficult .................................... 3 
Very difficult ............................. 4 
 
6. Has this changed in the last six 
months? 
 
 Don’t know .............................. 0 
More difficult ............................ 1 
Stable ...................................... 2 
Easier ...................................... 3 
Fluctuates ................................ 4 
 
7. Who have you bought LSD from in the 
last six months? (multiple responses 
allowed) 
 
Haven’t used LSD ................. 0 
Used not scored .................... 7 
Friends .................................. 1 
Known dealers ...................... 2 
Workmates ............................ 3 
Acquaintances ....................... 4 
Unknown dealers .................. 5 
Other ..................................... 6 
(Specify                                   ) 
 
8. What venues do you normally score 
LSD at? (multiple responses allowed) 
 
Haven’t used LSD ................... 0 
Used not scored .................... 11 
Home ....................................... 1 
Dealer's home ......................... 2 
Friend's home .......................... 3 
Raves/doofs/dance parties .... 12 
Nightclubs ............................... 6 
Pubs/Bars ................................ 7 
Private parties ......................... 8 
Day Clubs .............................. 8a 
Street ....................................... 9 
Agreed public location* ......... 13 
Work ...................................... 14 
Educational institute .............. 15 
Acquaintances house ............ 16 
Other ..................................... 10 
(Specify                                   ) 
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*eg. car, car park, train station, park 
8a. In the last six months where have you 
usually used LSD? (ie where have you 
spent time while under the influence) (read 
out all locations; record all that apply) 
 
Haven’t used LSD ...................... 0 
Home ......................................... 1 
Dealer's home ............................ 2 
Friend's home ............................ 3 
Raves/doofs/dance parties ........ 13 
Nightclubs .................................. 6 
Pubs ........................................... 7 
Private party ............................... 8 
Day Clubs .................................. 8a 
Restaurant/ café ........................ 9 
Public place (street/park) ........... 10 
Car/other vehicle (passenger) ... 14 
Car /other vehicle (driver) .......... 15 
Outdoors*  .................................. 16 
Live music event** ..................... 17 
Work .......................................... 18 
Educational institute ................... 19 
Acquaintances house ................ 20 
Other .......................................... 12  
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals 
 
8b. Where were you the last time you 
used LSD? (one response only) 
 
Haven’t used LSD ..................... 0 
Home .......................................... 1 
Dealer's home ............................ 2 
Friend's home ............................. 3 
Raves/doofs/dance parties ......... 13 
Nightclubs .................................. 6 
Pubs ........................................... 7 
Private party ............................... 8 
Day Clubs ................................... 8a 
Restaurant/ café ......................... 9 
Public place (street/park) ........... 10 
Car/other vehicle (passenger) .... 14 
Car /other vehicle (driver) ........... 15 
Outdoors*  .................................. 16 
Live music event** ...................... 17 
Work ........................................... 18 
Educational institute ................... 19 
Acquaintances house ................. 20 
Other .......................................... 12  
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals 
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MDA 
Again, please only answer if you feel  
confident of your knowledge in this area. 
 
Note to interviewer: 
Participant able to answer?  Y/N (circle) 
If yes, ensure all questions coded 
 
1. How much does MDA cost at the 
moment?  $_______/cap 
or 
$______other measure (specify_________) 
 
 
1a. How much did MDA cost the last time 
you purchased it? $______/cap 
or 
$______other measure (specify_________) 
 
 
2. Has the price of MDA changed in the 
last six months? 
 
Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
 
3. How strong would you say MDA is at 
the moment? 
 
 Don’t know .............................. 0 
Low ......................................... 1 
Medium ................................... 2 
High ........................................ 3 
Fluctuates ............................... 4 
 
 
4. Has the strength of MDA changed in the 
last six months? 
 
 Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
 
 
5. How easy is it to get MDA at the 
moment? 
 
Don’t know .............................. 0 
Very easy ................................ 1 
Easy ........................................ 2 
Difficult .................................... 3 
Very difficult ............................. 4 
 
6. Has this changed in the last six 
months? 
 
 Don’t know .............................. 0 
More difficult ............................ 1 
Stable ...................................... 2 
Easier ...................................... 3 
Fluctuates ................................ 4 
 
7. Who have you bought MDA from in the 
last six months? (multiple responses 
allowed) 
 
Haven’t used MDA .................. 0 
Used not scored ...................... 7 
Friends .................................... 1 
Known dealers ........................ 2 
Workmates .............................. 3 
Acquaintances ......................... 4 
Unknown dealers .................... 5 
Other ....................................... 6 
(Specify                                   ) 
 
8. What venues do you normally score 
MDA at? (multiple responses allowed) 
 
Haven’t used MDA .................. 0 
Used not scored .................... 11 
Home ....................................... 1 
Dealer's home ......................... 2 
Friend's home .......................... 3 
Raves/doofs/dance parties .... 12 
Nightclubs ............................... 6 
Pubs/Bars ................................ 7 
Private parties ......................... 8 
Day Clubs .............................. 8a 
Street ....................................... 9 
Agreed public location ........... 13 
Work ...................................... 14 
Educational institute .............. 15 
Acquaintances house ............ 16 
Other ..................................... 10 
(Specify                                   ) 
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*eg. car, car park, train station, park 
8a. In the last six months where have you 
usually used MDA (ie where have you 
spent time while under the influence) ? 
(read out all locations; record all that 
apply) 
 
Haven’t used MDA .................... 0 
Home ........................................ 1 
Dealer's home ........................... 2 
Friend's home ........................... 3 
Raves/doofs/dance parties ....... 13 
Nightclubs ................................. 6 
Pubs .......................................... 7 
Private party .............................. 8 
Day Clubs ................................. 8a 
Restaurant/ café ....................... 9 
Public place (street/park) .......... 10 
Car/other vehicle (passenger) .. 14 
Car /other vehicle (driver) ......... 15 
Outdoors*  ................................. 16 
Live music event** .................... 17 
Work ......................................... 18 
Educational institute .................. 19 
Acquaintances house ............... 20 
Other ......................................... 12  
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals 
 
8b. Where were you the last time you 
used MDA? (one response only) 
 
Haven’t used MDA .................... 0 
Home .......................................... 1 
Dealer's home ............................ 2 
Friend's home ............................. 3 
Raves/doofs/dance parties ......... 13 
Nightclubs .................................. 6 
Pubs ........................................... 7 
Private party ............................... 8 
Day Clubs ................................... 8a 
Restaurant/ café ......................... 9 
Public place (street/park) ........... 10 
Car/other vehicle (passenger) .... 14 
Car /other vehicle (driver) ........... 15 
Outdoors*  .................................. 16 
Live music event** ...................... 17 
Work ........................................... 18 
Educational institute ................... 19 
Acquaintances house ................. 20 
Other .......................................... 12  
(Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals 
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Ketamine (Special K) 
Again, please only answer if you feel 
confident of your knowledge in this 
area. 
 
Note to interviewer: 
Participant able to answer?  Y/N (circle) 
If yes, ensure all questions coded 
 
1. How much does ketamine cost at the 
moment? $_______/gram 
or 
$______other measure (specify_________) 
 
 
1a. How much did ketamine cost the last 
time you purchased it? $______/gram 
or 
$______other measure (specify_________) 
 
 
2. Has the price of ketamine changed in 
the last 6 months? 
 
Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
 
3. How strong would you say ketamine is 
at the moment? 
 
 Don’t know .............................. 0 
Low ......................................... 1 
Medium ................................... 2 
High ........................................ 3 
Fluctuates ............................... 4 
 
 
4. Has the strength of ketamine changed 
in the last 6 months? 
 
 Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
5. How easy is it to get ketamine at the 
moment? 
 
Don’t know .............................. 0 
Very easy ................................ 1 
Easy ........................................ 2 
Difficult .................................... 3 
Very difficult ............................. 4 
 
6. Has this changed in the last 6 months? 
 
 Don’t know .............................. 0 
More difficult ............................ 1 
Stable ...................................... 2 
Easier ...................................... 3 
Fluctuates ................................ 4 
 
7. Who have you bought ketamine from in 
the last six months? (multiple responses 
allowed) 
 
Haven’t used ketamine ............ 0 
Used not scored ...................... 7 
Friends .................................... 1 
Known dealers ........................ 2 
Workmates .............................. 3 
Acquaintances ......................... 4 
Unknown dealers .................... 5 
Other ....................................... 6 
(Specify                                   ) 
 
8. What venues do you normally score 
ketamine at? (multiple responses allowed) 
 
Haven’t used ketamine ............ 0 
Used not scored .................... 11 
Home ....................................... 1 
Dealer's home ......................... 2 
Friend's home .......................... 3 
Raves/doofs/dance parties .... 12 
Nightclubs ............................... 6 
Pubs/Bars ................................ 7 
Private parties ......................... 8 
Day Clubs .............................. 8a 
Street ....................................... 9 
Agreed public location* ......... 13 
Work ...................................... 14 
Educational institute .............. 15 
Acquaintances house ............ 16 
Other ..................................... 10  
(Specify                                   ) 
*eg. car, car park, train station, park 
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8a. In the last six months where have you 
usually used ketamine (ie where have you 
spent time while under the influence)? 
(read out all locations; record all that 
apply) 
 
Haven’t used ketamine ........... 0 
Home ...................................... 1 
Dealer's home ......................... 2 
Friend's home ......................... 3 
Raves/doofs/dance parties ... 13 
Nightclubs ............................... 6 
Pubs ........................................ 7 
Private party ............................ 8 
Day Clubs ............................. 8a 
Restaurant/ café ..................... 9 
Public place (street/park) ...... 10 
Car/other vehicle (passenger)14 
Car /other vehicle (driver) ..... 15 
Outdoors*  ............................. 16 
Live music event** ................ 17 
Work ..................................... 18 
Educational institute .............. 19 
Acquaintances house ........... 20 
Other ..................................... 12  
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals 
 
8b. Where were you the last time you 
used ketamine? (one response only) 
 
Haven’t used ketamine .............. 0 
Home .......................................... 1 
Dealer's home ............................ 2 
Friend's home ............................. 3 
Raves/doofs/dance parties ......... 13 
Nightclubs .................................. 6 
Pubs ........................................... 7 
Private party ............................... 8 
Day Clubs ................................... 8a 
Restaurant/ café ......................... 9 
Public place (street/park) ........... 10 
Car/other vehicle (passenger) .... 14 
Car /other vehicle (driver) ........... 15 
Outdoors*  .................................. 16 
Live music event** ...................... 17 
Work ........................................... 18 
Educational institute ................... 19 
Acquaintances house ................. 20 
Other .......................................... 12  
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals
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GHB (GBH, liquid e, fantasy, blue) 
Again, please only answer if you feel 
confident of your knowledge in this area. 
 
Note to interviewer: 
Participant able to answer?  Y/N  (circle) 
If yes, ensure all questions coded 
 
1. How much does GHB cost at the 
moment? $_______/mls 
or 
$______other measure (specify_________) 
 
1a. How much did GHB cost the last time 
you purchased it? $______/mls 
or 
$______other measure (specify_________) 
 
 
2. Has the price of GHB changed in the 
last six months? 
 
Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
 
3. How strong would you say GHB is at 
the moment? 
 
 Don’t know .............................. 0 
Low ......................................... 1 
Medium ................................... 2 
High ........................................ 3 
Fluctuates ............................... 4 
 
 
4. Has the strength of GHB changed in the 
last six months? 
 
 Don’t know .............................. 0 
Increasing ............................... 1 
Stable ...................................... 2 
Decreasing .............................. 3 
Fluctuates ............................... 4 
 
 
 
 
5. How easy is it to get GHB at the 
moment? 
 
Don’t know .............................. 0 
Very easy ................................ 1 
Easy ........................................ 2 
Difficult .................................... 3 
Very difficult ............................. 4 
 
6. Has this changed in the last six 
months? 
 
 Don’t know .............................. 0 
More difficult ............................ 1 
Stable ...................................... 2 
Easier ...................................... 3 
Fluctuates ................................ 4 
 
7. Who have you bought GHB from in the 
last six months? (multiple responses 
allowed) 
 
Haven’t used GHB ................. 0 
Used not scored .................... 7 
Friends .................................. 1 
Known dealers ...................... 2 
Workmates ............................ 3 
Acquaintances ....................... 4 
Unknown dealers .................. 5 
Other ..................................... 6 
(Specify                                   ) 
 
8. What venues do you normally score 
GHB at? (multiple responses allowed) 
 
Haven’t used GHB .................. 0 
Used not scored .................... 11 
Home ....................................... 1 
Dealer's home ......................... 2 
Friend's home .......................... 3 
Raves/doofs/dance parties .... 12 
Nightclubs ............................... 6 
Pubs/Bars ................................ 7 
Private parties ......................... 8 
Day Clubs .............................. 8a 
Street ....................................... 9 
Agreed public location* ......... 13  
Work ...................................... 14 
Educational institute .............. 15 
Acquaintances house ............ 16 
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Other ..................................... 10  
(Specify                                   ) 
*eg. car, car park, train station, park* 
8a. In the last six months where have you 
usually used GHB (ie where have you 
spent time while under the influence)? 
(read out all locations; record all that 
apply) 
 
Haven’t used GHB ..................... 0 
Home ......................................... 1 
Dealer's home ............................ 2 
Friend's home ............................ 3 
Raves/doofs/dance parties ........ 13 
Nightclubs .................................. 6 
Pubs ........................................... 7 
Private party ............................... 8 
Day Clubs .................................. 8a 
Restaurant/ café ........................ 9 
Public place (street/park) ........... 10 
Car/other vehicle (passenger) ... 14 
Car /other vehicle (driver) .......... 15 
Outdoors*  .................................. 16 
Live music event** ..................... 17 
Work .......................................... 18 
Educational institute ................... 19 
Acquaintances house ................ 20 
Other .......................................... 12  
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals 
 
 
 
 
 
8b. Where were you the last time you 
used GHB? (one response only) 
 
Haven’t used GHB .................... 0 
Home .......................................... 1 
Dealer's home ............................ 2 
Friend's home ............................. 3 
Raves/doofs/dance parties ......... 13 
Nightclubs .................................. 6 
Pubs ........................................... 7 
Private party ............................... 8 
Day Clubs ................................... 8a 
Restaurant/ café ......................... 9 
Public place (street/park) ........... 10 
Car/other vehicle (passenger) .... 14 
Car /other vehicle (driver) ........... 15 
Outdoors*  .................................. 16 
Live music event** ...................... 17 
Work ........................................... 18 
Educational institute ................... 19 
Acquaintances house ................. 20 
Other .......................................... 12  
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festival 
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Cannabis 
 
Again, please only answer these questions if you are confident of your knowledge in this 
area. 
 
Note to interviewer: 
Participant able to answer this section on Hash/Hash Oil?  Y/N  (circle) 
If yes, ensure all questions coded 
 
Hash and Hash Oil  
 
Bought this amt? 
  
Yes            No 
Circle response 
 
     1               0 
 
     1               0 
 
1b. Have you bought any hash or hash oil in the last 6 months? (if so 
ask amount and how much they paid for each from last time they bought 
it) (single figure only here – no ranges) 
 
- a gram of hash .............. $_________gram 
- a cap of hash oil ............ $_________cap 
 
Hydro 
 
Note to interviewer: 
Participant able to answer this section on Hydro?  Y/N  (circle) 
If yes, ensure all questions coded 
 
 
Able to answer? 
Yes             No 
 
Circle response 
     1               0 
     1               0 
 
 
 
 
Bought this amt? 
Yes            No 
Circle response 
 
 
     1               0 
     1               0 
     1               0 
     1               0 
     1               0 
     1               0 
     1               0 
 
 
1. How much does hydro cost at the moment? (can put ranges here) 
 
$_________gm  
$_________ounce 
Other amt ____$_____ 
 
 
1a. What amounts of hydro have you bought I the last 6 months? 
[Record amounts – if have not bought that amount in last 6 months circle no and 
leave $ blank] 
 
What did you pay last time you bought each amount? (single figure only here – 
no ranges) 
 
 
$_______gram 
$_______2 gms 
$_______3 gms 
$_______’bag’ 
$_______quarter ounce 
$_______half ounce 
$_______ounce 
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2.  Has the price of hydro changed in 
the last six months? 
   Don't know .................... 0  
   Increasing ..................... 1   
 Stable ............................ 2  
 Decreasing .................... 3   
 Fluctuating .................... 4  
  
 
3.  How strong would you say hydro is 
at the moment? 
 Don't know .................... 0   
 High  ............................. 1   
 Medium ......................... 2   
 Low ............................... 3   
 Fluctuates ..................... 4   
 
4. Has the strength of hydro 
changed in the last 6 months? 
 Don't know .................... 0   
 Increasing ..................... 1   
 Stable ............................ 2   
 Decreasing .................... 3   
 Fluctuating .................... 4   
 
5.  How easy is it to get hydro at the 
moment? 
 Don't know .................... 0   
 Very easy ...................... 1   
 Easy .............................. 2   
 Difficult .......................... 3   
 Very difficult .................. 4   
  ......................................  
6.  Has this changed in the last 6 
months? 
 Don't know ..................... 0   
 More difficult .................. 1   
 Stable ............................ 2   
 Easier ............................ 3   
 Fluctuates ...................... 4   
   
7a. Who have you bought hydro from in 
the last six months? (multiple responses 
allowed) 
Don’t use ................................. 0 
Street dealer ........................... 1 
Friends .................................... 2 
Gift from friend ........................ 3 
Known dealers ........................ 4 
Workmates .............................. 5 
Acquaintances ........................ 6 
Unknown dealers .................... 7 
Other ....................................... 8 
 (Specify                                   ) 
 
7b. What venues (locations) do you 
normally score (buy) hydro at? (multiple 
responses allowed) 
 
Don’t use ................................... 0 
Home delivery ........................... 1 
Dealer's home ........................... 2 
Friend's home ........................... 3 
Acquaintance’s house ............... 4 
Mobile dealer ............................. 5 
Street market ............................. 6 
Agreed public location* ............. 7 
Work .......................................... 8 
Other ......................................... 9 
 (Specify                                   ) 
 
*eg. car, car park, train station, park 
 
WA keeping following two questions; 
optional for other jurisdictions 
 
9.    Last time you used either hydro, as 
far as you know, what was the original 
source?  
 
 Don't know ............................................ 0  
 Grew own .............................................. 1  
 Smalltime 'backyard'user/grower .......... 2  
 Large scale cultivator/supplier  
 (eg crime syndicate,bikie gangs etc) ..... 3  
 Other (specify)_______________ 
 
If did not answer 'Don't know', 
 
 
10.  How sure of that are you?  
 
 Very sure ................................. 1  
 Moderately sure ...................... 2  
 Moderately unsure .................. 3 
  
 Very unsure ............................. 4 
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Bush 
 
Note to interviewer: 
Participant able to answer this section on Bush?  Y/N  (circle) 
If yes, ensure all questions coded 
 
                                           
 
Able to answer? 
Yes             No 
 
Circle response 
     1               0 
     1               0 
 
 
 
 
Bought this amt? 
Yes            No 
Circle response 
 
     1               0 
     1               0 
     1               0 
     1               0 
     1               0 
     1               0 
     1               0 
 
 
1. How much does bush cost at the moment? (can put ranges here) 
 
$_________gm  
$_________ounce 
Other amt ____$_____ 
 
 
1a. What amounts of bush have you bought I the last 6 months? 
[Record amounts – if have not bought that amount in last 6 months circle no 
and leave $ blank] 
 
What did you pay last time you bought each amount? (single figure only 
here – no ranges) 
 
$_______gram 
$_______2 gms 
$_______3 gms 
$_______’bag’ 
$_______quarter ounce 
$_______half ounce 
$_______ounce 
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2. Has the price of bush changed in the 
last six months? 
   Don't know .................... 0   
 Increasing ..................... 1  
 Stable ............................ 2   
 Decreasing .................... 3   
 Fluctuating .................... 4   
 
3.  How strong would you say bush is at 
the moment? 
 Don't know .................... 0   
 High  ............................. 1   
 Medium ......................... 2   
 Low ............................... 3   
 Fluctuates ..................... 4   
 
4. Has the strength of bush changed 
in the last 6 months? 
 Don't know .................... 0   
 Increasing ..................... 1   
 Stable ............................ 2   
 Decreasing .................... 3   
 Fluctuating .................... 4   
 
5.  How easy is it to get bush at the 
moment? 
 Don't know .................... 0   
 Very easy ...................... 1   
 Easy .............................. 2   
 Difficult .......................... 3   
 Very difficult .................. 4   
 
6.  Has this changed in the last 6 
months? 
 Don't know ..................... 0   
 More difficult .................. 1   
 Stable ............................ 2   
 Easier ............................ 3   
 Fluctuates ...................... 4   
  
7a. Who have you bought bush from in the 
last six months? (multiple responses 
allowed) 
Don’t use ................................. 0 
Street dealer ........................... 1 
Friends .................................... 2 
Gift from friend ........................ 3 
Known dealers ........................ 4 
Workmates .............................. 5 
Acquaintances ......................... 6 
Unknown dealers .................... 7 
Other ....................................... 8 
 (Specify                                   ) 
 
7b. What venues (locations) do you 
normally score (buy) bush at? (multiple 
responses allowed) 
 
Don’t use ................................... 0 
Home delivery ........................... 1 
Dealer's home ........................... 2 
Friend's home ........................... 3 
Acquaintance’s house ............... 4 
Mobile dealer ............................. 5 
Street market ............................. 6 
Agreed public location* ............. 7 
Work .......................................... 8 
Other ......................................... 9 
 (Specify                                   ) 
 
*eg. car, car park, train station, park 
   
WA keeping the following two questions; 
optional for other jurisdictions 
 
9.    Last time you used either bush, as far 
as you know, what was the original 
source?  
 Don't know ................................................ 0  
 Grew own .................................................. 1  
 Smalltime 'backyard'user/grower ............. 2  
 Large scale cultivator/supplier 
(eg crime syndicate,bikie gangs etc) ............... 3  
Other 
(specify)_______________________ 
 
If did not answer 'Don't know', 
 
10.  How sure of that are you?  
 
 Very sure ............. ................ 1 
 Moderately sure .. ................ 2 
 Moderately unsure ............... 3 
 Very unsure ......... …………..4 
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SECTION C(i): DRUG INFORMATION  
The following section asks about how you obtain more information about ecstasy and 
other party drugs. This includes information about the content and purity of ecstasy 
and other party drugs and the ways you make your experience with them safer and 
healthier.  
 
1. How often do you find out what the content and purity is of other party drugs 
(excluding ecstasy) before taking them? (mark one response only) 
 
Never ................................................. 0 
Sometimes ......................................... 1 
About half the time ............................. 2 
Most times .......................................... 3 
Always ................................................ 4 
 
1a.  How often do you find out what the content and purity is of ecstasy before taking 
them? (mark one response only) 
 
Never ................................................. 0(Go to Q3) 
Sometimes ......................................... 1 
About half the time ............................. 2 
Most times .......................................... 3 
Always ................................................ 4 
 
2. How do you find out about the content and purity of ecstasy before you take them? 
(mark all that apply). 
 
I don’t .............................................................................   0 (Go to Q2b) 
Dealer ............................................................................   1 (Go to Q2b) 
Friends that have taken it already .....  ............................   2 (Go to Q2b) 
Other people that have taken it already .........................   3 (Go to Q2b) 
Personal experience ......................................................  4 (Go to Q2b) 
Information pamphlets ...........................   5(specify______________) (Go to Q2b) 
Websites .................................................  6(specify______________) (Go to Q2b) 
**Testing kits  7(specify______________) (Go to Q2a) 
Other .......................................................  8(specify______________) (Go to Q2b) 
 
2a.  **If yes to using ‘testing kits’ in Q2, how often do you test your ecstasy before taking it? 
(mark one response only) 
 
Sometimes ........................................ 1 
About half the time ............................ 2 
Most times ......................................... 3 
Always ............................................... 4 
 
2b.  Are you aware of any limitations of pill-testing methods such as reagent tests? (to be 
answered by all respondents) 
 
No .............................................................. 0 
Yes  ........................................................... 1(Specify_______________________) 
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2c.  Would you still take the pill if pill testing (circle answer): (to be answered by all 
respondents) 
 
(i) indicated that it contained an ecstasy-like substance (MDMA, MDA etc)?  ... Yes/No 
(ii) indicated that it contained an amphetamine- type substance? ...................... Yes/No 
(iii) indicated that it’s ketamine? ........................................................................... Yes/No 
(iv) ... indicated that it contained opiates       Yes/No 
(v)  that it contained 2CB/2CI? Yes/No 
(vi) that it contained PMA? Yes/No 
(vii) that it contained DXM?        Yes/No 
(viii) showed no reaction (ie. begin substance and/ or unknown substance) Yes/No 
 
3.  In the last 6 months, how often have you bought a drug and it has turned out to have a 
different content or purity than you expected? (mark one response only) 
 
Never .................................................................... 0 
Sometimes ............................................................ 1 
About half the time ................................................ 2 
Most times ............................................................. 3 
Always ................................................................... 4 
 
4. Which of the following information resources would you personally find useful if 
available locally? (mark all that apply). 
 
None ...................................................................... 0 
Information pamphlets ........................................... 1 
Posters ................................................................... 2 
Postcards ............................................................... 3 
Music CDs .............................................................. 4 
Video/DVDs ........................................................... 5 
Local website ......................................................... 6 
Testing kits ............................................................. 7 
Venue outreach workers (at events)  ..................... 8 
Other ...................................................................... 9  
(Specify______________) 
 
5.  Can you tell me how much you agree with the following statements? 
(answer each question – prompt for categories 0-4)  
 
0 = Strongly agree 1 = Agree 2 = Neutral 3 = Disagree  4 = Strongly Disagree 
5a Logos are a good indication of what the tablet/pill will be like?  
5d.  I do not care what is in the ecstasy tabs I take, so long as I have a good 
time?  
5e.  Using ecstasy should be legal?  
5f.  Selling ecstasy should be legal?  
5g.       I know what is in the pills I take.  
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SECTION D: 
 
(i)  AUDIT 
These questions are related to your use of alcohol. Remember, any information you 
provide is completely confidential. 
 
Interviewer note: please write the number in the box on the side 
Q1. How often do you have a drink containing alcohol? 
 0  Never 1 Monthly or 
less 
2 2-4 times a 
month 
3 2-3 times a 
week 
4 4 or more 
times a week
Q2. How many drinks containing alcohol do you have on a typical day when you are 
drinking? 
0 1 or 2 1 3 or 4 2 5 or 6 3 7 to 9 4 10 or more 
Q3. How often do you have six or more drinks on one occasion? 
0 Never 1 Less than 
monthly 
2 Monthly 3 Weekly 4 Daily or 
almost daily 
Q4. How often during the last year have you found that you were not able to stop drinking 
once you had started? 
0 Never 1 Less than 
monthly 
2 Monthly 3 Weekly 4 Daily or 
almost daily 
Q5. How often during the last year have you failed to do what was normally expected from 
you because of drinking? 
0 Never 1 Less than 
monthly 
2 Monthly 3 Weekly 4 Daily or 
almost daily 
Q6. How often during the last year have you needed a first drink in the morning to get 
yourself going, after a heavy drinking session? 
0 Never 1 Less than 
monthly 
2 Monthly 3 Weekly 4 Daily or 
almost daily 
Q7. How often during the last year have you had a feeling of guilt or remorse after 
drinking? 
0 Never 1 Less than 
monthly 
2 Monthly 3 Weekly 4 Daily or 
almost daily 
Q8. How often during the last year have you been unable to remember what happened the 
night before because you had been drinking? 
0 Never 1 Less than 
monthly 
2 Monthly 3 Weekly 4 Daily or 
almost daily 
Q9. Have you or someone else been injured as a result of your drinking? 
0 No 2 Yes , but not in last year 4 Yes, during the last year 
 
Q10. Has a relative or friend or doctor or other health worker been concerned about your 
drinking or suggested you cut down? 
0 No 2 Yes , but not in last year 4 Yes, during the last year 
 
Coding only (TOTAL)
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 (ii) Kessler Psychological Distress Scale 
These questions are related to how you have been feeling over the last 4 weeks. 
Remember, any information you provide is completely confidential. 
 
  
In the last 4 weeks, about how often – 
 
1. Did you feel tired out for no good 
reason? 
 
All of the time  1  
Most of the time 2  
Some of the time 3  
A little of the time 4  
None of the time  5 
 
2. Did you feel nervous? 
 
All of the time  1  
Most of the time 2  
Some of the time 3  
A little of the time 4  
None of the time  5 Note: If 
response 5 chosen, go to Q4 
 
3. Did you feel so nervous that nothing 
could calm you down? 
 
All of the time  1  
Most of the time 2  
Some of the time 3  
A little of the time 4  
None of the time  5 
 
4. Did you feel hopeless? 
 
All of the time  1  
Most of the time 2  
Some of the time 3  
A little of the time 4  
None of the time  5 
 
5. Did you feel restless or fidgety? 
 
All of the time  1  
Most of the time 2  
Some of the time 3  
A little of the time 4  
None of the time  5 Note: If 
response 5 chosen, go to Q7 
 
6. Did you feel so restless that you could 
not sit still? 
 
All of the time  1  
Most of the time 2  
Some of the time 3  
A little of the time 4  
None of the time  5 
 
7. Did you feel depressed? 
 
All of the time  1  
Most of the time 2  
Some of the time 3  
A little of the time 4  
None of the time  5 
 
8. Did you feel that everything was an 
effort? 
 
All of the time  1  
Most of the time 2  
Some of the time 3  
A little of the time 4  
None of the time  5 
 
9. Did you feel so sad that nothing could 
cheer you up? 
 
All of the time  1  
Most of the time 2  
Some of the time 3  
A little of the time 4  
None of the time  5 
 
10. Did you feel worthless? 
 
All of the time  1  
Most of the time 2  
Some of the time 3  
A little of the time 4  
None of the time  5 
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AISS (Arnett, 1994) 
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1 I can see how it would be interesting to marry someone from a foreign country A B C D 
2 When the water is very cold, I prefer not to swim even if it is hot day A B C D 
3 If I have to wait in a long line, I’m usually patient about it A B C D 
4 When I listen to music, I like it to be loud A B C D 
5 When taking a trip, I think it is best to make as few plans as possible and just take it as it comes. A B C D 
6 I stay away from movies that are said to be frightening or highly suspenseful. A B C D 
7 I think it is fun and exciting to perform or speak before a group A B C D 
8 If I were to go to an amusement park, I would prefer to ride the rollercoaster or other fast rides. A B C D 
9 I would like to travel to places that are strange and far away A B C D 
10 I would never like to gamble with money, even if I could afford it A B C D 
11 I would have enjoyed being one of the first explorers of an unknown land A B C D 
12 I like a movie where there are a lot of explosions and car chases A B C D 
13 I don’t like extremely hot and spicy foods. A B C D 
14 In general, I work better when I’m under pressure A B C D 
15 I often like to have a radio or TV on while I’m doing something else, such as reading or cleaning up. A B C D 
16 It would be interesting to see a car accident happen A B C D 
17 I think it’s best to order something familiar when eating in a restaurant. A B C D 
18 I like the feeling of standing next to the edge of a high place and looking down. A B C D 
19 If it were possible to visit another planet or the moon for free, I would be among the first in line to sign up. A B C D 
20 I can see how it must be exciting to be in a battle during a war. A B C D 
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SECTION E: Effects of party drug use 
(i) Benefits and risks of ecstasy use 
(ii) Other risk behaviour 
(iii) Help seeking behaviour and other problems 
 
(i) Benefits and risks of ecstasy use 
 
Interviewer note: (i) Please attempt to code using options listed (ii) Do not prompt 
 
 
1. Do you think there are any benefits associated with taking ecstasy? 
 
No  ............................................................... 0 (Go to 2) 
Yes  ............................................................... 1 (Go to 1a) 
Don’t know ..................................................... 2 (Go to 2) 
 
 
1a. Can you tell me up to THREE of the biggest benefits you perceived to be associated 
with YOUR ecstasy use? (mark up to three) 
 
Enhanced closeness/bonding/empathy with others (including friends) .................................... 1 
Enhanced communication/talkativeness/more social  .............................................................. 2 
Enhanced mood (eg euphoria/wellbeing/happiness) ................................................................ 3 
The high/rush/buzz ...................................  ................................................................................ 4 
Increased energy/stay awake ..................  ................................................................................ 5 
Enhanced appreciation of music and/or dance ......................................................................... 6 
Fun (enjoyable night/good time) ..............  ................................................................................ 7 
Increased confidence/decreased inhibitions ............................................................................. 8 
Relax/escape/release ...............................  ................................................................................ 9 
Drug effects (eg hallucinations/insight/clarity/creativity/heightened senses) .......................... 10 
Different to effects of alcohol (eg non-violent/safer environment/no hangover) ..................... 11 
Enhanced sexual experience .................................................................................................. 12 
Feeling in control/ focused ...................................................................................................... 13 
Cheap ...................................................................................................................................... 14 
Other (Specify__________) .................................................................................................... 15 
 
 
 39
 
Interviewer note: (i) Please attempt to code using options listed (ii) Do not prompt 
 
2. Do you think there are any risks associated with taking ecstasy? 
 
No  ................................................................. 0 (Skip to ‘Other risk behaviour’) 
Yes  ................................................................. 1 (Go to 2a) 
Don’t know ....................................................... 2 (Skip to ‘Other risk behaviour’) 
 
2a. Can you tell me up to THREE of the biggest risks you think are associated with YOUR 
ecstasy use? (mark up to three) 
 
Psychological harms 
Addiction/dependence ............................................................................................................... 1 
Depression ................................................................................................................................ 2 
Anxiety/panic ............................................................................................................................. 3 
Paranoia .................................................................................................................................... 4 
Psychosis .................................................................................................................................. 5 
Lack of motivation ..................................................................................................................... 6 
Other psych harm (Specify____________) .............................................................................. 7 
Neuropsychological harms 
Memory impairment .................................................................................................................. 8 
Damage to brain function (eg. Brain cells /neurological damage) ............................................ 9 
Cognitive impairment .............................................................................................................. 10 
Physical Harms 
General acute physical problems (eg. vomiting/headaches/trouble sleeping/weight loss) .......................... 11 
Dehydration ............................................................................................................................. 12 
Over hydration ......................................................................................................................... 13 
Body temperature regulation (overheating) ............................................................................ 14 
Long-term physical problems (eg. cardiac/lungs/ulcers/respiratory/nasal damage) ............... 15 
Non-fatal OD (passing out/coma) ........................................................................................... 16 
Fatal overdose (death) ............................................................................................................ 17 
Accidents ................................................................................................................................. 18 
Other physical harm (Specify____________) ......................................................................... 19 
Harms related to illicit status 
Unknown drug strength/ purity ................................................................................................ 20 
Unknown drug contaminants/ cutting agents .......................................................................... 21 
Other (Specify____________) ................................................................................................ 22 
Effects of intoxication 
Impaired decision making/risk taking ...................................................................................... 23 
Increased vulnerability ............................................................................................................ 24 
Driving risk............................................................................................................................... 25 
Sex risk .................................................................................................................................... 26 
Aggression/violent behaviour .................................................................................................. 27 
Taking more drug than intended  ............................................................................................ 28 
Other harms 
Legal/police problems ............................................................................................................. 29 
Financial problems .................................................................................................................. 30 
Social/relationship problems ................................................................................................... 31 
Employment problems ............................................................................................................ 32 
Unknown long-term harm ........................................................................................................ 33 
Lack of knowledge (eg. not being aware of risks/don’t know how to use safely) ................... 34 
Other harm (Specify____________) ....................................................................................... 35 
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(ii) Other risk behaviour 
 
1. Have you ever overdosed (passed out and unable to be woken/fallen into a coma) on any 
party drugs? 
 
No    .............................................................. 0 (Skip to ‘Driving’) 
Yes    .............................................................. 1 
Don’t know   .............................................................. 2 (Skip to ‘Driving’) 
 
1a. How many times have you ever overdosed on any party drug? 
 
______________ times 
 
 
1aa. Have you overdosed on any party drug in the past 6 months?  
 
No  ........................................................ 0 (Skip to ‘Driving section’) 
Yes  ........................................................ 1 (Go to Q1b to 1j) 
Don’t know .............................................. 2 (Skip to ‘Driving’) 
 
1b. Specify MAIN drug (mark only one) 
 
Ecstasy  .................................................. 1 
Meth powder (speed/goey/whiz) ............. 2 
Meth base (paste/pure) ........................... 3 
Crystal Meth (ice/shabu) ......................... 4 
Pharmaceutical stimulants .................... 4a 
Cocaine ................................................... 5 
LSD ......................................................... 6 
Mushrooms…………………………………6a 
MDA ........................................................ 7 
Ketamine ................................................. 8 
GHB (GBH/liquid e/fantasy) .................... 9 
Amyl nitrite ............................................ 10 
Nitrous oxide ......................................... 11 
Cannabis ............................................... 12 
Alcohol .................................................. 13 
Heroin ................................................... 14 
Methadone ............................................ 15 
Other opiates ........................................ 16 
Benzodiazepines ................................... 17 
Other ..................................................... 18 
 
(Specify                                   ) 
 
1c. Specify ALL OTHER drugs used at same 
time (mark all that apply) 
No other drug  ......................................... 0 
Ecstasy  ................................................... 1 
Meth powder (speed/goey/whiz) .............. 2 
Meth base (paste/pure) ........................... 3 
Crystal Meth (ice/shabu).......................... 4 
Pharmaceutical stimulants..................... 4a 
Cocaine ................................................... 5 
LSD ......................................................... 6 
Mushrooms…………………………………6a 
MDA ........................................................ 7 
Ketamine ................................................. 8 
GHB (GBH/liquid e/fantasy) ..................... 9 
Amyl nitrite ............................................. 10 
Nitrous oxide ......................................... 11 
Cannabis ............................................... 12 
Alcohol ................................................... 13 
Heroin .................................................... 14 
Methadone ............................................ 15 
Other opiates ......................................... 16 
Benzodiazepines ................................... 17 
Other ..................................................... 18 
 
(Specify                                   ) 
 
 
1d. How long ago was your most recent overdosed on any party drug? 
 
_____________months (<= 1 month = 1 etc) 
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1e. Last time you overdosed, where were you? 
 
Home ............................................ 1 
Dealer's home ............................... 2 
Friend's home ............................... 3 
Raves/doofs/dance parties ......... 13 
Nightclubs ..................................... 6 
Pubs .............................................. 7 
Private party .................................. 8 
Day Club ..................................... 8a 
Restaurant/ café ........................... 9 
Public place (street/park) ............ 10 
Car/other vehicle (passenger) .... 14 
Car /other vehicle (driver) ........... 15 
Outdoors*  ................................... 16 
Live music event** ...................... 17 
Work ........................................... 18 
Educational institute .................... 19 
Acquaintances house ................. 20 
Other ........................................... 12 
 (Specify                                   ) 
 
*eg. beach, bushwalking, camping 
**eg. concerts, music festivals etc 
 
1f. The last time you overdosed what was the main drug you attribute to your overdose? 
(mark only one) 
 
Ecstasy  .................................................. 1 
Meth powder (speed/goey/whiz) ............. 2 
Meth base (paste/pure) ........................... 3 
Crystal Meth (ice/shabu) ......................... 4 
Pharmaceutical stimulants .................... 4a 
Cocaine ................................................... 5 
LSD ......................................................... 6 
Mushrooms ........................................... 6a 
MDA ........................................................ 7 
Ketamine ................................................. 8 
GHB (GBH/liquid e/fantasy/1,4B/GBL) ... 9 
Amyl nitrite ............................................ 10 
Nitrous oxide ......................................... 11 
Cannabis ............................................... 12 
Alcohol .................................................. 13 
Heroin ................................................... 14 
Methadone ............................................ 15 
Other opiates ........................................ 16 
Benzodiazepines ................................... 17 
Other ..................................................... 18 
 (Specify                                   ) 
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1g. The last time you overdosed what other drugs had you taken? 
(more than one response allowed) 
 
Ecstasy  .................................................. 1 
Meth powder (speed/goey/whiz) ............. 2 
Meth base (paste/pure) ........................... 3 
Crystal Meth (ice/shabu) ......................... 4 
Pharmaceutical stimulants .................... 4a 
Cocaine ................................................... 5 
LSD ......................................................... 6 
Mushrooms ........................................... 6a 
MDA ........................................................ 7 
Ketamine ................................................. 8 
GHB (GBH/liquid e/fantasy/1,4B/GBL) ... 9 
Amyl nitrite ............................................ 10 
Nitrous oxide ......................................... 11 
Cannabis ............................................... 12 
Alcohol .................................................. 13 
Heroin ................................................... 14 
Methadone ............................................ 15 
Other opiates ........................................ 16 
Benzodiazepines ................................... 17 
Other ..................................................... 18 
 (Specify                                   ) 
 
1h. The last time you overdosed on any party drugs, what happened/what treatment did you 
receive? 
 
On-site help   ............................................................ 1 
Attended on-site by ambulance ........................................ 2 
Taken by friends to hospital .............................................. 3 
Taken by ambulance to hospital ....................................... 4 
Other     ............................................................ 5 
(please specify____________________) 
 
1i. The last time you overdosed on any party drugs, how long had you been partying before 
you overdosed? _____________hours 
 
1j. The last time you overdosed on any party drugs, how long had it been since you last ate 
a meal? ______________hours 
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(v) Driving 
 
1a. Have you driven a car in the last 6 months? 
 
No ….0 (Skip to ‘Help Seeking Behaviour) 
Yes ….1 (Go to Q1b) 
 
1b. Have you driven while ‘under the influence’ (over the limit) of alcohol in the past 6 
months? 
 
No……0   (If no go to Q1d) 
Yes….1   (If yes go to Q1c) 
 
1c. How many times have you driven while ‘under the influence’ of alcohol in the last 6 
months 
 
Number of times_____________ 
 
1cc. Have you been RBT tested in the last six months? (roadside breath testing) 
No  ......................... 0 (Skip to Q1d) 
Yes  ............................ 1 (Go to 1ccc) 
 
1ccc. If yes, were you over the legal limit?  
No (never in last six months) .............  ........................... 0 (Skip to Q1d) 
Yes (one or more times in last six months) ....................  .. 1  
 
1d. Have you driven after taking illicit drug(s) in the last 6 months? 
 
No……..0 (Skip to Q1m) 
Yes……1 (Go to 1e) 
 
1e. How many times have you driven after taking illicit drug(s) in the last 6 months? 
 
Number of times_____________ 
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1f. After which illicit drug(s) have you driven soon after taking in the last six months? (mark 
all that apply) 
 
Ecstasy ................................................... 1 
Methamphetamine powder ..................... 2 
Methamphetamine base ......................... 3 
Crystal Methamphetamine ...................... 4 
Pharmaceutical stimulant ...................... 4a 
Cocaine ................................................... 5 
LSD ......................................................... 6 
Mushrooms ........................................... 6a 
MDA ........................................................ 7 
Ketamine ................................................. 8 
GHB ........................................................ 9 
Amyl nitrite ............................................ 10 
Nitrous oxide ......................................... 11 
Cannabis ............................................... 12 
Heroin ................................................... 14 
Methadone ............................................ 15 
Other opiates ........................................ 16 
Benzodiazepines ................................... 17 
Other ..................................................... 18 
(Specify                                   ) 
 
 
1g. Last time you drove after taking any illicit drug(s), which drug(s) had you taken? (mark all 
that apply) 
 
Ecstasy ................................................... 1 
Methamphetamine powder ..................... 2 
Methamphetamine base ......................... 3 
Crystal Methamphetamine ...................... 4 
Pharmaceutical stimulant ...................... 4a 
Cocaine ................................................... 5 
LSD ......................................................... 6 
Mushrooms ........................................... 6a 
MDA ........................................................ 7 
Ketamine ................................................. 8 
GHB ........................................................ 9 
Amyl nitrite ............................................ 10 
Nitrous oxide ......................................... 11 
Cannabis ............................................... 12 
Heroin ................................................... 14 
Methadone ............................................ 15 
Other opiates ........................................ 16 
Benzodiazepines ................................... 17 
Other ..................................................... 18 
(Specify                                   ) 
 
1h. Last time you drove after taking any illicit drug(s), how long after taking the drug(s) did 
you drive? 
 
__________ hours 
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1i. Last time you drove after taking any illicit drug(s), how impaired did you feel your driving 
was? 
 
Not at all impaired ........................... 0 
Slightly impaired .............................. 1 
Moderately impaired ....................... 2 
Substantially impaired ..................... 3 
Totally impaired ............................... 4 
 
1j. Have you ever been tested for drug driving by the police roadside drug testing buses (not 
an alcohol breath test, but a saliva drug test)? 
 
No  ................................................ 0 (Skip to Q1m) 
Yes, once ........................................ 1  
Yes, more than once ....................... 2 
 
 
1k. If yes, what was the most recent result? 
 
Negative .......................................... 0 (Skip to Q1m) 
Positive ........................................... 1 
Inconclusive .................................... 2 
Don’t know/didn’t get result ............. 3 
 
1l. If your most recent result was positive, what did it test for? 
 
Cannabis ......................................... 1 
Amphetamine .................................. 2 
MDMA ............................................. 3 
 
1m. Nominate the degree of risk you perceive to be associated with driving soon after (within 
an hour) of taking the following drugs? 
 
 
0 = don’t know 1 = no risk,  2 = low risk  3 = moderate risk 4 = high risk 
i. Over the legal blood alcohol limit  
ii. Ecstasy  
iii.  Methamphetamine (speed, base, crystal)  
iv.  LSD  
v.  Ketamine  
vi. GHB  
vii. Cannabis  
viii. Benzodiazepines  
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(iii) Help seeking behaviour and other problems 
 
I am going to read out a list of medical and health services and want to know if you 
have accessed them in the last six months in relation to your party drug use. 
 
Note to interviewer:  
Eg: Have you accessed first aid in relation to your use of party drugs in the last six months?  
If no, code 0 and move to next service. If yes, code 1 and ask:  
What was main drug involved/main drug of concern? Use codes from List A below Do not prompt 
What was the main issue of concern? Use codes from List B below Do not prompt 
Read out all service types 
 
 
1. Service Accessed? 
1= Yes 
0= No 
Main drug? 
(Code from List A 
below) 
Main issue? 
(Code from List B 
below) 
First aid     
Ambulance    
Emergency department    
Hospitalisation (admitted)    
GP    
Counsellor    
Drug and alcohol worker    
Social/welfare worker    
Psychologist    
Psychiatrist    
Telephone counselling    
Internet counselling    
Other (Specify________)    
 
Note to interviewer: Any services accessed?            Y/N        (Circle. If no, skip and fill in database) 
LIST A - DRUGS FOR CODING PURPOSES: 
1 Ecstasy 
2 Meth powder (speed) 
3 Meth base 
4 Crystal meth 
4a. Pharmaceutical stimulants 
5 Cocaine 
6 LSD 
6a Mushrooms 
7 MDA 
8 Ketamine 
9 GHB 
10 Amyl nitrite 
11 Nitrous oxide 
12 Cannabis 
13 Alcohol 
14 Heroin 
15 Methadone 
16 Other opiates 
17 Antidepressants 
18 Benzodiazepines 
19 Poly drug (2 or more drugs) 
LIST B - ISSUES FOR CODING PURPOSES: 
1 Overdose 
2 Dependence/ addiction 
3 Anxiety 
4 Depression 
5 Aggression/violent behaviour 
6 Psychosis 
7 Other psychological problems eg. phobias, 
paranoia 
8 Acute physical problems eg. dehydration, 
heart palpitations 
9 Pre existing health condition 
10 Information/advice on drug effects (including 
sustained frequency of use, amount used, 
combination, withdrawal, 
contaminants/impurities) 
11 Medication prescription  
12 Social/ relationship issues 
13 Other (Specify___________) 
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2a. Has your party drug use caused any relationship/social problems in the past 
six months?  (i.e. with a partner, friends, family) 
 
No ............................................... 0 (Skip to 3a) 
Yes ............................................. 1 (Go to 2b) 
 
2b. What was the main relationship problem you experienced in the last 6 months? 
 
  
No relationship problems .................................. 0 
Arguments ........................................................ 1 
Mistrust/anxiety ................................................. 2 
Ending a relationship ........................................ 3 
Violence ............................................................ 4 
Kicked out of home ........................................... 5 
Other  ................................................................ 6 
(Specify _____________) 
 
2c.  What was the main drug you attributed this problem to? (mark one only) 
 
No relationship problems ...................................................................... 0 
Ecstasy  ................................................................................................ 1 
Methamphetamine powder (speed/goey/whiz) ..................................... 2 
Methamphetamine base (paste/pure)................................................... 3 
Crystal methamphetamine (ice/shabu) ................................................. 4 
Pharmaceutical stimulants ................................................................. 4a 
Cocaine ................................................................................................ 5 
LSD ...................................................................................................... 6 
Mushrooms ........................................................................................ 6a 
MDA ..................................................................................................... 7 
Ketamine .............................................................................................. 8 
GHB ..................................................................................................... 9 
Amyl nitrate ........................................................................................ 10 
Nitrous oxide ...................................................................................... 11 
Cannabis ............................................................................................ 12 
Alcohol ............................................................................................... 13 
Heroin ................................................................................................. 14 
Methadone ......................................................................................... 15 
Other opiates ...................................................................................... 16 
Tobacco ............................................................................................. 17 
Antidepressants ................................................................................. 18 
Benzodiazepines ................................................................................ 19 
Polydrug use (more than 2 drugs) ...................................................... 20 
Other .................................................................................................. 21 
(Specify                                   ) 
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3a. Has your party drug use caused any financial problems in the past six 
months? 
 
No ...................................................... 0 (Skip to 4a) 
Yes .................................................... 1 (Go to 3b) 
 
 
3b. What was the main money problem have you experienced? 
 
No money problems .......................................... 0 
No money for recreation/luxuries ...................... 1 
In debt/owing money ......................................... 2 
No money for food/rent ..................................... 3 
Other  ................................................................ 4 
(Specify _____________) 
 
3c. What was the main drug you attributed this problem to? (mark one only) 
 
No financial problems ........................................................................... 0 
Ecstasy  ................................................................................................ 1 
Methamphetamine powder (speed/goey/whiz) ..................................... 2 
Methamphetamine base (paste/pure)................................................... 3 
Crystal methamphetamine (ice/shabu) ................................................. 4 
Pharmaceutical stimulants ................................................................. 4a 
Cocaine ................................................................................................ 5 
LSD ...................................................................................................... 6 
Mushrooms ........................................................................................ 6a 
MDA ..................................................................................................... 7 
Ketamine .............................................................................................. 8 
GHB ..................................................................................................... 9 
Amyl nitrate ........................................................................................ 10 
Nitrous oxide ...................................................................................... 11 
Cannabis ............................................................................................ 12 
Alcohol ............................................................................................... 13 
Heroin ................................................................................................. 14 
Methadone ......................................................................................... 15 
Other opiates ...................................................................................... 16 
Tobacco ............................................................................................. 17 
Antidepressants ................................................................................. 18 
Benzodiazepines ................................................................................ 19 
Polydrug use (more than 2 drugs) ...................................................... 20 
Other .................................................................................................. 21 
(Specify                                   ) 
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4a. Has your party drug use caused any legal/police problems in the past six 
months?   
 
No ...................................................... 0 (Skip to 5a) 
Yes .................................................... 1 (Go to 4b) 
 
 
4b. What was the main police problem have you experienced? 
 
No legal problems .............................................................. 0 
Cautioned by police ........................................................... 1 
Arrested ............................................................................. 2 
Feel like being followed / surveillance by undercover ........ 3 
Convicted of a crime .......................................................... 4 
Imprisoned ......................................................................... 5 
Other  ................................................................................. 6 
(Specify _____________) 
 
 
4c. What was the main drug you attributed this problem to? (mark one only) 
 
No legal/police problems ...................................................................... 0 
Ecstasy  ................................................................................................ 1 
Methamphetamine powder (speed/goey/whiz) ..................................... 2 
Methamphetamine base (paste/pure)................................................... 3 
Crystal methamphetamine (ice/shabu) ................................................. 4 
Pharmaceutical stimulants ................................................................. 4a 
Cocaine ................................................................................................ 5 
LSD ...................................................................................................... 6 
Mushrooms ........................................................................................ 6a 
MDA ..................................................................................................... 7 
Ketamine .............................................................................................. 8 
GHB ..................................................................................................... 9 
Amyl nitrate ........................................................................................ 10 
Nitrous oxide ...................................................................................... 11 
Cannabis ............................................................................................ 12 
Alcohol ............................................................................................... 13 
Heroin ................................................................................................. 14 
Methadone ......................................................................................... 15 
Other opiates ...................................................................................... 16 
Tobacco ............................................................................................. 17 
Antidepressants ................................................................................. 18 
Benzodiazepines ................................................................................ 19 
Polydrug use (more than 2 drugs) ...................................................... 20 
Other .................................................................................................. 21 
(Specify                                   ) 
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5a. Has your party drug use caused any work/study problems in the past six 
months?   
 
No ...................................................... 0 (Skip to Section F) 
Yes .................................................... 1 (Go to 5b) 
 
 
5b. What was the main work/study problem have you experienced?  
 
No work/study problems ............................... 0 
Trouble concentrating ................................... 1 
Reduced work performance .......................... 2 
Unmotivated .................................................. 3 
Sick leave/not attending classes ................... 4 
Sacked/quit job/can't find work ..................... 5 
Other  ............................................................ 6 
(Specify _____________) 
 
5c. What was the main drug you attributed this problem to? (mark one only) 
 
No relationship problems ...................................................................... 0 
Ecstasy  ................................................................................................ 1 
Methamphetamine powder (speed/goey/whiz) ..................................... 2 
Methamphetamine base (paste/pure)................................................... 3 
Crystal methamphetamine (ice/shabu) ................................................. 4 
Pharmaceutical stimulants ................................................................. 4a 
Cocaine ................................................................................................ 5 
LSD ...................................................................................................... 6 
Mushrooms ........................................................................................ 6a 
MDA ..................................................................................................... 7 
Ketamine .............................................................................................. 8 
GHB ..................................................................................................... 9 
Amyl nitrate ........................................................................................ 10 
Nitrous oxide ...................................................................................... 11 
Cannabis ............................................................................................ 12 
Alcohol ............................................................................................... 13 
Heroin ................................................................................................. 14 
Methadone ......................................................................................... 15 
Other opiates ...................................................................................... 16 
Tobacco ............................................................................................. 17 
Antidepressants ................................................................................. 18 
Benzodiazepines ................................................................................ 19 
Polydrug use (more than 2 drugs) ...................................................... 20 
Other ...................................................  .............................................. 21 
(Specify                                   ) 
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SECTION F: Injecting risk behaviour 
Interviewer note: Has participant ever 
injected? (refer back to Q3, Pg3) 
 
No  .......................................................... 0  
Yes .......................................................... 1  
If no, skip to Q17 
If yes, say: 
 
You said previously that you have 
injected a drug at some time. This next 
section is about injecting behaviour. 
 
1. The first time you injected, were you 
‘under the influence’ of other drugs? 
 
No  ........................................ 0 (Skip to Q2) 
Yes ........................................ 1 (Go to 1a) 
 
1a.  Specify drugs (mark all that apply): 
Ecstasy  ...................................................... 1 
Methamphetamine powder (speed/goey/whiz) .. 2 
Methamphetamine base (paste/pure) ................ 3 
Crystal methamphetamine (ice/shabu) .............. 4 
Pharmaceutical stimulants ............................... 4a 
Cocaine .............................................................. 5 
LSD .................................................................... 6 
MDA ................................................................... 7 
Ketamine ............................................................ 8 
GHB (GBH/liquid e/fantasy) ............................ 9 
Amyl nitrite........................................................ 10 
Nitrous oxide .................................................... 11 
Cannabis .......................................................... 12 
Alcohol .............................................................. 13 
Heroin ............................................................... 14 
Methadone ....................................................... 15 
Other opiates .................................................... 16 
Benzodiazepines .............................................. 17 
Other ................................................................ 18 
(Specify                                   ) 
 
2.  How did you learn to inject? (mark all that 
apply) 
Don’t inject self ........................................ 0 
Friend/partner ......................................... 1 
Needle Exchange .................................... 2 
Other User .............................................. 3 
Website ................................................... 4 
Information pamphlet .............................. 5 
Indirectly from a health professional ....... 6 
Other ....................................................... 7 
(Specify_____________) 
Interviewer note: Has participant injected in 
the last six months? (refer back to Table 7, 
Pg4&5) 
 
No  .......................................................... 0  
Yes .......................................................... 1  
If no, skip to Q17 
If yes, say: 
 
This next set of questions are about 
injecting behaviour in the last six 
months. 
 
3.  What was the last drug you injected? 
(mark one option only) 
Ecstasy ....................................................... 1 
Methamphetamine powder (speed/goey/whiz) .. 2 
Methamphetamine base (paste/pure) ................ 3 
Crystal methamphetamine (ice/shabu) .............. 4 
Pharmaceutical stimulants ............................... 4a 
Cocaine ....................................................... 5 
LSD ............................................................. 6 
MDA ............................................................ 7 
Ketamine ..................................................... 8 
GHB (GBH/liquid e/fantasy) ........................ 9 
Heroin  ...................................................... 10 
Methadone  ............................................... 11 
Other opiates ............................................ 12 
Benzodiazepines ...................................... 13 
Steroids ..................................................... 14 
Other ......................................................... 15 
(Specify                                   ) 
 
4.  What places did you inject in the last six 
months? (read out list, mark all that apply) 
 
Own home .............................................. 0 
Friends’ home ......................................... 1 
Dealers’ home ......................................... 2 
Street, park or bench .............................. 3 
Venue toilet (eg. pubs/clubs) .................. 4  
Public toilet ............................................. 5  
Sex venue ............................................... 6 
Car  ........................................................ 7 
Commercial injecting room ..................... 8 
MSIC (NSW only) ................................... 9  
Other ..................................................... 10 
(specify  )
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5.  Where did you get your needles from in 
the last six months? (read out list, mark all 
that apply) 
 
NSP (needle and syringe program) ........ 0 
NSP vending machine ............................ 1 
Chemist ................................................... 2 
Partner .................................................... 3 
Friend ...................................................... 4 
Dealer ..................................................... 5 
Other ....................................................... 6 
 
(Specify______________) 
 
6.  Did you find it difficult to get new needles 
in the last six months? 
 
No  ................................... 0 (Skip to 7) 
Yes  .................................... 1 (Go to 6a) 
 
6a. What were the reasons for this? (mark 
all that apply) 
 
Don’t know where to get them ................ 0 
Opening hours of the service/chemist ..... 1 
Location of the service/chemist ............... 2 
Stigma* ................................................... 3 
Can’t afford them .................................... 4 
Other ....................................................... 5 
 
(Specify______________) 
 
*Stigma associated with buying needles from a 
chemist/accessing NSP 
 
7.  How many times have you injected any 
drug in the last six months?  
 
________________times 
 
8.  How many times in the LAST MONTH 
have you used a needle after someone else 
had already used it? (mark only one) 
 
No times .................................................. 0 
One time ................................................. 1 
Two times ................................................ 2 
3-5 times ................................................. 3 
6-10 times ............................................... 4 
More than 10 times ................................. 5 
 
What about in the last SIX months: 
9.  How many times in the last SIX MONTHS 
have you used a needle after someone else 
had already used it? (mark only one) 
 
No times .................................................... 0 
One time ................................................... 1 
Two times ................................................. 2 
3-5 times ................................................... 3 
6-10 times ................................................. 4 
More than 10 times ................................... 5 
 
10.  How many different people have used a 
needle before you in the last six months? 
(mark only one) 
 
None ......................................................... 0 
One person ............................................... 1 
Two people ............................................... 2 
3-5 people ................................................. 3 
6-10 people ............................................... 4 
More than 10 people ................................. 5 
 
11.  Who were these people? (mark all that 
apply) 
 
No people ................................................. 0 
Regular sex partner .................................. 1 
Casual sex partner .................................... 2 
Close friends ............................................. 3 
Acquaintance ............................................ 4 
Other ......................................................... 5 
(Specify______________) 
 
12.  How many times in the last six months 
has someone used a needle after you had 
used it? (mark only one) 
 
No times ..................................................... 0 
One time ................................................... 1 
Two times ................................................. 2 
3-5 times ................................................... 3 
6-10 times ................................................. 4 
More than 10 time ...................................... 5 
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13.  What injecting equipment have you 
used after someone else in the last six 
months? (read out list, mark all that apply) 
 
No equipment ........................................ 0 
Spoons or mixing containers ................. 1 
Filters .................................................... 2 
Tourniquets ........................................... 3 
Water .................................................... 4 
Other ..................................................... 5 
(Specify______________) 
 
14.  Who did you usually inject with in the 
last six months? (mark all that apply)  
 
No people ................................................ 0 
Regular sex partner ................................ 1 
Casual sex partner .................................. 2 
Close friend/s .......................................... 3 
Acquaintance/s ....................................... 4 
Other ....................................................... 5 
(Specify______________) 
 
15.  How often did you inject yourself in the 
last six months? (mark only one) 
 
Every time ............................................... 0 
Often ....................................................... 1 
Sometimes .............................................. 2 
Rarely ...................................................... 3 
Never ...................................................... 4 
 
15a  If you don’t inject yourself, who typically 
injects you? (mark all that apply) 
 
 Partner .....................................1 
 Friend ......................................2 
 Family member ........................3 
 Acquaintance ...........................4 
 Stranger ...................................5 
 Other (Specify__________) 
 
 
16.  Have you injected while ‘under the 
influence’ or ‘coming down’ from ecstasy or 
other party drugs in the last six months? 
(mark only one) 
 
No (neither) ................................. 0 (SkipQ17) 
No (inject party drugs but not while intoxicated  
 .......................................................... 1(SkipQ17) 
Yes, under the influence ............. 2 
Yes, coming down ...................... 3 
Yes, both ..................................... 4 
 
 
16a. How many times have you done this in 
the last six months?  
 
________________times 
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Section F(i): Blood Borne Virus Vaccination and Testing  
 
These next questions are about blood borne virus vaccination and testing. Given the 
sensitive nature of these questions you have the opportunity to complete this section 
yourself. Again, anything you say is confidential. 
 
IF PARTICIPANT CHOOSES TO SELF-COMPLETE, HAND QUESTIONNAIRE TO THEM NOW 
AND ASK THEM TO READ FROM BELOW: 
 
Please remember these questions are optional and that you don’t have to answer 
anything you don’t want to.  If you would like information about blood borne viruses 
including risk behaviour and where to get tested, remind me at the end of the survey 
to give you details.  
 
17.  Have you ever been vaccinated 
against hepatitis B?  
 
No ......................................... 0 (Skip to Q18) 
Yes, didn’t finish schedule ....................... 1  
Yes, completed schedule ......................... 2  
Don’t know ............................ 3 (Skip to Q18) 
 
17a. What was the MAIN reason for being 
vaccinated against hepatitis B? (mark one 
only) 
 
At risk (injecting drug use) ....................... 0 
At risk (sexual) ......................................... 1 
Going overseas ........................................ 2 
Vaccinated as a child ............................... 3 
Work ......................................................... 4 
Don’t know/can’t remember ..................... 5 
Other ........................................................ 6 
 
(specify__________________) 
 
18.  Have you ever been tested for 
hepatitis C? 
 
No ......................................... 0 (Skip to Q19) 
Yes, in the last year ................................. 1 
Yes, more than one year ago ................... 2 
Don’t know ............................ 3 (Skip to Q19) 
 
18a.  What was the result of your last 
hepatitis C test? 
 
Don’t have hep C (negative) .................... 0 
Have hep C (positive) .............................. 1 
Don’t know/ Didn’t get result .................... 2 
19.  Have you ever been tested for HIV? 
 
No ......................................... 0 (Skip to Q20) 
Yes, in the last year ................................. 1  
Yes, more than one year ago .................. 2  
Don’t know ............................ 3 (Skip to Q20) 
 
19a.  If yes, what was the result of your 
last HIV test? 
 
Don’t have HIV (negative) ....................... 0 
Have HIV (positive) ................................. 1 
Don’t know ............................................... 2 
 
20.  Have you ever had any other sexual 
health check up, such as a swab, urine or 
other blood test? (Note to interviewer: do 
not code HCV/HIV blood tests) 
 
No ............................................................ 0  
Yes, in the last year ................................. 1  
Yes, more than one year ago .................. 2  
Don’t know ............................................... 3 
 
20a.  Have you ever been diagnosed with 
a sexually transmitted infection (STI) eg. 
chlamydia, gonorrhoea? 
 
No ............................................................ 0  
Yes, in the last year ................................. 1  
Yes, more than one year ago .................. 2  
Don’t know ............................................... 3 
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Section G: Sexual Risk Behaviour 
 
This next section contains questions 
about sex. Given the sensitive nature 
of these questions you have the 
opportunity to complete this section 
yourself. 
 
IF PARTICIPANT CHOOSES TO SELF-
COMPLETE, HAND QUESTIONNAIRE TO 
THEM NOW AND ASK THEM TO READ 
FROM BELOW: 
 
Please remember these questions are 
optional and that you don’t have to 
answer anything you don’t want to. 
Please note that ‘sex’ in these 
questions refers to penetrative sex (the 
penetration of penis/fist of 
vagina/anus).  
 
 
1.  How many people have you had 
penetrative sex with in the last six months? 
 
None  ................................ 0 (Skip to Section H) 
One person .................................................... 1 
Two people ..................................................... 2 
3-5 people ...................................................... 3 
6-10 people .................................................... 4 
More than 10 people ...................................... 5 
 
2.  How often have you used 
condoms/dams/gloves when having sex with 
your regular partner(s) in the last six months? 
(mark only one) 
 
No regular Partner  ......................................... 0 
Every time ...................................................... 1 
Often ............................................................... 2 
Sometimes ..................................................... 3 
Rarely ............................................................. 4 
Never .............................................................. 5 
 
3.  How often did you use 
condoms/dams/gloves when you had sex with 
casual partners in the last six months? (mark 
only one) 
 
No casual Partner  ......................................... 0 
Every time ...................................................... 1 
Often ............................................................... 2 
Sometimes ..................................................... 3 
Rarely ............................................................. 4 
Never .............................................................. 5 
 
 
4.  How many times did you have anal sex in 
the last six months? (mark only one) 
 
Not in the last six months ..............................  0 
Monthly or less (1-6 times) ...........................  1 
Fortnight or less (7-12 times) ........................  2 
Weekly or less (13- 24 times)  ....................... 3 
Three times a week or less (25-72 times)  .... 4 
Daily or less (73-180)  .................................... 5 
More than once a day (181+) ........................ 6 
 
 
5.  Have you had penetrative sex while using 
ecstasy or other party drugs in the last six 
months? (mark only one) 
 
No ................................. 0 (Skip to Section H) 
Yes ............................................... 1 (Go to 5a) 
 
5a.  How many times have you had 
penetrative sex while using party drugs in the 
last six months? (mark only one) 
 
Once  ............................................................. 1 
Twice .............................................................. 2 
3-5 times ........................................................ 3 
6-10 times ...................................................... 4 
More than 10 times ........................................ 5 
 
5b.  The last time you had sex while using 
party drugs, what drugs were you using (mark 
all that apply) 
 
Ecstasy  ................................................................ 1 
Methamphetamine powder (speed/goey/whiz) ..... 2 
Methamphetamine base (paste/pure) ................... 3 
Crystal methamphetamine (ice/shabu) ................. 4 
Pharmaceutical stimulants .................................. 4a 
Cocaine ................................................................. 5 
LSD ....................................................................... 6 
MDA ...................................................................... 7 
Ketamine ............................................................... 8 
GHB (GBH/liquid e/fantasy) .................................. 9 
Amyl nitrite .......................................................... 10 
Nitrous oxide ....................................................... 11 
Cannabis ............................................................. 12 
Alcohol ................................................................ 13 
Heroin ................................................................. 14 
Methadone .......................................................... 15 
Other opiates ...................................................... 16 
Benzodiazepines ................................................. 17 
Other ................................................................... 18 
(Specify                                   ) 
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5c.  While using party drugs when having sex 
with a regular partner in the last six months, 
how often have you used 
condoms/dams/gloves? (mark only one) 
 
No regular partner .......................................... 0 
Not using with regular partner ........................ 1 
Every time ...................................................... 2 
Often ............................................................... 3 
Sometimes ..................................................... 4 
Rarely ............................................................. 5 
Never .............................................................. 6 
 
 
5d.  While using party drugs when having sex 
with a casual partner in the last six months, 
how often have you used 
condoms/dams/gloves? (mark only one) 
 
No casual partner ........................................... 0 
Not using with casual partner ......................... 1 
Every time ...................................................... 2 
Often ............................................................... 3 
Sometimes ..................................................... 4 
Rarely ............................................................. 5 
Never .............................................................. 6 
 
 
6. Have you been diagnosed with an STI in the 
past 12 months? 
 
No      0 
Yes      1 
 
6a. If yes, which STI? (mark all that apply) 
 
Gonorrhea     1 
Chlamydia    .2 
Syphilis     .3 
Other_________    4 
 
 
THIS IS THE END OF THE SEXUAL 
RISK SECTION. PLEASE RETURN 
QUESTIONNAIRE TO THE 
INTERVIEWER NOW. 
 
 57
SECTION H: Crime 
 
The next set of questions are about crime in the 
last month. We don’t want to know the details of 
any of the crimes you’ve committed, just the 
types of crime you may have been involved in 
during the last month. Please remember, your 
answers are completely confidential. 
 
1. Have you been arrested in the last 12 
months? 
 No ............................ 0 (Skip to Q3) 
 Yes .......................... 1 (Go to Q2) 
 
2.  What were you arrested for? (can mark 
more than one) 
 
  Was not arrested ............................ 0 
 Use/possession .............................. 1 
 Dealing/trafficking .......................... 2 
 Property crime ................................ 3 
 Fraud .............................................. 4 
 Violent crime .................................. 5 
 Alcohol and driving ......................... 7 
 Other drugs and driving ..................... 8 
 Other driving offence ...................... 9 
 Prostitution ..................................... 10 
 Other .............................................. 6
 (Specify__________________) 
 
 
Interviewer note: For each of the following four 
crime areas, firstly ask the participant if they 
have committed that type of crime in the last 
month. If no, skip to the next crime type 
 
 
Property Crime 
 
3.  How often, on average, during the last 
month have you committed a property crime? 
(e.g. shoplifting, break and enter, stealing a 
car, receiving stolen goods)   
 
 No property crime .......................... 0 
 Less than once a week .................. 1 
 Once a week .................................. 2 
 More than once a week .................. 3 
 (but less than daily) 
 Daily ............................................... 4 
 
 
 
Dealing 
 
4.  How often, on average, during the last 
month have you sold drugs to someone FOR 
CASH PROFIT*? 
 
 No drug dealing ................................ 0 
 Less than once a week ..................... 1 
 Once a week ..................................... 2 
 More than once a week .................... 3 
 (but less than daily) 
 Daily .................................................. 4 
 
*Interviewer note: cash profit – purchased 
drugs and on-sold them for a cash profit (more 
than the amount to cover personal use) 
 
 
Fraud 
 
5.  How often, on average, during the last 
month have you committed a fraud? (e.g. 
forging cheques, forging prescriptions, social 
security scams, using someone else’s credit 
card) 
 
 No fraud ......................................... 0 
 Less than once a week .................. 1 
 Once a week .................................. 2 
 More than once a week ................. 3 
 (but less than daily) 
 Daily ............................................... 4 
 
 
Crimes Involving Violence 
 
6.  How often, on average, during the last 
month have you committed a crime involving 
violence? (e.g. assault, violence in a robbery, 
armed robbery, sexual assault, breaking 
apprehended violence orders) 
 
 No violent crime .............................. 0 
 Less than once a week ................... 1 
 Once a week ................................... 2 
 More than once a week .................. 3 
 (but less than daily) 
 Daily ................................................ 4 
 
 
CRIME TOTAL _____ 
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SECTION J: GENERAL TRENDS 
 
1.  In the last six months about what proportion of your friends and 
acquaintances have used ecstasy? 
 
All  ........................................ 0 
Most ........................................ 1 
About half ................................ 2 
A few ....................................... 3 
None ....................................... 4 
 
 
2.  Is there anything new happening in drug use among you or your friends in 
the last six months (eg new drug types, different types of users, increase in 
drug use by some users)? 
 
No  ........................................ 0 
Yes  ........................................ 1 
 
If yes, please specify: 
 
 
 
 
 
 
 
 
 
 
3.  Have there been any changes in police activity towards party drug users in 
the last six months?  
 
Don't know .............................. 0 
Less activity ............................ 1 
Stable ...................................... 2 
More activity ............................ 3 
 
If yes, please specify: 
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4.  Has police activity made it more difficult for you to score drugs in the last 
six months? 
 
No  ........................................ 0 
Yes  ........................................ 1 
 
 
4a. Have you seen sniffer dogs in the last 6 months? 
 
No ....... 0          (If no, skip to Q5) 
Yes ...... 1 
 
4b. How many times have you seen sniffer dogs in the last 6 months? 
 
________ times 
 
4c. What precautions do you take if you know/hear that sniffer dogs are going 
to be at an event? 
 
Hide drugs better                                                           0 
Purchase drugs at party/event from known source 1 
Purchase drugs at party/event from unknown source 2 
Decide not to take drugs to that event  3 
Other (please specify) _____________________________ 
 
4d. Have you had drugs on you when you have seen sniffer dogs at an event? 
 
No ....... 0 
Yes ...... 1 
 
If yes, what did you do when you saw the sniffer dogs? 
 
Dispose of the drugs ........    0 
Took them to avoid being detected 1 
Caught by the police ........    2 
Other (please specify___________) 
 
4d. What would your reaction be if you saw sniffer dogs at an event and had 
drugs on you?  
 
Dispose of the drugs                                             0 
Take the drugs so they can not be detected 1 
Other (please specify) ____________________________ 
 
 
5.  Have you participated in this study before? 
 
No ...........................................0 (Go to 6) 
Yes ..........................................1 (Go to 5a) 
Don't know ..............................3 (Go to 6) 
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5a.  If yes, when was that? 
 
 Don't know ....................... 0 
 1997 ................................. 1 
2000 ................................. 2 
2001 .................................3 
2002 ................................. 4 
2003 ................................. 5 
2004 ................................. 6 
2005 ................................. 7 
 
 
6.  Have you participated in the IDRS (IDU survey) before? 
 
No ............................................. 0 (Go to 7) 
Yes  ........................................... 1 (Go to 6a) 
Don't know ................................ 3 (Go to 7) 
 
 
6a.  If yes, when was that? 
 
 Don't know ....................... 0 
 1995 ................................. 1 
 1996 ................................. 2 
 1997 ................................. 3 
 1998 ................................. 4 
 1999 ................................. 5 
 2000 ................................. 6 
 2001 ................................. 7 
 2002 ................................. 8 
 2003 ................................. 9 
2004 .................................10 
2005 .................................11 
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7.  Any other comments you would like to make about ecstasy or party drugs  
generally? 
 
 
 
 
 
 
8.  Where was respondent recruited from? (mark only one) 
 Internet ...................................... 1 
 Snowballing .............................. 2 
 Street Press .............................. 3 
 Fliers ......................................... 4  
            
Other (specify)_______________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
END OF QUESTIONNAIRE 
 
APPROXIMATELY HOW LONG DID THE INTERVIEW TAKE? 
 
 _______ MINS 
 
  
 
 
Can personality factors help predict risk-taking and harm 
reduction behaviour in ecstasy users? 
 
Thank you for your interest in this research. This study is part of a research project 
conducted by Ashley Lynch (DPsych student) and Dr Raimondo Bruno at the University of 
Tasmania.  This study has been cleared in accordance with the ethical review processes 
of the University of Tasmania and within the guidelines of the National Statement on 
Ethical Conduct in Human Research (Approval Number H10474).  Your participation is 
completely voluntary.  If you would like more information on any aspect of this study, 
please email your question(s) to Ashley Lynch at epersonality@psychol.utas.edu.au 
 
What is the purpose of this study? 
 
The purpose of this study is to investigate the relationship between the personality traits of 
impulsiveness and conscientiousness, and how they may influence risk-taking and risk-
mitigating (harm reduction) behaviours in people who regularly use ecstasy.   
 
What will I be asked to do? 
 
Taking part in this study involves completing questionnaires and should take about 30 
minutes in total.  Questions ask about drug use and health, driving practices and sexual 
experiences, as well as questionnaires about your personality style.     
 
What are the benefits of participating in this study? 
 
Upon completion you may choose to be entered into a prize draw to win one of three $100 
amazon.com gift certificates.  Your participation will also assist us to better understand the 
role that personality plays in risk-taking and harm reduction behaviours.  Understanding 
this will help to develop better harm reduction programs. 
 
Are there any risks associated with participating in this study? 
 
This study involves no more than minimal risk to you, i.e., the level of risk encountered in 
daily life.  No deception is involved in this study.  However, should you become 
uncomfortable or upset whilst completing the survey, please stop the survey and seek 
assistance from the following service providers, all operating 24 hours a day, 7 days a 
week (within Australia): 
 
 Alcohol and Drug Information Service 1 800 811 944 
 
 Life Line 13 11 14 
 
 Turning Point Alcohol and Drug Centre Counselling Service  
1 800 888 236 
 
 If you do not reside in Australia, your may find your local service provider on the 
International White and Yellow Pages, www.wayp.com 
 
It is also important for you to know that all questions are optional.  Please skip any 
questions in this survey that you feel uncomfortable about answering.   
 
How will confidentiality be maintained and my privacy 
protected? 
 
Our server uses a 128bit encryption which is backed by Verisign, the world’s largest 
security certificate provider.  This is the same level of encryption used by banks and the 
Australian Tax Office. Therefore, the responses you provide will remain completely 
anonymous and confidential, as the risk of identification is negligible.   
 
However, you may also choose to use an anonymizer, which will mask your IP address. 
This will mean that both the computer you are using as well as the responses you provide 
will be completely unidentifiable. Anonymizers work by insert a fake computer in between 
your computer and our server, hence masking your IP address.  For more information, 
see: 
http://htmlblock.co.uk/anonymous_web_browser/  
http://www.torproject.org/  
http://www.thefreecountry.com/security/anonymous.shtml 
 
How do I participate? 
 
By signing the following consent form, you indicate that you have read the information on 
this page and you are agreeing to participate in this research study. If you do not wish to 
participate, we thank you for your time.  If you wish to discontinue your participation at any 
point during the study, you may choose to do so. 
 
Concerns and Complaints 
 
If you have any questions about this study, please contact Ashley Lynch or Dr Raimondo 
Bruno at epersonality@psychol.utas.edu.au 
 
This study has been approved by the Tasmanian Social Science Human Research Ethics 
Committee. If you have concerns or complaints about the conduct of this study, you may 
contact the Executive Officer of the Human Research Ethics Committee (Tasmania) 
Network on 03 6226 7479 or human.ethics@utas.edu.au.  The Executive Officer is the 
person nominated to receive complaints from research participants. Please quote Ethics 
Reference Number H10474. 
 
Consent Form  
 
1. I have read and understood the 'Information Sheet' for this study. 
2. I understand the nature and possible effects of this study. 
3. I understand that this study involves answering questions about personality, drug 
use, health, driving practices and sexual experiences.   
4. I understand that all questions are optional and that I may choose to not answer 
any questions that I am uncomfortable with. 
3. I understand that all research data will be securely stored on a password protected 
server at the University of Tasmania. 
5. I understand that my participation is voluntary and that I cannot be identified in any 
way.   
 
 
 
Participant Pseudonym: 
Pseudonym Signature: Date: 
 
 
Statement by Investigator  
 I have explained this project and the implications of participation in it to 
this volunteer and I believe that the consent is informed and that he/she 
understands the implications of participation  
If the Investigator has not had an opportunity to talk to participants prior to them 
participating, the following must be ticked. 
 The participant has received the Information Sheet in which my details 
have been provided so that participants have had opportunity to contact 
me prior to them consenting to participate in this project. 
 
Name of investigator: Ashley Lynch 
 
Signature of investigator:  
Thank you for choosing to participate in this survey.  The questions that follow ask about 
your drug use and health, driving practices, sexual experiences and your personality style.  
Please answer only those questions that you feel comfortable to answer.  All questions are 
optional and you do not have to answer any questions you do not want to.   
 
 
About You 
 
Please indicate your sex:  
Male  Female  
 
What is your age?  ___________ 
 
What country do you live in? 
Australia       Other  (please indicate) _____________________________ 
 
If in Australia, what state/territory do you live in? (please choose one response only) 
ACT  
NSW  
NT  
QLD  
TAS  
VIC  
WA  
 
How are you currently employed? (please choose one response only)  
Not employed   
Full time   
Part time / casual     
Full time student      
Full time student + part time / casual work   
Part time student + part time / casual work   
Home duties  
  
Are you currently in any form of drug treatment?   Yes   No  
 
Have you ever been in prison (i.e., convicted of an offence)? Yes        No  
 
Which of the following best describes your sexual identity?  
(please choose one response only) 
Heterosexual   
Gay male     
Lesbian    
Bisexual  
 
Drug Use 
 
How old were you when you first tried ecstasy? ______________ 
 
How have you mainly used ecstasy in the last six months (i.e., more than half the time)? 
(please choose one response only) 
Swallowed    
Injected     
Shelved/shafted (vaginal/anal administration)   
Snorted     
Smoked  
Haven’t taken ecstasy in the last 6 months  
 
If you have not taken ecstasy in the last 6 months, we thank you for your time and 
information you have provided us thus far.  This study is seeking people who have used 
ecstasy in the last 6 months.  If you indicated you have not used ecstasy in the last 6 
months, you do not meet eligibility requirements for this study.  Thank you again for your 
time and interest.  If you have used ecstasy in the last 6 months, please continue.   
 
Have you ever injected any drug? Yes     No  
 
What is your main drug of choice (i.e., favourite or preferred drug)?  
(please choose one response only) 
Ecstasy  
Methamphetamine (e.g., speed, paste, ice)  
Cocaine  
LSD  
Mushrooms  
Cannabis  
Alcohol  
Heroin  
Benzodiazepines (e.g., sedatives such as Valium, Xanax, Restoril)  
Other  (please indicate) _______________________________________ 
 
Which of the following drugs have you tried? (please tick all that apply) 
Ecstasy  
Methamphetamine   
Cocaine  
LSD  
Ketamine  
GHB (e.g., GBL, liquid e, fantasy)  
Cannabis  
Alcohol  
Mushrooms  
 
Have you used the following drugs in the last 6 months?  
 
Ecstasy   Yes     No  
If yes, how often have you used ecstasy in the last 6 months?  
Less than monthly   
Monthly   
Fortnightly    
Weekly   
More than once a week  
The last time you used ecstasy, how many pills did you take in that session (i.e., the 
continuous period of use without sleep)? ___________________ 
 
In a typical session when you are using ecstasy, how many pills do you usually take? ____ 
 
Methamphetamine   Yes      No  
If yes, how often have you used methamphetamine in the last 6 months?  
Less than monthly   
Monthly   
Fortnightly    
Weekly   
More than once a week  
 
Cocaine   Yes       No  
If yes, how often have you used cocaine in the last 6 months?   
Less than monthly   
Monthly   
Fortnightly    
Weekly   
More than once a week  
 
LSD   Yes       No  
If yes, how often have you used LSD in the last 6 months?   
Less than monthly   
Monthly   
Fortnightly    
Weekly   
More than once a week  
 
Ketamine   Yes      No  
If yes, how often have you used ketamine in the last 6 months?  
Less than monthly   
Monthly   
Fortnightly    
Weekly   
More than once a week  
 
GHB   Yes      No  
If yes, how often have you used GHB in the last 6 months? 
Less than monthly   
Monthly   
Fortnightly    
Weekly   
More than once a week  
 
Cannabis   Yes      No  
If yes, how often have you used cannabis in the last 6 months? 
Less than monthly   
Monthly   
Fortnightly    
Weekly   
More than once a week  
 
Alcohol    Yes     No  
If yes, how often have you used alcohol in the last 6 months?   
Less than monthly   
Monthly   
Fortnightly    
Weekly   
More than once a week  
 
Mushrooms    Yes      No  
If yes, how often have you used mushrooms in the last 6 months? 
Less than monthly   
Monthly   
Fortnightly    
Weekly   
More than once a week  
 
Drugs and Health  
Please remember all questions are optional and that you do not have to answer any 
questions you do not want to. 
 
In the last 6 months, have you used any stimulants or related drugs (e.g., ecstasy, 
amphetamines, cocaine, ketamine, GHB, LSD) for more than 48 hours continuously 
without sleep?    Yes        No  
 
If yes, how many times have you done this in the last 6 months? ___________________ 
 
On which drugs have you done this in the last 6 months? (please tick all that apply) 
Ecstasy  
Methamphetamine  
Cocaine  
LSD  
Mushrooms  
MDA  
Ketamine  
GHB  
Amyl nitrite  
Nitrous oxide  
Cannabis  
Alcohol  
Other   (please indicate) _____________________________________ 
 
In the last 6 months, in a typical session where you are using ecstasy, do you usually (i.e., 
more than half the time) consume more than 5 standard drinks of alcohol?   Yes     No  
 
In the last 6 months, in a typical session where you are using ecstasy, do you usually (i.e., 
more than half the time) take any type of methamphetamine?    Yes       No  
 
Have you ever accidentally overdosed on any stimulant drugs (e.g., ecstasy, 
methamphetamine, cocaine, etc.)?     Yes       No  
 
If yes, has this happened in the last 12 months?    Yes     No  
 
If yes, the last time you overdosed on a stimulant drug, what was the main drug you 
attribute your overdose to? (please choose one response only) 
Ecstasy  
Methamphetamine  
Cocaine  
MDA   
Other  (Please indicate) _________________________________ 
 
What other drugs were you also using at that time? (please tick all that apply) 
No other drug  
Ecstasy  
Methamphetamine  
Cocaine  
LSD  
Mushrooms  
MDA  
Ketamine  
GHB  
Amyl nitrite  
Nitrous oxide  
Cannabis  
Alcohol  
Heroin  
Methadone  
Other Opiates  
Benzodiazepines   
Other  (please indicate) __________________________________ 
 
How often do you find out the content and purity of ecstasy tablets before you take them? 
Never   
Sometimes   
About half the time    
Most times    
Always  
 
How often do you find out the content and purity of other party drugs (excluding ecstasy) 
before you take them?  
Never   
Sometimes   
About half the time    
Most times    
Always  
 
How often do you use a pill testing kit to find out the content and purity of ecstasy tablets 
before you take them? 
Never   
Sometimes   
About half the time    
Most times    
Always  
 
What strategies, if any, have you used in order to minimise the ‘comedown’ following 
ecstasy use or to avoid longer-term negative side effects?   
 
 Haven’t used 
this method 
Used this method 
to reduce the 
‘comedown’ only 
Used this 
method to 
reduce longer-
term negative 
side effects only 
(i.e., problems in 
the days or 
weeks after 
using)  
Used this 
method to 
both to 
reduce 
‘comedown’ 
as well as 
reducing 
longer-term 
negative side 
effects 
Reduce how 
often you use 
ecstasy 
   
Decrease the 
amount of 
ecstasy taken on 
each occasion  
   
Healthy lifestyle 
(e.g., sleep, 
exercise, diet) 
   
Drinking water    
Taking breaks or 
‘chilling out’ 
   
Taking other illicit 
drugs 
   
Taking 
prescription 
medications 
   
Obtain ecstasy 
pills from a 
reliable source 
   
Purchase fewer 
ecstasy pills per 
occasion  
   
 
Have you ever engaged in preloading (i.e., taking vitamins or other products) before using 
ecstasy?   Yes      No  
 
If yes, how frequently have you engaged in preloading before using ecstasy in the last six 
months?   
Rarely   
One quarter of the time   
Half the time   
Three quarters of the time   
Always   
I have not engaged in preloading in the last 6 months  
 
If you have engaged in preloading in the last 6 months, please indicate what substances 
you have used when preloading: (please tick all that apply) 
Multivitamins  
5-HTP  
Magnesium  
Fruit or fruit juice  
Vitamin B Complex  
Vitamin C  
Vitamin E  
ALA  
Guarana or energy drink  
Antidepressants  
Milk  
Other  (please indicate) ___________________________________ 
 
If you have practiced preloading in the last 6 months, please indicate your reason(s) for 
this: (please tick all that apply) 
Reduce ‘comedown’  
Reduce brain damage or neurotoxicity  
Increase the pleasurable effects of ecstasy  
Reduce negative side effects  
Prevent fatigue, getting ill or feeling run down  
Worth a try  
Other  (please indicate) _________________________________________________ 
 
Have you ever engaged in postloading (i.e., taking vitamins or other products) after using 
ecstasy?    Yes       No  
 
If yes, how frequently have you engaged in postloading after using ecstasy in the last six 
months? 
Rarely   
One quarter of the time   
Half the time   
Three quarters of the time   
Always   
I have not engaged in postloading in the last 6 months  
 
If you have engaged in postloading in the last 6 months, please indicate what substances 
you have used when postloading: (please tick all that apply) 
Multivitamins  
5-HTP  
Magnesium  
Fruit or fruit juice  
Vitamin B Complex  
Vitamin C  
Vitamin E  
ALA  
Guarana or energy drink  
Antidepressants  
Milk  
Sleeping tablets  
St. John’s Wort  
Turkey  
Other  (please indicate) ________________________________________ 
 
If you have practiced postloading in the last 6 months, please indicate your reason(s) for 
this: (please tick all that apply) 
Reduce ‘comedown’  
Reduce brain damage or neurotoxicity  
Increase the pleasurable effects of ecstasy  
Reduce negative side effects  
Prevent fatigue, getting ill or feeling run down  
Worth a try  
Other  (please indicate) __________________________________________________ 
 
Driving 
Please remember all questions are optional and that you do not have to answer any 
questions you do not want to. 
 
Have you driven a motor vehicle in the last 6 months?   Yes      No  
If no, please skip ahead to the Sexual Experiences part of the questionnaire 
If yes, please continue with the below questions 
 
Have you driven while under the influence of alcohol (i.e., over the legal limit) in the last 6 
months?    Yes      No  
 
Have you driven soon after taking illicit drugs in the last 6 months?    Yes       No  
 
If yes, how many times have you driven after taking illicit drugs in the last 6 months? ____ 
 
After which illicit drugs have you driven soon after taking in the last 6 months?  
(please tick all that apply) 
Ecstasy  
Methamphetamine  
Cocaine  
LSD  
Mushrooms  
MDA  
Ketamine  
GHB  
Amyl nitrite  
Nitrous oxide  
Cannabis  
Heroin  
Methadone  
Other opiates  
Benzodiazepines  
Other  (please indicate) ___________________________________ 
 
The last time you drove after taking illicit drugs, how do you think it impacted on your 
driving ability? 
Quite impaired     
Slightly impaired     
No impact    
Slightly improved    
Quite improved   
 
Below is a list of statements.  Please tick the circle to indicate your opinion about each 
statement.  There are no right or wrong answers.   
 
 Strongly 
Agree 
 
Agree Neutral Disagree Strongly 
Disagree 
I would get in the car with a driver who 
has been drinking if I knew and trusted 
him or her 
    
I couldn’t live with myself if I hurt 
another human being in traffic  
    
I would not even consider riding with a 
drunk person  
    
There are many traffic rules which 
cannot be obeyed in order to keep up 
the traffic flow  
    
I would be very unpopular if I should 
ask the person driving to drive more 
carefully  
    
Sometimes it is necessary to ignore 
violations of traffic rules  
    
Driving 5 or 10 kms above the speed 
limit is OK because everyone does it  
    
Driving-off-the-road accidents are so 
rare that there is no need to worry  
    
Sometimes it is necessary to bend the 
traffic rules to arrive on time  
    
Sometimes it is necessary to take 
chances in traffic  
    
It is acceptable to drive in excess of 
110 km/h on a straight road if there are 
no other vehicles within a km distance  
    
Driving is more than transportation, it is 
also speeding and fun  
    
The risk of dying young in an traffic 
accident is so low that you can ignore it 
    
A driver who is speeding is a more 
attractive person than a driver who 
always follow the rules  
    
I might get in the car with a driver who 
has been drinking  
    
You should always follow the traffic 
rules, regardless of the driving 
conditions  
    
When people drive they like to be 
different – not to be ordinary, cautious 
drivers  
    
If you have good skills, speeding is OK     
Most people like to show off their skills 
by driving fast  
    
I think it’s OK to speed if the traffic 
conditions allow you to do so  
    
If I should ask my friends to drive more 
carefully, it would be perceived as 
hassle  
    
If I should cause an accident, I hope to 
be the one who’s hurt  
    
People usually drive faster when their 
friends are in the car  
    
It is better to drive smoothly than 
always to follow the traffic rules  
    
If you are a safe driver, it is acceptable 
to exceed the speed limit by 10 km/h in 
areas where it is permitted to drive at 
80–90 km/h 
    
Adolescents have a need for fun and 
excitement in traffic  
    
Hurting someone else with my car 
would scar me for life  
    
Drunk driving is not as risky as people 
think it is  
    
Sometimes it is necessary to bend the 
rules to keep traffic going  
    
Speeding and excitement belong 
together when you are driving  
    
A person who take chances and 
violates some traffic rules is not 
necessarily a less safe driver  
    
Sometimes it is necessary to break the 
traffic rules in order to get ahead  
    
Boys prefer girls who dare to get into a 
car when you are speeding  
    
You should always obey laws while 
driving  
    
It is more important to keep up the     
traffic flow rather than always follow the 
traffic rules  
How often do you: Never 
 
Rarely Some 
times 
Often Very 
Often 
Exceed the speed limit in built-up areas 
(by more than 10 km/h) 
    
Exceed the speed limit on country 
roads (by more than 10 km/h)  
    
Drive through an amber light when it is 
about to turn red  
    
Disregard a red light on an empty road      
Overtake the car in front when it is 
driving at the speed limit  
    
Drive too close to the car in front      
Drive the wrong way down a one-way 
street  
    
Drive fast because the opposite sex 
enjoys it  
    
Ignore traffic rules to in order to get 
ahead in traffic  
    
Bend the traffic rules in order to get 
ahead in traffic  
    
 
Sexual Experiences 
Please remember all questions are optional and that you do not have to answer any 
questions you do not want to. 
 
Have you ever been tested for HIV?    Yes      No  
 
Have you ever had any other sexual health check up, such as a swab, urine or other blood 
test?     Yes        No   
 
Have you ever been diagnosed with a sexually transmitted infection?   Yes      No   
 
How many people have you had penetrative sex with in the last 6 months?  
None   
One person   
Two people   
3-5 people   
6-10 people   
More than 10 people  
 
Have you had penetrative sex with a casual partner in the last six months?  Yes     No  
 
If yes, have you had penetrative sex with a casual partner while using ecstasy or other 
party drugs in the last 6 months?    Yes        No   
 
If yes, on these occasions where you had penetrative sex with a casual partner but had 
not used ecstasy or other party drugs, how often did you use condoms/dams/gloves?   
Every time         
Often         
Sometimes       
Rarely       
Never   
Only had sex when using ecstasy or other party drugs  
 
If yes, on these occasions where you had penetrative sex with a casual partner and had 
used ecstasy or other party drugs, how often did you use condoms/dams/gloves?   
Every time         
Often         
Sometimes       
Rarely       
Never   
 
Below is a list of statements.  Please tick the circle to indicate your opinion about each 
statement.  There are no right or wrong answers.   
 
 Almost 
Never 
Rarely Sometimes Often Almost 
Always 
It is a hassle to use condoms     
Condoms interfere with romance     
People can get the same pleasure 
from “safer” sex as from unprotected 
sex 
    
The sensory aspects (smell, touch, 
etc.) of condoms make them 
unpleasant 
    
The idea of using a condom doesn’t 
appeal to me 
    
I think “safer” sex would get boring 
fast 
    
Condoms ruin the natural sex act     
My sexual experiences do not put me 
at risk for HIV/AIDS 
    
With condoms, you can’t really “give 
yourself over” to your partner 
    
If I had sex and I told my friends that I 
did not use condoms, they would be 
angry or disappointed 
     
If I had a date, I would probably not 
drink alcohol or use drugs. 
    
If a friend knew that I might have sex 
on a date, he/she would ask me if I 
were carrying a condom 
    
When I socialise, I usually drink 
alcohol or use drugs. 
    
I may have had sex with someone 
who was at risk for HIV/AIDS 
    
“Safer” sex reduces the mental 
pleasure of sex 
    
My friends talk a lot about “safer” sex     
If a friend knew that I had sex on a 
date, he/she wouldn’t care if I had 
used a condom or not 
    
Using condoms interrupts sex play     
There is a possibility that I have 
HIV/AIDS 
    
When I think that one of my friends 
might have sex on a date, I ask them 
if they have a condom 
    
The proper use of a condom could 
enhance sexual pleasure 
    
If I thought that one of my friends had 
sex on a date, I would ask them if they 
used a condom 
    
Condoms are irritating     
My friends and I encourage each 
other before dates to practice “safer” 
sex 
    
I am at risk for HIV/AIDS.     
Generally, I am in favour of using 
condoms 
    
 
Personality Questions 
 
Listed below are 10 statements that describe people’s behaviour.  Please use the rating 
scale to indicate how accurately each statement describes you.  Describe yourself as you 
honestly see yourself and how you generally are now, not how you wish to be in the future.   
 
 Very 
Inaccurate
Moderately 
Inaccurate 
Neither 
Inaccurate  
nor Accurate 
Moderately 
Accurate 
Very 
Accurate
 
I try to forgive and forget     
I return extra change 
when a cashier makes a 
mistake 
    
I like to be of service to 
others 
    
I act according to my 
conscience 
    
I anticipate the needs of 
others   
    
I take others’ interests 
into account 
    
I am polite to strangers     
I am able to cooperate     
with others 
I appreciate people who 
wait on me 
    
I try not to think about 
the needy 
    
 
Listed below are statements that people may either agree or disagree with.  For each item, 
indicate how much you agree or disagree with what the item says.  Choose only one 
response to each statement.  Please be as accurate and honest as you can be.  Respond 
to each item as if it were the only item.  That is, don't worry about being "consistent" in 
your responses.   
 Very true 
for me 
Somewhat 
true for me 
Somewhat 
false for me 
Very false
for me 
Even if something bad is about to 
happen to me, I rarely experience fear or 
nervousness.  
   
I go out of my way to get things I want.    
When I'm doing well at something I love 
to keep at it. 
   
I'm always willing to try something new if 
I think it will be fun. 
   
When I get something I want, I feel 
excited and energized. 
   
Criticism or scolding hurts me quite a bit.    
When I want something I usually go all-
out to get it. 
   
I will often do things for no other reason 
than that they might be fun. 
   
If I see a chance to get something I want 
I move on it right away. 
   
I feel pretty worried or upset when I think 
or know somebody is angry at me.  
   
When I see an opportunity for something 
I like I get excited right away.  
   
I often act on the spur of the moment.    
If I think something unpleasant is going 
to happen I usually get pretty "worked 
up." 
   
When good things happen to me, it 
affects me strongly. 
   
I feel worried when I think I have done 
poorly at something important. 
   
I crave excitement and new sensations.    
When I go after something I use a "no 
holds barred" approach. 
   
I have very few fears compared to my 
friends. 
   
It would excite me to win a contest.    
I worry about making mistakes.    
Below is a list of 12 questions.  Please tick yes or no in response to each question.  
Please be as accurate and honest as possible.   
 
 Yes No 
If you say you will do something, do you always keep your promise no 
matter how inconvenient it might be? 
 
Are all your habits good and desirable ones?  
Do you always practise what you preach?  
Were you ever greedy by helping yourself to more than your share of 
anything? 
 
Have you ever blamed someone for doing something you knew was 
really your fault? 
 
Have you ever taken anything (even a pin or button) that belonged to 
someone else? 
 
Have you ever broken or lost something belonging to someone else?  
Have you ever said anything bad or nasty about anyone?  
As a child, were you ever cheeky to your parents?  
Have you ever cheated at a game?  
Have you ever taken advantage of someone?  
Do you sometimes put off until tomorrow what you ought to do today?  
 
People differ in the ways they act and think in different situations.  Please read each 
statement and tick the appropriate circle to indicate how well the statement describes you.  
Do not spend too much time on any statement.  Answer quickly and honestly.   
 
 Rarely/ 
Never 
Occasionally Often Almost Always/ 
Always 
I plan tasks carefully.    
I do things without thinking.    
I make-up my mind quickly.    
I am happy-go-lucky.    
I don’t “pay attention.”    
I have “racing” thoughts.    
I plan trips well ahead of time.    
I am self controlled.    
I concentrate easily.    
I save regularly.    
I “squirm” at plays or lectures.    
I am a careful thinker.    
I plan for job security.    
I say things without thinking.    
I like to think about complex problems.    
I change jobs.    
I act “on impulse.”    
I get easily bored when solving thought 
problems. 
   
I act on the spur of the moment.    
I am a steady thinker.    
I change residences.    
I buy things on impulse.    
I can only think about one thing at a 
time. 
   
I change hobbies.    
I spend or charge more than I earn.    
I often have extraneous thoughts when 
thinking. 
   
I am more interested in the present 
than the future. 
   
I am restless at the theater or lectures.    
I like puzzles.    
I am future oriented.    
 
 
Thank you for completing this survey! 
 
Your time and information is greatly appreciated.   
 
To thank you for your participation, you may choose to enter a prize draw to win one of 
three $100 amazon.com gift vouchers.  If you would like to enter this draw, please visit 
http://www.utas.edu.au/psychol/epersonality.htm and follow the instructions.   
  
Alternatively, to enter the prize draw, you may write your valid email account in the space 
provided below.  Please note that to protect your anonymity, we request that you use an 
email account that is not connected to your name in any way.  If required, you may create 
an anonymous free account by accessing www.hotmail.com or www.gmail.com 
 
Your email address: 
Confirm email address: 
 
The prizes will be randomly drawn on December 1, 2009.  If you are successful, you will 
be contacted by email and provided with information on how to access your online 
voucher.  Winners will be given 7 days to collect their vouchers; any unclaimed prizes will 
be re-drawn and subsequent winners will be notified.   
 
If you have any further questions or comments regarding this study, please contact Ashley 
Lynch on epersonality@psychol.utas.edu.au 
 
If you have questions regarding drugs and health, contact the Alcohol and Drug 
Information Service on 1800 811 944.  This is a free call, available 24 hours, 7 days a 
week within Australia.   
 
Thank you again for your participation.   
 
 
